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SOMMAIRE 
Contexte 
La maladie d’Alzheimer (MA), maladie neurodégénérative progressive chronique liée à l'âge, 
devient un enjeu majeur de santé publique étant donné le poids de la maladie et le vieillissement 
de la population. A l’heure actuelle, seuls des traitements symptomatiques existent; le 
développement de nouveaux traitements capables de ralentir ou d’arrêter l'évolution de la 
maladie est donc une priorité pour la recherche. L'efficacité des nouveaux traitements doit être 
démontrée dans des essais randomisés, mais ce type d’essai dans la MA est relativement 
nouveau et soulève de nombreux problèmes méthodologiques, tels que le choix de la population 
cible et du critère de jugement principal ainsi que la durée de suivi. De part la nature de la 
maladie (déclin progressif des fonctions cognitives et des activités de la vie quotidienne) et l’âge 
des patients (associé à un nombre élevé de comorbidités et des risques compétitifs de décès), il 
existe un risque accru de sorties d’étude (ce que l’on appelle l’attrition), générateur de biais.  
 
Comment minimiser le taux de données manquantes dans les essais cliniques sur la MA et 
comment gérer les données manquantes lors des analyses statistiques ?  
Le phénomène de l’attrition et des données manquantes est classiquement observé dans les 
études observationnelles longitudinales. Cependant, les données manquantes, qu’elles soient 
ponctuelles ou liées à l’attrition, sont aussi une source majeure de biais dans les essais cliniques. 
Le risque d’attrition semble être plus élevé dans les essais sur la MA comparativement à ceux 
conduits dans d’autres populations, puisque les participants sont des personnes âgées 
présentant en général de nombreux comorbidités et nécessitant l’aide d’un « study partner » 
(qui peut être leur aidant informel) pour participer à l’étude. Il y a donc un double risque 
d’attrition puisque soit l’aidant soit le patient peut décider de ne plus vouloir (ou pouvoir) 
participer à l’essai. Nous avons réalisé une revue de la littérature étudiant les taux d’attrition 
observés dans les essais cliniques conduits en population âgée et en particulier parmi les 
personnes atteintes de MA. Ce travail a permis de mettre en évidence un taux élevé d’attrition 
dans les essais conduits parmi les personnes âgées, et plus particulièrement parmi les patients 
atteints de MA.    
Nous avons ensuite conduit une analyse dont l’objectif était d’identifier les facteurs associés à 
l’attrition afin d’expliquer le taux élevé d’attrition observé dans les études portant sur la MA et 
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d’identifier les participants présentant un risque majoré d’attrition. Ce travail a montré que des 
facteurs liés au patient (perte d’autonomie, non utilisation des médicaments spécifiques de la 
MA, prescription de médicaments autres qu’antidémentiels) ainsi que des facteurs liés à l’aidant 
(degré de fardeau, lien de parenté avec le patient) étaient prédictifs d’attrition dans une étude 
longitudinale de la MA. Dans les futures études conduites en population atteinte de MA, il 
semblerait donc judicieux de surveiller attentivement les patients les plus dépendants, les 
patients sans médicament spécifique et les patients ayant un aidant principal autre que le 
conjoint ou l’enfant. Ce travail suggère également que les patients dont l’aidant est épuisé ne 
viendraient plus aux consultations médicales alors que ce sont précisément ces couples patient/ 
aidant qui pourraient être les plus grands bénéficiaires des soins.       
Bien que l’absence (ou la limitation) de donnée manquante représente un objectif indiscuté, ces 
données manquantes apparaissent toutefois inévitables dans les essais cliniques pour la MA, en 
particulier du aux arrêts prématurés de suivi. Le choix de la méthode de gestion des données 
manquantes utilisée lors de l’analyse est donc une considération de premier ordre, car elle peut 
influencer l’intensité du biais présenté. Dans un essai randomisé testant un plan standardisé de 
soin et d’aide pour la MA, nous avons observé un taux particulièrement élevé de données 
manquantes dans la mesure du critère de jugement principal (statut fonctionnel). Une série 
d’analyses de sensibilité a donc été réalisée afin d’évaluer l’influence des différentes méthodes 
de gestion des données manquantes sur le critère de jugement principal. Quelle que soit la 
méthode utilisée, la conclusion restait identique (absence d’efficacité de l’intervention sur le 
critère de jugement principal). Cependant, les estimations de l’évolution du critère de jugement 
principal à deux ans dans chaque groupe, ainsi que la différence entre les groupes (intervention 
versus soins usuels) variaient considérablement selon la méthode d’analyse choisie. Nous avons 
démontré que les méthodes les plus simples, telles que l’analyse des cas complets et le 
remplacement des données manquantes par la dernière valeur observée, ne sont pas adaptées 
aux essais cliniques pour la MA puisque leurs hypothèses sous-jacentes sont manifestement 
violées.          
 
Optimisation du choix des critères de jugement dans les essais thérapeutiques et les 
essais de prévention 
Une autre considération méthodologique importante pour les essais dans la MA est le choix du 
critère de jugement principal. L’efficacité des nouveaux traitements parmi les patients déjà 
atteints d’une MA doit être démontré sur deux types de critères (cognitif et fonctionnel) ce qui 
entraine l’utilisation de deux critères de jugement co-primaires dans les essais cliniques. Nous 
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avons donc étudié la possibilité d’utiliser un critère de jugement global unique pour ces essais en 
évaluant les propriétés psychométriques du Clinical Dementia Rating-Sum of Boxes (CDR-SB) 
dans une cohorte de patients atteints d’une MA de stade léger à modéré et nous avons comparé 
la performance de cet outil avec celles des outils traditionnellement utilisés comme critères de 
jugement dans les essais cliniques pour la MA (ADAS-Cog, MMSE, ADL, IADL). Nous avons 
démontré que le CDR-SB mesurait à la fois la cognition et la fonction dans cette population, avec 
une faible variabilité du CDR SB dans le temps, d’où une très bonne sensibilité au changement 
interne.  Ainsi, le nombre de sujets nécessaires à la réalisation d’un essai clinique serait inférieur 
avec le CDR-SB comparativement aux critères de jugement habituels. Au vu de ces résultats, le 
CDR-SB apparait comme un critère de jugement unique prometteur pour les essais cliniques sur 
la MA. Des études complémentaires sont toutefois nécessaires afin de déterminer la pertinence 
clinique des changements sur cet outil et son utilité à d’autres stades de la maladie.     
Dans les essais de prévention de la MA, le critère de jugement considéré comme le « gold-
standard » est la conversion vers une démence de type Alzheimer. Cependant, son utilisation est 
rendue difficile du fait de la faible incidence de cette maladie dans les essais cliniques (les 
participants de ces essais de prévention semblent être en meilleure santé et plus éduqués que 
les non participants, et les sujets sortants d’étude prématurément étant probablement les plus à 
risque de développer une MA), de la difficulté à déterminer la date précise du début de la 
maladie, et de la nécessité de recourir à un comité de validation pour confirmer chaque 
diagnostic. Une alternative pourrait être d’utiliser la vitesse du déclin cognitif comme critère de 
jugement principal. Lors des analyses préliminaires d’une base de données temporaire d’un 
essai de prévention, nous avons étudié les trajectoires cognitives des sujets restés non-déments 
et des sujets diagnostiqués atteints d’une démence pendant la période de suivi de 5 ans. Ces 
analyses préliminaires ont suggéré un faible déclin cognitif chez les sujets non-déments au cours 
du suivi, mais une diminution précoce des scores de certains types de tests mnésiques (mémoire 
épisodique et de fluence verbale), plus de 4 à 5 ans avant le diagnostic de démence. De plus, un 
déclin sur un test cognitif global (MMSE) et un test fonctionnel (IADL) ainsi que des tests de 
rappel différé et de fluence verbale pendant la première année de suivi étaient prédictifs d’une 
conversion future vers la démence. Bien que le déclin cognitif soit clairement associé à une 
future démence, il ne peut encore être considéré comme un véritable critère de substitution 
puisqu’il est impossible de savoir, à l’heure actuelle, si une intervention capable de ralentir le 
déclin cognitif pourrait vraiment prévenir ou retarder le début de la démence. Des tests de 
mémoire épisodique et de fluence verbale sembleraient néanmoins être particulièrement 
pertinents comme critère de jugement cognitif pour les futurs essais de prévention de la 
démence.   
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Conclusions 
Pour conclure, suite aux échecs des essais récents, la méthodologie des essais cliniques pour la 
MA est en cours de développement. Pour les essais futurs, il est nécessaire de développer des 
critères de jugement cliniquement pertinents, fiables et multidimensionnels. Les critères de 
jugement devront être pertinents aux stades de la maladie étudiés et le rester durant toute la 
période de suivi, parfois longue. Le CDR-SB apparait comme un critère de jugement unique 
pertinent à des stades léger et modéré de la MA puisqu’il mesure à la fois la cognition et la 
fonction.  
Parallèlement, le défi que représente le problème des données manquantes nécessite de prévoir 
dès la conception des essais un certain nombre d’éléments tels que la fréquence, la durée et la 
complexité des évaluations avec une attention toute particulière au stress généré par les 
évaluations (à la fois pour le patient et pour l’aidant) et une surveillance attentive des sujets 
identifiés comme à risque de sortir d’étude prématurément. En contrôlant ainsi les données 
manquantes la validité interne et externe des essais cliniques devrait être améliorées.  De plus, 
l’utilisation des méthodes d’analyse appropriées, telles que l’imputation multiple ou des 
méthodes de maximum de vraisemblance, pour la gestion des données manquantes lors des 
analyses devraient limiter les biais.       
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SUMMARY 
Background 
Alzheimer’s disease (AD), a chronic progressive neurodegenerative disorder primarily affecting 
older people, is a growing public health concern given the burden of the disease, and the aging of 
the global population. Currently, only symptomatic treatments are available, so the development 
of new treatments able to slow or stop the disease process (“disease-modifying” treatments) is a 
research priority. Randomised trials are therefore required to demonstrate the efficacy (or lack 
thereof) of new treatments, but disease modifying trials are relatively new and raise a number of 
methodological challenges, including the definition of the target population, primary endpoint, 
and duration of follow-up.  Such trials are also complicated by the nature of the disease 
(increasing cognitive and functional impairment, decreasing autonomy), as well as the age of the 
patients (associated with a high level of co-morbidities, and competing risks of death), which can 
increase the risk of dropout, leading to bias.    
 
How can we minimise missing data in AD trials, and how should we handle missing data 
during statistical analyses? 
The issue of dropouts and missing data is a classical problem in longitudinal observational 
studies.  However, missing data, whether brought about by intermittent missed evaluations or 
dropout (attrition), are also a major source of potential bias in clinical trials.  The risk of attrition 
would seem to be greater in AD trials since they involve elderly persons, who generally have 
numerous co-morbidities, and require a study partner (who may be their caregiver) to 
participate in the study alongside them.  There is therefore a double risk of attrition, since either 
the caregiver or the patient may decide to withdraw from the study.  We carried out a literature 
review in order to highlight the level of attrition in clinical trials involving elderly people, and 
particularly those with AD.  This work showed that indeed there was a high level of attrition 
associated with studies involving elderly persons, and that rates were even higher in studies of 
people with Alzheimer’s disease. 
We then carried out an analysis to identify factors associated with attrition, in order to try to 
explain the high rate of attrition in studies of patients with Alzheimer’s disease, and to identify 
study participants at particular risk of attrition.  This work showed that both patient (loss of 
autonomy; non-use of anti-Alzheimer treatments; use of other treatments) and caregiver (level 
of burden; relationship with patient) factors were predictive of attrition in a longitudinal study 
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of Alzheimer’s disease patients.  It may therefore be useful in future AD studies to closely 
monitor in particular patients with poorer functional status, those not using anti-Alzheimer 
drugs, and those whose caregiver is not their spouse or child.  This work also suggests that 
patients with exhausted or highly burdened caregivers may no longer attend medical 
consultations, when they may be precisely the people that could most benefit from medical help.   
Although the ideal scenario is to avoid missing data in the first place, in AD trials a high rate of 
missing data, in particular due to dropout, seems almost inevitable.  The method of taking into 
account missing data in statistical analyses is therefore an important consideration in order to 
limit bias.  In a randomised intervention trial of an AD patient management plan, we noted a 
particularly high level of missing data, especially for the primary outcome, a measure of 
functional status.  A series of sensitivity analyses was therefore carried out in order to assess if 
the method of handling missing data would affect the primary study result.  All of the methods 
used led to the same overall conclusion: no effect of the intervention on the primary endpoint.  
However, the estimated mean 2-year decline in each group, as well as the difference between the 
intervention and usual care groups varied widely across the different types of analysis.  We 
demonstrated that simple methods of analysis, such as complete case and “last observation 
carried forward” are unsuitable for AD trials since their underlying hypotheses are clearly 
violated.   
 
Optimising the choice of endpoints in therapeutic and prevention trials 
Another important methodological consideration for AD trials is the choice of the primary 
endpoint.  For trials involving patients diagnosed with AD, the efficacy of new treatments must 
be demonstrated on both cognitive and functional endpoints, leading to the use of two co-
primary outcome measures.  We studied the possibility of using a single global primary endpoint 
for such trials by examining the psychometric properties of the Clinical Dementia Rating-Sum of 
Boxes (CDR-SB) in a cohort of very mild to moderate AD patients, and comparing it with 
traditionally used outcome measures for AD trials (ADAS-Cog, MMSE, ADL, IADL).  We 
demonstrated that the CDR-SB can be considered to measure both cognitive and functional 
impairment in very mild to moderate AD, and that the variability of mean changes over time was 
low, leading to excellent internal responsiveness, and smaller sample sizes compared to 
traditional primary outcome measures.  It is therefore a promising candidate as a sole primary 
endpoint for AD trials, although more work is required to determine the clinical relevance of 
CDR-SB changes and its usefulness as an endpoint at other disease stages 
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In AD prevention trials, the “gold-standard” primary endpoint is conversion to AD-type 
dementia, but its use is complicated in practice due to low incidence rates (associated with the 
fact that subjects who volunteer to participate in prevention trials seem to be healthier and 
more educated than non-participants, and also that subjects who are most likely to develop 
dementia during the trial are probably those most likely to drop out), the difficulties of 
determining the precise date of onset, and the need for a validation committee to confirm 
diagnoses.  An alternative is to use the rate of cognitive decline as a primary endpoint.  In 
preliminary analyses of a temporary database from a prevention trial, we studied the cognitive 
trajectories of those remaining dementia-free and those who were diagnosed with dementia 
during the 5 year follow-up period.  These initial analyses suggested that subjects who remained 
dementia-free underwent little cognitive decline, but that on tests of episodic memory and 
verbal fluency, decline was detectable more than 4-5 years prior to dementia diagnosis.  
Furthermore, decline on a global cognitive test (MMSE) and a functional test (IADL), as well as 
tests of delayed recall and verbal fluency, during the first year of follow-up was predictive of 
future conversion to dementia.  However, although cognitive decline is clearly associated with 
future dementia, it cannot yet be considered as a true surrogate endpoint as we cannot be sure 
that an intervention able to slow cognitive decline will truly prevent or delay onset to dementia 
and if cognitive measures alone are capable of detecting all of the potential effects of an 
intervention on the dementia process.  Measures of episodic memory and verbal fluency may 
however be particularly relevant cognitive endpoints for future trials aiming to delay dementia 
onset.   
 
Conclusions 
In conclusion, in light of the numerous failed phase III trials, the methodology of clinical trials for 
the prevention or treatment of AD is under continuous development. In future trials, 
investigators must endeavour to develop and employ clinically relevant, reliable and 
multidimensional measures for clinical endpoints.  Endpoints must be relevant to the stage of 
disease under study and must remain so right through to the end of long-term trials.  The CDR-
SB may be a suitable primary endpoint for trials conducted in mild to moderate AD since it is 
reliable, responsive and measures both cognition and function simultaneously.  
Additionally, given the challenge posed by missing data, certain elements must be carefully 
addressed during trial design phases, such as the frequency, duration and complexity of study 
evaluations, in particular to avoid stress to patients and caregivers.  Furthermore, subjects 
identified as being at risk of dropping out should be closely monitored.  Limiting missing data in 
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this way will help to improve the internal and external validity of AD trials, and the use of 
appropriate methods, such as multiple imputation or maximum likelihood analyses, for 
managing missing data should help to limit bias.     
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1. GENERAL INTRODUCTION  
1.1 ALZHEIMER’S DISEASE: A GROWING PUBLIC HEALTH PROBLEM 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterised by 
deteriorating cognitive function, especially memory, and progressive impairment in the ability 
to carry out activities of daily living, as well as the presence of neuropsychiatric symptoms and 
behavioural disturbances 1.  AD is currently diagnosed at the dementia stage 2-3.  Dementia is a 
clinical syndrome defined by global cognitive decline affecting memory and one other area of 
cognition that significantly interferes with the ability to perform activities of daily living 4. 
Alzheimer's dementia (or dementia of the Alzheimer type) is characterised by gradual onset and 
progression of decline primarily in cortical aspects of cognition (i.e. memory, language, praxis) 4-
5.   
It is now recognised that the underlying pathophysiological changes associated with AD, notably 
the accumulation of amyloid-beta (Aβ) and tau proteins in the brain, may begin many years 
prior to diagnosis 6-7 and that the clinical, biological and pathological features of AD arise 
progressively along a continuum from normal to end stage disease 8.  It has recently been 
suggested that AD could be diagnosed at a "prodromal" (i.e. early symptomatic) stage in which 
clinical symptoms, in particular episodic memory loss of the hippocampal type, are present but 
not severe enough to affect instrumental activities of daily living or merit a diagnosis of 
dementia 9.  Diagnosis at this stage would also require biomarker evidence of the presence of AD 
pathology. 
AD is primarily an age-related disease and is the commonest form of dementia in older adults, 
with age-specific incidence rates increasing exponentially with advancing age, after 65 years 10-
13.  Given the increasing dependency of AD patients, this disease places a considerable burden on 
patients and caregivers as well as on society, through the use of health care resources 14.  In 
2009, it was estimated that the total worldwide societal cost of dementia, based on an estimated 
34.4 million prevalent cases, was $422 billion, including $142 billion (34%) for informal care 15.     
The global population is currently undergoing a period of unprecedented aging: it is estimated 
that in 1950, people aged 60 or over represented 8% of the world’s population, compared to 
10% in 2000 and a projected 21% in 2050 16.  Given the impending increase in the number of 
older people, the prevalence of AD is expected to greatly increase in the years to come.  In 2006 
there were an estimated 26.6 million prevalent cases of AD worldwide and it is thought that this 
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number could quadruple by 2050 17.  In France, it is estimated that there were 766,000 cases of 
prevalent dementia in persons aged 75 years or older in 2004 18.  
This growing burden means that that AD is rapidly becoming a public health priority, especially 
since at the current time there are no curative or preventive treatments available.  A number of 
countries have announced national strategies to raise awareness of this disease, improve patient 
care and reinforce research efforts 19, including in France, the “Plan Alzheimer” for 2008-2012 
(http://www.plan-alzheimer.gouv.fr).   
1.2 CLINICAL TRIALS FOR ALZHEIMER'S DISEASE 
Given the impending Alzheimer’s disease “epidemic” and the lack of current treatment options, 
the development of new drugs or other interventions for the prevention or treatment of AD is a 
research priority.  This is highlighted by the large number of molecules that are currently under 
development or that have already been tested for Alzheimer’s disease (Figure 1, page 24).  These 
molecules are targeted towards various therapeutic targets, in particular the amyloid cascade 
and tau pathology.  The efficacy (or lack thereof) of new treatments must be demonstrated in 
randomised controlled trials (RCTs), but trials involving older adults diagnosed with or at risk of 
AD raise specific methodological challenges.   
Older people have traditionally been excluded from clinical research 20, but given that 
Alzheimer’s disease is primarily an age-related disease, new treatments must be tested in this 
population.  Prevention trials are also carried out in older adults since they are at greatest risk of 
developing AD.  With currently available endpoints, prevention trials carried out in younger 
participants would require follow-up periods of several decades.   There are multiple difficulties 
in carrying out research with older people 20, including the presence of co-morbidities and use of 
concomitant medications; hearing or vision impairments which may interfere with study 
evaluations; and physical or mobility problems.  Furthermore patients diagnosed with AD, or 
those in the early stages of the disease, have decreasing levels of autonomy brought about by 
increasing cognitive and functional impairment, and therefore become reliant on family 
members and/or other informal caregivers in order to be able to participate in research studies.  
Indeed, trials for AD generally require the presence of a study partner or informal caregiver to 
act as a proxy informant regarding the patient’s health status, and also for the measurement of 
caregiver outcomes, such as the level of burden.   
The only drugs currently marketed for AD are symptomatic treatments, and the search is on for 
a new generation of AD drugs which are able to slow or stop disease progression (“disease-
modifying treatments”) 21.  Although several potentially disease-modifying molecules have 
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shown promising signs in phase II trials 22-24, all phase III trials have so far failed 25-27.  These 
trials may have been negative because the molecules tested really were ineffective.  On the other 
hand, it may be that the methodology used did not enable efficacy to be demonstrated.  
Therefore, the methodology of AD trials is becoming increasingly debated since there is 
currently no consensus regarding the most appropriate methodology for these relatively new 
types of trials 28.   
 
FIGURE 1 - DRUGS CURRENTLY BEING INVESTIGATED FOR ALZHEIMER'S DISEASE THERAPY, 
ACCORDING TO THE MOST ADVANCED PHASE OF STUDY AND MAIN THERAPEUTIC PATHWAY 
Figure taken from 29 
Aβ=amyloid β. BBS1=anti-β-site antibodies. BDNF=brain-derived neurotrophic factor. 
EGCg=epigallocatechin-3-gallate. IVIg=intravenous immunoglobulin. LMT=leuco-methylthioninium. 
MTC=methylthioninium chloride. NGF=nerve growth factor. NGXsc=NGX series compounds. 
PUFAs=polyunsaturated fatty acids. GSM=γ-secretase modulator. RCT=randomised controlled trial. *RCTs 
in Alzheimer's disease not ongoing. †Drugs approved for the treatment of Alzheimer's disease. 
 
Disease-modifying drugs or other interventions can be targeted at either persons with no clinical 
symptoms of AD (primary prevention); those with prodromal AD (i.e. the presence of early 
clinical symptoms, but no dementia); or indeed subjects diagnosed with dementia of the 
Alzheimer type (tertiary prevention) (Figure 2, page 25).  The definition of the target population 
for clinical trials is therefore an important methodological consideration, since disease-
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modifying drugs may only be effective at a certain stage of the disease.  Indeed, current thinking 
is that it may be too late to reverse or slow disease progression in subjects who are already at a 
moderate to severe stage AD dementia 30.  Therefore most putative disease modifying drugs 
have so far been tested in subjects with mild to moderate AD, but even at this early stage of 
clinical AD, the biological pathology of the disease may already be too widespread.   
 
FIGURE 2 - INTERVENTIONS FOR THE PRIMARY, SECONDARY OR TERTIARY PREVENTION OF 
ALZHEIMER’S DISEASE 
Disease stages are based on those proposed by Dubois et al 9.   
* includes interventions tested for the prevention of AD dementia, or for the preservation of cognitive 
function in older adults; ** tested in individuals with “mild cognitive impairment”  
ChEIs: Cholinesterase inhibitors; HRT: hormone replacement therapy; NSAIDs: non-steroidal anti-
inflammatory drugs 
 
The choice of the primary endpoint is also an important methodological consideration for AD 
trials.  The outcome of interest is generally cognitive and/or functional decline (the primary 
clinical features of AD), but the instrument used as the primary outcome measure must be 
adapted to the specific stage of the disease that is being studied.  The development of biomarker 
endpoints is an important goal for AD trials, particularly those aiming to prevent clinical onset of 
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AD, and so future trials may incorporate biomarker endpoints alongside or instead of clinical 
measures.   
The duration of treatment and follow-up is another important methodological consideration for 
AD disease modifying trials.  6 months was seen as the standard duration for trials of drugs with 
symptomatic effects on AD, but disease-modifying drugs may only have modest effects on the 
disease process, and so may require a much longer period of follow-up, such as 18 months or 
more.  This can be problematic since the longer the trial is, the greater the risk of attrition or 
dropout.  Indeed, both prevention and treatment trials for AD are likely to have a high attrition 
rate, simply because of the age of the participants and the nature of the disease, and this 
problem can be exacerbated by long follow-up periods and the burden of the cognitive 
evaluations that participants undergo on a fairly regular basis during AD trials.  The method of 
handling missing data, much of which is due to attrition (dropout), during statistical analyses is 
therefore another important methodological consideration for AD trials.   
The methodological characteristics and results of clinical trials testing disease-modifying or 
symptomatic treatments in mild to moderate AD (the most common target population) are 
presented in Table 1 (page 27) and Table 2 (page 30).  A total of 18 phase III trials testing 
potentially disease-modifying drugs or supplements were identified (in the PubMed database 
and the Clinicaltrials.gov trial registry).  Of these, nine had been completed as of November 
2010, six were ongoing and three had been stopped (Table 2).  The European Tramiprosate trial 
31 was stopped following the results of the initial US trial which showed no effect of treatment on 
cognitive or global change 32.  Treatment in the two trials of Semagacestat has recently been 
stopped due to interim results suggesting a worsening of cognitive and functional measures in 
patients receiving the active treatment 33.   
So far, the design of disease-modifying trials has been largely based on that of trials for 
symptomatic drugs: all have been double blind parallel group placebo-controlled studies aimed 
at mild to moderate AD, using cognitive and functional or global co-primary endpoints.  One 
major methodological difference is the duration of treatment, which is generally 18 months for 
disease-modifying drugs (Table 2; page 30) compared to a standard duration of only 6 months in 
trials for symptomatic drugs.  This longer duration is due to the expected modest efficacy of the 
new drugs being tested, and the need to show “disease modifying” as opposed to “symptomatic” 
effects 21. Furthermore, many disease modifying trials have also measured biomarkers, such as 
brain volume changes, as secondary endpoints with the aim of demonstrating disease 
modification.  The majority of the disease-modifying trials have been “add-on” designs, meaning 
that patients could be treated with symptomatic drugs whilst on the trial.   
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TABLE 1 - PHASE III CLINICAL TRIALS OF SYMPTOMATIC TREATMENTS FOR PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE 
Author / Trial 
name 
Intervention 
[type*] 
Study 
Population 
N Follow-up Primary 
endpoint(s) 
Secondary 
endpoints 
Attrition§ Data analysis 
& methods for 
handling 
missing data# 
Results 
Winblad 2001 34 
 
Donepezil (5-
10mg/day)  
mild to 
moderate AD 
(MMSE 10-26) 
286 12 months Global dementia 
assessment (GBS) 
Cognition, function 32.9% ITT; ANCOVA 
with LOCF 
Effect on GBS borderline at 1 
year (p=0.054), but 
significant at earlier time 
points 
Significant effect at 1 year on 
cognition and function 
Wilcock / GAL-
GBR-2 35 
Galantamine 
(24mg/d) versus 
donepezil 
(10mg/day)  
Moderate AD 
(MMSE 9-18) 
182 12 months Functional abilities 
(BADL) 
Cognition, 
behavioural and 
psychological 
symptoms, caregiver 
burden 
20.7% ITT; ANCOVA 
(change from 
baseline to last 
recorded 
assessment) 
No differences between 
groups 
Mohs 2001 / 
312 Study 36 
 
Donepezil (5-
10mg/day)  
Moderate AD 
(MMSE 12-20) 
431 12 months Functional decline 
(ADFACS); global 
decline (increase in 
CDR rating) 
Cognition 26.9% ITT with at least 
1 post-baseline 
assessment; 
survival 
analysis 
38% efficacy reduction in the 
risk of functional decline 
Rogers 1998 37 Donepezil (5-
10mg/day)  
Mild to 
moderate AD 
(MMSE 10-26) 
319 5.5 months Cognitive (ADAS-
Cog) and global 
function (CIBIC-
plus) 
Cognition, global 
status, QOL 
- PP & ITT; 
ANCOVA with 
LOCF 
 
Statistically significant 
improvements in ADAS-cog & 
CIBIC plus scores, relative to 
placebo 
Rogers 1998 38 
 
Donepezil (5-
10mg/day)  
Mild to 
moderate AD 
(MMSE 10-26) 
468 
 
3 months Cognitive (ADAS-
Cog) and global 
function (CIBIC-
plus) 
Cognition, global 
status, QOL 
12.0% ITT with at least 
1 post-baseline 
assessment; 
ANCOVA with 
LOCF 
Statistically significant 
improvements in ADAS-cog, 
CIBIC plus, and MMSE scores, 
relative to placebo 
Burns 1999 39 
 
Donepezil (5-
10mg/day)  
Mild to 
moderate AD 
(MMSE 10-26) 
818 5.5 months Cognitive (ADAS-
Cog) and global 
function (CIBIC-
plus) 
Function, global 
status, QOL 
22.7% ITT, ANCOVA 
with LOCF 
Statistically significant 
improvements in cognitive 
(ADAS-cog), and global 
(CIBIC plus) function, 
compared to placebo 
Homma 2000 40 
 
Donepezil (5 
mg/d)  
Mild to 
moderate AD 
(MMSE 10-26) 
268 5.5 months Cognitive and global 
function (ADAS-Cog, 
CGIC) 
Other global 
assessments 
14.6% PP & ITT; Mann 
Whitney U Test 
Statistically significant 
improvements in cognitive 
(ADAS-cog), and global 
(CIBIC plus) function, 
compared to placebo 
Rosler 1999 41 
 
Rivastigmine (1-
4 or 6-12 mg/d) 
Mild to 
moderate AD 
(MMSE 10-26) 
725 6 months Cognitive and global 
function (ADAS-Cog, 
CGIC, PDS) 
Cognition, global 
status 
19.9% OC; t-test with Statistically significant 
improvements in cognitive 
and global function, in the 
high dose group compared to 
placebo 
Raskind 2000 / Galantamine Mild to 636 6 months Cognitive (ADAS- Function 31.1% OC (ITT with Galantamine significantly 
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Author / Trial 
name 
Intervention 
[type*] 
Study 
Population 
N Follow-up Primary 
endpoint(s) 
Secondary 
endpoints 
Attrition§ Data analysis 
& methods for 
handling 
missing data# 
Results 
GAL-USA-1 42 
 
(24-32 mg/d)  moderate AD   
(MMSE 11-24, 
ADAS-Cog 
≥12) 
Cog) and global 
function (CIBIC-
plus) 
LOCF as 
secondary 
analysis); 
ANCOVA 
improved cognitive (ADAS-
cog/11) and global (CIBIC+) 
function relative to placebo 
Wilcock 2000 
/GAL-INT-1 43 
Galantamine 
(24-32 mg/d)  
Mild to 
moderate AD 
(MMSE 11-24, 
ADAS-Cog 
≥12) 
653 6 months Cognitive (ADAS-
Cog) and global 
function (CIBIC-
plus) 
Function 19.6% 
 
OC (ITT with 
LOCF as 
secondary 
analysis); 
paired t-test 
Galantamine significantly 
improved cognitive and 
global function relative to 
placebo.  
Tariot 2000  / 
GAL-USA-10 44 
 
Galantamine (8, 
16 or 24 mg/d)  
Mild to 
moderate AD 
(MMSE 10-22, 
ADAS-Cog 
≥18) 
978 5 months Cognitive (ADAS-
Cog) and global 
function (CIBIC-
plus) 
Function 20.3% OC (ITT with 
LOCF as 
secondary 
analysis); 
ANOVA 
Significantly better outcomes 
for all measures compared to 
placebo for the two highest 
dose groups 
Wilkinson 2001 
45 
Galantamine (18, 
24 or 36 mg/d)  
Mild to 
moderate AD 
(MMSE 13-24) 
285 3 months Cognitive function 
(ADAS-Cog) 
Global function 
(CGIC, PDS) 
27.7% ITT, ANOVA 
with LOCF 
Those treated with 24mg/d  
had significantly better 
outcomes for all measures 
compared to placebo 
Rockwood 2001 
46 
 
Galantamine (24 
- 32 mg/d)  
Mild to 
moderate AD 
(MMSE 11-24, 
ADAS-Cog 
≥12) 
386 
 
3 months 
 
Cognitive (ADAS-
Cog) and global 
function (CIBIC-
plus) 
Function, 
behavioural 
symptoms 
25.4% OC (ITT with 
LOCF as 
secondary 
analysis); 
ANOVA 
Galantamine produced a 
significantly better outcome 
on cognitive and global 
function than placebo, as well 
as significant benefits on 
basic and instrumental ADL.   
NCT00235716* 
 
Vitamine E 
(1000 IU twice 
daily) and 
memantine 
(20mg/d) 
Mild to 
moderate AD 
(MMSE 11-24) 
Est. 840 Up to 48 months Cognition (ADAS-
Cog) and function 
(ADCS-ADL) 
- - - Not yet available 
Mulnard 2000 47 Estrogen (0.625 
or 1.25 mg/d) 
Women with 
mild to 
moderate AD 
(MMSE 12-28) 
120 12 months Global change 
(CGIC) 
Global function, 
cognition, mood, 
function 
19.2% ITT; ordinal 
logistic 
regression with 
LOCF 
No effect on primary or 
secondary endpoints 
Aisen 2000 48 Prednisone (10-
20mg) 
Mild to 
moderate AD 
(MMSE 13-26) 
138 12 months Cognitive change 
(ADAS-Cog) 
Global status, 
Depression 
21.7% ITT; ANCOVA 
with imputation 
of mean decline 
of treatment 
group 
No effect on cognitive decline 
compared to placebo 
Courtney / 
AD2000 49 
 
Donepezil (5-
10mg/day)  
Mild to 
moderate AD 
566 (486 
entered 
long-
term 
phase) 
Treatment given 
for as long as 
judged 
appropriated – 14 
months initially 
Entry to 
institutional care; 
progression of 
disability (loss of 
basic or 
Functional ability, 
behavioural and 
psychological 
symptoms, cognition, 
caregiver 
- Survival 
analysis 
No effect on 
institutionalisation or 
progression to disability 
 
Significant effect at 2 years on 
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Author / Trial 
name 
Intervention 
[type*] 
Study 
Population 
N Follow-up Primary 
endpoint(s) 
Secondary 
endpoints 
Attrition§ Data analysis 
& methods for 
handling 
missing data# 
Results 
planned instrumental, 
activities on the 
BADL) 
psychological 
wellbeing, death 
from AD 
cognition and function 
* ClinicalTrials.gov identifier; § At study end unless otherwise specified (includes deaths); # For primary endpoint 
 
AD: Alzheimer’s disease; ADAS-Cog: Alzheimer’s Disease Assessment Scale – Cognitive subscale; ADFACS: Alzheimer’s disease Functional Assessment and Change Scale; ANCOVA: 
analysis of covariance; ANOVA: analysis of variance; BADL: Bristol Activities of Daily Living; CDR: Clinical Dementia Rating; CDR-SB: Clinical Dementia Rating – Sum of Boxes; CGIC: 
clinical global impression of change; CIBIC-plus: Clinician Interview Based Impression of Severity - plus caregiver interview; GBS: Gottfries-Brane-Steen scale; ITT: intention to treat; 
LOCF: last observation carried forward; MMSE: Mini Mental Status Examination; OC: observed case; PDS: Progressive Deterioration Scale; PP: per protocol; QOL: quality of life; 
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TABLE 2 - PHASE III CLINICAL TRIALS OF DISEASE-MODIFYING TREATMENTS FOR PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE 
Author / Trial 
name* 
Intervention [type*] Study 
Population 
N Follow-
up 
Primary 
endpoint(s) 
Secondary 
endpoints 
Attrition§ Data analysis & methods for 
handling missing data# 
Results 
Aisen 2008 / 
VITAL 50 
High-dose 
supplements (5 mg/d 
of folate, 25 mg/d of 
vitamin B6, 1 mg/d of 
vitamin B12) [DM] 
Mild to 
moderate AD 
(MMSE 14-26) 
409 18 
months 
Cognitive change 
(ADAS-Cog) 
Cognition, function, 
global status, QOL, 
neuro-psychiatric 
disorders 
15.9% ITT; GEE No beneficial effects on 
primary endpoint 
NCT00088673 Tramiprosate (3APS/ 
Alzhemed) 
Mild to 
moderate AD 
(MMSE 16-26) 
1052 18 
months 
Cognitive (ADAS-
Cog) and global 
(CDR-SB) change 
Brain volume change 
(MRI) 
- - No significant effects 
NCT00217763 Tramiprosate (3APS/ 
Alzhemed) 
Mild to 
moderate AD 
(MMSE 16-26) 
Est. 
930 
18 
months 
Cognitive (ADAS-
Cog) and global 
(CDR-SB) change 
- - - Trial discontinued 
NCT00574132 Bapineuzumab Mild to 
moderate AD 
(MMSE 16-26); 
APOE Ɛ4 non-
carriers 
Est. 
1300 
18 
months 
Cognition and 
function 
(instruments not 
reported)  
Cognition, global 
status 
- - Trial ongoing 
NCT00676143 Bapineuzumab Mild to 
moderate AD 
(MMSE 16-26); 
APOE Ɛ4 
carriers 
Est. 
800 
18 
months 
Cognition and 
function 
(instruments not 
reported) 
 
Cognition, global 
status 
- - Trial ongoing 
NCT00675623/ 
CONNECTION 
Dimebon (5mg or 
20mg) 
Mild to 
moderate AD 
(MMSE 10-24), 
not using ChEI 
or memantine 
Est. 
525 
6 
months 
Cognition (ADAS-
Cog) and global 
function (CIBIC-
Plus) 
Function, neuro-
psychiatric 
symptoms 
- - No effect on primary or 
secondary outcome 
measures compared to 
placebo 
NCT00829374 Dimebon (5mg or 
20mg) 
Mild to 
moderate AD 
(MMSE 12-24), 
using donepezil 
Est. 
1050 
 
12 
months 
Function (ADCS-
ADL) and 
cognition (ADAS-
Cog) 
Global status, neuro-
psychiatric 
symptoms, resource 
utilization, QOL 
- - Trial ongoing 
NCT00904683 Solanezumab 
(LY2062430) (400mg 
IV every 4 weeks) 
Mild to 
moderate AD 
(MMSE 16-26) 
Est. 
1000 
19 
months 
Cognition (ADAS-
Cog) and 
function (ADCS-
ADL)  
Global status, neuro-
psychiatric 
symptoms, vMRI, 
cognition, resource 
utilization, QOL, 
plasma Aβ 
- - Trial ongoing 
NCT00905372 Solanezumab 
(LY2062430) (400mg 
IV every 4 weeks) 
Mild to 
moderate AD 
(MMSE 16-26) 
Est. 
1000 
19 
months 
Cognition (ADAS-
Cog) and 
function (ADCS-
ADL)  
Global status, neuro-
psychiatric 
symptoms, vMRI, 
cognition, resource 
utilization, QOL, 
- - Trial ongoing 
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Author / Trial 
name* 
Intervention [type*] Study 
Population 
N Follow-
up 
Primary 
endpoint(s) 
Secondary 
endpoints 
Attrition§ Data analysis & methods for 
handling missing data# 
Results 
plasma Aβ 
NCT00594568 Semagacestat 
(LY450139) (100mg 
or 140mg/d) 
Mild to 
moderate AD 
(MMSE 16-26) 
Est. 
1500 
24 
months 
Cognitive and 
functional 
decline (outcome 
measures not 
stated) 
FDG-PET, vMRI, AV-
45-PET, CSF tau, QOL 
- - Trial stopped based on 
preliminary results 
(treatment did not slow 
disease progression, and 
was associated with a 
worsening of cognitive 
and functional measures) 
NCT00762411/ 
IDENTITY-2 
Semagacestat 
(LY450139) (60 - 
140mg/d) 
Mild to 
moderate AD 
(MMSE 16-26) 
Est. 
1100 
 
24 
months 
Cognitive (ADAS-
Cog) and 
functional 
(ADCS-ADL) 
decline  
Cognition, global 
status, neuro-
psychiatric 
symptoms, resource 
utilization, QOL, 
FDG-PET, vMRI,  CSF 
tau 
- - Trial stopped based on 
preliminary results 
(treatment did not slow 
disease progression, and 
was associated with a 
worsening of cognitive 
and functional measures) 
NCT00104013 Xaliproden 
(SR57746A) 
Mild to 
moderate AD 
(MMSE 16-26) 
1455 18 
months 
Cognitive (ADAS-
Cog) and global 
(CDR-SB) status 
Cognition, function - ITT; Random coefficient 
regression model 
No clinical benefit 
NCT00103649 Xaliproden 
(SR57746A) 
Mild to 
moderate AD 
(MMSE 16-26) 
1306 18 
months 
Cognitive (ADAS-
Cog) and global 
(CDR-SB) status 
Cognition, function - ITT; Random coefficient 
regression model 
No clinical benefit 
Feldman 2010 / 
LEADe 51 
Atorvastatin 
(80mg/d) 
Mild to 
moderate AD 
(MMSE 13-25), 
using donepezil 
640 18 
months 
Change in 
cognitive (ADAS-
Cog) and global 
function (ADCS-
CGIC) 
Neuro-psychiatric 
symptoms, cognition, 
global status, 
function 
29.2% Modified ITT (all randomized 
subjects who took at least 1 
dose and provided baseline 
and at least 1 post-baseline 
measurements); least-squares 
mean repeated-measures 
analysis 
No significant differences 
compared to placebo on 
primary or secondary 
endpoints 
NCT00053599/  
CLASP 
Simvastatin (20-
40mg/d) 
Mild to 
moderate AD 
(MMSE 12-26) 
Est. 
400 
18 
months 
Change in 
cognitive (ADAS-
Cog) and global 
function (ADCS-
CGIC) 
Cognition, function, 
behavioural 
disturbances, QOL, 
economic indicators 
- - Not yet reported 
Green 2009 52 
 
Tarenflurbil (R-
flurbiprofen) (400mg 
or 800mg twice a 
day) 
Mild AD (MMSE 
20-26) 
1684 18 
months 
Cognitive (ADAS-
Cog) and 
functional 
(ADCS-ADL) 
change 
Global function, 
cognition, neuro-
psychiatric 
symptoms, QOL, 
caregiver burden 
37.7% ITT; ANCOVA with z-score 
LOCF 
No effect on primary 
endpoints 
Quinn 2010 53 
 
DHA (2g/day) Mild to 
moderate AD 
(MMSE 14-26) 
402 18 
months 
Cognitive (ADAS-
Cog) and global 
(CDR-SB) status 
Function, neuro-
psychiatric 
symptoms 
26.6% ITT, linear mixed effects 
regression models 
No effect on primary 
endpoints 
NCT00818662 Immune Globulin 
Intravenous, 10% 
(400mg/kg every 2 
weeks) 
Mild to 
moderate AD 
(MMSE 16-26) 
Est. 
360 
18 
months 
Cognition and 
global function 
(instruments not 
stated) 
Cognition, global 
function, activities of 
daily living, behavior, 
QOL 
- - Ongoing 
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* For unpublished studies, the ClinicalTrials.gov identifier is given (NCT….); § At study end unless otherwise specified (includes deaths); # For primary endpoint 
Aβ: amyloid beta; AD: Alzheimer’s disease; ADAS-Cog: Alzheimer’s Disease Assessment Scale – Cognitive subscale; ADCS-ADL: Alzheimer’s Disease Cooperative Study – Activities of 
Daily Living; APOE: Apolipoprotein E; CDR-SB: Clinical Dementia Rating – Sum of Boxes; ChEI: cholinesterase inhibitor; CIBIC-plus: Clinician Interview Based Impression of Severity - 
plus caregiver interview; CSF: Cerebrospinal fluid; Est. : estimated; FDG-PET: (18) fluoro-2- deoxyribose - positron emission tomography; GEE: generalized estimating equations; ITT: 
intention to treat; MMSE: Mini Mental Status Examination; MRI: magnetic resonance imaging; QOL: quality of life; vMRI: volumetric magnetic resonance imaging  
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1.3 METHODOLOGICAL EXPLANATIONS FOR INCONSISTENT RESULTS IN 
PREVENTION STUDIES FOR ALZHEIMER’S DISEASE 
Given the long preclinical period of AD before the onset of symptoms, it would appear to be 
accessible to prevention strategies, and indeed it may be that disease modifying treatments are 
most effective individuals at earlier stages of the disease process before biological damage to the 
brain becomes too widespread.  Observational epidemiological studies have suggested a number 
of potentially protective factors for AD, but few primary prevention trials have been carried out 
to date 54-56, and so far, just as with trials carried out in symptomatic patients, results have been 
disappointing.  Interventions tested in primary prevention trials have mainly been based on 
epidemiological evidence from observational studies, rather than the specific development of a 
pharmacological intervention targeting a particular part of the disease process.  An initial 
literature review was carried out to identify and characterise the methodological aspects of 
RCTs testing interventions for the prevention of cognitive decline, dementia or Alzheimer’s 
disease.  This work has been published in the Journal of Alzheimer’s Disease (see Appendix; 
article 1): 
Coley N and Andrieu S, Aisen P et al.  
Methodological issues in primary prevention trials for neurodegenerative dementia.  
Journal of Alzheimers Disease 2009; 16(2): 235-70 
 
The interventions tested so far include nutritional supplements (homocysteine-lowering 
vitamins [folate, vitamins B6/B12], vitamin E, multivitamins); physical exercise; cognitive 
training; hormone replacement therapy (HRT); non-steroidal anti-inflammatory drugs (NSAIDs: 
aspirin, naproxen, celecoxib); ginkgo biloba, and anti-hypertensive treatments.  Target 
populations were primarily defined by age, although eligibility criteria for some trials were also 
based on AD risk factors such as memory complaints, family history of dementia, or nutritional 
status (for nutritional interventions).  Follow-up periods ranged from 3 to 8.5 years for studies 
measuring dementia incidence, and were shorter for those measuring only cognitive decline.  
The methods and results of the trials that assessed dementia incidence or cognitive decline as a 
primary endpoint are summarised in Table 3 (page 36).   
 
As shown in Table 3, the vast majority of prevention trials carried out so far have not been able 
to demonstrate a positive effect of the intervention tested on the prevention of AD or cognitive 
decline, even though longitudinal observational studies have provided relatively consistent 
evidence regarding the factors investigated.  A second literature review was therefore 
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undertaken to compare the results of longitudinal observational studies and RCTs carried out in 
the field of AD prevention, and to identify methodological inconsistencies which could help to 
explain differences in results between observational and interventional studies targeting the 
same intervention.  The full review has been published in Epidemiologic Reviews (see Appendix: 
article 2): 
Coley N, Andrieu S, Gardette V, Gillette-Guyonnet S, Sanz C, Vellas B, Grand A.  
Dementia prevention: methodological explanations for inconsistent results.  
Epidemiologic Reviews 2008; 30: 35-66 
 
The main conclusions from this work are summarised below.   
METHODOLOGICAL PROBLEMS IN OBSERVATIONAL STUDIES 
A first explanation for these differing results can be focused on the methodology of the 
observational studies.  By design, observational studies are more prone to bias and confounding 
than RCTs, which are generally considered the “gold standard” of epidemiological research 57.  A 
whole range of potential biases can invalidate the results of observational studies 58.  We only 
included prospective longitudinal studies in our review in order to ensure that temporal 
relationships were properly accounted for.  However, other forms of bias that we identified as 
being particularly problematic in observational studies assessing risk factors for AD include: 
1. Measurement bias 
An example of potential measurement bias was observed in longitudinal studies assessing 
diabetes as a risk factor for cognitive decline or dementia.  In two studies 59-60, diabetes was only 
assessed through self-reports, rather than objective biological measurements, meaning that the 
exposure measurement could have been biased.  Also, it was noted that longitudinal studies of 
nutritional factors may also be particularly prone to recall and measurement bias as intakes 
were often quantified based on self-reported questionnaires only. 
2. Confounding 
Confounding is a major risk for observational studies, especially when it arises from unknown or 
unmeasurable factors.  Longitudinal studies assessing the effects of social engagement or activity 
participation on cognition in later life may have been particularly affected by confounding since 
the level of social engagement or activity participation could also be an indicator of previous life 
experiences 61, such as education level or socio-economic status.  All of the longitudinal studies 
we reviewed controlled for subjects’ level of education in their analyses, but only a few included 
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other indicators of social economic status.  Social engagement and activity participation could 
also be indicative of a good lifestyle in general, and so the seemingly protective effect of such 
activities may actually reflect a protective effect of an overall healthy lifestyle.  Other 
confounders which could affect social engagement or activity participation include depression, 
general health status and personality, but these factors were not always considered 62.   
3. Healthy user bias 
Healthy user bias is particularly problematic for studies assessing pharmacological prevention 
strategies, such as HRT.  In observational studies, women treated with HRT tend to be more 
educated and healthier than non-treated and women and have an overall healthier lifestyle 63-70.  
In particular, they are less likely to have potential contraindications to HRT, including vascular 
risk factors which are also risk factors for dementia, thus potentially confounding associations 
between HRT and dementia.   
4. Protopathic bias 
A low level of exposure to a protective factor (e.g. a low level of social engagement or activity 
participation) may be indicative of the onset of a neurodegenerative process that is not yet 
clinically apparent.  However, we noted that in most domains where this was applicable, the 
authors of observational studies made particular attempts to control for this form of bias.   
5. Attrition bias   
A general problem in longitudinal studies, and one that is emphasised in studies of older people, 
is that of attrition, i.e. the loss of participants during follow-up.  Since older people who drop out 
of or can no longer be contacted during population-based longitudinal studies are likely to be in 
poorer health than continuing participants 71, the remaining sample may be biased, which could 
threaten the validity of the results obtained.   
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TABLE 3 - PRIMARY PREVENTION TRIALS FOR ALZHEIMER’S DISEASE OR COGNITIVE DECLINE OF AT LEAST SIX MONTHS DURATION 
Author / Trial 
Name 
Intervention Study Population N Follow-up Primary 
endpoint 
Main 
secondary 
endpoints 
Attrition* Data 
analysis§ 
Results 
DeKosky / GEM 
study 55 
Ginkgo biloba extract (240mg) Volunteers aged 75 
years or older with 
normal cognition or 
MCI 
3069 median 
6.1 years 
Incident 
dementia and AD 
(DSM-IV) 
Cognitive 
decline 
18.7% ITT; Survival 
analysis 
No effect on dementia 
incidence 
Vellas / 
GuidAge 72-73 
Ginkgo biloba extract (240mg) Adults aged ≥70 
years with 
spontaneously 
reported subjective 
memory complaints, 
MMSE≥26 
2854 5 years Incident AD 
(DSM-IV, 
NINCDS-ADRDA) 
Cognitive 
decline 
31.1% ITT; Survival 
analysis 
No effect on overall AD 
incidence 
ADAPT 54 Naproxen (220mg bid) or 
celecoxib (200mg bid) 
≥ 70 years, first-
degree relatives 
with AD-like 
dementia, free of 
dementia and 
cognitive 
impairment 
2528 5 years 
(planned) 
Incident AD 
(DSM-IV, 
NINCDS-ADRDA) 
Cognitive 
decline 
11% after 
mean FUP 
of 21 mo 
ITT; Survival 
analysis 
No effect on AD incidence 
(trial terminated early) 
Schumaker / 
WHIMS 56 
Estrogen (0.625mg) +/- 
progestin (2.5mg) 
Post-menopausal 
women aged 65 - 79 
years 
4532 + 
2947 
5-8 years 
(planned) 
Incident 
dementia and AD 
(DSM-IV) 
MCI 
incidence 
- ITT; Survival 
analysis 
Estrogen therapy alone 
did not reduce dementia 
or MCI incidence and 
increased the risk for both 
endpoints combined. 
 
Estrogen plus progestin 
increased the risk for 
probable dementia 
PREADVISE  Selenium (200 µg/d)  and/or 
vitamin E (400 IU/d) 
Men aged ≥ 60 
years, free of 
dementia 
10700 
(projected) 
9-12 years Incident AD - (trial 
ongoing) 
- Trial ongoing 
Sano / 
PREPARE 74 
Estrogen (0.625 mg/d) +/- 
progestin (2.5mg) 
women, aged ≥ 65 
years, family history 
of AD 
900 
(planned) 
3 years 
(planned) 
Incident AD 
(NINCDS-ADRDA) 
and memory 
decline 
(immediate & 
delayed recall of 
verbal and non-
verbal memory)
  
- (trial 
ongoing) 
- Intervention stopped, 
results not yet available 
Lautenschlager 
/ FABS 75 
Home-based 24-week physical 
activity intervention 
Adults aged ≥50 
years  with memory 
problems but free of 
dementia 
170 1.5 years Change in 
cognitive function 
(ADAS-Cog) 
Other 
measures of 
cognition 
18.2% ITT; Multiple 
imputation 
and mixed-
effect model 
Intervention was 
associated with a modest 
improvement in cognition 
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Author / Trial 
Name 
Intervention Study Population N Follow-up Primary 
endpoint 
Main 
secondary 
endpoints 
Attrition* Data 
analysis§ 
Results 
with repeated 
measures 
Eussen 76 Vitamin B12 (1000µg) +/- folic 
acid (400µg) 
≥ 70 years, mild 
vitamin B deficiency, 
MMSE ≥19 
195 6 months Change in 
cognitive function 
(word fluency)  
Other 
measures of 
cognition 
16.9% 
 
PP; mixed 
models 
No improvement in 
cognitive function 
Wolters 77 Multivitamins (150mg vitC, 50 
mg magnesium, 36mg vitE, 
16mg pantothenic acid, 9 mg 
beta-carotene, 3.4mg 
pyridoxine, 3.2mg riboflavin, 
2.4mg thiamine, 400µg folic 
acid, 200µg biotin, 60µg 
selenium, 9µg cobalamin) 
healthy women aged 
≥ 60 years 
241 6 months Change in 
cognitive function 
(WAIS-III symbol 
search) 
Other 
measures of 
cognition 
8.7% PP No effect on cognitive 
performance 
Kang / WHS – 
cognitive 
substudy 78-79 
Vitamin E (600 IU on alternate 
days) or aspirin (100mg on 
alternate days) 
≥ 65 years, women 6377 4 years 
(cognitive 
follow-up) 
Change in 
cognitive function 
(composite score) 
Verbal 
memory 
- General linear 
models for 
repeated 
measures 
No effect of either 
treatment on cognition    
McMahon 80 Folate (1000µg) + vitB6 (10mg) 
+ vit B12 (500µg) vs. placebo 
healthy subjects, 
aged ≥65 years, with 
raised plasma 
homocysteine 
concentrations, free 
of dementia 
276 2 years Change in 
cognitive function 
(COWAT, Rey 
Auditory Verbal 
Learning Test) 
Other 
measures of 
cognition 
8.3% CC; GEE No improvement in 
cognitive function 
Dangour / OPAL 
81  
n-3 long-chain polyunsaturated 
fatty acids (0.5 g 
docosahexaenoic acid and 0.2 g 
eicosapentaenoic acid) 
70-79 years, MMSE 
≥24 
867 2 years Change in 
cognitive function 
(CVLT) 
Other 
measures of 
cognition 
13.7% ITT, ANCOVA No improvement in 
cognitive function 
Binder 82 Conjugated estrogens 
(0.625mg) plus trimonthly 
medroxyprogesterone acetate 
(5 mg/d for 13 days) 
≥ 75 years, post-
menopausal women, 
free of dementia 
67 9 months Change in 
cognitive function 
(battery of 
cognitive tests, 
primary test not 
defined) 
- 16.4% PP; t-test of 
mean change 
No effect on any cognitive 
measure 
Oken 83 Yoga (1 class/ wk) or aerobic  
exercise (1 class/wk) 
65-85 years 135 6 months Change in 
cognitive function 
(Stroop Test) 
Other 
measures of 
cognition 
12.6% CC; ANCOVA No effect on cognitive 
function 
Willis / ACTIVE 
84 
cognitive training interventions 
(memory, reasoning, or speed) 
≥ 65 years, 
MMSE>22 
2832 5 years Functional 
abilities 
Other 
measures of 
cognition 
33% ITT; mixed 
effects model 
Reasoning training 
resulted in less functional 
decline in self-reported 
IADL.  Compared with the 
control group, cognitive 
training resulted in 
improved cognitive 
abilities specific to the 
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Author / Trial 
Name 
Intervention Study Population N Follow-up Primary 
endpoint 
Main 
secondary 
endpoints 
Attrition* Data 
analysis§ 
Results 
abilities trained that 
continued 5 yrs after the 
initiation of the 
intervention 
Dodge  / Oregon 
Study 85 
Ginkgo biloba extract (240mg) ≥ 85 years; CDR=0; 
MMS > 23 
118 3.5 years Mild cognitive 
decline (CDR 0 to 
0.5) 
Decline in 
memory 
function  
33.1% Survival 
analysis 
Ginkgo biloba had no 
effect on cognitive or 
memory decline overall.  
In a secondary analysis, a 
protective effect of ginkgo 
biloba was seen in 
compliant subjects 
Ho 86 Soy-derived isoflavones 
(80mg/d) 
Post-menopausal 
community dwelling 
women aged 55-76 
years, free of 
dementia 
191 6 months Change in 
cognitive function 
(battery of 
cognitive tests, 
primary test not 
defined) 
- 12.0% Modified ITT; 
repeated 
measures 
ANOVA 
No effect on cognitive 
function 
Yaffe 87 Ultra low dose estradiol patch 
 (0.014mg/d) 
Postmenopausal 
women aged 60-80 
417 2 years Change in 
cognitive function 
(battery of 
cognitive tests, 
primary test not 
defined) 
HRQOL 9.8% ITT; mixed 
linear 
regression 
No effect on change in 
cognitive function 
Williamson / 
ACCORD-MIND 
88 
Intensive glycemic control; 
treatment to increase HDL 
cholesterol and lower 
triglycerides; and intensive 
treatment of systolic blood 
pressure 
Age ≥55 years; type 
2 diabetes being 
treated with open-
label simvastatin 
2977 4 years Cognitive 
function (Digit 
Symbol 
Substitution Test) 
Other 
measures of 
cognition; 
total brain 
volume 
(MRI) 
(trial 
ongoing) 
- Results not yet published 
Gillette-
Guyonnet  / 
MAPT 89 
Multidomain intervention 
(nutritional advice, physical 
exercise, cognitive training); 
omega 3 (docosahexaenoic acid; 
800 mg /d) 
Frail older adults, 
aged 70 years and 
over 
1680 3 years Cognitive 
function (Free & 
Cued Selective 
Reminding Test) 
Other 
cognitive 
measures; 
neuro-
imaging  
(trial 
ongoing) 
- Trial ongoing 
*At study end unless otherwise specified (includes deaths) 
§ For primary endpoint 
- not reported 
 
 
39 
 
OTHER METHODOLOGICAL EXPLANATIONS 
Aside from the problems of bias and confounding in observational studies, a number of other 
methodological explanations were proposed to explain the inconsistencies in results between 
observational and experimental studies: 
1. Study population 
One of the problems in prevention trials is the selection of the study population.  Observational 
studies tend to be either population-based, or at least aim to be representative of a given 
population.  However, the people who agree to participate in prevention trials for AD are a 
highly selected population of individuals who probably differ to those who do not take part in 
terms of education, health behaviours and general lifestyle 90.  Indeed, lower than expected 
incidence rates of AD are a common problem in prevention trials, perhaps because participants 
are “too healthy”, meaning that they can be underpowered to detect treatment effects.      
Also, those enrolled in prevention trials are probably those who are least susceptible to the 
intervention, since they may already have a relatively healthy lifestyle in terms of diet, exercise, 
social contacts etc, or they may already be receiving nutritional fortification through public 
health measures.  A trial of vitamin supplementation may be more beneficial in those with poor 
nutritional status, than in those who already have sufficient intakes.  Of seven trials testing the 
effects of homocysteine-lowering vitamins (vitamins B6, B12 and/or folic acid) on cognitive 
performance or cognitive decline 76, 80, 91-95, only one found consistent positive effects on multiple 
cognitive domains.  This trial targeted older individuals with raised homocysteine levels, which 
could explain the difference in results with other trials, although it should be noted that three 
other trials 76, 80, 95 found no effect of supplementation in subjects with particular nutritional 
deficiencies.   
2. Design of the intervention  
There may also be major differences between the nature of the interventions used in prevention 
trials, and the nature of the risk/protective factors studied in observational studies.  This 
problem can be illustrated by the variety of vitamin doses used in nutritional studies.   For 
example, folate supplements ranged from 200µg 96 to 2500µg 94 per day in intervention trials.  
The lowest dose used was lower than the US RDA (400µg/day). In the FACIT trial 92, which found 
folate supplementation to have beneficial effects on cognitive decline, 800µg was given daily to 
elderly individuals with raised homocysteine concentrations.  Two trials 80, 94 used higher doses 
of folate, but detected no cognitive benefits.  A longitudinal study 97 found those in the highest 
quintile of folate intake (≥ 487.9µg) to have a lower risk of developing AD than those in the 
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lowest quintile (≤292.9µg), but it is unlikely that those in the highest quintile had intakes as high 
as those used in some RCTs.  Therefore, it may be that results regarding the prevention of 
dementia through nutritional supplementation varied across different studies due to the doses 
of vitamins used.  The form of vitamins may also be important. Vitamin E exists in several 
different forms, more than one of which may be required for a protective effect on cognition 98.  
In the Women's Health Study, a supplement containing only the α-tocopherol form was used, 
and no effect was observed on cognition 78.  Furthermore, the duration of exposure to the factor 
under study is also likely to be an important factor, and may differ between observational and 
interventional studies.   
3. Window of exposure 
Another potential difference between observational and interventional studies is the "window of 
exposure", i.e. the time of life at which individuals are exposed to the intervention.  This has been 
particularly discussed in the domain of HRT, since much of the observational evidence pointed 
towards a protective effect of HRT, whereas the largest intervention trial showed that HRT was 
actually associated with an increased risk of dementia 56.  It has been suggested that HRT needs 
to be started around the immediate post-menopausal period for a beneficial effect 99-104 but the 
participants enrolled in prevention trials were perhaps too old (65 years and older at baseline) 
and so the appropriate window of exposure may have been missed.  Likewise, some 
observational evidence suggests that NSAIDs or antihypertensive drugs may be more beneficial 
against dementia or cognitive decline if started in midlife 105-106, but prevention trials using these 
drugs have so far only been carried out in late life.   
4. Duration of intervention and follow-up 
Another difference between observational and intervention studies was the duration of follow-
up.  For example, in studies in the domain of nutrition, the duration of follow-up in the 
longitudinal studies was generally 3 years or more, but only 2 RCTs 78, 92 were of similar length.  
The duration of both supplementation and follow-up may affect observed effects on cognition in 
RCTs, but the Women's Health Study did not observe any cognitive benefits after more than 9 
years of vitamin E supplementation.   
5. Outcome measures 
The outcome measures used in observational and interventional studies could also explain some 
of the conflicting results.  For example, all of the prevention trials testing a nutritional 
supplement assessed the effects of the intervention on cognitive decline, but many observational 
studies assessed the association between nutrients and dementia incidence rather than 
41 
 
cognitive decline.  It has not yet been proven that cognitive decline is a surrogate marker for the 
onset of dementia, and so the two endpoints cannot be used interchangeably.  Furthermore, 
numerous cognitive tests exist which can target either global cognitive function, or individual 
cognitive domains, such as episodic memory or executive function, and so a positive effect may 
be observed with certain measures but not others.   
6. Insufficient statistical power 
Some of the smaller trials, in particular those testing HRT 82, 107-109 or Ginkgo biloba 85, 110-111 did 
not report a sample size calculation and so it was not possible to determine whether or not they 
were sufficiently powered to be able to detect treatment effects.  However, given the small 
numbers of participants and short length of follow-up, many were likely to be statistically 
underpowered.  Other trials did report sample size calculations, but some were still 
underpowered due to lower than expected cognitive decline or dementia incidence 72, 81.  This is 
a particular problem in prevention trials due to the selection of the study population, as 
discussed above.  Statistical power may also have been insufficient in some trials due to a higher 
than expected dropout rate 72  
7. Attrition bias 
In addition to affecting statistical power, attrition may also affect the detection of treatment 
effects in RCTs through bias.  For example, in the SHEP study, which found no effect of 
antihypertensive-treatment on cognitive decline or dementia, sensitivity analyses suggested that 
differential dropout may have obscured potential treatment effects 112. Some other trials of 
antihypertensives reported high rates of dropout 113 or discontinuation of study medication 114, 
which could have affected results.    
     
42 
 
1.4 THESIS AIMS 
The overall aims of this work were to identify the major methodological problems in clinical 
trials for the prevention or treatment of AD, and to examine in more detail issues relating to 
endpoints and missing data in order to provide solutions for future trials, using data from 
longitudinal studies of AD patients (the results obtained from such analyses can be used to 
inform the design of future clinical trials), and data from randomised controlled trials for the 
prevention or treatment of AD.  The focus of this work is trials for mild-moderate AD, and 
prevention trials.  
The specific questions addressed were: 
1. How high are attrition rates in AD trials, and are they higher than in clinical trials 
in other domains? 
2. What can be done during the planning and implementation stages of AD trials to 
limit attrition? 
3. How can statistical analyses in AD trials be optimised in the presence of missing 
data? 
4. Is it advantageous to use a single primary endpoint instead of two co-primary 
endpoints in AD trials, and could a currently available global measure be a 
suitable single primary endpoint? 
5. In prevention trials, how useful is cognitive decline as a primary endpoint, and 
can it be used as a surrogate for dementia incidence? 
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2. ATTRITION AND MISSING DATA  
2.1 INTRODUCTION 
2.1.1 MISSING DATA IN ALZHEIMER’S DISEASE STUDIES 
Missing data due to dropouts, or attrition, is a long-recognised problem in longitudinal studies 
115-116.  However, missing data, whether brought about by intermittent missed evaluations or 
dropout, are also a major source of potential bias in clinical trials 117. A high level of missing data 
may threaten the internal and external validity of a trial.  If, for example, subjects who complete 
a trial differ systematically from those who drop out before the end of the follow-up period, the 
remaining sample may be a biased representation of the initial study population and any results 
based on just those who complete the trial may not be generalisable to other populations. Thus, 
missing data can affect the external validity of clinical trials.  Internal validity, on the other hand, 
may be affected if the fact that data are missing is related to the outcome under study. Treatment 
effectiveness may be over- or under-estimated depending on the reasons for missing data (e.g. 
adverse events or perceived lack of efficacy) and the methods used to take into account missing 
data in analyses.  
However missing data arise and whatever the reason for the missingness, a loss of statistical 
power is likely to result, due to decreasing numbers of participants and greater variability in 
estimations.    
In AD trials, the problem of missing data is exacerbated by a number of factors, many of which 
are related to the nature of the disease, for example, decreasing autonomy, worsening health, 
frailty, institutionalisation, hospitalisation or death 118.  Furthermore, in light of the age of AD 
patients, there is a high risk of co-morbidities which may also affect health status and trial 
participation.  Withdrawals or refusals in AD trials may be particularly high because of the 
demanding nature of the evaluations used. In cardiovascular or cancer clinical trials, the primary 
endpoint is typically the occurrence of a distinct event, such as death or recurrence of a certain 
type of cancer or a cardiovascular event.  However, in AD, the use of mortality endpoints is not 
feasible due to the very large sample sizes or follow-up periods that would be required, as well 
as competing risks of death from other causes given the age of AD patients, and there are no 
other unequivocal events that could be measured 119. Therefore, current primary endpoints in 
AD trials are based on clinical measures of cognitive or functional status as well as global 
evaluations 120. The clinical evaluations required to assess these endpoints are generally time-
consuming and are usually carried out a number of times throughout the trial. Phase 3 trials for 
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disease modifying drugs typically require 12-18 months follow-up, with evaluations often taking 
place every 6 months. Thus, participating in a clinical trial may represent a significant burden for 
AD patients, as well as their caregivers who are usually required to accompany patients to study 
visits in order to complete proxy evaluations and for the measurement of caregiver outcomes, 
such as the level of caregiver burden.  Missing data in AD trials can therefore also arise from 
factors related to the caregiver, such as his or her health status (bearing in mind that the 
caregiver is often the spouse of the AD patient and so may also be elderly with various health 
problems), as well as the level of caregiver burden 121.  Furthermore, dropout from clinical trials 
may occur due to a perceived lack of efficacy, because disease-modifying AD drugs may be slow 
acting or have only modest effects.   
Examples of rates of missing data and methods used to handle missing data in primary and 
sensitivity analyses in long-term RCTs published in major journals, as well as AD RCTs were 
identified as part of a literature review on the subject of attrition in geriatric research.  The 
information about AD trials is included in Table 1 (page 27). The entire review has been 
published in the Journal of Nutrition, Health and Aging (see Appendix; article 3): 
Gardette V, Coley N, Toulza O, Andrieu S. 
Attrition in geriatric research: how important is it and how should it be dealt with? 
J Nutr Health Aging. 2007;11(3):265-71.   
 
Although a high rate of attrition seems almost inevitable in AD trials, it is still important to try 
and limit where possible this phenomenon 122.  Bonding and tracking are some of strategies used 
to try and limit attrition and missing data in clinical studies 123-124, and the identification of 
factors that are predictive of dropout or missing data can help to tailor such strategies to 
subjects at most risk of dropping out, and may also suggest potentially modifiable factors.  
However, even if special efforts are made to try and limit the number of dropouts, there will 
always be a certain level of missing data in AD trials which must be considered when analysing 
and interpreting trial results.   
2.1.2 MISSING DATA MECHANISMS AND CLASSIFICATIONS 
Several general classifications have been proposed to describe missing data in research studies. 
Firstly, in longitudinal studies a distinction can be made between “monotone” and “non-
monotone” missing data.  In the case of dropout, missing data are described as “monotone”; data 
are collected up to a certain time point, after which the subject drops out of the study and no 
more evaluations are performed 125.  Non-monotone missing data, on the other hand, arise when 
only certain evaluations or visits are missed, potentially at various different time points, after 
which the subject continues to participate in the study as normal.   
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A widely used classification system for missing data was proposed by Little and Rubin 126-127. 
They suggest that missing data arise through three different mechanisms.  Firstly, data may be 
considered as missing completely at random (MCAR) if they are missing for reasons completely 
unrelated to the observed and unobserved data, and dropout and the outcome of interested are 
independent.  For example, a subject may drop out of a study because of moving house, a single 
visit may be missed due to a public transport strike, or certain data may be lost due to an 
administrative error. In all of these cases, data can be considered to be MCAR.  However, in 
reality, most missing data in clinical trials are generally unlikely to be MCAR.  The second 
mechanism proposed for missing data is that they may be missing at random (MAR).  In this 
situation, the reason for missingness depends on data that have already been observed, but not 
on the unobserved (missing) data.  Examples of missing data arising through the MAR 
mechanism include dropout related to baseline characteristics (e.g. patients who are older or 
who have poorer health at baseline may be more likely to dropout than younger subjects or 
those in better health), or dropout because since the beginning of the trial the subjects health 
has markedly improved or deteriorated, as demonstrated by the observed longitudinal data.  
With this mechanism, it is assumed that the future trajectories of subjects who drop out are 
similar to those who share the same past measurements and covariate values, whether or not 
they dropout 128.  Finally, missing data may be considered missing not at random (MNAR) if the 
mechanism is neither MCAR nor MAR.  In this case the missingness depends on the unobserved 
data (i.e. the data that would have been observed had the subject been assessed), even after 
taking into account data already observed. An example of data MNAR might be a subject who 
drops out of a trial due to a sudden decline in health which was not observed at any of the 
previous visits and could not be predicted from any of the observed variables.  If the subject 
attended the next visit, this decline would be recorded, but if the subject drops out then this 
information will be missing.  Evidently, it is impossible to know in a clinical trial if data are 
MNAR because the missingness depends on information that we do not know. We can simply 
hypothesise that data may be MNAR.   
Other classifications that have been proposed for missing data include a distinction between 
ignorable or non-ignorable missingness; data which are MCAR or MAR may be considered as 
ignorable, while data which are MNAR are considered non-ignorable 129.  Non-ignorable missing 
data are also sometimes known as “informative” missing data, with ignorable missing data 
classed as “non-informative” 130.   
Knowledge of or hypotheses regarding the underlying missing data mechanisms in clinical trial 
data are important in order to be able to use adapted statistical methods for data analysis and in 
order to be able to draw plausible and unbiased conclusions about treatment effects. 
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2.1.3 STATISTICAL METHODS FOR HANDLING MISSING DATA 
Intention-to-treat (ITT) is the standard method used in primary analyses of RCTs 131.  ITT 
analyses require that patients be analysed in the groups they were randomised into, regardless 
of whether or not they complied with the treatment they were given.  Strictly speaking, all 
randomised subjects should be included in the analysis. Missing data must therefore be taken 
into consideration and either the missing values be imputed, or the type of data analysis used 
must not exclude subjects with missing data 130.  Various methods have been proposed to handle 
missing data in statistical analyses of longitudinal clinical trials, each with its own underlying 
hypotheses and strengths and limitations which are discussed below.    
However, before choosing a method to handle missing data in analyses, missing data should be 
described, for example, giving the rate of missing data per visit and/or per group, and detailing 
the reasons for missingness or dropout.  Also, for longitudinal data it may be helpful to examine 
the evolution of the disease over time according to the moment of dropout 119.  This may give an 
idea as to the mechanism of missing data, or at least give an indication if data are MCAR or MAR.  
Finally, the characteristics of dropouts and completers can be compared to determine if there 
are any factors associated with dropouts or missing data for certain variables.   
Once the level of missingness and the underlying mechanisms have been considered, there are 
three general approaches to the analysis of incomplete data: (1) analysis of complete cases only; 
(2) imputation of the missing data before analysis; and (3) analysis of incomplete data 130.  The 
principal methods used for each type of approach are outlined below.   
COMPLETE CASE ANALYSIS 
A complete case analysis (also known as “listwise deletion” or “casewise deletion”) includes only 
individuals with complete observations; those with missing data are simply excluded.  In order 
for this type of analysis to be valid, missing data must be MCAR, implying that the subjects 
included in the analysis are a random sample of the initial population.  The advantage of this 
type of analysis is its simplicity, and that it provides a full dataset that can be used with any kind 
of standard analysis technique.  No complicated statistical methods are required to deal with the 
missing data, and many statistical software packages exclude subjects with missing data from 
analysis by default anyway.  However, this type of analysis has many limitations, not least 
because the hypothesis of MCAR is rarely plausible in clinical trials 130.  Also, the sample size may 
be drastically reduced, and as a result, statistical tests will lack power.  Thus, results from a 
complete case analysis will generally be biased, and this type of analysis is only useful if there 
are very few dropouts and the missingness mechanism is MCAR.   
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Available case analysis (also known as “pairwise deletion”) is a similar and also commonly used 
deletion technique, in which cases are removed if they have missing data for the analysis of 
interest.  In this way, a given subject may contribute to some analyses, but not others, and so 
each analysis is based on a different subsample of the original population.  This approach can be 
considered as an improvement over complete case analysis since the loss of statistical power 
will be reduced, but it suffers from the same major limitation in that the missing data must be 
MCAR.   
IMPUTATION 
SIMPLE IMPUTATION 
Simple imputation consists of creating an artificial value with which to replace each missing 
value.  This procedure enables the generation of a “complete” data set which can then be 
analysed as usual.  The values to be imputed can be determined using a variety of different 
techniques, for example replacing missing values by the mean of the observed values of subjects 
in the same treatment group, or the mean value of subjects with similar covariates.  The value to 
be imputed can also be determined through regression analysis based on covariates.  Depending 
on the technique used, missing data must be either MCAR or MAR for simple imputation.  The 
inferences based on datasets completed with simple imputation are only valid if the underlying 
hypotheses (missingness mechanism and imputation model) hold true.  Furthermore, the 
variance of estimated parameters will be underestimated if imputed values are simply treated as 
observed values (especially if there is a high level of missing data) because there is no reflection 
of the sampling variability.  
One simple imputation method that has been widely used in longitudinal clinical trials, including 
AD trials 132-133, is “last observation carried forward” (LOCF).  As the name suggests, any missing 
values for the outcome of interest are replaced by the last observed value of the same subject.  
The main underlying hypothesis of this method is that there is no change in the endpoint being 
measured from the last observed value until the planned study end.  This is a fairly unlikely 
situation in most clinical trials, and especially in progressive diseases such as AD, and so the use 
of LOCF can give rise to biased results (which can be either over- or under-estimated) 125.  
Furthermore, as with other simple imputation methods, a second problem with using LOCF is 
the underestimation of the variance.  Despite widespread criticism of this method 130, 134-138, its 
use persists in clinical trials 22, perhaps because of its simplicity, ease of implementation and the 
belief that the potential bias from using LOCF leads to a “conservative” analysis 133, 139.  Two 
similar methods of imputation are “baseline carried forward” and “worst observation carried 
forward”.   
48 
 
A recent development on the LOCF technique which has been suggested for AD trials is the “Z-
score-LOCF” approach 140.  The aim of this approach is to take into account the disease 
progression that occurs once the patient has dropped out of the study by carrying forward the 
patient’s z-score relative to the group mean at the last observation, rather than carrying forward 
the last observation itself.  For example, if a patient drops out of a trial and at the last completed 
evaluation he/she scored 1 standard deviation below the group mean for a given endpoint, any 
missing data for the same endpoint at future visits will be imputed with a value that is 1 
standard deviation below the group mean at each time point for which observations are missing.  
This approach, which assumes that data are MAR, retains the relative simplicity of LOCF, whilst 
attempting to reduce the associated bias 140.  However, the variability will still be 
underestimated, and the true decline may be underestimated if a patient undergoes rapid 
decline after dropout.  Furthermore, the group means used to impute the data for missed visits 
will only be based on the patients who are still in the trial, but it is likely that these subjects will 
have better scores than those who have dropped out.     
MULTIPLE IMPUTATION 
Multiple imputation was developed by Rubin, and consists of replacing each missing value by a 
series of M plausible values 141. The number of imputations (M) must be ≥2, and traditionally it 
was though that 5 – 10 imputations were generally sufficient in most situations 141-142.  More 
recently, however, it has been suggested that a higher number of imputations should be used, in 
particular in order to retain sufficient statistical power for detecting small effect sizes 143.  Each 
imputed value is drawn from the conditional distribution of the missing observation given the 
observed data (e.g. covariates or scores on the same scale at previous time points) and random 
error variance is introduced in order to restore the lost variability 139, 144.  There are various 
methods for obtaining “plausible” values, including the use of covariate distributions, propensity 
scores, group means or random values contained within the group distribution.   
Each new data set is analysed using a standard method of data analysis, and the results are 
combined, using a series of rules defined by Rubin which take into account within and between 
imputation variance 141, to produce single point and variance estimates.  The final estimation 
obtained through multiple imputation better reflects the uncertainty due to non-response that 
simple imputation methods 127.  When using this approach in the usual manner it is assumed that 
missing data are MAR.  Further assumptions depend on the underlying model used to perform 
the multiple imputation (i.e. the variables included in the imputation model, method of 
imputation, etc.).  This method has a number of advantages, including the fact that it is less 
biased than simple imputation methods 125, it takes into account the variability and incertitude 
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of the value meaning that standard errors are valid, the loss of statistical power is limited, and 
information from covariates can be taken into account even if the covariates are not included in 
the primary analysis of the endpoint.  Furthermore, unlike some of the more complex methods 
for missing data, multiple imputation can be performed using standard statistical software.       
ANALYSIS OF INCOMPLETE DATA 
MAXIMUM LIKELIHOOD ESTIMATION 
Instead of filling in missing values, maximum likelihood methods use all of the available data 
(both complete and incomplete) to identify the population parameter values that have the 
highest probability of producing the sample data using log likelihood functions 145.  Mixed effects 
models are an example of likelihood-based analyses that may be used for the analysis of 
longitudinal data.  Although this approach in itself is not recent, the application of such models 
for the analysis of clinical trials data is a relatively recent development 146.  Mixed effects models 
model jointly all the observations in a longitudinal trial, without imputation or adjustment for 
the missing value mechanism.  Thus all available data from a trial can be used, which may limit 
the loss of power arising from missing data.  Missing data are considered to be MAR with this 
approach.  Treatment effects in longitudinal clinical trials can be estimated using data from all 
time points (a “slopes analysis”), rather than just the change from baseline.  Time trends can 
therefore be better modelled.  Furthermore, the standard error (SE) is properly modelled as this 
approach takes into account the correlations between repeated measures on the same 
individual.  This approach should produce unbiased results if missing data are MCAR or MAR. 
However, it is not adapted to data that are MNAR.   
OTHER METHODS 
Other, more complex statistical methods also exist for the analysis of data with missing 
observations, for example for example pattern mixture 138, 147 selection 148 or latent class 149 
models.  These methods are more adapted to data that are MNAR, but are not adapted for the 
primary analysis of a clinical trial in particular because they rely on numerous untestable 
assumptions 125, 150, and cannot necessarily be carried out using standard statistical software.   
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2.1.4 CHAPTER AIMS 
The overall goal of the work presented in this chapter was to examine the problem of missing 
data in AD trials.  Firstly, data from a longitudinal cohort study of AD patients that was similar in 
design to a disease-modifying trial (evaluations every 6 months using standard assessment tools 
that are widely used in clinical trials) were analysed in order to describe the level and causes of 
attrition, one of the major causes of missing data in AD studies, and to determine patient and 
caregiver factors that were predictive of attrition.  The aim of this work was to try and identify 
factors that could inform the design of strategies to limit missing data in future clinical trials.   
Despite increased efforts to limit attrition, a certain amount of missing data in AD trials is almost 
inevitable.  Therefore, a case study of the missing data in a randomised trial of a management 
plan for AD patients was performed and the effects of using different methods for managing 
missing data for the primary outcome measure during statistical analyses were assessed in a 
series of sensitivity analyses.  The aim of this work was to illustrate the magnitude of the 
problem of missing data in AD trials, and to demonstrate the importance of the choice of analytic 
method in AD trials with missing data.     
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2.2 DETERMINANTS OF ATTRITION IN A COHORT OF AD PATIENTS 
The work presented in this section has been published in Neuroepidemiology (see Appendix; 
Article 4): 
Coley N, Gardette V, Toulza O et al.    
Predictive factors of attrition in a cohort of Alzheimer disease patients (the REAL.FR 
study).  
Neuroepidemiology. 2008;31(2):69-79.   
 
2.2.1 METHODS 
STUDY POPULATION  
The REAL.FR study (REseau sur la maladie d’ALzheimer FRançais) is a French multi-centre 
prospective study of patients with AD which began in 2000 with the objectives of studying the 
natural history of AD and its management. A detailed study protocol of the study has been 
published 151. The study was approved by the Institutional Review Boards of each participating 
University.  
The study was carried out in 16 university hospital neurology, geriatric, or psychiatry 
departments in 10 French cities. The study population (n=686) consisted of community-
dwelling AD patients enrolled during consultation in one of these centres. At the time of 
enrolment, the subjects met the criteria for dementia of Alzheimer type as defined by DSM-IV 
and NINCDS-ADRDA (National Institute of Neurological and Communicative Diseases and 
Stroke/Alzheimer Disease and Related Disorders Association) criteria 2-3, and had a Mini Mental 
State Examination (MMSE) 152 score between 10 and 26. All patients were required to be looked 
after by an informal caregiver.   
ASSESSMENTS  
At inclusion and twice yearly, each patient underwent a standardized gerontological evaluation 
carried out by trained physicians and neuropsychologists.  The main instruments used in the 
study are described in Table 4 (page 52).  Socio-economic data were also collected (level of 
education, income, living arrangements, use of home help and care services, receipt of state 
dependency allowance).  Furthermore, caregiver status (child, wife, husband, other) was 
reported and the level of caregiver burden was assessed using the Zarit Burden Interview 153.  
Events such as hospitalization, institutionalization, and treatment changes were also noted.     
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TABLE 4 - INSTRUMENTS USED IN THE REAL.FR STUDY 
Instrument Abbreviation Description Scoring 
Alzheimer's Disease 
Assessment Scale-
cognitive subscale 154 
ADAS-Cog 11-item measure of global cognitive 
functioning, covering the domains of 
orientation, memory, language, 
praxis and attention.     
Total scores range from 0–70. 
Higher scores indicate more 
impairment.   
Mini Mental State 
Examination 152 
MMSE 30 item measure of global cognitive 
function, covering the domains of 
orientation, learning, attention, 
memory and language 
Scores range from 0-30.  Higher 
scores indicate better cognitive 
performance.  
Approximate scoring categories:  
25-30: normal cognition 
20-24: mild AD 
11-19: moderate AD 
<10: severe AD 
Reisberg Global 
Deterioration Scale 
155 
 Global measure of impairment based 
on cognitive, functional and 
neuropsychiatric symptoms 
The instrument is divided into 7 
stages: 
1: No cognitive decline  
2: Very mild cognitive decline (age-
associated memory impairment) 
3: Mild cognitive decline (MCI or 
early AD) 
4: Moderate cognitive decline (mild 
dementia/AD) 
5: Moderately severe cognitive 
decline (moderate dementia/AD) 
6: Severe cognitive decline 
(moderately severe dementia/AD) 
7: Very severe cognitive decline 
(severe dementia/AD) 
Clinical Dementia 
Rating 156 
CDR Staging instrument for the severity 
of AD covering six categories: 
Memory, Orientation, Judgment and 
Problem Solving, Community Affairs, 
Home and Hobbies, and Personal 
Care.   
Scores for each category are 
assigned by clinicians following a 
semi-structured interview with the 
patient and an informant.   
Impairment in each category is 
scored on a 5-point scale.   
CDR global ratings range from 0-3 
(0=no dementia; 0.5=questionable 
dementia; 1=mild dementia; 
2=moderate dementia; 3=severe 
dementia), and are calculated from 
individual box scores using a 
complex algorithm.   
Activities of Daily 
Living 157 
ADL Functional scale measuring 6 basic 
activities of daily living: bathing, 
dressing, toileting, transferring, 
continence and feeding.   
Each item is scored on a 3-point 
scale: 1=completely autonomous; 
0.5=requires partial help; 
0=completely dependent.    
Total scores range from 0-6.  Higher 
scores indicate higher autonomy. 
Instrumental 
Activities of Daily 
Living 158 
IADL Functional scale measuring 8 
instrumental activities of daily 
living: ability to use telephone; 
shopping; food preparation*; 
housekeeping*; laundry*; 
transportation; responsibility for 
medications; ability to handle 
finances.   
*These items were excluded from 
our analyses due to a high level of 
“Non applicable” responses 
Each item was coded in a binary 
fashion as “dependent” (0) or 
“autonomous” (1). 
Total scores range from 0 to 5.  
Higher scores indicate higher 
autonomy.   
Neuropsychiatric 
Inventory 159 
NPI Evaluates 12 neuropsychiatric 
disturbances common in dementia.  
The frequency and severity of each 
disturbance are rated, and the total 
score, ranging from 0 to 144, is 
obtained by summing the product of 
the frequency and severity scores 
for each item.   
Mini Nutritional 
Assessment 160 
MNA 18-item measure of nutritional 
status involving anthropometric, 
Total score ranges from 0 to 30.   
Scores between 17 and 23.5 indicate 
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nutritional and general assessments.   a risk of malnourishment, and 
scores <17 represent 
malnourishment. 
Zarit Burden 
Interview 153 
ZBI 22 item measure of caregiver burden Each item is evaluated on a 5-point 
Likert scale (0-4) 
Total scores range from 0 to 88, with 
a score greater than 20 representing 
some level of burden 
 
TRACKING MEASURES  
Subjects who missed follow up visits were contacted by telephone and mail if necessary, in order 
to determine the reason for non-attendance (Figure 3, page 53). When applicable, a second visit 
was offered to the caregiver, with or without the patient, and if this was not possible or was 
refused, a short questionnaire was administered by telephone or at the patient’s/caregiver’s 
home to assess the patient’s status (mobility, autonomy, cognitive functions, occurrence of 
medical event(s), change in the patient’s entourage and cholinesterase inhibitor use).  For losses 
to follow up, the general practitioner and the second caregiver were telephoned in order to 
obtain data regarding the patient. 
 
FIGURE 3 - TRACKING PROCEDURES IN THE REAL.FR STUDY 
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STATISTICAL ANALYSES 
In the statistical analysis of the study population at inclusion, mean values ± standard deviation 
(SD) and proportions were used to describe quantitative and qualitative variables, respectively. 
Attrition was considered as a binary dependant variable. The outcome “length of follow up/time 
to drop out” was documented for each subject, and defined as the difference between the date of 
inclusion and the date of censoring (date of dropout or 2 year evaluation). 
Causes of attrition were classified as follows: 
- patient or family/caregiver refusal, 
- death   
- institutionalisation if it prevented the patient attending study visits, 
- impossible to locate or contact (i.e. lost to follow up), 
- other (relocation, patient medical problems, worsened health preventing continued 
participation, caregiver problems, transfer to another study centre, other) 
A survival analysis was performed to identify baseline factors associated with the time of 
dropout.  Cox regression models were used and results are displayed as hazard ratios (HR) and 
95% confidence intervals (95% CI).  Variables with a p-value <0.25 in bivariate analyses were 
included in a multivariate analysis in order to take into account potential confounders.  The 
model was stratified by centre.  A manual backwards stepwise selection procedure was used to 
determine the final multivariate model.  Tests based on interaction with time were used to 
assert the proportional hazards assumption of the Cox model.  P-values were considered 
statistically significant at the level of 0.05. 
A sensitivity analysis was performed in the same way to determine baseline factors associated 
with dropout for reasons other than death.   
 
2.2.2 RESULTS 
BASELINE CHARACTERISTICS 
A total of 686 patients were included in the REAL.FR study between 2000 and 2002.  Patient and 
caregiver characteristics at baseline are summarised in Table 5 (page 55).  Most patients were 
recruited from geriatric departments (83.4%), and the mean age of the cohort was 77.9 ± 7 
years.  Although they had been diagnosed with AD for a mean of 13.2 ±13.4 months, many 
patients were still at a stage of moderate impairment, with 54% completely independent for 
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basic activities of daily living.  87.6% had at least one behavioural disturbance according to the 
NPI.  Following the baseline visit, 89% (n=611) of patients in the cohort were treated with a 
ChEI (78% were treated before this visit, and 76 patients were prescribed a ChEI for the first 
time during this visit). Although all patients were required to have an informal (i.e. non-
professional) caregiver, more than a quarter lived alone. 60% of patients had a female caregiver, 
most often their wife or daughter.  At inclusion, the mean caregiver score on the Zarit scale was 
22.6 ±16, and 50% of caregivers reported some degree of burden (Zarit > 20).  At this early stage 
of the disease, the level of health care support remained low: 20% of patients had nursing help, 
either at home or in a private practice, 44% had a home-help, and only 2% used day care 
facilities.   
TABLE 5 - BASELINE DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE REAL.FR COHORT 
 1:All 
patients 
(n=686) 
 
2: Patients 
remaining in the 
study 
(n=408) 
3: Dropouts 
(n=278) 
p § 
Age (mean ± S.D.) 77.9  ± 6.8 77.1 ± 6.7 79.0 ± 6.8 <0.001 
Sex (%) 
    Male  
    Female 
 
28.9 
71.1 
 
27.0 
73.0 
 
31.6 
68.4 
0.183 
No co-morbidities (%) 
    0 
    1 
    ≥ 2 
 
24.2 
35.1 
40.7 
 
29.2 
36.7 
34.1 
 
17.0 
32.8 
50.2 
<0.001 
ChEI use‡ (%) 89.1 93.1 83.1 <0.001 
MMSE (mean ± S.D.) 20.0 ± 4.2 20.50 ± 4.0 19.3 ± 4.4 <0.001 
ADAS-cog (mean ± S.D.) 17.9 ± 8.2 16.7 ± 7.3 19.5 ± 9.1 <0.001(1) 
ADL (mean ± S.D.) 5.4 ±0.9 5.6 ± 0.7 5.2 ± 1.1 <0.001(3) 
IADL activities of daily living (%) 
≤ 2 
> 2 
 
49.2 
50.8 
 
57.4 
42.6 
 
37.3 
62.7 
<0.001 
CDR (%) 
    0.5 
    1 
    2 or 3 
 
34.2 
42.1 
23.7 
 
40.3 
41.6 
18.1 
 
25.2 
42.8 
32.0 
<0.001 
NPI (frequency*severity) (mean ± S.D) 15.3 ± 15.3 14.4 ± 14.1 16.7 ± 16.9 0.126(2) 
MNA≤23.5 (%) 33.2 29.2 39.1 0.008 
Medical assistance † (%) 68.2 67.0 70.0 0.415 
Non-Medical assistance  # (%) 50.5 47.9 54.2 0.105 
Level of education  (%) 
    Technical/high school certificate or higher 
    Early secondary education 
    Primary school certificate 
    Elementary or illiterate 
 
20.1 
22.3 
36.3 
21.3 
 
20.5 
23.2 
33.3 
23.0 
 
19.6 
21.0 
40.6 
18.8 
0.250 
Caregiver status and patient living 
arrangements  (%) 
spouse 
child - non-cohabiting ¶ 
child - cohabiting  
other 
 
 
53.4 
21.6 
16.0 
9.0 
 
 
57.1 
23.0 
12.5 
7.4 
 
 
47.9 
19.4 
21.2 
11.5 
0.002 
Caregiver sex (%) 
Female 
 
59.3 
 
56.0 
 
64.1 
0.034 
Caregiver age (mean ± S.D.) 64.7 ±13.2 65.2 ± 13.3 63.9 ± 13.0 0.214 
Zarit (mean ± S.D.) 22.6 ± 15.9 21.4 ± 14.8 24.4 ± 17.2 0.117(2) 
§ between columns 2 and 3.  Unless stated otherwise, p-values are Student’s T-test for continuous 
variables, and Chi-squared tests for categorical variables; ‡ Including patients who were prescribed a ChEI 
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during the baseline visit; † Outpatient clinics, nurse home visits, speech therapist, physiotherapist, doctor; 
# home help, day centre, night time assistance, day time assistance, meals on wheels, personal alarm; (1) 
Test carried out after log transformation of variable; (2) Test carried out after square root transformation 
of variable; (3) Kruskal-Wallis test; ¶”Cohabiting” implies that the patient was not living alone, but it does 
not necessarily mean that the patient was living with the caregiver 
ADAS-cog: Alzheimer Disease Assessment Scale-cognitive subscale; ADL: Activities of Daily Living; CDR: 
Clinical Dementia Rating; ChEI: Cholinesterase inhibitor; IADL: Instrumental Activities of Daily Living; 
MMSE: Mini Mental Status Examination; MNA: Mini Nutritional Assessment; NPI: Neuropsychiatric 
Inventory;  
 
ATTRITION RATE 
278 (40.5%) of the 686 patients had dropped out by 2 years of follow-up (Figure 4, page 56).  
The dropout incidence rate was 29.13 /100 person years (95% CI: 25.70-32.56).   
The frequency of dropouts between each wave (percentage of the remaining patients at the 
beginning of each wave) was constant at around 12%, giving a cumulative rate of attrition of 
12.4%, 23%, 32.2% and 40.5%  at 6, 12, 18, and 24 months, respectively.   
 
 
FIGURE 4 - ATTRITION BETWEEN EACH 6-MONTH VISIT IN THE REAL.FR STUDY 
Attrition in each wave was defined as the percentage of dropouts in relation to the number of patients 
remaining in the study at the previous visit.  
 
CAUSES OF DROPOUT 
The reasons for dropout were: 
- Refusal (n=58; 20.86%) 
- Death (n=56; 20.14%) 
- Nursing home placement (n=55; 19.78%) 
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- Loss to follow-up (n=55; 19.78%) 
- Moved house (n=15; 5.4%) 
- Medical problem (n=14; 5%) 
- Caregiver problem (n=7; 2.5%) 
- Patient moved to another centre (not participating in the study) (n=6; 2.16%) 
- Other (n=12; 4.3%) 
Due to small numbers, the last five causes were merged together into an “other causes” category 
for further analyses (n= 54; 19.4%).   
Examination of the causes of attrition over time suggested that the proportion of dropouts due 
to death and institutionalization tended to increase over the course of the study, while the 
proportions of dropouts due to refusals and losses to follow-up was greatest in the first wave 
(Figure 5, page 57). 
 
 
FIGURE 5 - CAUSES OF ATTRITION IN THE REAL.FR STUDY ACCORDING TO FOLLOW-UP PERIOD 
 
FACTORS ASSOCIATED WITH DROPOUT 
BIVARIATE ANALYSES 
We included patient socio-demographic and medical characteristics, as well as caregiver 
characteristics in the initial bivariate analysis of factors associated with attrition.  Patient age 
was the only socio-demographic factor associated with an increased risk of attrition (Table 6,  
page 58): patients who were older at baseline were at greater risk of dropping out of the study 
during follow-up.   
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TABLE 6 - PATIENT SOCIO-DEMOGRAPHIC FACTORS PREDICITVE OF ATTRITION IN THE REAL.FR STUDY 
(BIVARIATE ANALYSIS) 
Inclusion parameters  HR 95% CI p (χ2) 
Sex, N=686 
  female  
  male 
 
1 
1.17 
 
- 
0.91-1.50 
 
- 
0.229 
Age (years), N=686 1.03 1.02-1.05 <0.001 
Level of education, N=681 
  Technical school, high school certificate or higher 
    Early secondary education 
    Primary school certificate 
    Elementary or illiterate 
 
1 
1.003 
1.25 
0.94 
 
- 
0.69-1.45 
0.91-1.73 
0.64-1.38 
0.250 
- 
0.986 
0.172 
0.763 
Monthly household income (Euros), N=680 
  >2 287 € 
  1 500-2 287 € 
  <1 500 €  
 
1 
1.30 
1.30 
 
- 
0.93-1.82 
0.97-1.74 
0.174 
- 
0.129 
0.077 
HR : hazard ratio; 95% CI : 95% confidence interval 
 
 
Patients with a history of cardiac problems, poorer nutritional status, and increasing cognitive 
or functional decline were also found to be at greater risk of dropping out of the study in the 
bivariate analysis (Table 7; page 58).  Of the behavioural disturbances evaluated by the NPI, only 
hallucinations were found to be significantly associated with attrition.  Conversely, patients who 
were diagnosed with AD between 6 and 24 months ago were less likely to drop out than those 
diagnosed less than 3 months ago, as were those using a ChEI treatment or those using 1 to 3 
other types of medication (as compared to no other types of medication).   
 
TABLE 7 - PATIENT MEDICAL FACTORS PREDICTIVE OF ATTRITION IN THE REAL.FR STUDY (BIVARIATE 
ANALYSIS) 
Inclusion parameters HR 95% CI p (χ2) 
Length of time since diagnosis, N=686 
  <3 months 
  3-6 months 
  6-12 months 
 12-24 months 
  ≥24 months 
Not available 
 
1 
0.80 
0.46 
0.65 
0.79 
0.74 
 
- 
0.52-1.21 
0.30-0.68 
0.45-0.94 
0.55-1.14 
0.49-1.12 
0.006 
- 
0.290 
0.0001 
0.021 
0.205 
0.156 
History of cardiac problems1, N=686 
  no 
  yes 
  not available 
 
1 
1.53 
0.79 
 
- 
1.18-1.98 
0.47-1.32 
0.002 
- 
0.001 
0.366 
MNA, N=671 
  >23.5 
  ≤23.5 
 
1 
1.40 
 
- 
1.10-1.78 
 
- 
0.006 
Medical assistance2, N=667 
  no 
  yes 
 
1 
1.13 
 
- 
0.87-1.47 
 
- 
0.343 
Non-medical assistance3,  N=670    
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Inclusion parameters HR 95% CI p (χ2) 
  no 
  yes 
1 
1.21 
- 
0.95-1.54 
- 
0.117 
ChEI (at end of 1st visit) N=686 
  not treated 
  treated 
 
1 
0.46 
 
- 
0.34-0.63 
 
- 
<0.001 
No. other treatments, N=684 
  0 
  1 - 3 
  ≥4 
 
1 
0.67 
0.89 
 
- 
0.45-1.01 
0.60-1.33 
0.040 
- 
0.059 
0.586 
Total MMSE score, N=684 0.95 0.93-0.98 <0.001 
Total ADAS-cog score, N=673 1.03 1.01-1.04 <0.001 
CDR score, N=682 
  0.5 
  1 
  2 or 3 
 
1 
1.50 
2.13 
 
- 
1.11-2.01 
1.56-2.91 
<0.001 
- 
0.007 
<0.001 
Number of ADL limitations, N=686 
  0 
  ≥1 
 
1 
1.75 
 
- 
1.38-2.22 
 
- 
<0.001 
IADL (no. Independent activities/5), N=665 
  ≤2 
  >2 
 
1 
1.84 
 
- 
1.44-2.36 
 
- 
<0.001 
NPI delusions, N=686  
  Yes 
 
1.19 
 
0.88-1.62 
 
0.256 
NPI hallucinations, N=686 
  Yes 
 
1.87 
 
1.26-2.77 
 
0.001 
NPI agitation/aggression, N=686 
  Yes 
 
1.02 
 
0.80-1.30 
 
0.870 
NPI depression/dysphoria, N=686 
    Yes 
 
1.05 
 
0.82-1.33 
 
0.704 
NPI anxiety, N=686 
    Yes 
 
1.23 
 
0.97-1.56 
 
0.083 
NPI euphoria, N=686 
    Yes 
 
0.92 
 
0.57-1.46 
 
0.711 
NPI apathy/indifference, N=686 
  Yes 
 
1.02 
 
0.81-1.30 
 
0.843 
NPI, disinhibition N=686 
    Yes 
 
1.36 
 
0.97-1.92 
 
0.076 
NPI irritability/lability, N=686 
    Yes 
 
0.95 
 
0.75-1.22 
 
0.709 
NPI aberrant motor activity, N=686 
    Yes 
 
0.92 
 
0.69-1.22 
 
0.552 
NPI sleep disturbances, N=686 
  Yes 
 
1.24 
 
0.91-1.70 
 
0.168 
NPI appetite abnormalities, N=685 
    Yes 
 
1.12 
 
0.85-1.47 
 
0.437 
1 (atrial fibrillation/ arrhythmia, angina, MI, arteritis, congestive heart failure)  
2 (Outpatient clinics, nurse home visits, speech therapist, physiotherapist, doctor), 
3 (home help, day centre, night time assistance, day time assistance, meals on wheels, personal alarm) 
ADAS-cog: Alzheimer Disease Assessment Scale-cognitive subscale; ADL: Activities of Daily Living; CDR: Clinical 
Dementia Rating; ChEI: Cholinesterase inhibitor; IADL: Instrumental Activities of Daily Living; MI: myocardial 
infarction; MMSE: Mini Mental Status Examination; MNA: mini-nutritional assessment; NPI: Neuropsychiatric 
Inventory 
 
 
Certain caregiver factors were also associated with attrition in the bivariate analysis (Table 8; 
page 60): caregiver status combined with living arrangements, and the level of caregiver burden 
were predictive of dropout, while patients with a male caregiver were less likely to drop out of 
the study than those with a female caregiver). 
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TABLE 8 - CAREGIVER FACTORS PREDICTIVE OF ATTRITION IN THE REAL.FR STUDY (BIVARIATE 
ANALYSIS) 
Inclusion parameters HR 95% CI p (χ2) 
Caregiver sex, N=678 
  female 
  male 
 
1 
0.78 
 
- 
0.61-0.99 
 
- 
0.045 
Caregiver age (years), N=668 0.995 0.987-1.004 0.313 
Caregiver status and living arrangements, N=686 
  spouse 
  child - non-cohabiting  
  child - cohabiting 
  other 
 
1 
0.98 
1.75 
1.67 
 
- 
0.71-1.34 
1.29-2.38 
1.13-2.46 
<0.001 
- 
0.882 
<0.001 
0.009 
Caregiver burden (Zarit score), N=638 1.009 1.002-1.017 0.015 
 
MULTIVARIATE ANALYSIS 
597 patients were included in the multivariate analysis, including 249 dropouts and 348 
patients remaining in the study (Table 9; page 60). 89 subjects were excluded from this analysis 
due to missing data for one or more of the variables included in the initial multivariate model.  In 
particular, the Zarit caregiver burden score was missing for 48 subjects, the IADL score was 
missing for 21 subjects, and the MNA score was missing for 15 subjects.  Caregiver status 
differed between patients included and excluded from the multivariate analysis: for patients 
excluded, 59.6% of caregivers were the patient’s spouse, 25.8% were the patient’s son/daughter 
and 14.6% had an “other” relationship with the patient; compared to 52.4%, 39.4% and 8.2% 
respectively for patients included in the analysis (p=0.018).  There were no differences in terms 
of patient or caregiver age or sex, or MMSE, ADL or NPI scores. 
 
Table 9 - Multivariate analysis of predictive factors of attrition in the REAL.FR study 
(N=597; model stratified by centre) HR 95% CI p (χ2) 
 Caregiver status and living arrangements  
  (ref : spouse)  
  Child – non-cohabiting   
  Child – cohabiting   
  Other  
 
1 
0.78 
1.04 
1.67 
 
- 
0.54-1.12 
0.72-1.50 
1.08-2.59 
0.023 
 
0.183 
0.840 
0.021 
 No. ADL limitations : ≥1 vs. 0  1.37 1.03-1.82 0.030 
 Total Zarit score 1.01 1.005-1.022 0.001 
 Use of ChEI* (yes vs. no) 0.40 0.27-0.59 <0.001 
 No. other treatments   
  (ref : 0)   
  1 to 3  
  ≥4   
 
1 
0.57 
0.68 
 
- 
0.36-0.89 
0.43-1.06 
0.046 
 
0.014 
0.087 
The following variables were also introduced into the initial model, but did not remain in the final model: MMSE, time 
elapsed since diagnosis, history of cardiac problems, CDR score, patient age, MNA, number of IADL limitations and 
hallucinations on NPI scale. 
* at end of baseline visit 
 
61 
 
After adjustment for all variables found to be significant in the bivariate analyses, the following 
factors remained independently associated with attrition in the multivariate analysis:  
(i) Being cared for by an unrelated caregiver, i.e. not a spouse or child 
(ii) Loss of autonomy 
(iii) Increasing caregiver burden 
(iv) Use of a ChEI 
(v) Use of 1 to 3 other types of medication compared to the use of no other types of 
medication 
The first three factors were associated with an increased risk of attrition, while the use of a ChEI 
or 1 to 3 other types of medication were associated with a decreased risk.   
 
A sensitivity analysis was conducted to identify the factors associated with attrition due to 
causes other than death (Table 10; page 61).  Results of the multivariate sensitivity analysis 
were similar to the initial multivariate analysis except that the “caregiver status/living 
arrangements” variable was no longer predictive of attrition.   
 
TABLE 10 - MULTIVARIATE ANALYSIS OF PREDICTIVE FACTORS OF PREVENTABLE ATTRITION IN THE 
REAL.FR STUDY 
(N=547; model stratified by centre) HR 95% CI p (χ2) 
 No. ADL limitations : ≥1 vs. 0  1.44 1.06-1.97 0.021 
 Total Zarit score 1.01 1.003-1.022 0.007 
 Use of ChEI* (yes vs. no) 0.40 0.26-0.62 <0.001 
 No. other treatments   
  (ref : 0)   
  1 to 3  
  ≥4   
 
1 
0.50 
0.60 
 
- 
0.30-0.83 
0.36-1.00 
0.028 
 
0.008 
0.050 
The following variables were also introduced into the initial model, but did not remain in the final model: MMSE, time 
elapsed since diagnosis, history of cardiac problems, CDR score, patient age, patient level of education, caregiver 
status/living arrangements,, MNA, number of IADL limitations and hallucinations, delusions, anxiety, disinhibition and 
night-time behaviour on the NPI scale. 
* at end of baseline visit 
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2.2.3 DISCUSSION 
The aim of this analysis was to describe the level and causes of attrition after 2 years of follow-
up in an AD longitudinal study and to identify baseline factors predictive of future attrition in 
order to help design strategies to minimize the level of missing data in future studies, including 
randomised controlled trials. To our knowledge, only one previous study has specifically 
examined factors associated with attrition in a cohort of AD patients 161, but unlike the present 
study, this work did not evaluate the relationship between caregiver characteristics and 
attrition.  The REAL.FR study is one of the largest longitudinal cohorts of AD patients in Europe, 
in which subjects were followed up relatively frequently (twice yearly) for at least 2 years using 
standardised and validated tools that are commonly used in clinical trials.    
After 2 years of follow-up, the attrition rate in our study was 41%.  Each cause (death, refusal, 
institutionalization, loss to follow-up, others) accounted for around 20% of dropouts, although 
the percentage of attrition attributable to each cause varied over time.  Attrition in this study 
may have been affected by the fact that it was carried out in reference centres belonging to a 
national network of AD centres.  Certain patients and caregivers may have been less likely to 
take part in the study in the first place, due to the perceived burden of the study visits, but for 
those that did enrol, one could imagine that attrition was limited due to the fact that patients 
were more compliant because they were being followed up in a reference centre.  In addition, 
the tracking methods used (cf. Figure 3, page 53) in the study may have limited the observed 
level of attrition.  However, the population included in this study is probably fairly 
representative of the types of patients generally included in clinical trials for AD.   
The frequency of attrition in this study remained stable over time, at approximately 12% per 6 
month wave.  This corresponds with the findings in some longitudinal studies of the elderly 162-
163, but is lower than others 164. 
We identified 3 other longitudinal AD studies in which attrition rates including deaths were 
calculated: 
- LASER-AD (N=224 AD patients): attrition rate of 11.6% at 6 months and 25% at 18 
months 165; 
- PREDICTORS (N=236 AD patients): attrition rate of 28% and 2 years and 56.8% at 5 
years  166;  
- Study reported by Starkstein et al. (N=354 AD patients): 30% attrition rate (% of 
patients not completing a follow-up visit between 1 and 4 years after initial assessment)  
167).   
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In the Consortium to Established a Registry for Alzheimer’s Disease (CERAD) cohort, an attrition 
rate, excluding deaths, of 10.5%  was observed amongst 978 AD patients and 466 controls (often 
a spouse of the AD patient) in the first year of follow-up 161.  This rate is lower than the 19% 
observed after 1 year excluding death in REAL.FR, but the CERAD rate also includes control 
subjects.   
The attrition rate in REAL.FR therefore appears to be generally higher than in these other AD 
cohorts.  This could be explained by methodological differences, for example, inclusion criteria 
concerning the severity of the disease.  In REAL.FR, death accounted for a lesser proportion of 
the attrition than in other studies, indicating that other causes, such as loss of contact, 
institutionalization and medical problems were more prominent.   
Some authors have suggested that in RCTs, a loss to follow-up of 5% or less may be of little 
concern, but that losses of 20% or more may introduce considerable bias 168.  However, it may be 
unwise to set an explicit value to assess the risk for bias  because the type of missing data must 
also be taken into account 169.  In practice, the occurrence of missing data is generally not 
completely at random.  It is therefore important to consider overlapping methodological issues 
and the direction of the potential bias on a case by case basis, and to form hypotheses about the 
missingness mechanism, in particular to determine whether or not dropout is associated with 
outcome 170.     
We also identified baseline factors that were predictive of attrition in our study.  Previous 
studies of factors associated with attrition in AD cohorts have mainly been based on unadjusted 
analyses. Certain factors have been suggested, such as age, race, MMSE score, apathy, level of 
education, and type of dementia diagnosis 161, 167, 171, but results are inconsistent across studies.   
In our multivariate analysis, a loss of autonomy was predictive of dropout: patients with one or 
more limitation on the ADL scale had a risk of attrition 1.37 times higher than subjects with no 
limitations.  However, the level of baseline cognitive impairment did not remain associated with 
dropout in the multivariate analysis.   
Patients using a ChEI were 2.5 times less likely to drop out of the study than untreated patients.  
The REAL.FR cohort was established in 2000, meaning that a high proportion of subjects (89%) 
were treated with ChEIs.  The efficacy of ChEIs has been demonstrated for mild to moderate AD 
patients 172, so it is probable that treated patients were more likely to attend consultations in 
order to receive their medication, demonstrating a “protective” effect of ChEI use on attrition.  
An explanation for the non-use of ChEIs, apart from contra-indications, could be that certain 
patients or their caregivers may refuse this type of treatment, perhaps because they have 
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difficulties in accepting the pathology and in receiving medical care or advice.  Such patients may 
therefore be less likely to remain in the study. Also, patients who were non-users of ChEIs at 
baseline may have previously been prescribed this medication and discontinued use because 
adverse drug reaction, which may affect the patients’ or caregiver’s confidence in the medical 
care being received, thus making them more likely to drop out of the study. 
Patients using 1 to 3 types of medication other than ChEIs were also found to be 1.75 times less 
likely to drop out of the study than those taking no other types of medication.  These patients 
may have been receiving increased medical care and attention as they probably had co-
morbidities, and we hypothesize they may present an increased compliance in medication use as 
well as in the study. 
The remaining factors found to be associated with attrition concern caregiver characteristics.  
We found that an increase of 1 point on the Zarit burden scale was associated with a 1.4% 
increase in the risk of attrition. To our knowledge, caregiver burden has never been examined as 
a determinant of attrition in studies of AD patients, although it has been found to be associated 
with institutionalization 173.  It is therefore important to be able to recognize and support 
exhausted caregivers in order to limit attrition in studies involving AD patients.  It has been 
suggested that caregivers play an important role in decision making about patient care, for 
example regarding medication use 174-175, yet attrition prevention strategies have generally not 
been targeted towards caregivers 176. It is also important that caregivers understand the benefits 
of the patient’s participation in clinical research studies.     
Furthermore, patients looked after by an unrelated caregiver (i.e. not their spouse or child) were 
found to be 1.7 times more likely to drop out of the study than those cared for by their spouse in 
our original multivariate analysis including deaths as a cause of attrition.  Koss et al also found 
that that patients whose spouse was also included in the study (in their case as a control) were 
less likely to drop out than patients who did not have a spouse taking part  161.  However, once 
we removed subjects who discontinued our study due to death, caregiver status was no longer 
predictive of attrition.  In contrast, all of the other factors associated with overall attrition 
remained associated with “preventable” attrition, i.e. due to causes other than death.   
We did not find patient age or cognitive impairment to be associated with dropout in this study, 
although a systematic review of attrition in large population-based studies of the elderly noted 
that in multivariate analyses, increasing age and poor cognitive performance were the only 
factors consistently associated with preventable attrition (i.e. all types of attrition excluding 
death) 71.  Our results may indicate that above a certain level of cognitive impairment, 
differences in the cognitive performance between patients may not affect attrition. 
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We have only identified one other study which has specifically analyzed factors associated with 
attrition in a cohort of AD patients in multivariate analyses.  In this study, Koss et al. reported 3 
factors associated with attrition: non white status, patients’ spouse not enrolled in the study as a 
control, and inadequate involvement by the study site 161 but we did not assess these factors in 
our study as they were either not relevant or not available (due to national ethical guidelines).  
However, as in our study, patient age, level of education, and cognitive status were not 
associated with attrition. 
This study was an exploratory investigation into the causes of attrition and may have some 
limitations. Our population is probably unrepresentative of the entire Alzheimer population, 
because the patients included in our study had a diagnosis of probable AD, and had been 
referred to an AD expert centre.  However, this population may be representative of a typical 
placebo group in an add-on trial, and so our results could be extrapolated to the clinical trial 
setting.   
Our results are largely dependent on the definition of attrition used in our study. Moreover, we 
only considered baseline factors as possible determinants of attrition and did not take into 
account the fact that some of these factors (e.g. caregiver burden, cognitive status) may have 
changed during the follow-up period.  Also, we were not able examine causes of sub-groups of 
attrition, such as refusal, due to small numbers of patients.   
We were only able to include 597 of the 686 subjects in our main multivariate analysis due to 
missing data for certain variables included in the model, in particular for the Zarit caregiver 
burden score.  The main difference between subjects included and those excluded from the 
analysis was the relationship between the caregiver and the patient: amongst those excluded 
from the analysis, there was a greater proportion of child and “other” (i.e. not spouse or child) 
caregivers compared to those included in the analysis. 
Despite these limitations, this study of attrition is useful because the REAL.FR study involves one 
of the largest cohorts of AD patients so far studied, in which determinants of attrition have 
seldom been studied.  The characteristics of the REAL.FR study mean that these results are 
probably also applicable to longitudinal clinical trials involving AD patients.  Furthermore, this 
study is the first to examine caregiver characteristics as factors associated with attrition.  
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2.3 MANAGEMENT OF MISSING DATA IN A RANDOMIZED TRIAL 
INVOLVING AD PATIENTS 
The work presented in this section has been submitted to Current Alzheimer Research for 
publication: 
Coley N, Gardette V, Cantet C, Gillette-Guyonnet S,  Nourhashemi F, Vellas B, Andrieu S.  
How should we deal with missing data in clinical trials involving Alzheimer's disease 
patients?   
Submitted to Current Alzheimer Research 
 
2.3.1 METHODS 
PARTICIPANTS AND STUDY DESIGN  
The PLASA (Plan de Soin et d’aide dans la maladie d’Alzheimer) intervention study was a French 
nationwide trial using a cluster randomised design to compare the effectiveness of a 
comprehensive specific care plan for Alzheimer disease versus usual care in patients managed in 
memory clinics in 50 different centres for 2 years 177-178.  Memory clinics in university or general 
hospitals constituted the unit of randomization, with patients as the unit of analysis.  
Intervention allocation was based on a randomization procedure stratified by hospital teaching 
status (university or general hospital), centre specialities (neurology, psychiatry and geriatric 
medicine) and by membership to a previous national Alzheimer disease research program 
network 151.  University hospital memory centres were asked to recruit their first 30 patients 
who fulfilled the inclusion criteria and who agreed to take part in the study, and the general 
hospital memory centres were asked to include their first 20 patients In total, 1131 patients 
meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer 
Disease and Related Disorders Association (NINCDS-ADRDA) criteria 3 for probable or possible 
AD with a Mini Mental State Examination (MMSE) 152 score between 12 and 26 were included 
between June 2003 and July 2005.  Participants were required to be aged 65 years or more, to be 
community-dwelling, and to have a designated caregiver.  The study was funded by the French 
Hospital Clinical Research Programme (PHRC) and was approved by the institutional review 
board and ethics committee of Toulouse University.  Written informed consent was obtained 
from all participants and their caregivers. 
Patients in the intervention group were evaluated every 6 months, while those in the usual care-
control group were assessed annually, although consultations between these assessments were 
permitted if considered necessary by the physician in charge of the patient.   
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If a patient dropped out of the study, the investigating centre was asked to fill in a dropout form 
indicating information such as the time of and reason for dropout.  Patients were only classed as 
dropouts once they were specified as such by the investigating centre (i.e. when a dropout form 
was filled in).  For example, if a patient did not attend the 12 month visit, and was declared to 
have dropped out at the 24 month visit, the time of dropout was considered to be 24 months, 
and the 12 month visit was considered simply as missed.   
OUTCOME MEASURES AND OTHER VARIABLES 
ADCS-ADL 
The primary outcome measure was the Alzheimer’s Disease Cooperative Study-Activities of 
Daily Living (ADCS-ADL), a 23-item scale administered to caregivers by a trained interviewer.  It 
was developed in the late 1990s as an AD-specific measure of physical function for use in clinical 
trials 179. The caregiver is asked to focus on the patient’s performance over the last 4 weeks.  The 
first 6 items of the instrument refer to basic activities of daily living (ADLs: eating, walking, 
toileting, bathing, grooming and dressing), with the remaining items assessing more complex 
instrumental activities of daily living (IADLs: telephoning, conversation, shopping, reading, 
writing, hobbies etc).  Performance on each item is scored from 0 (nonperformance or need for 
extensive help) to the highest score (ranging from 2-7 depending on the item) which denotes 
independent performance. Total scores range from 0 to 78, with lower scores indicating greater 
impairment in functioning.  The ADCS-ADL has good test-retest reliability, and was designed to 
be sensitive to changes in disease progression 179.  The official French translation of the scale 
was used in this study (see Appendix).    
Data management: As the ADCS-ADL instrument is not adapted for patients living in nursing 
homes, the questions concerning IADLs were all set to missing for institutionalised patients.  
Therefore, the total score was also missing for these patients  
No imputation strategy was given by the authors of the ADCS-ADL meaning that the total score 
would be missing if one or more items were missing.  Initially, 35% of patients at baseline, 52% 
of subjects present at the 1 year visit and 62% of those present at the two year visit had a 
missing ADCS-ADL score.  An initial investigation showed that 91% of patients at with missing 
data at baseline, 65% of those with missing data at the 1 year visit and 61% of those with 
missing data at the two year visit had less than 5 items missing.  Around 20% of patients with a 
missing score at the 1 or 2 year visits did not have data for any of the ADCS-ADL items, and 
nearly all of the others had missing data for more than half of the items.  Missing data for two 
items in particular (6b, 18c) appeared to be related misunderstandings brought about by the 
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questionnaire layout used in our study and so specific imputation strategies were used for 
patients who had missing data for only these two items, enabling the recovery of total scores for 
144 patients at baseline, 96 patients at 1 year and 98 patients at 2 years.  Then, up to 5 missing 
items were imputed for each subject based on the mean scores of all of the available items for 
that patient so as to calculate a total score based as much as possible on the patient’s own 
observed data.     
OTHER VARIABLES 
Other data collected for each patient at baseline, and where applicable during follow-up include: 
- MMSE 152: a 30-item measure of global cognitive function covering the domains of 
learning, attention, memory and language.  Scores range from 0-30 with higher scores 
indicating better cognitive performance.   
- Alzheimer Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) 
180: the clinician rates the patient's status at baseline on a scale from 1 (normal) to 7 
(severely impaired), and then at the following visits rates the change in status on a scale 
from 1 (very much improved) to 7 (very much worsened) 
- Quality of Life-Alzheimer disease (QOL-AD) scale 181: 13-item questionnaire completed 
by both the patient and the caregiver in order to measure AD patients’ quality of life. 
Total scores range from 13-52 (higher scores indicate better QOL).  Following the 
authors’ instructions, up to 2 missing items per patient were replaced by the mean of the 
available items for the same patient.  
- Occurrence of institutionalisation, hospitalisations or death   
- Sociodemographics: age, sex, level of education, occupation, living arrangements 
- Medical history: length of time since AD diagnosis and since start of symptoms, use of 
AD-specific and other medications, presence of co-morbidities 
- Caregiver characteristics: age, sex, relationship to patient 
STATISTICAL METHODS 
All analyses were carried out using STATA version 11.  
BASELINE CHARACTERISTICS 
Baseline data are presented as descriptive statistics.  Normally distributed continuous variables 
are presented as mean (SD) and non-normal continuous variables are presented as median 
(IQR).  Categorical variables are presented as numbers (%).   
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DETERMINATION OF FACTORS ASSOCIATED WITH DROPOUT 
Cox regression models were used to determine baseline factors associated with time to dropout.  
Results are displayed as hazard ratios (HR) and 95% confidence intervals (95% CI).  All 
dropouts were included in this analysis, including those who dropped out due to death.  Survival 
time was calculated as the time until the 2-year visit for subjects who completed the study, and 
the time until dropout for subjects who did not complete the study.  If the exact time of dropout 
could not be determined from the data, the midpoint between the previous visit and the visit at 
which the patient dropped out was considered to be the time of dropout.  Bivariate analyses 
were first conducted, and variables with a p-value <0.2 were then included in a multivariate 
analysis which was stratified by centre.  A manual backwards stepwise selection procedure was 
used to determine the final multivariate model.  The proportional hazards assumption was 
verified using Schoenfeld residuals.  
ESTIMATION OF OUTCOME EVOLUTION AND INTERVENTION EFFECT USING 
DIFFERENT METHODS OF MANAGEMENT OF MISSING DATA 
Change in the primary outcome measure (ADCS-ADL) over time and the effect of the 
intervention on the rate of change were estimated using 6 different analyses.  All analyses were 
carried out on an ITT basis, but 34 patients living in sheltered accommodation at baseline were 
excluded since they had high levels of missing data at baseline for the primary outcome measure 
at baseline, as this instrument was not a suitable measure of function for them. 
CHANGE FROM BASELINE ANALYSES  
Three different “change from baseline” analyses were carried in order to compare mean 2-year 
changes in the ADCS-ADL across treatment groups.  A multilevel regression model was used 
(using the stata “xtmixed” command) to test the intervention effect, taking into account the 
clustering of the data within centres.   The response variable was the 2-year change in ADCS-ADL 
score.  The following underlying hypotheses were verified graphically for each model: 
homoscedascity of residuals; normality of residuals; normality of random effects.  The three 
“change from baseline” analyses were: 
1. A complete case analysis using observed ADCS-ADL data (with imputation of up to 5 missing 
items as detailed above).  Only patients with an ADCS-ADL score at baseline and 2 years 
were included in the analysis.  This method assumed that missing data were MCAR. 
2. A LOCF analysis in which missing ADCS-ADL scores were replaced with the last observed 
value.  All patients with at least a baseline ADCS-ADL score were included in this analysis.  
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This method assumed that patients who dropped out of the study did not undergo any more 
functional changes after their last assessment. 
3. A z-score LOCF analysis in which missing ADCS-ADL scores were replaced by a score that 
was the same number of standard deviations from the treatment group mean at that time 
point as at the subject’s last observed valued (i.e. the z-score was carried forward rather 
than the last observation).  The same patients were included as in the LOCF analysis.   This 
method assumed that data were MAR, and that the rate of change in dropouts compared to 
the group mean was similar before and after dropout.     
 
LONGITUDINAL MIXED EFFECTS MODEL 
A longitudinal mixed effects model was also used to estimate the effect of the intervention on the 
rate of ADCS-ADL change over 2 years with the assumption that missing data were MAR.  In this 
model, missing data are not replaced, but all available data is included in the model even if data 
is only present at one time point.  The stata xtmixed command was again used to perform the 
analysis.  The response variable was the ADCS-ADL total score, and the independent variables 
were intervention group and time as well as their interaction.  Two levels of clustering were 
taken into account: repeated measurements on the same individual, and nesting of individuals 
within centres.  A patient*time interaction term was included in the random effects in order to 
allow the effect of time to vary randomly among patients, corresponding to a subject-specific 
slope (random slope).  The significance of the random slope was tested using the likelihood-ratio 
test.  The effect of the intervention on the rate of decline in the ADCS-ADL score over time was 
assessed by testing the coefficient of the group*time interaction term using a z-test (the null 
hypothesis tested was that the coefficient=0).  The following underlying hypotheses were 
verified graphically: homoscedascity of the residuals; normality of the residuals; normality of the 
random effects residuals.  The results of this model are presented as β coefficients with standard 
errors (SE) and p-values.     
MULTIPLE IMPUTATION 
Multiple imputations of missing ADCS-ADL scores were performed under the MAR hypothesis 
using data augmentation (stata “mi mvn impute” command), an iterative Markov chain Monte 
Carlo (MCMC) method, to impute missing values under a multivariate normal model.  20 
imputation cycles were performed with 200 iterations in the burn-in period and between each 
cycle.  The worst linear function (WLF) was assessed graphically in order to assess the 
convergence of the model and the independence of the imputed datasets.  The following baseline 
variables which were associated with baseline ADCS-ADL scores and/or missing scores were 
included in the imputation model: patient age, sex, time since diagnosis, level of education, time 
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since onset of symptoms, Clinician’s CGI rating, MMSE score, centre/cluster indicator variable, 
and living status.  1- and 2-year ADCS-ADL and MMSE scores were also included.  Imputations 
were performed separately for each randomisation group, so as to preserve group-specific 
relationships between variables.  In order to take into account the hierarchical data structure we 
used a simple procedure suggested by Graham 144 which involves using a series of dummy 
variables to represent affiliation to a particular centre or cluster.  Since we had a high number of 
centres in our study, we reduced the number of clusters by grouping together similar centres 
according to their mean baseline ADCS-ADL scores. 
Following imputation ADCS-ADL scores which were<0 were rounded up to 0 (the minimum 
score on the scale) and values which were >78 were rounded down to 78 (the maximum score).  
The following numerical diagnostics were conducted to check for potential problems with the 
imputed ADCS-ADL values: identification of (i) an absolute difference in means between 
observed and imputed values greater than 2 SD, or (ii) a ratio of variances of the observed and 
imputed values less than 0.5 or greater than 2 182.  No problems were detected.   
The resulting 20 multiply imputed datasets were each analysed using the same change from 
baseline and longitudinal mixed effects models described above.  The results were combined 
using Rubin’s variance formula for combining within- and between-imputation variability 
(“Rubin’s rules”) 141 to give single point estimates averaged across all of the datasets.   
   
2.3.2 RESULTS 
BASELINE CHARACTERISTICS 
In total, 1131 patients from 50 memory clinics were randomised to either the intervention 
(N=26 memory clinics/574 patients) or control (N=24 memory clinics/557 patients) group.  The 
primary study analysis, carried out using a mixed effects model, found no effect of the 
intervention on the main study outcome measure, the ADCS-ADL 177. 
The baseline characteristics of the two groups are shown in Table 11 (page 72).  The two groups 
were comparable at baseline with both groups having a mean age of approximately 80 years.  
Roughly two thirds of participants were female in both groups.  The level of education and 
household income was similar in both groups.  Nearly all of the patients were using AD 
medication at baseline and more than 90% were using one or more other types of medication as 
well.  The baseline ADCS-ADL score was slightly higher in the intervention group (55.2 ± 14.4 vs. 
53.6 ± 15.3), while the MMSE and CGI scores were slightly higher in the control group (20.0 ± 4.1 
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vs. 19.4 ± 3.9 and 4.0 ± 1.0 vs. 3.7 ± 0.9, respectively).  All patients were looked after by an 
informal caregiver.  In both groups, almost 50% of caregivers were the spouse of the patient. 
 
TABLE 11 - BASELINE CHARACTERISTICS OF PATIENTS INCLUDED IN THE PLASA STUDY 
Characteristic Intervention group 
(N=574) 
Control group (N=557) 
Patient Characteristics   
Age (mean ± SD) 80.2 ± 5.9 80.2 ± 5.6 
Sex (% female) 66.5% 70.9% 
Time (years) since onset of symptoms (median [IQR]) 3 [2-5] 3 [2-5] 
Time (years) since diagnosis (median [IQR])  1 [0-2] 1 [0-2] 
Level of education (%) 
    None 
    Elementary 
    Primary school certificate 
    Technical qualification 
    A-level or higher 
 
0.5% 
24.3% 
40.9% 
19.6% 
14.7% 
 
0.9% 
25.4% 
38.4% 
20.5% 
14.8% 
Household monthly income (%) 
    < 760 € 
    760-1525 € 
    1525-2300 € 
    2300-3000€ 
    > 3000 € 
 
8.4% 
45.6% 
23.4% 
13.6% 
9.1% 
 
12.0% 
42.6% 
23.7% 
10.7% 
11.0% 
Living arrangements (%) 
   Alone 
   With spouse 
    With another family member 
    Other 
 
32.6% 
53.1% 
11.2% 
3.1% 
 
29.3% 
51.9% 
16.0% 
2.9% 
Use of AD medication* (%) 96.7% 96.4% 
Use of ≥1 other types of medication (%) 96.3% 92.5% 
≥1 hospitalisations in previous month (%) 5.3% 6.0% 
ADCS-ADL** (mean ±SD) 53.0 ± 15.6 51.1 ± 16.3 
MMSE (mean ±SD) 19.5 ± 3.9 20.0 ± 4.1 
QOL-AD: patient self-rated (mean ±SD) [score/52] 34.5 ± 5.3 34.9 ± 5.3 
QOL-AD: caregiver rated (mean ±SD) [score/52] 31.0 ± 5.3 31.2 ± 5.7 
CGI  (mean ±SD) [score/7] 3.7 ± 0.9 4.0 ± 1.0 
Caregiver characteristics   
Age (mean ± SD) 64.0 ± 13.7 64.6 ± 13.6 
Sex (% female) 66.2% 61.0% 
Status (%) 
    Spouse 
    Son/daughter 
    Other 
 
47.2% 
44.4% 
8.4% 
 
49.9% 
42.0 
8.1 
* At the end of the baseline visit; ** Following imputation of up to 5 missing items 
 
PARTICIPANT FOLLOW-UP 
The flow of participants through the study is shown in Figure 6 (page 73).  Approximately 25% 
of patients in both groups did not attend the 1 year study visit (Table 12; page 73).   Around 
18.5% of patients had dropped out by this point, and around 6.5% missed the visit for other 
reasons.  Approximately 40% of patients in each group missed the two year visit, with the 
majority (30-34%) of these patients having dropped out of the study by this point.  The rate of 
dropouts did not differ significantly between groups (p=0.227).   
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FIGURE 6 - FLOW OF PARTICIPANTS THROUGH THE PLASA STUDY 
(Figure taken from 177) 
TABLE 12 - LEVEL OF ATTENDANCE AT STUDY VISITS IN THE PLASA STUDY 
Visit 
Intervention group Control group Total 
N % N % N % 
Baseline       
   Attended visit 574 100 557 100 1131 100 
1 year       
   Attended visit 430 74.92 414 74.33 844 74.62 
       
   Missed visit 37 6.45 40 7.18 77 6.81 
   Dropped out 107 18.64 103 18.49 210 18.57 
   Total did not attend visit 144 25.09 143 25.67 287 25.38 
 2 years       
   Attended visit 335 58.37 343 61.58 678 59.95 
       
   Missed visit 42 7.32 44 7.90 86 7.60 
   Dropped between 1- & 2- year visits 90 15.68 67 12.03 157 13.88 
   Dropped out before 1 year visit 107 18.64 103 18.49 210 18.57 
   Total did not attend visit 239 41.64 214 38.42 453 40.05 
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DESCRIPTION OF DROPOUTS 
REASONS FOR DROPOUT 
The reasons for dropout of the 367 patients who did not complete the study are shown in Table 
13 (page 74).  The main reasons were death (approximately 25% of dropouts in each group), 
refusal (around 20% of dropouts in each group) and institutionalisation (11.2% of dropouts in 
the intervention group and 17.7% of dropouts in the control group).  Approximately 10% of 
dropouts in each group had multiple reasons for dropout. Around 10% of dropouts in the 
intervention group and 6.5% of subjects in the control group were lost to follow-up.   
 
TABLE 13 - REASONS FOR DROPOUT IN THE PLASA STUDY 
Reason 
Intervention 
group 
Control group Total 
N % N % N % 
Death 56 28.43 43 25.29 99 26.98 
Refusal 44 22.34 34 20.00 78 21.25 
Institutionalisation* 22 11.17 30 17.65 52 14.17 
Multiple reasons* 21 10.66 16 9.41 37 10.08 
Lost to follow-up 20 10.15 11 6.47 31 8.45 
Patient medical problem (related or not to AD) 12 6.09 14 8.24 26 7.08 
Caregiver problem 9 4.57 4 2.35 13 3.54 
Moved out of area 7 3.55 3 1.76 10 2.72 
Other 5 2.54 4 2.35 9 2.45 
Unknown 1 0.51 11 6.47 12 3.27 
TOTAL 197 100.00 170 100.00 367 100.00 
*If institutionalisation was given as one of multiple reasons for dropout, the reason was re-coded as 
institutionalisation.    
 
FACTORS ASSOCIATED WITH DROPOUT 
In order to explore the underlying reasons for missing data in the PLASA study, the factors 
associated with time to drop out were determined using a survival analysis.  In the bivariate 
analysis (Table 14; page 75), older age, and poorer baseline MMSE, ADCS-ADL and CGIC scores 
were all significantly associated with an increased risk of dropping out, as was the caregiver 
status.  A multivariate analysis was then conducted to determine the independent effects of each 
factor on the risk of dropout after controlling for the effects of the other factors (Table 14; page 
75).  Patients who had poorer cognitive (lower MMSE score) or functional (lower ADCS-ADL 
score) status at baseline had a significantly greater risk of dropping out compared to those with 
better cognitive function and those with better functional status.      
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TABLE 14 - FACTORS PREDICTIVE OF DROPOUT IN THE PLASA STUDY 
 Bivariate analysis Multivariate analysis (N=897) 
Characteristic HR p 95% CI HR P 95% CI 
Patient age (Ref: <75 years) 
   75-80 
   80-85 
   ≥85 years 
 
1.03 
1.18 
2.11 
 
0.872 
0.21 
<0.001 
 
0.73-1.44 
0.85-1.63 
1.51-2.96 
- - - 
Patient sex (Ref: male) 
   Female 
 
0.93 
 
0.539 
 
0.75-1.16 
   
Level of education: (Ref: None/ Elementary) 
    Primary school certificate 
    Technical qualification 
    A-level or higher 
 
0.89 
0.89 
1.27 
 
0.364 
0.460 
0.133 
 
0.68-1.15 
0.65-1.21 
0.93-1.75 
- - - 
Household monthly income (Ref: <760 €/month ) 
   760-1525 €/month 
   1525-2300 €/month 
   2300-3000 €/month 
   >3000 €/month 
 
0.88 
1.04 
0.85 
1.02 
 
0.478 
0.832 
0.470 
0.929 
 
0.61-1.26 
0.71-1.52 
0.54-1.33 
0.65-1.61 
   
Time since diagnosis (Ref: 0 years) 
1 year 
2 years 
> 2 years 
 
0.88 
1.01 
1.11 
 
0.328 
0.960 
0.465 
 
0.67-1.14 
0.74-1.37 
0.84-1.46 
   
Time since onset of symptoms (Ref: Q1: (most recent)) 
  Q2 
  Q3 
  Q4 
 
0.79 
1.01 
1.09 
 
0.136 
0.967 
0.563 
 
0.58-1.07 
0.77-1.31 
0.81-1.47 
   
Use of AD treatment (Ref: No) 
   Yes 
 
0.84 
 
0.522 
 
0.49-1.43 
   
Use of other treatments (Ref: 0) 
   1-3 
   ≥4 
 
0.82 
0.87 
 
0.379 
0.526 
 
0.53-1.27 
0.56-1.34 
   
CGIC (Ref: normal/very mild impairment) 
  Mild impairment 
  Moderate impairment 
  Marked impairment 
  Severe/very severe impairment 
 
0.98 
1.60 
2.14 
3.66 
 
0.932 
0.067 
0.004 
<0.001 
 
0.58-1.65 
0.97-2.64 
1.28-3.58 
1.92-7.00 
§   
MMSE score (Ref: Q4 (highest scores)) 
   Q1 (lowest score) 
   Q2 
   Q3 
 
1.93 
1.62 
1.03 
 
<0.001 
0.004 
0.882 
 
1.42-2.62 
1.16-2.24 
0.73-1.45 
 
2.01 
1.76 
1.22 
 
<0.001 
0.005 
0.327 
 
1.37-2.95 
1.19-2.62 
0.82-1.82 
ADCS-ADL score (Ref: Q4 (highest scores)) 
   Q1 
   Q2 
   Q3  
 
1.88 
1.23 
1.42 
 
<0.001 
0.199 
0.063 
 
1.42-2.50 
0.90-1.67 
0.98-2.07 
 
1.72 
1.26 
1.54 
 
0.001 
0.168 
0.030 
 
1.26-2.34 
0.91-1.75 
1.04-2.28 
Caregiver age (Ref: Q1 (youngest subjects)  
   Q2 
   Q3 
   Q4 
 
0.93 
0.81 
0.95 
 
0.648 
0.162 
0.726 
 
0.70-1.25 
0.61-1.09 
0.71-1.26 
§   
Caregiver sex (Ref: male)  
   Female 
 
1.06 
 
0.579 
 
0.86-1.32 
   
Caregiver status/living arrangements (Ref: spouse) 
 Son/daughter, not living with patient 
 Son/daughter, living with patient 
Other 
 
1.01 
1.47 
1.69 
 
0.900 
0.049 
0.002 
 
0.81-1.28 
1.00-2.15 
1.20-2.37 
- - - 
Type of centre (Ref: CHG) 
   CHU 
 
1.14 
 
0.199 
 
0.93-1.40 
 
 
  
Centre size (Ref: ≤20 patients) 
   21 – 24 patients 
   25 – 30 patients 
   >30 patients 
 
0.97 
0.82 
1.00 
 
0.847 
0.195 
0.973 
 
0.74-1.28 
0.61-1.11 
0.76-1.31 
   
Group (Ref: intervention group) 
   Control group 
 
0.88 
 
0.227 
 
0.72-1.08 
   
Q: quartile 
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- : variable included in initial multivariate model, but did not remain in final model following backwards 
stepwise selection procedure.  
§ Variable not included in the multivariable model due to colinearity 
The multivariate model was stratified by centre.   
CHANGE IN OUTCOME MEASURES OVER TIME ACCORDING TO DROPOUT STATUS 
Mean scores (with 95% CIs) on the ADCS-ADL, MMSE and QOL-AD scales in the intervention and 
control groups according to dropout status are presented graphically.  The evolution of the 
ADCS-ADL over 2 years appeared to be roughly linear in study completers in both groups 
(Figure 7, page 76).  At baseline, subjects who went on to drop out of the study at or before 1 
year had significantly lower ADCS-ADL scores than study completers in both groups.  The slope 
of decline during the first year in study completers appears to be similar to that of subjects who 
dropped out at the 2 year visit.  Scores appear to be lower at all time points in the dropout 
group, although the differences between mean scores of study completers and subjects who 
dropped out at 2 years were not significantly different.   
We also examined the evolution of the other outcome measures according to dropout status.  
Subjects who dropped out of the study at any time had significantly lower MMSE scores than 
study completers at baseline in both groups (Figure 8, page 77).  Subjects who dropped out at 
the 2 year visit also had significantly lower scores than study completers at the 12 month visit in 
both groups.   
 
 
FIGURE 7 - MEAN ADCS-ADL SCORES OVER TIME IN THE PLASA STUDY ACCORDING TO DROPOUT 
STATUS AND INTERVENTION GROUP 
The dashed lines represent the 95% confidence intervals for the empirical means.  “Dropouts 1-2y” 
indicates subjects who dropped out between the 1- and 2-year visits, and “Dropouts before 1y” indicates 
subjects who dropped out between baseline and the 1-year visit. 
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FIGURE 8 - MEAN MMSE SCORES OVER TIME IN THE PLASA STUDY ACCORDING TO DROPOUT STATUS 
AND INTERVENTION GROUP 
The dashed lines represent the 95% confidence intervals for the empirical means.  “Dropouts 1-2y” 
indicates subjects who dropped out between the 1- and 2-year visits, and “Dropouts before 1y” indicates 
subjects who dropped out between baseline and the 1-year visit. 
 
Patients who dropped out of the study before the 1 year visit also had significantly lower QOL 
(as rated by their caregivers) at baseline in both groups compared to study completers (Figure 9, 
page 77).   
 
FIGURE 9 - MEAN CAREGIVER-RATED PATIENT QUALITY OF LIFE SCORES IN THE PLASA STUDY 
ACCORDING TO DROPOUT STATUS AND INTERVENTION GROUP 
The dashed lines represent the 95% confidence intervals for the empirical means.  “Dropouts 1-2y” 
indicates subjects who dropped out between the 1- and 2-year visits, and “Dropouts before 1y” indicates 
subjects who dropped out between baseline and the 1-year visit. 
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OTHER MISSING OUTCOME DATA 
In addition to missing data due to dropouts and missed visits, the primary outcome variable was 
also missing (after imputation of up to 5 items) for 37 patients (3.3%) at baseline, 153 of the 844 
patients (18.1%) present at the 1 year visit, and 166 of the 678 patients (24.5%) present at the 
two year visit.  The rate of missing data for the primary outcome measure amongst patients 
present at the visit was significantly higher in the intervention group than in the control group at 
all time points (Baseline: 4.5% vs. 2.0%, p=0.016; 1 year visit: 22.8% vs. 13.3%, p<0.001; 2 year 
visit: 32.2% vs. 16.9%, p<0.001).     
 
ESTIMATION OF ADCS-ADL EVOLUTION DURING THE TRIAL AND EFFECT OF THE 
INTERVENTION 
A summary of the results of each of the six analyses are presented in Table 15 (page 79) and 
Figure 10 (page 80).  Observed mean values calculated from the subjects present at each visit 
are also presented in the graph for comparison.   
COMPLETE CASE ANALYSIS 
The subset of subjects (i.e. those with a baseline and 2-year score; N=507) included in the 
complete case analysis had higher mean scores at baseline and 1 year than the observed mean 
scores in the whole population.  The mean score at 2 years in these subjects was higher than 
those estimated by all of the methods using the MAR assumption (Z-score LOCF, Longitudinal 
mixed model, multiple imputation analyses), but slightly lower than the estimated 2-year mean 
score in the LOCF analysis.   
The mean change from baseline in the complete case analysis was -13.25 points in the 
intervention group and -11.66 points in the control group; neither was significantly different 
from any of the estimated mean changes from baseline obtained in the analyses based on the 
MAR assumption.  The mean change from baseline was not significantly different between 
groups (p=0.230) indicating that the intervention did not affect functional decline.   
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TABLE 15 - COMPARISON OF MEAN ADCS-ADL SCORES AND INTERVENTION EFFECTS IN THE PLASA STUDY USING DIFFERENT STATISTICAL METHODS 
Analysis 
Mean ADCS-ADL score ± SE [95% CI] a Mean 2-y change from baseline ± 
SE [95% CI] 
Intervention 
effect T0 T1 year T2 years 
Group:  Intervention Control Intervention Control Intervention Control Intervention Control 
Complete case (N=507) 57.12 ± 0.90 
[54.35; 58.90] 
53.76 ± 0.89  
[52.01; 55.51] 
52.15 ± 1.15 
[49.89; 54.41] 
49.18 ± 1.06  
[47.10; 51.26] 
43.84 ± 1.22 
[41.44; 46.24] 
42.06 ± 1.09 
[39.91; 44.22] 
-13.25  ± 0.98 
[-15.18; -11.33] 
-11.66  ± 0.89 
[-13.41; -9.91] 
-1.59 (p=0.230) 
LOCF (N=1086) 53.08 ± 0.66 
[51.79; 54.38] 
51.40 ± 0.69 
[50.04; 52.77] 
49.32 ± 0.73 
[47.90; 50.75] 
46.98 ± 0.75 
[45.51; 48.46] 
45.77 ± 0.76 
[44.28; 47.27] 
43.27 ± 0.78 
[41.73; 44.82] 
-7.07 ± 0.81 
[-8.67; -5.47] 
-8.16 ± 0.83 
[-9.79; -6.53] 
1.09 (p=0.350) 
Z-score LOCF (N=1086) 53.08 ± 0.66 
[51.79; 54.38] 
51.40 ± 0.69  
[50.04; 52.77] 
47.86 ± 0.77 
[46.35; 49.37] 
45.29 ± 0.78  
[43.76; 46.82] 
40.69 ± 0.81 
[39.10; 42.29] 
39.54 ± 0.82  
[37.94; 41.15] 
-12.34 ± 0.58 
[-13.49; -11.20] 
-11.88 ± 0.59 
[-13.04; -10.72] 
-0.46 (p=0.580) 
Longitudinal mixed effects 
model (N=1097) 
52.63 ± 1.06 
[50.54; 54.71] 
51.52 ± 1.09 
[49.39; 53.65] 
46.14 ± 1.10 
[43.98; 48.30] 
45.42 ± 1.11 
[43.23; 47.60] 
39.66 ± 1.28 
[37.15; 42.16] 
39.31 ± 1.26 
[36.84; 41.78] 
-12.97 ±  0.82 
[-14.58; -11.36] 
-12.21 ± 0.75 
[-13.69; -10.73] 
-0.76 (p=0.497) 
Multiple imputation: 
change from baseline 
analysis (N=1097) 
52.90 ± 0.67  
[51.59; 54.22] 
51.43 ± 0.69  
[50.06; 52.79] 
46.82 ± 0.88  
[45.07; 48.56] 
45.17 ± 0.81 
[43.57; 46.78] 
38.89 ± 1.07  
[36.78; 41.01] 
38.48 ± 0.91 
[36.69; 40.28] 
-13.94 ± 1.06 
[-16.05; -11.84] 
-12.97 ± 0.92 
[-14.80; -11.15] 
-0.97 (p=0.503) 
Multiple imputation: 
longitudinal mixed model 
analysis (N=1097) 
52.78 ± 1.06 
[50.70; 54.86] 
51.66 ± 1.07 
[49.55; 53.78] 
45.80 ± 1.11 
[43.62; 47.98] 
45.36 ± 1.09 
[43.21; 47.51] 
38.82 ± 1.32 
[36.22; 41.43] 
39.06 ± 1.23 
[36.64; 41.48] 
-13.95 ± 0.91 
[-15.79; -12.12] 
-12.60 ± 0.75 
[-14.08; -11.12] 
-1.34 (p=0.279) 
a Means and standard errors at each time point were calculated from empirical data for the complete case, LOCF and z-score LOCF analyses, and from the model 
coefficients for the longitudinal mixed effects models.   
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FIGURE 10 - ESTIMATED MEAN ADCS-ADL SCORES AT EACH TIME POINT IN THE PLASA STUDY 
ACCORDING TO INTERVENTION GROUP AND STATISTICAL METHOD 
LOCF: last observation carried forward; MI: multiple imputation; Long. mixed model: longitudinal mixed model 
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LOCF ANALYSIS 
All 1086 patients with a baseline ADCS-ADL score after missing item imputation were included 
in the LOCF analysis.  Mean 2-year ADCS-ADL scores according to this method were significantly 
higher than those obtained in the analyses based on the MAR assumption.  They also appeared 
higher than in the complete case analysis, although the difference was not significant.   
The estimated mean change from baseline was -7.27 points in the intervention group and -8.13 
points in the control group.  Both estimates were significantly lower than those obtained in all of 
the other analyses.  The difference between groups was not significant (difference: 1.09; 
p=0.350).     
Z-SCORE LOCF CHANGE FROM BASELINE ANALYSIS 
As with the standard LOCF analysis, all 1086 patients with a baseline ADCS-ADL score were 
included in the Z-score LOCF analysis.   The estimated mean ADCS-ADL score at 2 years in both 
groups was numerically, but not significantly, higher than in the other MAR analyses.     
The mean change from baseline was -12.36 and -11.86 in the intervention and control groups 
respectively; neither estimate was significantly different from the complete case analysis or 
from any of the other MAR analyses, and the difference between the two groups was not 
statistically significant (difference: -0.46; p=0.580).   
LONGITUDINAL MIXED EFFECTS MODEL 
All patients were included in the longitudinal mixed effects model (N=1087).  The estimated 
mean scores at baseline using this model were similar to all of the other methods, except for the 
complete case analysis.  At 2 years, estimated mean scores in both groups were similar to those 
estimated from the other MAR methods.   
Likewise, estimated mean changes from baseline (-12.97 and -12.21 in the intervention and 
control groups respectively) were similar to those estimated from other MAR analyses, as well 
as that of the complete case analysis.  Again, the difference in evolution between the two groups 
was not statistically significant (-0.76, p=0.497)     
MULTIPLE IMPUTATION 
The multiply imputed datasets were analysed using both a change from baseline analysis and a 
longitudinal mixed effects model.  There was little difference in the results between the two 
methods.  Both produced estimates for the mean 2 year ADCS-ADL scores and the mean change 
from baseline that were not significantly different to those obtained in the other MAR methods 
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and the complete case analysis, although numerically the multiple imputation analyses produced 
the highest estimates of the two year change from baseline in both groups.  The difference 
between groups was not significant in either analysis.     
 
2.3.3 DISCUSSION 
Using data from a multi-centre randomised controlled trial in AD, we compared different 
methods for handling missing data and analysing treatment effects.  All methods led to the same 
overall conclusion: no effect of the intervention on the primary outcome measure.  However, the 
estimated mean 2-year decline in each group as well as differences between groups varied 
widely across methods.   
Less than 50% of subjects were included in the complete case analysis, causing a considerable 
loss of power.  In this analysis, the ITT principle was not respected since not all randomised 
subjects were analysed.  The MCAR assumption, on which complete case analyses are based, 
does not appear to be valid in our study since our analyses showed that patients who dropped 
out differed from those who remained in the study, and that outcome evolution varied according 
to dropout status.   
The LOCF analysis substantially underestimated the 2-year ADCS-ADL decline in both groups 
compared to all of the other methods.  In the intervention group, the estimated change (-7.07 
points) was only approximately half as much as that estimated from the multiply imputed data (-
13.95).  In the LOCF analysis, 357 subjects were considered to have no change from baseline, but 
304 of these subjects (170 in the intervention group and 134 in the control group) did not 
actually have an ADCS-ADL score after the first visit, so the “no change” values for these subjects 
were artificial.  Thus, the validity of this analysis is extremely questionable, since it is highly 
unlikely that these patients underwent no decline: all of the analyses showed a significant 
decline over time in ADCS-ADL scores in both groups.  The fact that there were more subjects 
with an artificial decline of 0 in the intervention group compared to the control group may have 
led to an overestimation of the intervention effect 148.  Indeed, the estimated intervention effect 
in this analysis favoured the intervention group (although it was not statistically significant), 
whereas in all of the other analyses, the data suggested greater decline in the intervention group 
than in the control group.  In fact, the LOCF analysis may be even more biased than the complete 
case analysis in our study.  Despite widespread criticism of this method 130, 134-138, its use persists 
in clinical trials, perhaps because of its simplicity, ease of implementation and the belief that the 
potential bias from using LOCF leads to a “conservative” analysis 132-133, 139.  Our results confirm 
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the view of other authors 118 that LOCF is not appropriate for primary analyses of long-term AD 
trials.     
The Z-score LOCF approach seems more valid than the standard LOCF analysis since the 
underlying assumption takes into account the fact that AD patients undergo decline over time.  
The estimated 2-year declines in ADCS-ADL scores were greater using this method than 
standard LOCF imputation and were within about half a point of the 2-year change estimates 
from the longitudinal mixed model.  However, the assumption that the Z-score of patients in 
relation to their group mean remained constant over time may be invalid, in particular because 
the group means at the 1- and 2-year visits were only calculated from the available subjects, and 
therefore may have been higher than the real group means that would have been observed had 
all of the patients been present at these visits.  Thus the imputed data based on Z-scores for 
patients with missing data may have been too high.            
Both the longitudinal mixed model and the multiple imputation procedures were based on the 
assumption of MAR, and produced similar results, although in the longitudinal mixed model, 
estimated mean 2-year ADCS-ADL scores were numerically higher and the estimated mean 
changes from baseline were numerically lower.  The mixed model only took into account 
previous ADCS-ADL scores in the MAR assumption, whereas the multiple imputation model also 
took into account baseline variables associated with ADCS-ADL scores and missing data, as well 
as MMSE and ADCS-ADL scores over time, thus employing a broader MAR assumption based on 
observed covariates.  This method produced larger estimates of the mean change from baseline 
in each group, and lower estimated mean 2-year ADCS-ADL scores than all of the other methods.  
The results from the multiple imputation analyses would seem plausible given our hypothesis 
that subjects who dropped out of the study and had missing data for the primary outcome 
measure were more impaired than those present at the end of the study.   The MAR assumption 
may be more plausible under multiple imputation than under the mixed model approach, since 
more predictive information can be used in multiple imputation 142, 183-184.  The use of additional 
covariates in the imputation model may have been particularly important in our trial given that 
the primary study outcome measure was missing even amongst some subjects who did not miss 
study visits.  However, the MAR assumption is still only truly justified if we are sure that we 
included all variables predictive of missingness or ADCS-ADL scores in the imputation model 185.   
In light of our results, it would seem that MAR methods are more suited to AD trial data than 
complete case or LOCF analysis.  Other studies comparing different statistical methods for the 
management of missing data have drawn similar conclusions 146, 148, 186-187.  The validity of MAR 
methods must nonetheless be assessed, especially when there is a high level of missing data.     
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The MAR assumption remains plausible in AD trials, even though subjects who complete such 
trials differ from those who drop out, since it allows missingness to depend on observed data, 
such as baseline characteristics and previous measures of impairment at different time points 
throughout the trial.  However, the assumption of MAR is unverifiable and we cannot be sure 
that some data are not MNAR 188.  Multiple imputation models which include large numbers of 
predictor variables, or indeed other MAR analyses which include a sufficient number of 
covariates, should help to make the MAR assumption more plausible and help to limit the impact 
of MNAR missingness 142, 183-184.  However, the MAR assumption is still only truly justified if we 
are sure that we included all variables predictive of the dependent variable or missingness in the 
imputation model 185.  Other more complex statistical techniques which are more adapted to 
MNAR data, such as selection or pattern mixture models, are available.  However, such 
approaches cannot always be carried out in standard statistical software and are not adapted for 
the primary analysis of a clinical trial since they rely on numerous untestable assumptions 125, 
150.  They may, however, be useful for sensitivity analyses 188. 
One issue that we did not specifically consider in our analyses is how to deal with missing data 
due to death.  We treated dropout due to death in the same way as other forms of dropout, and 
therefore our estimated trajectories for these patients may have been over-optimistic 189.  
Statistical methods specifically adapted to longitudinal data with missing data due to death have 
been developed 190 and could also be employed in sensitivity analyses for AD trials.    
As part of this study of missing data in the PLASA trial, we identified low baseline cognitive and 
functional status as predictors of dropout.  Functional impairment was also found to be 
predictive of dropout in the REAL.FR observational study, presented earlier in this chapter.   
Cognitive impairment was not associated with dropout in the REAL.FR study, although it has 
been found to be predictive of attrition in population-based longitudinal studies of the elderly 71.  
Greater caregiver burden was found to be predictive of dropout in the REAL.FR study, even after 
taking into account the patient's level of impairment.  We did not assess caregiver burden as a 
predictor of dropout in the PLASA study since it was only measured in the intervention group. 
Also, the “caregiver status/living arrangements” variable was associated with attrition in 
REAL.FR, but not in PLASA.  Compared to the PLASA study, there were more spousal caregivers 
(53.4% vs. 48.2, p=0.031) and less child caregivers (37.6% vs. 43.3%, p=0.017) in REAL.FR, 
while the proportion of “other” caregivers was similar in both studies (8.5% and 9.0%, p=0.71).  
The difference in the proportions of patients living alone (31.0% in PLASA versus 26.8% in 
REAL.FR) was borderline significant (p=0.057).   
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The use of anti-dementia drugs, as well as the use of other types of medication were associated 
with a lower risk of dropout in the REAL.FR study, but were not associated with dropout in 
PLASA.  However, nearly all of the patients included in PLASA were receiving anti-dementia 
drugs at baseline.     
Other differences in study methodology and study participants which could explain the 
differences in results between the two studies concerning predictors of attrition include: 
- PLASA was a randomised controlled trial, whereas REAL.FR was an observational study. 
- Patients were evaluated every 6 months in REAL.FR; in PLASA, patients in the 
intervention group were also evaluated every 6 months, but those in the control group 
were only evaluated annually. 
- REAL.FR was carried out in university hospitals only, whereas PLASA also involved 
general hospitals. 
- The attrition rate was slightly lower in PLASA (32.5%) than REAL.FR (40.5%) at 2 years. 
- Compared to patients in REAL.FR, patients in PLASA were slightly older, were more often 
treated with anti-dementia drugs and had a slightly lower level of education. 
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2.4 CHAPTER CONCLUSION AND RECOMMENDATIONS 
The work presented in the first part of this chapter described the level of attrition in a 
longitudinal observational study of AD patients, and identified baseline factors that were 
predictive of dropout.  In the second part, the level and causes of missing data in a longitudinal 
randomised trial were described, and the impact of using different methods of management of 
missing data on the primary analysis was assessed. 
This work confirms that missing data pose a significant threat to the validity of AD clinical 
research.  We found dropout rates of 40.5% and 32.5% at 2 years respectively in an 
observational and randomised controlled experimental study involving AD patients.  
Furthermore, there were also high levels of missing data for the primary outcome measure in 
the randomised trial even amongst patients who were present at study evaluations.     
Certain patient (poor functional status, non-use of ChEIs, use of other types of medication) and 
caregiver (relationship with patient, level of subjective burden) factors were predictive of 
dropout, suggesting that data is generally not missing completely at random.  The finding that 
caregiver factors are associated with patient attrition is particularly original since previous 
studies of attrition have not focused on caregiver factors.   
The second part of this chapter showed that the methods of missing data management and 
analysis have the potential to significantly affect the results and conclusion of clinical trials 
involving AD patients.  It was also demonstrated that simple methods of data analysis, such as 
complete case and LOCF, which have traditionally been used in clinical trials, are not suitable for 
long-term AD trials since their underlying hypotheses are clearly violated.   Modern techniques, 
such as maximum likelihood and multiple imputation, are based on more realistic hypotheses, 
namely that missing data are MAR, and would seem more adapted to the missing data in AD 
studies.  Since we can never be sure of the underlying mechanism of missing data, and further 
sensitivity analyses using methods with less restrictive assumptions are to be encouraged.   
Despite the availability of a variety statistical techniques for dealing with missing data, the best 
way to deal with it is to avoid it in the first place 122.  We have identified both patient and 
caregiver factors which were predictive of dropout in our studies.  These factors can be used to 
target attrition prevention strategies to subjects at most risk of dropping out.   
In light of these analyses, the following recommendations concerning attrition and missing data 
in AD studies can be suggested: 
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1. Given the potential impact of missing data on longitudinal observational and 
experimental studies involving AD patients, particular attention should be paid to this 
problem from the study design phase right through to the analysis, interpretation and 
presentation of results.   
2. Suitable tracking procedures and attrition prevention strategies should be designed and 
employed throughout the trial.  Particular attention should be paid to patients with 
poorer cognitive or functional status at baseline and those who are not using anti-
dementia medications, as well as patients looked after by a caregiver who is not their 
child or spouse.  Furthermore, interventions aimed at reducing caregiver burden might 
help increase patient participation in clinical studies, in addition to any potential effects 
on quality of life and patient management.  In the PLASA study, an initial trial of a 
telephone contact procedure for caregivers who did not reply to a postal questionnaire 
about the patient’s status suggested that telephone contacts may be a simple and 
efficient way of reducing missing data in AD studies (see appendix for details).   
3. Outcome measures should be carefully chosen and must be suitable for use with all 
patients throughout the duration of the study, which even in clinical trials may now be as 
long as 2 years.  Given the progressive nature of AD, patients decline over two years and 
some become institutionalised, so the outcome measures must be appropriate for 
different stages of disease severity and different settings.   
4. Investigators should be thoroughly trained in the completion of study outcome 
measures, and timely monitoring procedures should be employed in order to detect any 
data completion problems.  
5. Alternative forms of data collection should be considered in order to reduce the burden 
of study visits: e.g. home visits, telephone/postal evaluations, which should in turn 
reduce the amount of missing data. 
6. Retrieved dropout visits should be planned from the study outset and carried out 
systematically in order to obtain a minimum of information for all dropouts where 
possible: for example whether or not the patient is still alive, current living 
arrangements, and if possible some form of assessment of cognitive and/or functional 
status.  This information then needs to be incorporated into the trial analyses, perhaps as 
part of sensitivity analyses.   
7. A thorough examination of missing data including determining the rate and causes, and 
identification of differences between patients with and without missing data, should be 
carried out in order to assess the suitability of the planned analysis methods, and the 
potential impact of missing data on study results.     
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8. Complete case and LOCF analyses are not suitable methods of analysis for long-term AD 
trials.  The MAR hypothesis seems more suitable than the MCAR for AD trials.  However, 
since the missingness mechanism cannot be tested, sensitivity analyses using methods 
based on different assumptions, including MNAR, would be helpful in order to assess the 
robustness of the results observed in the primary analysis.   
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3. ENDPOINTS 
3.1 INTRODUCTION 
3.1.1 DEFINITION OF ENDPOINTS 
Endpoints are used to judge the effects of interventions in clinical trials.  They are generally 
measures of disease outcomes, such as survival, changes in health status or quality of life, or 
relief of symptoms.  The reliability, validity, and responsiveness of the outcome measures used 
influences their ability to accurately estimate the effect of an intervention, to detect clinical 
change, and has implications for calculations of sample size 191.  Ideally, endpoints should be: 
- relevant to disease process  
- reliable and free from measurement or assessment error 
- sensitive to treatment differences and disease progression 
- measurable within a reasonable period of time   
- easily interpretable 
- reflective of the research question (e.g. determination of the efficacy or safety of an 
intervention) 
Most trials measure several endpoints (or outcomes) which can be distinguished into primary 
and secondary endpoints.  The primary endpoint (or primary outcome measure) is the pre-
specified outcome which is considered to be of greatest importance to patients and/or other 
stakeholders, such as policy makers, clinicians or funders 192.   Definition of the primary endpoint 
is one of the most important decisions in the design of clinical trials, since it affects the target 
population, sample size, the rationale for the use of the intervention in clinical practice, and cost-
effectiveness considerations.  Other outcomes of interest are measured by secondary endpoints.  
Such endpoints can contribute to the interpretation of a clinical result, although the primary 
conclusions should be based on the primary endpoint alone.   
The CONOSRT guidelines recommend the use of previously validated scales or consensus 
guidelines for outcome measures in order to improve the quality of measurement, and assist in 
comparisons with other similar studies 192.   
Another important consideration for endpoints is their “clinical relevance”, i.e. what the effect 
means in clinical practice and in particular to the patient.  The “minimal clinically important 
difference” for any given measurement is considered to be the smallest difference between two 
assessments that have a perceived impact on disability and/or handicap, or the smallest 
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treatment effect that would bring about a change in patient management, taking into account the 
side effects, costs and inconveniences 193.   
Surrogate endpoints are becoming increasingly discussed as alternatives to true clinical 
endpoints.  They can be considered as laboratory measurements (often known as "biomarkers") 
or physical signs that substitute for clinically meaningful endpoints 194.  Surrogate endpoints 
therefore do not directly measure clinical benefit (or harm, or lack of benefit) to the patient, but 
they are expected to predict it based on epidemiologic, therapeutic, pathophysiologic or other 
scientific evidence 195.  Surrogate endpoints are useful because they may be measurable earlier 
on in the disease process than clinical endpoints, thus enabling earlier intervention.  They may 
also be more objectively measurable, and may reduce the size and/or duration of clinical trials, 
thus reducing cost, and also potentially reduce the rate of dropouts.  Surrogate endpoints are 
useful if they can be easily measured and are highly correlated with direct endpoints of clinical 
relevance, but they must be formally validated before they can be officially used as surrogate 
markers in clinical trials.  Simply being a correlate of the clinical outcome of interest is not 
sufficient; to be a true surrogate endpoint, the effects of an intervention on the surrogate must 
reliably predict the overall effect of the intervention on the clinical outcome 194.  In practice, this 
requirement can be difficult to demonstrate, since for example, the intervention may affect the 
clinical outcome by several pathways or mechanisms which are not all mediated by the 
surrogate 194.  Some examples of commonly used surrogate endpoints include the reduction of 
arterial blood pressure as a surrogate for the reduction of the incidence of stroke, congestive 
heart failure and subsets of cardiovascular death in antihypertensive drug trials 196; and changes 
to HIV plasma viral load and CD4 counts as substitutes for clinical outcomes such as death or the 
occurrence of opportunistic infections in HIV trials 197.   
 
3.1.2 METHODOLOGICAL CONSIDERATIONS FOR ENDPOINTS IN AD TRIALS 
The endpoints used in AD trials are still subject to discussion, in particular due to the changing 
characteristics of AD trials and the patients included in them.  For example, it is becoming 
increasingly possible to diagnose patients earlier on in the disease course 7, meaning that 
interventions can be tested in patients with much milder levels of impairment.  Outcome 
measures that have traditionally been used in symptomatic AD trials carried out in patients with 
mild to moderate AD, may not be appropriate for use in patients with much milder forms of the 
disease because they may not measure the most relevant aspects of the disease in its early 
stages.    
91 
 
Another problem arises because most AD trials are now “add-on” designs (i.e. a new treatment is 
tested in addition to the existing standard-of-care regime), since the patients included are 
already being treated with symptomatic AD drugs.  There may therefore be fewer clinically 
detectable differences between patients receiving the investigational drug and those receiving 
the placebo, and less decline may be observed on standard outcome measures.  Therefore, 
outcome measures must be sensitive enough to detect relatively small changes.       
Furthermore, since most trials are now aimed at disease-modifying drugs, they are of longer 
duration than the standard 6 month trials used to demonstrate the efficacy of symptomatic 
treatments 21.  This means that the outcome measures used must be valid at different stages of 
the disease process, since although patients may only have very mild forms of the disease at 
baseline, their level of impairment is likely to progress throughout the course of the trial.  Given 
the long duration of these trials, the outcome measures used should not be burdensome to 
participants or their caregivers, since this could lead to high dropout rates.   
There has been much discussion regarding the demonstration of disease modifying effects, as 
opposed to symptomatic effects, in clinical trials.  Some authors have proposed new study 
designs (e.g. randomised start or withdrawal designs 198, staggered start trials 199) for this 
purpose, but they may be complicated to implement in practice.  Drug regulatory authorities 
have stated that they will require proof of changes in biomarkers as well as clinical effects in 
order for claims of disease modification to be considered 200.  Therefore, huge efforts are 
currently being put into biomarker research 201-202, with the hope of validating biomarkers as 
surrogate endpoints.  However, clinical outcome measures will also continue to be used for the 
foreseeable future, particularly in trials involving patients already diagnosed with AD.   
The outcomes used in AD, such as measures of cognition or function, are indirect measurements 
of underlying disability, which is a “latent” variable that we cannot easily measure 191.  As 
mentioned above, the “clinical relevance” of changes on outcome measures is an important 
consideration, but this can be difficult to determine in particular for continuously scored rating 
scales, such as the typical measures of cognitive function used in AD trials.  Indeed, there have 
been relatively few attempts to establish the minimal clinically important difference in the field 
of neurology in general 203-205, and even less so in AD 206.   
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3.1.3 CURRENT ENDPOINTS IN AD TRIALS 
Drug regulatory authorities currently require the demonstration of simultaneous improvement 
in both cognitive and functional domains in AD drug trials - the European Medicines Agency 
(EMEA) states that “two primary endpoints should be stipulated reflecting the cognitive and the 
functional domain”28.  There is no clear “gold-standard” endpoint for AD trials. However the 
Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) 154 is currently the most 
commonly used cognitive test in trials for mild to moderate AD, generally in conjunction with a 
functional (e.g. ADCS-ADL) or global (e.g. CIBIC-plus, CDR) co-primary endpoint 120.   
Despite its widespread use, the ADAS-Cog is not a perfect outcome measure for AD trials for a 
number of reasons, including, inadequate coverage of all relevant cognitive domains, 
insensitivity to very mild impairments, difficulties in determining the clinical relevance of 
changes, high within- and between-subject variability, and the potential for learning effects 
following repeated evaluations 207-209.    
The use of two co-primary endpoints also means that for a trial to be considered positive, 
significant effects must be found on both primary outcome measures, and a correction for 
multiple testing should be used, meaning that more subjects need to be enrolled in order to have 
sufficient statistical power to detect differences on both instruments simultaneously.   
A variety of secondary endpoints can also be included in AD trials, covering a variety of other 
aspects related to the disease, such as behavioural and psychological symptoms of dementia 
(BPSD), quality of life and pharmacoeconomics.  However, such endpoints are not the focus of 
this work and so will not be discussed further.   
 
ENDPOINTS IN PRIMARY PREVENTION TRIALS 
Given the difficulties of achieving disease modification in symptomatic AD, focus is now turning 
to earlier intervention in the disease process, i.e. trying to prevent AD rather than cure it.  The 
overall goal of primary prevention trials is to reduce the incidence of AD or delay its onset.  The 
“gold standard” endpoint for prevention trials is therefore the diagnosis of dementia of the 
Alzheimer type, according to validated standardized criteria, such as those of the DSM-IV and 
NINCDS-ADRDA 2-3.  This is a clinically relevant endpoint, since dementia is a clearly defined 
medical condition.  However, the use of dementia incidence as an endpoint in clinical trials is 
complicated in practice.  Firstly, the incidence of dementia remains relatively low in prevention 
trials, probably due to the characteristics of those who volunteer to participate in such trials, 
who are probably in better health than those who do not participate 210.  Also, the incidence rate 
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may be affected by dropout, since subjects who go on to develop dementia may be precisely 
those who drop out of such studies.  If dementia onset occurs after a participant has withdrawn 
from the study, it will not be included in the study analysis.  In order to have sufficient power to 
detect treatment effects, prevention studies using dementia incidence as the primary endpoint 
therefore require large numbers of subjects (generally at least 3000) and long follow-up periods 
(upwards of 5 years).   
The second difficulty with using dementia incidence as the primary endpoint in prevention trials 
is linked to the fact that it may be difficult for investigators to determine the precise moment of 
conversion to dementia in subjects who are being regularly followed-up given the continuum 
between normal aging, MCI or very early AD, and AD type dementia.  Furthermore, all diagnoses 
in prevention trials must be validated by a diagnostic committee, adding an extra level of 
complexity to the study.     
An alternative primary endpoint for primary prevention trials is the rate of cognitive decline, 
which is more easily measurable than dementia incidence.  Analyses are based on the slope of 
cognitive decline calculated from repeated measures on study participants.  Therefore several 
data points are used for each subject (rather than just a single binary outcome) in the study 
analysis, which means there will be increased statistical power compared to a time-to-event 
analysis.  Furthermore, appropriate statistical models 139, 142 enable all participants to be 
included in analyses of cognitive decline, even if they do not complete the whole follow-up 
period.  Thus, trials using cognitive decline as their primary endpoint require fewer subjects and 
shorter follow-up periods than trials measuring dementia incidence.  The main difficulties 
associated with using the rate of cognitive decline as the primary endpoint for prevention trials 
are (i) it is not a valid “surrogate marker” of dementia incidence – an intervention able to 
decrease the rate of cognitive decline will not necessarily have an effect on dementia incidence; 
and (ii) it is difficult to determine the clinical relevance of cognitive decline in itself, so an 
intervention that can “significantly” reduce cognitive decline might have very limited benefits in 
clinical practice.  Furthermore, there is no standardized battery of cognitive tests that has been 
developed for prevention trials, meaning that each trial may use very different outcome 
measures, making it difficult to compare results across studies 120. 
Given the difficulties of using dementia incidence as a primary endpoint in prevention trials, it is 
clear that surrogate endpoints that could be measured as a substitute for dementia incidence, 
would be of particular use in this setting.  However, currently, there are no validated surrogate 
endpoints for AD.  Various biomarkers, including cerebrospinal fluid (CSF) or plasma Aβ and tau, 
and molecular and structural  imaging, are candidate surrogate endpoints for AD prevention 
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trials, but are far from being validated as such 211.  An alternative surrogate endpoint for 
prevention trials is cognitive decline, which, although in itself is also a clinical endpoint, i.e. “a 
characteristic or variable that reflects how a patient feels, functions or survives” 195, rather than 
a biomarker, could still be considered as a “surrogate endpoint” for prevention trials if it can be 
demonstrated that intervention-induced changes in cognitive function are directly related to the 
onset of dementia.   
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3.1.4 CHAPTER AIMS 
The main goal of the work presented in this chapter was to examine the suitability of potential 
new endpoints for AD trials.   
Given the complexities of using two co-primary endpoints, as is currently the case in AD trials, it 
might be preferable to use a single primary endpoint.  In the case of AD, this single endpoint 
would need to cover both cognitive and functional domains.  A similar approach is used in 
Parkinson’s disease, for example, where the sum of the activities of daily living (ADL) and motor 
function sections of the Unified Parkinson’s Disease Rating Scale 212 is a commonly used 
endpoint for both symptomatic and disease-modification trials 213.   The aim of the first analysis 
in this chapter was therefore to assess the suitability of the CDR-SB, a widely used measure of 
global disease progression, as a single primary endpoint for very mild to moderate AD trials, 
instead of the usual two co-primary endpoints.   The validity and responsiveness of the CDR-SB 
were assessed using data from the REAL.FR cohort study, with the specific aims of (i) 
demonstrating that the CDR-SB has clear cognitive and functional components and that changes 
in the CDR-SB score reflect changes in both components; (ii) studying its convergent validity 
with other cognitive and functional tests; (iii) determining internal and external responsiveness 
of the CDR-SB and other measures, and (iv) comparing data quality and trial sample sizes for the 
CDR-SB and traditional primary endpoints.   
Given the difficulties of using dementia incidence as the primary endpoint in prevention trials, 
and the fact that biomarkers are still far from being validated as surrogate endpoints, the aim of 
the second section was to carry out a preliminary exploration of cognitive decline in a 
longitudinal prevention trial, with a view to validating cognitive decline as a surrogate endpoint 
for AD prevention trials.  Trajectories of cognitive decline on various tests were studied in older 
adults with memory complaints, using data from the GuidAge trial, in order to visualise 
differences in cognitive trajectories of subjects who remained dementia free, and those who 
were diagnosed with dementia during 5 year follow-up.  Further analyses were also conducted 
to assess whether 1-year changes in cognitive or functional test scores were predicative of 
future dementia diagnosis, and to determine which tests were the most predictive.   
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3.2 SUITABILITY OF THE CDR-SB AS A SINGLE PRIMARY ENDPOINT FOR 
AD TRIALS 
The work presented in this section has been submitted for publication to Alzheimer’s and 
Dementia : 
Coley N, Andrieu S, Jaros M,  Weiner M, Cedarbaum J, Vellas B.   
Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for 
Alzheimer’s disease trials.   
Submitted to Alzheimer’s & Dementia   
 
3.2.1 METHODS 
PARTICIPANTS AND STUDY DESIGN 
Participants were from the REAL.FR study which is described on page 51.  
We included in these analyses subjects with a baseline CDR rating of 0.5 (who were considered 
to have very mild AD) and those with a baseline CDR rating of 1-2 (who were considered to have 
mild to moderate AD).  15 patients with a Clinical Dementia Rating (CDR) of 3 at baseline, 
considered as “severe dementia”, were excluded from the present analyses, as were 4 subjects 
with a missing CDR rating at baseline.   
INSTRUMENTS 
The CDR was initially developed as a staging instrument for the severity of AD 156 and covers six 
categories: Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and 
Hobbies, and Personal Care.  Impairment in each category/box is scored on a 5-point scale by 
clinicians following a semi-structured interview with the patient and an informant: 0=no 
impairment; 0.5=questionable impairment; 1=mild impairment; 2=moderate impairment; and 
3=severe impairment (but Personal Care has no “questionable impairment” level) 214.  CDR 
global ratings range from 0-3 (0=no dementia; 0.5=questionable dementia; 1=mild dementia; 
2=moderate dementia; 3=severe dementia), and are calculated from individual box scores using 
a complex algorithm.  CDR-SB scores are calculated by simply summing the box scores, and 
range from 0-18 (higher scores indicate more impairment).  Separate cognitive (sum of memory, 
orientation & judgment and problem solving boxes) and functional (sum of community affairs, 
home and hobbies, and personal care) subscores have been proposed 215.  The French version of 
the CDR was used in this study (see Appendix).   
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The instruments used in the REAL.FR study are described in Table 4 (page 52). Those used in 
these analyses were:  
- ADAS-Cog 154,  
- MMSE 152,  
- ADL 157 
- IADL 158  
- Reisberg Global Deteriatioration Scale 155  
All instruments were scored as described in Table 4, but an additional scoring system was used 
for the IADL, in which each of the 5 items was rated on an ordinal scale ranging from 1 to 3, 4 or 
5 depending on the item, giving total scores ranging from 5 to 19, with higher scores indicating 
more impairment. 
STATISTICAL METHODS 
Unless stated otherwise, all analyses were carried out in three populations: (i) subjects with a 
CDR global rating of 0.5 at baseline (“very mild” AD); (ii) subjects with a CDR global rating of 1-2 
at baseline (”mild-moderate” AD); and (iii) all subjects (CDR global rating 0.5-2 at baseline).   
Baseline characteristics are presented as means (standard deviation) for continuous variables, 
and numbers (percentages) of subjects for categorical variables.   
Internal reliability of the CDR-SB was assessed using Cronbach’s alpha (in the whole population 
only).  Coefficients ≥0.70 are considered as acceptable 216. 
Baseline, 2-year and 2-year change scores for each of the 6 CDR boxes were subjected to factor 
analysis using principle factors extraction with promax rotation to determine if the CDR-SB has 
separate cognitive and functional domains.  It was hypothesised a priori, based on previous 
work 215, that the three “cognitive” items would load together on one factor and that the three 
“functional” items would load on a second factor 
Convergent validity was assessed firstly by calculating Spearman correlations between the CDR-
SB and its individual components, and the other cognitive and functional tests at baseline and 
two years in the three populations described above.  Secondly, regression analyses were 
performed to determine the proportion of variance (adjusted R² statistic) of a global measure, 
the Reisberg Global Deterioration Scale 155, explained in a model containing ADAS-Cog, ADL and 
IADL scores as explanatory variables compared to a model containing the CDR-SB as an 
explanatory variable.  These models included all subjects (very mild, mild and moderate AD). 
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Internal responsiveness characterises the ability of a measure to change over time 217, and was 
evaluated using effect size (ES; mean change from baseline divided by standard deviation of 
baseline scores) and standardised response mean (SRM; mean change from baseline divided by 
standard deviation of change from baseline) statistics calculated on 2-year change from baseline 
scores.  A higher ES or SRM indicates better responsiveness: values of 0.20, 0.50 and 0.80 or 
greater for either measure are considered to represent small, moderate and large 
responsiveness, respectively 217.   
External responsiveness examines the extent to which changes in a measure over time relate to 
corresponding changes in a reference measure 217.   Firstly, Spearman coefficients were 
calculated to evaluate correlations between 2-year changes in the CDR-SB and 2-year changes in 
the other cognitive and functional measures.  Secondly, median changes in the CDR-SB were 
calculated in sub-groups defined as declining, remaining stable, or improving on other measures 
and presented as boxplots (carried out in the whole population only).  Finally, Receiver 
Operating Characteristic (ROC) curves were used to compare change in the CDR-SB with 
“clinically relevant” change on the ADAS-Cog, ADL and IADL scales in the whole population.  
Three definitions of clinically relevant change on the ADAS-Cog were identified in the literature, 
corresponding to an increase of ≥ 3 points, ≥4 points and >7 points 218-219.  ROC curves were 
calculated for each of the 3 definitions.   The area under the ROC curve (AUC) represents the 
probability that the measure under investigation correctly classifies patients compared to the 
external criteria 217, 220.  AUCs of 0.7-0.8 are thought to represent acceptable discrimination, 
those of 0.8-0.9 represent excellent discrimination, and areas >0.9 represent outstanding 
discrimination 221.   
Finally, proportions of subjects with missing data, and floor and ceiling effects on each test were 
calculated, and hypothetical clinical trial sample sizes using the CDR-SB or ADAS-Cog as the 
primary endpoint were calculated based on data obtained in this study. The stata “sampsi” 
command was used for all calculations with the following parameters: power=80%; alpha=0.05 
(2-sided); trial duration=2 years.  Attrition rates were based on those observed in this study.   
All analyses were performed using Stata version 9.2 (StataCorp LP, College Station, Texas).   
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3.2.2 RESULTS 
TABLE 16 - PATIENT CHARACTERISTICS AT BASELINE IN THE REAL.FR STUDY ACCORDING TO GLOBAL 
CDR SCORE 
Characteristic 
CDR 0.5 at 
baseline 
(N=233) 
CDR 1-2 at 
baseline 
(N=434) 
All subjects (CDR 0.5-
2) 
(N=667) 
Age 76.2 (5.9) 79.2 (7.0) 78.1 (6.8) 
Sex: N(%) 
Male 
Female 
 
78 (33.5) 
155 (66.5) 
 
115 (26.5) 
319 (73.5) 
 
193 (28.9) 
474 (71.1) 
Education: N(%) 
Elementary or illiterate 
Primary school certificate 
Early secondary education 
Technical/high school certificate or higher 
 
36 (15.6) 
93 (40.3) 
58 (25.1) 
44 (19.1) 
 
106 (24.6) 
147 (34.1) 
90 (20.9) 
88 (20.4) 
 
142 (21.5) 
240 (36.3) 
148 (22.4) 
132 (19.9) 
Living arrangements: N(%) 
At home, alone 
At home, with spouse 
At home, with family 
Sheltered accommodation 
Other 
 
63 (27.0) 
152 (65.2) 
16 (6.9) 
1 (0.4) 
1 (0.4) 
 
115 (26.5) 
242 (55.8) 
58 (13.4) 
11 (2.5) 
8 (1.8) 
 
178 (26.7) 
394 (59.1) 
74 (11.1) 
12 (1.8) 
9 (1.4) 
Cholinesterase inhibitor: N(%) 
Yes 
No 
 
204 (87.5) 
29 (12.5) 
 
371 (85.5) 
63 (14.5) 
 
575 (86.2) 
92 (13.8) 
MMSE 23.2 (2.6) 18.4 (4.0) 20.1 (4.2) 
ADAS-Cog 12.4 (4.1)] 20.6 (8.3) 17.7 (8.1) 
ADL 5.8 (0.4) 5.3 (0.9) 5.5 (0.8) 
No. ADL limitations N(%) 
0 
≥1 
 
191 (82.0) 
42 (18.0) 
 
180 (41.5) 
254 (58.5) 
 
371 (55.6) 
296 (44.4) 
IADL (5 items, score/19) 9.1 (2.9) 13.5 (3.1) 12.0 (3.7) 
IADL (5 items, score/5) 3.5 (1.2)] 2.0 (1.2) 2.5 (1.4) 
No. IADL limitations N(%) 
0 
1 
2 
3 
4 
5 
 
52 (22.9) 
70 (30.8) 
60 (26.4) 
32 (14.1) 
12 (5.3) 
1 (0.4) 
 
11 (2.6) 
34 (8.1) 
99 (23.6) 
121 (28.8) 
116 (27.6) 
39 (9.3) 
 
63 (9.7) 
104 (16.1) 
159 (24.6) 
153 (23.7) 
128 (19.8) 
40 (6.2) 
CDR global rating: N(%) 
0.5 
1 
2 
 
233 (100) 
0 (0) 
0 (0) 
 
0 (0) 
288 (66.4) 
146 (33.6) 
 
233 (34.9) 
288 (43.2) 
146 (21.9) 
CDR-SB 3.2 (0.9) 7.9 (2.6) 6.3 (3.1) 
CDR cognitive subsum 2.1 (0.7) 4.12 (1.4) 3.4 (1.5) 
CDR functional subsum 1.1 (0.5) 3.8 (1.6) 2.8 (1.9) 
Reisberg Global Deterioration Scale: N(%) 
2 
3 
4 
5 
6 
 
0 (0) 
69 (29.6) 
154 (66.1) 
10 (4.3) 
0 (0) 
 
1 (0.2) 
8 (1.8) 
176 (40.6) 
224 (51.6) 
25 (5.8) 
 
1 (0.2) 
77 (11.5) 
330 (49.5) 
234 (35.1) 
25 (3.8) 
Data are presented as mean (SD) unless specified otherwise.   
ADAS-Cog: Alzheimer’s Disease Assessment Scale – Cognitive subscale; ADL: activities of daily living; CDR: Clinical 
Dementia Rating; CDR-SB: CDR-sum of boxes; IADL: instrumental activities of daily living; MMSE: Mini Mental Status 
Examination.   
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The baseline characteristics of the included subjects are described in Table 16 (page 99).  233 
subjects (35%) had very mild AD at baseline (CDR=0.5), while 434 subjects (65%) had mild-
moderate AD (CDR=1-2).   
 
DATA QUALITY AND FLOOR AND CEILING EFFECTS 
A CDR-SB score could be calculated for 99.4% of all patients at baseline, and 96% of subjects 
present at the 2 year visit (Table 17; page 101).  Similar proportions of scores were available for 
the ADAS-Cog, MMSE, ADL and IADL scales.     
The distributions of baseline, 2-year and 2-year change scores for the CDR-SB in each population 
are shown in Figure 11 (page 100).  There was some evidence of floor effects (score=18, i.e. 
poorest possible score) in 2 year scores, in particular in the subgroup of subjects classed as 
having mild-moderate AD at baseline.   
 
FIGURE 11 – DISTRIBUTION OF CDR-SB BASELINE, 2-YEAR AND 2-YEAR CHANGE SCORES IN VERY MILD 
AND MILD-MODERATE AD SUBJECTS IN THE REAL.FR STUDY 
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The presence of floor and ceiling effects was further explored by calculating the proportion of 
subjects with the best and worst possible scores for each of the measures studied (Table 17, 
page 101).  There were no floor or ceiling effects on any of the cognitive measures.  The CDR-SB 
showed no ceiling effects (score=0, i.e. best possible score), and floor effects were seen in <5% of 
subjects at 2 years (0.8% of subjects classed as very mild at baseline and 7% of subjects classed 
as mild-moderate at baseline).  Half of subjects at baseline, and a third at 2 years showed ceiling 
effects on the ADL.  The IADL demonstrated floor effects in nearly a quarter of subjects at 2 
years.   
TABLE 17 - DATA QUALITY AND FLOOR AND CEILING EFFECTS IN THE REAL.FR STUDY 
 Time point/ Population 
 Baseline  2 years 
Test 
All 
REAL.fr 
patients 
(N=686*) 
Very 
mild  
(N=233) 
Mild-
Moderate  
(N=434) 
 Patients classed 
as very mild to 
moderate at 
baseline 
(N=345) 
Patients 
classed as 
very mild at 
baseline 
(N=135) 
Patients classed 
as mild-
moderate at 
baseline 
(N=210) 
(a) Percentage of subjects with an analysable score 
CDR-SB score 99.4 100 100  96.2 97.8 95.2 
Adas-Coga 98.1 99.1 97.5  91.7 95.5 88.7 
MMSE 99.7 99.6 100  98.0 99.2 97.1 
ADL 100 100 100  99.1 100 98.6 
IADL/5 96.9 97.4 96.8  93.0 94.8 91.9 
(b) Percentage of subjects with floor & ceiling effects 
CDR-SB=0  0 0 0  0 0 0 
CDR-SB=18 0.1 0 0  4.5 0.8 7.0 
Adas-Coga = 0 0 0 0  0 0 0 
Adas-Coga = 70 0 0 0  0 0 0 
MMSE = 30 0 0 0  0 0 0 
MMSE = 0 0 0 0  0.3 0 0.5 
ADL = 6 54.4 82.0 41.5  33.0 57.0 17.4 
ADL = 0 0 0 0  0.6 0 1.0 
IADL/5 = 5 9.5 22.9 2.6  1.9 4.7 0 
IADL/5 = 0 7.1 0.4 9.3  23.1 6.3 34.2 
* including patients with a CDR rating of 3 or those with a missing CDR rating at baseline (since otherwise 
rates of missing data for the CDR-SB could not be calculated) 
a Data quality and floor and ceiling effects for the ADAS-Cog at 2 years were only calculated for subjects 
with an MMSE score ≥10 at the 2-year visit since subjects with an MMSE<10 were given the Severe 
Impairment Battery instead of the ADAS-Cog.   
 
 
STRUCTURAL VALIDITY AND INTERNAL CONSISTENCY 
Factor analyses showed that CDR-SB “cognitive” items loaded together on one factor and 
“functional” items loaded together on a second factor for baseline, 2 year and 2-year change 
scores for subjects classed as mild-moderate at baseline, and for 2-year and 2-year change 
scores for subjects classed as very mild at baseline (Table 18; page 103).  For very mild subjects 
at baseline the Personal Care item did not load on either factor (loadings <0.3).  The other two 
functional items also had relatively low (≤0.41) loadings in this subgroup.     
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Cronbach’s alpha values were 0.88, 0.82, and 0.83 for the CDR-SB and cognitive and functional 
subsums, respectively, in the total population, indicating good internal consistency.       
 
CONVERGENT VALIDITY 
Spearman correlations between the CDR-SB and other cognitive and functional tests were 
relatively low (±0.069[ADL] to ±0.356[ADAS-Cog]) at baseline in very mild subjects (Table 19; 
page 104).   Correlations were higher for mild-moderate subjects and all subjects taken together, 
but remained modest (mild-moderate: ±0.405[ADL] to ±0.565[MMSE]; all subjects: ±0.463[ADL] 
to ±0.662[MMSE]).  The functional subsum correlated best with the IADL or ADL and the 
cognitive subsum correlated best with the MMSE and ADAS-Cog.   
Regression analyses were conducted to determine the proportion of variation in baseline scores 
on the Reisberg scale explained by the CDR-SB, and the ADAS-Cog, ADL and IADL scales 
combined.  In a linear regression model containing ADAS-Cog, ADL and IADL scale scores as 
explanatory variables, the adjusted R² value was 0.4735, indicating that these three variables 
explained 47% of the variance in Reisberg scale scores (ADAS-Cog coefficient 0.05, p<0.001; ADL 
coefficient -0.03, p=0.365; IADL coefficient -0.06, p<0.001).  In the model containing the CDR-SB 
as the only explanatory variable, 55% of the variance was explained (CDR-SB coeff. 0.17, 
p<0.001).  Since the GDS is measured on a limited ordinal scale, analyses were repeated using 
logistic regression, with the outcome of interest being a score ≥5 compared to ≤4.  Again, both 
models explained a similar proportion of the variation in GDS scores (Pseudo R² = 0.4629 in 
CDR-SB model, and 0.4159 in the model containing ADAS-Cog, ADL and IADL scores).  There was 
little change in any of the models after adjustment for age, sex and education 
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TABLE 18 - FACTOR LOADINGS FOR CDR ITEMS IN THE REAL.FR STUDY FOR BASELINE, 2 YEAR AND 2-YEAR CHANGE SCORES (2 FACTOR SOLUTION, PROMAX 
ROTATION) 
 Baseline scores  2 year scores  2 year change scores 
   CDR stage at baseline CDR 0.5 CDR 1-2 CDR 0.5-2  CDR 0.5 CDR 1-2 CDR 0.5-2  CDR 0.5 CDR 1-2 CDR 0.5-2 
Item CF FF CF FF CF FF  CF FF CF FF CF FF  CF FF CF FF CF FF 
Memory 0.51 0.06 0.64 0.07 0.67 0.11  0.67 0.05 0.81 0.06 0.77 0.08  0.60 0.04 0.71 0.01 0.67 0.01 
Orientation 0.48 -0.05 0.65 0.04 0.66 0.15  0.61 0.13 0.79 0.07 0.74 0.13  0.64 0.14 0.62 0.03 0.62 0.07 
Judgement & problem 
solving 
0.36 0.06 0.54 0.16 0.55 0.25  0.64 0.10 0.74 0.16 0.73 0.17  0.61 0.10 0.61 0.13 0.62 0.09 
Community Affairs 0.07 0.35 0.25 0.51 0.30 0.58  0.23 0.66 0.04 0.68 0.12 0.71  0.16 0.66 0.06 0.61 0.06 0.66 
Home & hobbies 0.01 0.41 0.08 0.68 0.16 0.72  0.08 0.81 0.14 0.72 0.13 0.77  0.09 0.78 0.04 0.68 0.04 0.72 
Personal care -0.20 0.17 -0.02 0.57 0.05 0.64  -0.05 0.72 0.11 0.73 0.14 0.71  -0.03 0.65 0.04 0.60 0.07 0.53 
CDR: clinical dementia rating; CF: Cognitive factor; FF; Functional factor 
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TABLE 19 - SPEARMAN CORRELATIONS BETWEEN BASELINE SCORES OF INSTRUMENTS USED IN THE 
REAL.FR STUDY 
 CDR SB CDR Cog CDR Func ADAS-Cog MMSE ADL IADL /19 IADL /5 
Whole population (CDR 0.5-2 at baseline) 
CDR-SB score 1               
CDR cog. subsum 0.819 1       
CDR func. subsum 0.878 0.710 1      
ADAS-Cog 0.650 0.696 0.602 1     
MMSE -0.662 -0.700 -0.605 -0.757 1    
ADL -0.463 -0.324 -0.567 -0.311 0.297 1   
IADL (score/19) 0.614 0.502 0.692 0.492 -0.478 -0.618 1  
IADL (score/5) -0.563 -0.463 -0.637 -0.464 0.428 0.571 -0.920 1 
CDR 0.5 at baseline         
CDR-SB score 1        
CDR cog. subsum 0.800 1       
CDR func. subsum 0.579 0.040(ns) 1      
ADAS-Cog 0.356 0.364 0.089(ns) 1     
MMSE -0.312 -0.310 -0.071(ns) -0.478 1    
ADL -0.069(ns) 0.101(ns) -0.188** -0.007(ns) 0.006(ns) 1   
IADL (score/19) 0.247** 0.036(ns) 0.330 0.141* -0.130* -0.367 1  
IADL (score/5) -0.278 -0.047(ns) -0.388 -0.145* 0.077(ns) 0.337 -0.849 1 
CDR 1-2 at baseline         
CDR-SB score 1        
CDR cog. subsum 0.827 1       
CDR func. subsum 0.897 0.508 1      
ADAS-Cog 0.548 0.582 0.405 1     
MMSE -0.565 -0.592 -0.422 -0.701 1    
ADL -0.405 -0.148** -0.522 -0.180** 0.159** 1   
IADL (score/19) 0.500 0.299 0.554 0.315 -0.310 -0.559 1  
IADL (score/5) -0.426 -0.258 -0.468 -0.287 0.258 0.497 -0.895 1 
All p-values are <0.0001, except, ns: p>0.05; * 0.01 ≤ p ≤ 0.05; ** 0.0001< p <0.01 
ADAS-Cog: Alzheimer’s Disease Assessment Scale – Cognitive subscale; ADL: activities of daily living; CDR-SB: 
Clinical Dementia Rating -sum of boxes; CDR cog. subsum: CDR cognitive subsum; CDR func. subsum: CDR 
functional subsum; IADL: instrumental activities of daily living; MMSE: Mini Mental Status Examination 
 
INTERNAL RESPONSIVENESS 
At two years, 394 (59%) of subjects remained in the study and were included in the analyses of 
internal and external responsiveness. Two-year rates of change for the CDR-SB total score and 
cognitive and functional subsums were similar in very mild and mild-moderate patients despite 
different baseline scores (Figure 12, page 105).   
Mean 2-year CDR-SB and IADL changes from baseline were of similar magnitude in very mild 
and mild-moderate patients, but there was greater decline on the ADAS-Cog, MMSE and ADL in 
mild-moderate subjects (Table 20; page 105).  Two-year internal responsiveness was good for 
all tests in very mild subjects according to ES(>1) (Table 20; page 105).  In mild-moderate 
patients, effect size was moderate for the ADAS-Cog and good for all other measures.  
Standardised response means indicated moderate internal responsiveness for the ADL in very 
mild subjects and the ADAS-Cog in all subjects, and good internal responsiveness for all other 
tests.     
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FIGURE 12 - CHANGE FROM BASELINE IN CDR-SB SCORES IN VERY MILD AND MILD-MODERATE 
ALZHEIMER'S DISEASE PATIENTS THE REAL.FR SUDY  
Change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) and cognitive and functional 
subsums over time in (a) subjects with a CDR rating of 0.5 at baseline, and (b) subjects with a CDR rating 
of 1-2 at baseline.  
 
 Standard deviations at 6, 12, 18 and 24 months respectively are as follows: 
A) CDR 0.5 
CDR-SB score: 1.28, 1.89, 2.62, 3.18 
Functional subsum: 0.88, 1.18, 1.72, 1.98 
Cognitive subsum: 0.75, 1.11, 1.27, 1.61 
B) CDR 1-2 
CDR-SB score: 2.08, 2.65, 3.28, 3.35 
Functional subsum: 1.37, 1.68, 1.93, 2.10 
Cognitive subsum: 1.19, 1.40, 1.74, 1.78 
 
 
TABLE 20 - INTERNAL RESPONSIVENESS OF THE CDR-SB AND OTHER INSTRUMENTS IN THE REAL.FR 
STUDY 
 Mean 2-yr change from baseline (SD) Effect size 
Standardised 
response mean 
CDR population: 0.5 1-2 All 0.5 1-2 All 0.5 1-2 All 
 (N=135) (N=207) (N=342)       
CDR-SB 3.89 (3.18) 3.82 (3.35) 3.84 (3.28) 4.33 1.45 1.23 1.22 1.14 1.17 
ADAS-Cog 4.85 (6.11) 5.55 (7.65) 5.23 (6.98) 1.19 0.67 0.65 0.79 0.73 0.75 
MMSE -3.51 (3.86) -4.37 (4.61) -4.03 (4.34) -1.37 -1.09 -0.96 -0.91 -0.95 -0.93 
ADL -0.51 (0.98) -1.33 (1.47) -1.01 (1.36) -1.29 -1.50 -1.27 -0.52 -0.91 -0.74 
IADL/19 3.55 (3.02) 3.28 (2.89) 3.40 (2.94) 1.21 1.05 0.92 1.18 1.14 1.15 
IADL/5 -1.29 (1.27) -1.21 (1.11) -1.24 (1.18) -1.11 -1.00 -0.90 -1.02 -1.08 -1.06 
ADAS-Cog: Alzheimer’s Disease Assessment Scale – Cognitive subscale; ADL: activities of daily living; CDR-SB: Clinical 
Dementia Rating -sum of boxes; CDR cog. subsum: CDR cognitive subsum; CDR func. subsum: CDR functional subsum; 
IADL: instrumental activities of daily living; MMSE: Mini Mental Status Examination; SD: standard deviation 
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EXTERNAL RESPONSIVENESS 
In the whole population, two-year changes in the CDR-SB correlated most highly with 2-year 
MMSE and ADL changes, although magnitude was modest (coefficients≈0.5; Table 21; page 106).  
Compared to the very mild group, mild-moderate subjects showed a considerably stronger 
correlation between 2-year changes in the CDR-SB and ADL, a slightly stronger correlation 
between 2-year changes in the CDR-SB and MMSE, and a weaker correlation between changes 
on the CDR-SB and ADAS-Cog.  
TABLE 21 - SPEARMAN CORRELATIONS BETWEEN CDR-SB AND OTHER INSTRMENT 2-YEAR CHANGE 
FROM BASELINE SCORES IN THE REAL.FR STUDY 
 CDR SB CDR Cog CDR Func ADAS-Cog MMSE ADL IADL /19 IADL /5 
Whole population (CDR 0.5-2 at baseline) 
CDR-SB score 1        
CDR cog. subsum 0.837 1       
CDR func. subsum 0.888 0.512 1      
ADAS-Cog 0.392 0.363 0.318 1     
MMSE -0.534 -0.552 -0.407 -0.523 1    
ADL -0.548 -0.368 -0.571 -0.232** 0.327 1   
IADL (score/19) 0.434 0.301 0.430 0.372 -0.309 -0.290 1  
IADL (score/5) -0.335 -0.209** -0.357 -0.256 0.164** 0.214** -0.797 1 
CDR 0.5 at baseline         
CDR-SB score 1        
CDR cog. subsum 0.844 1       
CDR func. subsum 0.889 0.526 1      
ADAS-Cog 0.481 0.488 0.353** 1     
MMSE -0.495 -0.526 -0.368 -0.545 1    
ADL -0.455 -0.213* -0.557 -0.138(ns) 0.218* 1   
IADL (score/19) 0.400 0.266** 0.420 0.343** -0.204* -0.264** 1  
IADL (score/5) -0.365 -0.231** -0.402 -0.251** 0.128(ns) 0.245** -0.773 1 
CDR 1-2 at baseline         
CDR-SB score 1        
CDR cog. subsum 0.830 1       
CDR func. subsum 0.887 0.499 1      
ADAS-Cog 0.330** 0.261** 0.301** 1     
MMSE -0.561 -0.568 -0.440 -0.510 1    
ADL -0.651 -0.469 -0.642 -0.289** 0.381 1   
IADL (score/19) 0.464 0.335 0.444 0.410 -0.394 -0.358 1  
IADL (score/5) -0.312 -0.194** -0.327 -0.261** 0.200** 0.230** -0.826 1 
All p-values are <0.0001, except, ns: p>0.05; * 0.01 ≤ p ≤ 0.05; ** 0.0001< p <0.01 
ADAS-Cog: Alzheimer’s Disease Assessment Scale – Cognitive subscale; ADL: activities of daily living; CDR-SB: 
Clinical Dementia Rating -sum of boxes; CDR cog. subsum: CDR cognitive subsum; CDR func. subsum: CDR 
functional subsum; IADL: instrumental activities of daily living; MMSE: Mini Mental Status Examination 
 
Median CDR-SB 2-year change scores were highest in groups classed as declining on the ADAS-
Cog, ADL and IADL (Figure 13, page 107).  Highest median CDR-SB change scores were seen in 
groups classed as declining on other measures.  The “stable” groups generally showed 
intermediate CDR-SB scores, and the “improvement” groups showed the lowest median CDR-SB 
change scores, except when a 4-point cut-off was used for the ADAS-Cog; however, there were 
only 8 subjects in the improvement group in this analysis. 
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FIGURE 13 - MEDIAN TWO-YEAR CHANGES IN CDR-SB SCORES IN THE REAL.FR STUDY ACCORDING TO 
RATE OF CHANGE ON OTHER COGNITIVE AND FUNCTIONAL MEASURES 
A: 2-year ADAS-Cog changes defined as: Decline: ≥4 point gain [N=132], Stable: +/- <4 points [N=125], 
Improvement: ≥4 point decrease [N=8]; B: ADAS-Cog change using the following definition: Decline: ≥3 
point gain [N=154], Stable: +/- <3 points [N=96], Improvement: ≥3 point decrease [N=15]; C: two-year 
ADL change: Decline ≤-1 points [N=137], Stable +/- 0.5 points [N=190], Improvement ≥1 point [N=3]; D: 
two-year IADL change: Decline ≤-1 points [N=219], Stable: no change [N=69], Improvement ≥1 point 
[N=13]. 
ADAS-Cog: Alzheimer’s Disease Assessment Scale-Cognitive subscale; ADL: Activities of Daily Living: CDR-SB: 
Clinical Dementia Rating – Sum of Boxes; IADL: Instrumental Activities of Daily Living 
 
TABLE 22 - EXTERNAL RESPONSIVENESS OF THE CDR-SB IN THE REAL.FR STUDY ACCORDING TO 
RECEIVER OPERATING CHARACTERISTIC (ROC) CURVES 
Test Change definition AUC 95% CI 
ADAS-Cog (i) “Clinically detectable decline” (2-year change: ≥4 points) versus “no 
clinically detectable decline” (<4 points) 
0.68 0.61–0.74 
 (ii) “Moderate decline” ( ≥3 points) versus “no moderate decline” (<3 points) 0.68 0.62-0.74 
 (iii) “Severe decline” ( >7 points) versus “no severe decline” (≤7 points) 0.72 0.65-0.79 
IADL “Decline” (≤-1 points) versus “no decline” (>-1 points) 0.66 0.59-0.73 
ADL “Decline” (≤-1 points) versus “no decline” (>-1 points) 0.77 0.72-0.82 
The area under the curve (AUC) represents the probability that the CDR-SB correctly classified patients 
compared to the external criteria which are detailed in the “Change definition” column. 
CDR-SB: Clinical Dementia Rating -sum of boxes; ADAS-Cog: Alzheimer’s Disease Assessment Scale – 
Cognitive subscale; IADL: instrumental activities of daily living; ADL: activities of daily living; AUC: area 
under curve; 95% CI: 95% confidence interval 
 
The CDR-SB showed acceptable ability to discriminate patients undergoing decline on the ADL 
scale from those not undergoing decline (AUC=0.77; Table 22; page 107) and to discriminate 
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patients undergoing severe decline on the ADAS-Cog (>7 point increase over 2 years) from those 
not undergoing severe decline (AUC=0.72).  The AUCs for “clinically detectable” (2-year change 
≥4 points) and “moderate” (2-year change ≥3 points) ADAS-Cog decline, and IADL decline did 
not quite reach the acceptable 221 level of discrimination.   
   
SAMPLE SIZE CALCULATIONS 
For a two-year trial with 80% power to detect a 30% decrease in ADAS-Cog decline, the 
estimated sample size (taking into account dropouts) would be 810, 1236 and 1054 respectively 
for a study population of very mild, mild-to-moderate or very mild-to-moderate AD (Table 23; 
page 108).  A trial with 80% power to detect a 30% decrease in CDR-SB decline would require 
approximately 60% fewer subjects, with sample sizes of 342, 496 and 434 patients respectively 
for the same populations.  Trials aiming to detect a 50% reduction in CDR-SB decline would also 
require approximately 60% fewer subjects than trials aiming to detect a 50% reduction in 
ADAS-Cog decline (Table 23; page 108). 
 
TABLE 23 - SAMPLE SIZE REQUIREMENTS FOR A 2-YEAR CLINICAL TRIAL ACCORDING TO PRIMARY 
ENDPOINT, STUDY POPULATION AND EXPECTED TREATMENT EFFECT (BASED ON DATA FROM THE 
REAL.FR STUDY) 
Treatment effect /primary 
endpoint 
Target population 
Very mild AD (CDR 
0.5) 
Mild to moderate AD 
(CDR 1-2) 
Very mild to moderate AD 
(CDR 0.5-2) 
30% decrease in ADAS-Cog 
decline 
552 (810) 668 (1236) 622 (1054) 
30% decrease in CDR-SB 
decline  
232 (342) 268 (496) 256 (434) 
50% decrease in ADAS-Cog 
decline 
200 (294) 240 (444) 224 (380) 
50% decrease in CDR-SB 
decline  
84 (124) 98 (182) 92 (156) 
Sample size calculations were based on a two-group comparison of mean 2-year change from baseline 
scores with 80% power and a two-sided alpha level of 0.05.  Expected average 2-year changes from 
baseline and SD of change for the CDR-SB and ADAS-Cog in each population were based on those observed 
in the REAL.FR study (presented in Table 20; page 105).  
  
Numbers in parentheses represent sample sizes after taking into account attrition specific to each 
subpopulation (based on 2-year dropout rates observed in the REAL.FR study, i.e. 31.8% for very mild 
subjects; 45.9% for mild-moderate subjects, and 40.9% for all subjects taken together).  Sample sizes are 
rounded up to the nearest even number.   
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3.2.3 DISCUSSION 
This work provides a detailed a psychometric analysis of the CDR-SB, an instrument that is 
becoming more and more widely used as an endpoint in AD trials, but that has undergone 
relatively little evaluation of its performance compared to other measures 222.  In particular, we 
wanted to evaluate the suitability of the CDR-SB as a single primary endpoint for AD trials.  
Currently, two co-primary endpoints are used which must cover both cognition and function.28  
The main disadvantage of using two co-primary endpoints is that a correction for multiple 
statistical testing must be used (since the probability of one test being significant due to chance 
alone increases for each additional test), meaning that larger sample sizes are required.  For this 
reason, the CONSORT statement advocates the use of a single primary endpoint over co-primary 
endpoints in clinical trials 223.  A single primary endpoint that adequately reflects treatment 
effects on both cognition and function would therefore be of use for AD clinical trials.  
Furthermore, the ADAS-Cog, the most widely used co-primary endpoint, shows high variability 
which also increases sample sizes in AD trials. 
The major findings of this work are that the CDR-SB measures cognitive and functional 
impairment simultaneously and that it shows less variability than commonly used outcome 
measures, leading to excellent 2-year internal responsiveness and smaller sample sizes.  The 
relationship of changes on the CDR-SB to clinically relevant changes on other measures, 
however, requires further clarification.  This work represents a first step in the assessment of 
the CDR-SB as a single primary endpoint for AD trials.   
STRUCTURAL AND CONVERGENT VALIDITY 
It was possible to detect separate cognitive and functional factors within the CDR-SB for both 
very mild and mild-moderate subjects’ 2 year and 2-year change scores, and for baseline scores 
from mild-moderate subjects only.  Another study also provided evidence for distinct cognitive 
and functional factors in this scale, showing in exploratory factor analyses that 12-month 
changes on the CDR functional subsum loaded with the ADL change score, and 12-month 
changes on the CDR cognitive subsum loaded with the MMSE change score, while behavioural 
changes and education loaded on separate factors 215.  One explanation for our inability to 
demonstrate a two factor structure in very mild subjects at baseline may be an initial lack of 
functional impairment in this group.  We also found low baseline correlations between the CDR-
SB and functional measures in this population, perhaps for the same reason.  Higher, though 
modest, correlations were observed between the CDR-SB and other cognitive and functional 
measures in mild-moderate subjects.  Previous studies have found correlations of similar 
magnitude to those observed in our study between the CDR-SB and other cognitive measures 215, 
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224-225.  One study also assessed agreement (rather than association) between the CDR-SB, ADAS-
Cog and MMSE 225.  Agreement between tests was significantly worse for individuals with higher 
cognitive impairment, compared to those with less cognitive impairment.  For average and 
below-average levels of impairment, the MMSE and CDR-SB showed the best agreement of the 
three pairs of comparisons.     
Further evidence of convergent validity of the CDR-SB was provided in our study by the fact that 
it was able to explain as much, if not more, of the variance in the Reisberg Global Deterioration 
Scale as a model containing MMSE, ADL and IADL scores.   
RESPONSIVENESS 
Disease progression was detectable on the CDR-SB and its cognitive and functional subsums 
over two years in very mild and mild-moderate patients and all subjects taken together, and 
appeared to be of similar rate whatever the initial disease severity.   This finding supports the 
use of the CDR-SB in long-term clinical trials with a range of disease severities.  Importantly, the 
cognitive and functional domains seem to contribute roughly equally to changes in the total 
score.   
The internal responsiveness of the CDR-SB was very good according to measures of effect size 
and standardized response mean in all populations.  It has been argued that effect size depends 
on the magnitude of change observed, and not necessarily the ability of an instrument to detect 
that change 226-227.  However, the comparison of effect sizes of different instruments in the same 
sample can give an indication of the relative level of internal responsiveness of each instrument.   
We only calculated responsiveness for the CDR-SB total score.  It may also be useful to look at 
the responsiveness of individual items since there may be differential effects on different items 
227.  Also, we did not assess responsiveness in relation to an intervention with known effects on 
disease progression, but the CDR-SB has already been used to successfully detect treatment 
effects in clinical trials which also showed benefits on traditional cognitive outcome measures 37.     
As part of our analysis of the external validity of the CDR-SB, we assessed its ability to detect 
“clinically meaningful” changes on other measures.  One of the problems of using continuously 
scored rating scales in clinical trials is determining the clinical relevance of the changes 
observed.  For the ADAS-Cog, a 4-point change is usually considered as being “clinically 
important” 228-229, but we also assessed other cut-offs that have been suggested in the literature 
218-219.  The area under the ROC curve remained similar (0.68-0.72) whatever the cut-off used for 
the ADAS-Cog and indicated that the CDR-SB was only borderline acceptable in its 
discrimination of patients based on ADAS-Cog designations of clinically meaningful changes.  A 
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previous study suggested that with both 3- or 4-point cut-offs, an improvement on the ADAS-Cog 
corresponded to clinical improvement, but that decline on the ADAS-Cog often did not 
correspond to clinical decline on other measures 218.  Thus, the ADAS-Cog is perhaps a more 
reliable measure of clinically relevant improvement than clinically relevant decline.  We 
evaluated the responsiveness of the CDR-SB over two years, during which time very few patients 
showed improvement on any measure.  Accordingly, the ADAS-Cog may not be an ideal 
comparison measure.  The CDR-SB showed better ability to detect changes on the ADL.  
Functional measures, such as the ADL and IADL, probably represent more clinically meaningful 
outcomes than the ADAS-Cog, and are perhaps more suited to measuring decline than 
improvement.  It should however be noted that these functional instruments, like the CDR, are 
relatively subjective since they are based on caregiver evaluations rather than an objective 
evaluation of patient performance.  Furthermore, the loss of 1 ADL is a much severer decline 
than the loss of 3-4 ADAS-Cog points.  It may be that the ADL and IADL scales are not sensitive 
enough to detect smaller changes: while the loss of one ADL or IADL is clinically meaningful, it 
may not be the smallest detectable clinically meaningful functional change 208.  Other functional 
measures, such as the ADCS-ADL, which is widely used in current trials, may be more sensitive 
to changes in disease progression 179, but perhaps at the expense of measuring clinically 
meaningful changes.   
SAMPLE SIZE AND DATA QUALITY 
Our sample size calculations, based essentially on 2-year standardised response means, showed 
that the number of subjects required for a 2-year clinical trial aiming to slow decline by either 
30% or 50% would be greatly reduced if the CDR-SB were used instead of the ADAS-Cog, 
whatever the degree of severity of the study population.  We might expect less variability in the 
CDR-SB than the ADAS-Cog in our study since our populations were defined on the CDR global 
measure. However, a previous study which also evaluated sample sizes required for AD trials of 
varying durations found that trials using the CDR-SB or other clinical measures as the primary 
endpoint would require a much smaller sample size than trials using psychometric cognitive 
measures for 6-, 12- or 24-month trials 230.   
In contrast to some of the other scales used in this study, there were low levels of missing data 
for the CDR-SB and virtually no floor or ceiling effects in this population of very mild to 
moderate AD subjects, even after two years of follow-up, indicating the suitability of this 
measure for long-term trials during which disease severity is likely to progress.     
 
STRENGTHS AND LIMITATIONS 
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This work has a number of strengths and limitations.  The psychometric properties of the CDR-
SB were evaluated in a large cohort of AD subjects with a range of disease severities in a real-life 
setting.  Our study was carried out in university hospitals, so while our patients are not 
representative of the entire AD patient population, they may well be representative of a typical 
placebo group for an “add-on” trial (relatively mildly impaired community-dwelling patients 
with an identified informal caregiver and mostly treated with anti-dementia drugs).  The data 
used in these analyses were obtained during a cohort study and not a clinical trial, which could 
affect the comparability of these results with those from clinical trials.  There was perhaps less 
of an incentive for patients to participate in this study as there was no direct personal benefit 
offered.  
Only French subjects were included in this study, meaning that between-subject variability was 
likely to be lower than in an international trial.  It could also raise the question of the external 
validity of these results.  However, this was a multi-centre study, and validated French 
translations were used for all instruments.  Also, the correlations and sample size calculations 
obtained in this work were comparable to those already obtained in previous studies of US 
patients, as discussed above.  Only patients diagnosed with AD who were at a very mild to 
moderate stage of the disease were studied in this work.  The results are therefore not 
applicable to MCI or severe AD populations.  A concurrent project (Cedarbaum, et al manuscript 
in preparation) is, however, performing a similar assessment of the performance of the CDR-SB 
using data from subjects with MCI and early AD from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) in North America, in which the CDR-SB was administered in English and in 
Spanish.     
The analyses of internal and external responsiveness included only those subjects who provided 
CDR-SB data at the 2 year visit, i.e. 58% of the subjects classed as “very mild” at baseline and 
48% of the subjects classed as “mild to moderate” at baseline.  As shown in chapter 2, this is a 
highly selected population which differs from subjects who died or dropped out of the study for 
other reasons before this time.  Furthermore, the rate of dropouts in this observational study is 
higher than what would typically be expected in a randomised trial conducted in the same 
population (for example, the 2-year attrition rate in the PLASA trial was 32%), thus limiting the 
generalisability of these findings to a clinical trial setting.  Indeed, further studies of CDR-SB data 
collected during clinical trials are needed in order to validate the results obtained in this study.   
The CDR-SB is a relatively subjective measure and so its reliability depends on the clinician 
rating the patient, and the caregiver/informant.  Acceptable levels of inter-rater reliability for 
both the CDR-SB and global rating have been reported, although they appear lower for subjects 
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with lower levels of impairment 231-233.  As with all instruments using caregiver input, the 
reliability of the information provided by the caregiver is a particular concern.  This may depend 
on the amount of time spent with the patient, but also the caregiver’s level of cognition and 
subjective burden as well as the socio-cultural context.  Indeed, given the important role of 
caregivers in the evaluation of AD patients in clinical trials, there are surprisingly few eligibility 
criteria stated in clinical trial protocols that concern the caregiver, other than occasionally the 
amount of time spent with the patient.   
Finally, these analyses were based on “traditional” psychometric methods, and all scores were 
based on “raw” totals.  Given that the CDR was initially developed as a staging instrument, it is 
unlikely that change from a score of 1 to 2 on an individual item represents twice as much 
change as that from 0.5 to 1.  Also, we are not sure that each item contributes equally to the total 
score, or that 1-point changes are equivalent across all items.  Furthermore, a 1-point change in 
the total score at one end of the scale is not necessarily equivalent to a 1-point change at the 
other end.  “Modern” psychometric methods, such as Rasch analysis and Item Response Theory, 
can be used to study such questions (see191 for review), as has been done for the ADAS-Cog and 
MMSE 234-235.         
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3.3 COGNITIVE DECLINE AS A SURROGATE ENDPOINT IN PREVENTION 
TRIALS 
The analyses presented in this section were conducted as an initial, very preliminary step in the 
study of cognitive decline as a surrogate marker.  They were based on data from the GuidAge 
trial which had not yet finished at the time of analysis.  This work has not been submitted for 
publication since further, more in-depth analyses will be conducted once the GuidAge trial has 
been completed (this work will not be carried out until after submission of the thesis).   
3.3.1 METHODS 
PARTICIPANTS AND STUDY DESIGN 
These analyses were carried out on a temporary database including 763 subjects enrolled in the 
GuidAge trial.  The trial had not finished when this work was carried out, and so this was a 
convenience sample including subjects with available data at the time of analysis.  It therefore 
included primarily subjects who were enrolled earliest in the trial and who had finished the 5 
years of follow-up, and those who discontinued the study during follow-up either due to death 
or dropout, or due to reaching the study endpoint.  GuidAge was a randomized, double-blind, 
placebo-controlled trial, and data remained blinded during these analyses.    
The protocol of the GuidAge study has been published previously 236.  Briefly, participants were 
community dwelling older adults aged 70 years or more and older spontaneously complaining of 
memory problems to their doctor.  The criteria for inclusion were a Mini Mental State 
Examination (MMSE) 152 score >25, a Covi Anxiety Scale 237 score <6, and a Geriatric Depression 
Scale (GDS) 238 score <15.  Subjects with major objective memory impairment (Free and Cued 
Selective Reminding Test (FCSRT) 239 score <10th percentile for age, sex and sociocultural level), 
a Clinical Dementia Rating (CDR) 156 score >0.5, prevalent dementia (DSM-IV and NINCDS-
ADRDA criteria 2-3) or major depression or generalized anxiety (DSM-IV criteria) were excluded.     
Subjects were randomized to twice-daily doses of either 120mg standardized Ginkgo biloba 
extract  or a placebo of identical appearance, and were followed-up for up to 5 years.   
 
OUTCOMES 
The primary efficacy endpoint was the diagnosis of dementia of the Alzheimer’s type, according 
to DSM-IV and NINCDS-ADRDA criteria.  Diagnoses were determined during annual visits to 
reference memory centres during which cognitive, functional and emotional status were 
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evaluated using the tests outlined in Table 24 (page 115).  Dementia diagnostic criteria were 
assessed for all subjects at each visit.  Subjects could also be referred to the memory centre for 
an ad hoc visit if dementia onset was suspected by the family physician.  However, the vast 
majority of diagnoses were made during the annual visits.  All diagnoses of dementia were 
validated by an independent adjudication committee.  
 
TABLE 24 - INSTRUMENTS USED IN THE GUIDAGE STUDY 
Instrument Abbreviation Description Scoring 
Mini Mental State 
Examination 152 
MMSE 30 item measure of global cognitive 
function, covering the domains of 
orientation, learning, attention, 
memory and language 
Scores range from 0-30.  Higher 
scores indicate better cognitive 
performance. Scores of 25 or more 
are considered to represent normal 
performance.   
Clinical Dementia 
Rating 156 
CDR Staging instrument for the severity of 
AD covering six categories: Memory, 
Orientation, Judgment and Problem 
Solving, Community Affairs, Home 
and Hobbies, and Personal Care.   
Scores for each category are assigned 
by clinicians following a semi-
structured interview with the patient 
and an informant.   
Impairment in each category (or 
“box”) is scored on a 5-point scale.   
CDR global ratings range from 0-3 
(0=no dementia; 0.5=questionable 
dementia; 1=mild dementia; 
2=moderate dementia; 3=severe 
dementia), and are calculated from 
individual box scores using a complex 
algorithm.   
 
The “Sum of Boxes” score is 
calculated by simply summing the 
scores in each of the 6 boxes.  Total 
scores range from 0-18, with higher 
scores indicating greater impairment. 
Instrumental 
Activities of Daily 
Living 158 
IADL Functional scale measuring 8 
instrumental activities of daily living: 
ability to use telephone; shopping; 
food preparation*; housekeeping*; 
laundry*; transportation; 
responsibility for medications; ability 
to handle finances.   
*These items were excluded from our 
analyses due to a high level of “Non 
applicable” responses 
Each item was coded in a binary 
fashion as “dependent” (0) or 
“autonomous” (1). 
Total scores range from 0 to 5.  
Higher scores indicate higher 
autonomy.   
Free and Cued 
Selective 
Reminding Test 239 
FCSRT 16-item test of verbal episodic 
memory measuring both free and 
cued recall and  delayed recall.  
Following encoding, subjects are 
asked to name the 16 items 
spontaneously, and are cued for items 
they do not remember spontaneously.  
The “free” and “cued” recall trials are 
repeated 3 times.   
After 20 minutes, a delayed recall test 
is performed with free, and then cued, 
recall. 
The following scores were calculated: 
• Free recall: sum of the scores for 
the 3 free recall trials.  Scores 
range from 0-48.   
• Total recall: sum of the free and 
cued recall trials.  Scores range 
from 0-48.   
• Delayed free recall: sum of 
correctly named items in the 
delayed free recall trial.  Scores 
range from 0-16.   
• Delayed total recall: sum of the 
delayed free and cued recall 
trials.   
In all cases, higher scores indicate 
better performance.   
Trail Making Test 
240  
TMT Test of attention, speed of processing 
and executive function (part B).  Part 
A requires subjects to join up a series 
of consecutive numbers; and part B 
requires them to join up a series of 
The time taken (seconds) to complete 
each part of the test was recorded.  
Quicker completion times indicate 
better cognitive performance.   
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Instrument Abbreviation Description Scoring 
letters and numbers in order, 
alternating between letters and 
numbers.    
Verbal Fluency 241  VF Test of semantic memory.  Subjects 
are asked to name as many words as 
possible corresponding to either a 
category (e.g. fruits, animals) or 
words beginning with a given letter 
(e.g. P).   
The total number of correct answers 
(excluding repetitions) given in two 
minutes was recorded for each test.  
A higher score indicates better 
performance.   
Visual Analogue 
Scales measuring 
memory function 
and impairment in 
everyday life 
VAS Subjects are asked to rate their level 
of memory function on a 100mm scale 
going from 0 ("very badly") to 100 
("perfectly"), and then the level of 
inconvenience in everyday life caused 
by memory problems (100mm scale 
going from 0 "very inconvenienced" 
to 100 "none").  
Scores range from 0 to 100 with 
higher scores indicating better 
memory function and less 
inconvenience in everyday life for 
each scale, respectively.   
Geriatric 
Depression Scale 
238  
GDS 30-item self-reported instrument 
used to detect depression in the 
elderly 
Each item is scored on a binary scale 
(0/1), and the total score is obtained 
by summing the item scores.  Total 
scores of 0-9 are considered 
"normal", 10-19 are considered to 
represent "mild depression", and 20-
30 are considered to represent 
"severe depression" 
 
STATISTICAL METHODS 
In the first part of this analysis, annual mean scores (with 95% confidence intervals) were 
calculated for each cognitive and functional test for participants who remained dementia free, 
either until the end of the 5 year follow-up period or until the end of their participation in the 
trial; and for subjects diagnosed with dementia during the 1st, 2nd, 3rd, 4th or 5th year of the 
trial.  These scores were represented graphically, and the overlap of the 95% confidence 
intervals was assessed.  
The second part of the analysis aimed to determine which cognitive or functional tests best 
predicted future conversion to dementia.  Of the 763 subjects in the temporary database, 526 
were evaluated and were dementia-free at the 1 year visit and were included in this analysis.  
For each subject, the change in score on each test between baseline and 1 year was calculated.  A 
Cox regression model was performed for each of the tests: the dependent variable was time to 
dementia diagnosis, and the independent variable was the 1-year change in the test score.  All 
scores were calculated so that an increase of 1 point represented decline.  Each model was 
adjusted for age, sex, and education, with or without adjustment for the baseline score of the test 
in question.  Then, a multivariate analysis was performed (adjusted for age, sex, education and 
baseline MMSE score) in order to determine which test(s) best predicted future conversion to 
dementia.  All tests that were predictive of dementia onset at the level p<0.2 were included in 
the initial model, but in order to avoid problems of colinearity, only one score from the FCSRT, 
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TMT, verbal fluency and VAS tests could be included.  Standardised HRs in bivariate analyses 
and Akaike's information criterion (AIC) were therefore used to select which score should be 
included in the multivariate model.  A manual backwards stepwise selection process was then 
used to determine the final model.  For each model, the hazard ratio (HR) representing the risk 
of dementia associated with a decline of 1 point on each test was presented.   
All analyses were carried out using Stata version 9.2.   
 
3.3.2 RESULTS 
TRAJECTORIES OF COGNITIVE DECLINE 
A total of 763 subjects were included in this analysis, including 645 individuals who remained 
free of dementia until the end of their participation in the trial (250 completed the whole 5 year 
follow-up period), and 118 individuals who were diagnosed with dementia during the trial (45 
during the 1st year, 22 during the 2nd year, 21 during the 3rd year, 19 during the 4th year, and 11 
during the 5th year).  The characteristics of these subjects at baseline are presented in Table 25 
(page 119).   
Subjects who remained dementia-free and completed the 5 year follow-up period had better 
scores (numerically) on all of the cognitive tests at baseline than those who remained dementia-
free but did not complete the trial, but overlapping 95% confidence intervals suggested that 
most differences were not significant (Figure 14 to Figure 26, pages 120-132).  There was little 
decline in mean scores for any of the cognitive tests in subjects who remained free of dementia, 
and there was an indication of learning effects for the MMSE, FCSRT free and delayed free recall, 
Trail Making Test (parts A and B), and lexical verbal fluency scores  (Figure 14, Figure 16, Figure 
18, Figure 20, Figure 21, Figure 23; pages 120, 122, 124, 126-127, 129).   
Subjects diagnosed with dementia showed decline on all of the tests prior to diagnosis.  At 
baseline, an examination of 95% confidence intervals suggested that two of the tests 
distinguished subjects diagnosed with dementia at one time point from those diagnosed at 
another time point: mean baseline delayed free recall scores on the FCSRT appeared higher in 
subjects diagnosed during the 5th year than those diagnosed during the 1st or 3rd years (Figure 
18, page 124); and mean baseline delayed total recall scores on the FCSRT appeared higher in 
subjects diagnosed during the 5th year than those diagnosed during the 1st year (Figure 19, page 
125).  For all of the other tests, there was no apparent difference in mean baseline scores 
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amongst patients who went on to be diagnosed with dementia during the study, whatever their 
time of diagnosis 
Subjects with dementia diagnosed at any time point during the trial already appeared to have  
significantly lower mean free and total recall scores on the FCSRT at baseline than subjects who 
remained dementia-free (based on non-overlapping 95% confidence intervals), suggesting that 
decline in episodic memory may begin more than 5 years prior to dementia diagnosis (Figure 16, 
Figure 17, pages 122-123).  Based on 95% confidence intervals, mean delayed free and total 
recall FCSRT scores appeared significantly lower in subjects diagnosed 1-4 years after baseline 
than those who remained dementia free, but not in those diagnosed 5 years after baseline 
(Figure 18, Figure 19, pages 124-125). 
Subjects diagnosed up to 4 years after baseline also appeared to have lower categorical verbal 
fluency scores at baseline than those who remained dementia free (Figure 22, page 128), 
although lexical verbal fluency scores only appeared lower for those diagnosed 1 year after 
baseline (Figure 23, page 129).  Compared to subjects who remained dementia free, baseline 
Trail Making Test (parts A & B) only appeared lower for those diagnosed at 1 year (Figure 20, 
Figure 21, pages 126-127), while baseline CDR-SB scores appeared lower for subjects diagnosed 
at 1 or 3 years after baseline (Figure 26, page 132).   
Overlapping 95% confidence intervals for all groups of subjects suggested that the MMSE and 
IADL scales, as well as the VAS, did not distinguish at baseline between subjects who remained 
dementia free and those who went on to be diagnosed with dementia at any time point.     
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TABLE 25 – BASELINE CHARACTERISTICS OF SUBJECTS FROM THE GUIDAGE TRIAL INCLUDED IN THE TEMPORARY DATABASE, ACCORDING TO DEMENTIA 
STATUS DURING FOLLOW-UP 
Characteristic Population 
 Dementia-free 
(N=645) 
Dementia-free, 
completed trial 
(N=250) 
Dementia 
diagnosed 1st yr 
(N=45) 
Dementia 
diagnosed 2nd yr 
(N=22) 
Dementia 
diagnosed 3rd yr 
(N=21) 
Dementia 
diagnosed 4th yr 
(N=19) 
Dementia 
diagnosed 5th yr 
(N=11) 
Age, mean (SD), y 77.6 (4.3) 77.2 (3.6) 79.4 (3.8) 78.5 (3.6) 79.6 (5.3) 78.3 (3.6) 79.3 (3.4) 
Sex, no. (%) 
Female 
Male 
 
427 (66.2) 
218 (33.8) 
 
172 (68.8) 
78 (31.2) 
 
30 (66.7) 
15 (33.3) 
 
17 (77.3) 
5 (22.7) 
 
12 (57.1) 
9 (42.9) 
 
9 (47.4) 
10 (52.6) 
 
8 (72.7) 
3 (27.3) 
Education, no. (%) 
1. No diploma 
2. Primary school certificate 
3. Secondary education, without high 
school diploma 
4. High school diploma (Baccalaureate) 
or higher 
 
108 (16.7) 
269 (41.71) 
120 (18.6) 
 
148 (23.0) 
 
38 (15.2) 
91 (36.4) 
57 (22.8) 
 
64 (25.6) 
 
8 (17.8) 
22 (48.9) 
4 (8.9) 
 
11 (24.4) 
 
5 (22.7) 
12 (54.6) 
3 (13.6) 
 
2 (9.1) 
 
 
2 (9.5) 
10 (47.6) 
5 (23.8) 
 
4 (19.1) 
 
5 (26.3) 
8 (42.1) 
4 (21.1) 
 
2 (10.5) 
 
2 (18.2) 
6 (54.6) 
3 (27.3) 
 
0 (0) 
Comorbidities, no. (%) 
≤1 
2-5 
≥6 
 
68 (10.5) 
420 (65.1) 
187 (24.4) 
 
30 (12.0) 
172 (68.8) 
48 (19.2) 
 
3 (6.66) 
30 (66.66) 
12 (26.66) 
 
4 (18.2) 
10 (45.5) 
8 (36.4) 
 
2 (9.5) 
17 (81.0) 
2 (9.5) 
 
3 (15.8) 
10 (52.6) 
6 (31.6) 
 
2 (18.2) 
7 (63.6) 
2 (18.2) 
Duration of memory complaint, 
median (IQR), months 
36.1 (22.1-56.1) 35.8 (24.8-52.3) 38.2 (16.9-64.1) 30.0 (23.2-41.6) 28.6 (16.8-52.8) 43.8 (17.2-78.6) 25.7 (12.6-43.5) 
McNair & Kahn Scale, mean (SD), /80 26.0 (11.0) 26.0 (10.5) 27.0 (14.4) 27.8 (10.8) 28.3 (11.2) 33.3 (12.3) 34.9 (8.1) 
CDR, no. (%) 
0  
≥0.5* 
 
267 (41.4) 
378 (58.6) 
 
120 (48.0) 
130 (52.0) 
 
8 (17.8) 
37 (82.2) 
 
2 (9.1) 
20 (90.9) 
 
3 (14.3) 
18 (85.7) 
 
2 (10.5) 
17 (89.5) 
 
3 (27.3) 
8 (72.7) 
GDS, mean (SD), /30 6.6 (3.8) 6.3 (3.8) 7.7 (3.8) 7.0 (4.2) 6.0 (3.5) 7.6 (3.6) 8.5 (4.1) 
Covi Anxiety Scale, mean (SD), (/12) 1.4 (1.4) 1.3 (1.3) 1.4 (1.3) 1.4 (1.7) 1.4 (1.7) 2.5 (1.3) 1.4 (1.4) 
Smoking status, no. (%) 
Never 
Current 
Former 
 
476 (73.8) 
20 (3.1) 
149 (23.1) 
 
189 (75.6) 
7 (2.8) 
54 (21.6) 
 
35 (77.8) 
1 (2.2) 
9 (20.0) 
 
15 (68.2) 
1 (4.6) 
6 (27.3) 
 
13 (61.9) 
0 (0) 
8 (38.1) 
 
12 (63.2) 
0 (0) 
7 (36.8) 
 
9 (81.8) 
1 (9.1) 
1 (9.1) 
Alcohol consumption*,  
None 
Moderate 
High 
 
330 (51.6) 
234 (36.6) 
76 (11.9) 
 
120 (48.0) 
96 (38.4) 
34 (13.6) 
 
30(68.2) 
11 (25.0) 
3 (6.8) 
 
15 (71.4) 
5 (23.8) 
1 (4.8) 
 
10 (47.6) 
8 (38.1) 
3 (14.3) 
 
12 (63.2) 
6 (31.6) 
1 (5.3) 
 
7 (63.6) 
3 (27.3) 
1 (9.1) 
Able to perform 5-second one-leg 
balance test, no. (%) 
 
516 (80.5) 
 
208 (83.5) 
 
34 (77.3) 
 
21 (95.5) 
 
17 (85.0) 
 
13 (72.2) 
 
7 (63.6) 
* 1 subject (diagnosed with dementia at 1 year) had a CDR >0.5; **moderate: <20mg/d for women, <30mg/d for men; high: ≥20mg/d for women, ≥30mg/d for men 
120 
 
 
 
FIGURE 14 – EVOLUTION OF MEAN MMSE SCORES DURING THE GUIDAGE TRIAL ACCORDING TO 
DEMENTIA STATUS DURING FOLLOW-UP (DASHED LINES REPRESENT 95% CONFIDENCE INTERVALS)  
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FIGURE 15 – EVOLUTION OF MEAN IADL SCORES DURING THE GUIDAGE TRIAL ACCORDING TO 
DEMENTIA STATUS DURING FOLLOW-UP  (DASHED LINES REPRESENT 95% CONFIDENCE INTERVALS)  
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FIGURE 16 – EVOLUTION OF MEAN FREE RECALL SCORES OF THE FREE AND CUED SELECTIVE 
REMINDING TEST DURING THE GUIDAGE TRIAL ACCORDING TO DEMENTIA STATUS DURING FOLLOW-
UP (DASHED LINES REPRESENT 95% CONFIDENCE INTERVALS) 
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FIGURE 17 – EVOLUTION OF MEAN TOTAL RECALL SCORES OF THE FREE AND CUED SELECTIVE 
REMINDING TEST DURING THE GUIDAGE TRIAL ACCORDING TO DEMENTIA STATUS DURING FOLLOW-
UP (DASHED LINES REPRESENT 95% CONFIDENCE INTERVALS) 
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FIGURE 18 – EVOLUTION OF MEAN DELAYED FREE RECALL SCORES OF THE FREE AND CUED SELECTIVE 
REMINDING TEST DURING THE GUIDAGE TRIAL ACCORDING TO DEMENTIA STATUS DURING FOLLOW-
UP (DASHED LINES REPRESENT 95% CONFIDENCE INTERVALS) 
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FIGURE 19 – EVOLUTION OF MEAN DELAYED TOTAL RECALL SCORES OF THE FREE AND CUED 
SELECTIVE REMINDING TEST DURING THE GUIDAGE TRIAL ACCORDING TO DEMENTIA STATUS DURING 
FOLLOW-UP (DASHED LINES REPRESENT 95% CONFIDENCE INTERVALS) 
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FIGURE 20 – EVOLUTION OF MEAN TRAIL MAKING TEST PART A SCORES DURING THE GUIDAGE TRIAL 
ACCORDING TO DEMENTIA STATUS DURING FOLLOW-UP (DASHED LINES REPRESENT 95% 
CONFIDENCE INTERVALS) 
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FIGURE 21 – EVOLUTION OF MEAN TRAIL MAKING TEST PART B SCORES DURING THE GUIDAGE TRIAL 
ACCORDING TO DEMENTIA STATUS DURING FOLLOW-UP (DASHED LINES REPRESENT 95% 
CONFIDENCE INTERVALS) 
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FIGURE 22 – EVOLUTION OF MEAN CATEGORICAL VERBAL FLUENCY SCORES DURING THE GUIDAGE 
TRIAL ACCORDING TO DEMENTIA STATUS DURING FOLLOW-UP (DASHED LINES REPRESENT 95% 
CONFIDENCE INTERVALS) 
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FIGURE 23 – EVOLUTION OF MEAN LEXICAL VERBAL FLUENCY SCORES DURING THE GUIDAGE TRIAL 
ACCORDING TO DEMENTIA STATUS DURING FOLLOW-UP (DASHED LINES REPRESENT 95% 
CONFIDENCE INTERVALS) 
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FIGURE 24 – EVOLUTION OF MEAN PARTICIPANT SELF-RATED SCORES ON A VISUAL ANALOGUE SCALE 
MEASURING MEMORY FUNCTIONING DURING THE GUIDAGE TRIAL ACCORDING TO DEMENTIA STATUS 
DURING FOLLOW-UP (DASHED LINES REPRESENT 95% CONFIDENCE INTERVALS) 
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FIGURE 25 – EVOLUTION OF MEAN PARTICIPANT SELF-RATED SCORES ON A VISUAL ANALOGUE SCALE 
MEASURING THE IMPAT OF MEMORY PROBLEMS ON EVERYDAY LIFE DURING THE GUIDAGE TRIAL 
ACCORDING TO DEMENTIA STATUS DURING FOLLOW-UP (DASHED LINES REPRESENT 95% 
CONFIDENCE INTERVALS)    
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FIGURE 26 – EVOLUTION OF MEAN CDR-SUM OF BOXES SCORES DURING THE GUIDAGE TRIAL 
ACCORDING TO DEMENTIA STATUS DURING FOLLOW-UP (DASHED LINES REPRESENT 95% 
CONFIDENCE INTERVALS)  
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PREDICTION OF FUTURE DEMENTIA DIAGNOSIS 
This analysis included 526 subjects with baseline and 1 year cognitive evaluations who were 
free of dementia at the 1 year visit.  Of these, 454 subjects remained dementia free during the 
trial, and 72 were diagnosed with dementia after the 1st year.   
BIVARIATE ANALYSIS 
TABLE 26 – RISK OF DEMENTIA DIAGNOSIS AFTER 1 YEAR IN THE GUIDAGE STUDY ASSOCIATED WITH 
A 1-POINT DECLINE IN COGNITIVE TEST SCORES DURING THE FIRST YEAR OF FOLLOW-UP (BIVARIATE 
ANALYSIS) 
Test Model 1 Model 2 Standardised 
HR HR p 95%CI HR P 95%CI 
MMSE  
(N=519) 
1.15 0.002 1.05-1.26 1.26 <0.001 1.15-1.39 1.68 
IADL (score/5)  
(N=435) 
1.87 0.018 1.11-3.14 2.11 0.001 1.33-3.35 1.35 
FCSRT free recall  
(N=520) 
1.02 0.480 0.97-1.06 1.09 <0.001 1.04-1.15 1.79 
FCSRT total recall  
(N=517) 
1.03 0.218 0.98-1.10 1.08 <0.001 1.03-1.12 1.33 
FCSRT delayed free recall  
(N=517) 
1.19 0.001 1.08-1.32 1.32 <0.001 1.19-1.46 2.34 
FCSRT delayed total recall  
(N=512) 
1.33 <0.001 1.14-1.56 1.39 <0.001 1.24-1.55 1.61 
TMT – A  
(N=521) 
1.00 0.426 0.99-1.02 1.01 0.014 1.00-1.03 1.38 
TMT – B  
(N=511) 
1.00 0.775 0.99-1.00 1.00 0.162 1.00-1.01 1.18 
Categorical verbal fluency  
(N=519) 
1.05 0.018 1.01-1.09 1.13 <0.001 1.08-1.19 2.51 
Lexical verbal fluency  
(N=516) 
1.08 0.003 1.03-1.13 1.13 <0.001 1.07-1.20 2.28 
VAS: memory functioning  
(N=510) 
1.01 0.078 1.00-1.03 1.02 0.004 1.01-1.04 1.50 
VAS: memory impairment in 
everyday life (N=509) 
1.00 0.586 0.99-1.01 1.01 0.134 1.00-1.02 1.23 
CDR-SB  
(N=516) 
1.34 0.115 0.93-1.94 1.89 <0.001 1.38-2.59 1.54 
Model 1: adjusted for age, sex & education 
Model 2: adjusted for age, sex, education & baseline test score 
Standardised HR = HRSD (using baseline SD and HR from model 2) 
In the bivariate analysis, after adjustment for baseline test scores, a 1-point decline on all of the 
tests, except the TMT-B and the VAS of memory impairment in everyday life, was predictive of 
future dementia diagnosis (Table 26, page 133).  Adjustment for baseline scores increased the 
risk of dementia associated with a decline of 1 point for all of the tests, compared to models 
adjusted for age, sex and education only.  Since all of the tests are measured on different scales, 
standardized HRs were calculated which represented the risk of dementia associated with a 
decline of 1 standard deviation (of the study population’s baseline scores).  Standardised HRs 
showed that in the bivariate analysis, a decline of 1 SD on the verbal fluency tests, and on the 
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delayed free recall score of the FCSRT were associated with the greatest risk of dementia 
diagnosis (Table 26, page 133).   
 
MULTIVARIATE ANALYSES 
The following tests were included in the initial multivariate model: MMSE, IADL, FCSRT delayed 
free recall score, TMT-A, categorical verbal fluency, VAS of memory function, CDR-SB.  The final 
model, following a manual backwards stepwise selection procedure, is presented in Table 27 
(page 134).  For MMSE, IADL, FCSRT delayed free recall and lexical verbal fluency scores, a 1 
point decline during the first year of follow-up was independently associated with an increased 
risk of subsequent dementia diagnosis during the next 4 years.   
 
TABLE 27 – FINAL MULTIVARIATE MODEL SHOWING RISK OF DEMENTIA DIAGNOSIS AFTER 1 YEAR IN 
THE GUIDAGE STUDY ASSOCIATED WITH A 1-POINT DECLINE IN COGNITIVE TEST SCORES DURING THE 
FIRST YEAR OF FOLLOW-UP 
Variable (N=400) HR p 95% CI 
MMSE 1.30 <0.001 1.15-1.47 
IADL 1.80 0.030 1.06-3.05 
FCSRT delayed free recall score 1.15 0.023 1.02-1.29 
Lexical verbal fluency 1.07 0.014 1.00-1.15 
Age 1.07 0.043 1.00-1.15 
Sex 0.96 0.900 0.55-1.70 
Education (Ref class 1 (lowest level)) 
2 
3 
4 
 
1.61 
1.51 
0.58 
 
0.187 
0.357 
0.314 
 
0.79-3.29 
0.63-3.65 
0.20-1.68 
Baseline MMSE* 0.76 0.004 0.64-0.92 
Adjustment variables are shown in grey.   
* For baseline MMSE score, the HR is that associated with a 1-point increase in MMSE score 
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3.3.3 DISCUSSION 
These analyses provided a preliminary study of the patterns of cognitive decline and predictors 
of dementia during a prevention trial with the aim of informing the development of cognitive 
decline as a valid surrogate endpoint for AD prevention trials.   
TRAJECTORIES OF COGNITIVE DECLINE 
Descriptive analyses of cognitive trajectories suggested that there was little cognitive decline 
during the 5 years of follow-up in subjects who remained dementia free, in particular in those 
who completed the trial.  Since there were relatively few cases of dementia diagnosed, it is likely 
that the overall mean decline in the whole population would be similar to that of the dementia-
free subjects.  This means that even if cognitive decline is used as a primary endpoint for 
prevention trials instead of dementia incidence, it may still be difficult to detect treatment 
effects, in particular if they are modest, since participants are likely to undergo little decline.  
This lack of cognitive decline in the majority of subjects is perhaps surprising, since the study 
population was made up of people aged 70 or over with spontaneously reported subjective 
memory complaints, who in theory should have been at increased risk cognitive decline 242-243 
and developing AD 244.  However, subjects who accept to take part in long-term prevention trials 
differ from those who do not take part 210, in particular in this trial in terms of their level of 
education.  Also, we excluded subjects with the lowest scores on the FCSRT (score <10th 
percentile for age, sex and sociocultural level) who were perhaps those subjects with memory 
complaints who would have undergone more marked cognitive decline during the trial. 
For several neuropsychological tests, scores initially increased in subjects who remained 
dementia-free for the whole trial.  This could be explained by the presence of "learning effects" 
brought about by repeated testing, or it could be due to stress-induced poorer performance at 
the first evaluation  245.  It is probably most likely to be due to learning effects however in our 
study, since the increase in scores persisted to the second annual evaluation.     
In subjects who developed dementia, cognitive decline started well before dementia diagnosis 
on several of the neuropsychological tests used in this study.  Episodic memory (measured by 
the FCSRT) seemed to be the earliest affected cognitive domain in subjects who developed 
dementia, since even those diagnosed at 5 years had lower baseline scores than those who 
remained dementia-free, indicating that decline had begun more than 5 years before diagnosis.  
This is consistent with current thinking that episodic memory is one of the earliest and most 
significantly affected cognitive domains in AD 7 and that episodic memory deficits are predictive 
of future AD 246-248.  Categorical verbal fluency was also affected at least 4 years prior to 
dementia diagnosis in our study.  In the PAQUID population-based cohort study, performance on 
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a different test of categorical verbal fluency was found to be impaired as early as 12 years prior 
to diagnosis of AD 249.  Subjects diagnosed with dementia in the 5th year of follow-up in the 
GuidAge trial had baseline categorical verbal fluency scores that were similar to those of 
subjects diagnosed in the 3rd and 4th year of the trial, although the confidence interval 
overlapped that of the subjects who remained dementia-free.  This is most likely due to the small 
number of subjects diagnosed in the 5th year, which gave rise to very wide confidence intervals.  
It is quite possible that decline on this measure also started more than 4 years prior to diagnosis.  
However, even global deficits measured by the MMSE were detected around 9 years prior to 
dementia diagnosis in the PAQUID study, whereas in our trial, even subjects who were 
diagnosed at 1 year could not be distinguished by their MMSE scores at baseline from those who 
remained dementia free.  Thus, cognitive decline prior to dementia was detected later in the 
GuidAge trial than in PAQUID study.   This could be explained by a number of factors, in 
particular that dementia seems to have been diagnosed at a later stage in PAQUID than in 
GuidAge (based on graphical representation of results, the mean MMSE score at time of 
dementia diagnosis was approximately 17-18 in PAQUID 249 versus approximately 23-24 in 
GuidAge), perhaps because subjects were only evaluated every 2-3 years in PAQUID compared 
to annually in GuidAge.  Secondly, the level of education was higher in GuidAge than in PAQUID 
250, probably because PAQUID included a population-based sample, whereas participants in 
GuidAge had volunteered to take part in a 5 year prevention trial, and were thus a highly 
selected population.  GuidAge participants had also spontaneously complained of memory 
problems prior to inclusion in the trial.  In the PAQUID study, subjects with a higher level of 
education underwent sharper decline on the MMSE in the 4 years preceding AD diagnosis, and 
underwent less decline from 5 to 9 years prior to diagnosis than subjects with a lower level of 
education.  Other studies, however have suggested that although the level of education appears 
to influence cognitive performance it may not affect the rate of cognitive decline 251-252.  Finally, 
the GuidAge analyses presented here were very preliminary and based on descriptive methods 
only, whereas a more complex statistical procedure was used in the PAQUID study to model the 
cognitive trajectories.  The results obtained here therefore need to be validated once the whole 
GuidAge dataset is available using appropriate statistical methods.   
This work also suggested that there is considerable heterogeneity in the trajectories of cognitive 
decline between subjects in a prevention trial, in particular according to their future dementia 
status.  Furthermore, decline would appear to be non linear in many cases, in particular due to 
learning effects at the beginning of the trial, and accelerated decline prior to diagnosis in 
subjects who develop dementia.  Such factors therefore need to be taken into account during the 
analysis of cognitive decline in prevention trials.   
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In summary, in a population of elderly participants with spontaneously reported subjective 
memory complaints included in an AD prevention trial, overall there was little decline on 
cognitive measures in descriptive analyses.  This work requires confirmation with statistical 
models that are more appropriate for the study of longitudinal data, but suggests that for true 
primary prevention trials (i.e. carried out in healthy subjects with no symptoms of dementia) it 
may remain difficult to detect treatment effects using clinical measures alone.  This reflects the 
findings of a recent randomised trial of the effects of n-3 long-chain polyunsaturated fatty acid 
supplementation on cognitive function in older people which detected no cognitive decline in 
the control group over the two years of the trial and could not detect any treatment effects 81.  
Future prevention trials may well need to incorporate biomarkers into their assessments in 
order to have a greater chance of detecting treatment effects.  At the current time, biomarkers 
have not been validated as surrogate endpoints 211, but they can be of use for the identification of 
subjects who are most at risk of developing AD.  It is these subjects who are more susceptible to 
undergo more pronounced cognitive decline during prevention trials, and in whom it may be 
most important to test prevention strategies.   
Cognitive decline was detectable in episodic and semantic memory in subjects who went on to 
develop dementia more than 4-5 years before diagnosis in our trial, suggesting that 
neuropsychological tests targeting these cognitive domains may be particularly relevant 
outcome measures for future prevention trials since these domains may be particularly affected 
during the long preclinical phase that occurs prior to AD diagnosis.  This work also 
demonstrated that subjects enrolled in prevention trials may undergo different trajectories of 
cognitive decline than those participating in cohort studies.  This has implications in particular 
for determining sample size calculations and the length of follow-up and so must be taken into 
account during the design of future trials.  In particular, the specificities of the study population 
may explain the apparent differences in trajectories of cognitive decline in prevention trials, 
compared to population-based studies, in addition to the increased frequency of cognitive 
testing.   
 
PREDICTION OF FUTURE DEMENTIA 
The results of the survival analysis showed that 1-year decline on the MMSE, IADL, FCSRT 
delayed free recall, and lexical verbal fluency tests were independently predictive of future 
dementia diagnosis.  Although the MMSE and IADL tests did not discriminate at baseline 
between those who remained dementia free and those who went on to be diagnosed with 
dementia, a 1 point decline on these scales was nonetheless indicative of dementia onset, and 
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statistically, the MMSE test was most strongly associated with future dementia diagnosis.  This 
may be related to the fact that the multivariate model was adjusted for baseline MMSE scores, 
but not for baseline scores on other tests.   The outcome of interest in our model was dementia 
diagnosis during a 4-year period.  A previous study has suggested that a global pattern of low 
cognitive performance predicts short-term but not long-term onset of dementia, whereas 
isolated low memory performance predicts dementia in the long-term 253.  Given the results of 
our analysis of trajectories of cognitive decline, it could be that a decline in more global 
measures, such as the MMSE and IADL, are predictive of dementia onset in the short term only.   
Of note, with respect to the previous analyses regarding the utility of the CDR-SB as a primary 
endpoint for clinical trials, the 1-year change CDR-SB scores in was not predictive of future 
dementia onset in the multivariate model, suggesting that the CDR-SB may not be useful as a 
single primary endpoint in prevention trials.     
LIMITS  
There are a number of limits associated with the present analyses.  In addition to the limits 
mentioned above (simplicity of the analyses used to assess cognitive trajectories, the use of 
blinded data), it must also be noted that the independent committee in the GuidAge trial had 
access to all of the cognitive test results when validating dementia diagnoses and classifications.  
There was therefore a risk of circularity which could potentially weaken these results.  In 
particular, dementia diagnoses were based heavily on CDR global ratings, so the predictive value 
of CDR-SB may be difficult to determine in this study since it is clearly associated with CDR 
global ratings.  Also, the subjects included in these analyses (N=763) were only a subset of those 
enrolled in the GuidAge trial (N=2854).  This was a convenience sample including subjects with 
available data at the time of analysis.  The following subsets of participants are probably over-
represented in this database compared to the whole trial population: subjects who were 
enrolled first and completed the 5 year follow-up (follow-up was still ongoing for other subjects 
at the time of the analysis); subjects who dropped out of the trial early on; and those who were 
diagnosed with dementia earlier on in the trial.  There are not likely to be any major biases 
associated with this sample, except that it probably contains a higher proportion of dementia 
cases than the entire study population, but we were not concerned with the rate of conversion to 
AD in these analyses and so our results are probably unaffected by this point.   
Because the trial was still ongoing when these analyses were conducted, we could not include all 
of the GuidAge subjects diagnosed with dementia during the last 2 years of the trial.  Therefore, 
the subgroups of patients included in these analyses who were diagnosed at 4 or 5 years were 
relatively small, especially for the 5 year group, bringing about a lack of precision for estimates 
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relating to this group (for example, the confidence intervals in the first analyses were very large 
for the group diagnosed at 5 years).   
Finally, since the data were still blinded when these analyses were carried out, we could not take 
into account treatment effects which may have altered the trajectories of cognitive decline.   
 
IS COGNITIVE DECLINE A VALID SURROGATE ENDPOINT? 
Validation of surrogate endpoints for clinical trials has mostly been discussed with regards to 
biomarkers 195, but the principles of the validation process are also applicable to other potential 
surrogate endpoints which may be clinical entities in themselves and not necessarily 
biomarkers.  One author suggested that validation is “the process of linking a biomarker to a 
clinical endpoint, which shows that the biomarker can be a reliable alternative of the clinical 
outcome in a therapeutic trial" 254.   Drug regulatory authorities have stated that surrogate 
endpoints must be able to predict clinical benefit, and that their accuracy and precision must be 
demonstrated, in terms of correlations with the true clinical endpoint (meaning that patients 
having better results for the biological marker tend to have better results for the clinical efficacy 
endpoint), and reproducibility of the measure 255.  Thus, part of the validation process may 
involve demonstrating retrospectively how well a surrogate endpoint predicted a true clinical 
outcome in clinical trials 195.  Other important aspects of surrogate endpoints include biological 
plausibility 254, 256, and whether or not a single surrogate endpoint will be able to capture all 
treatment effects 195.   
Cognitive impairment is one of the key diagnostic criteria for AD diagnosis, and so it is clearly 
biologically plausible that slowing cognitive decline could delay dementia onset.  The present 
analyses have confirmed that cognitive decline occurs and is detectable prior to dementia 
diagnosis in a prevention trial setting, and that decline on certain cognitive tests is predictive of 
future dementia.  However, in order for cognitive decline to be considered as a surrogate 
endpoint, ultimately we need to demonstrate that interventions that are beneficial in clinical 
trials on the rate of cognitive decline are also able to decrease the incidence of dementia, and in 
particular we need to determine what effect size, in terms of delaying cognitive decline, would 
be required in order to significantly delay dementia onset.  In order to do this, we need data 
from trials measuring both cognitive decline and dementia incidence in which a treatment effect 
was detected, but as yet none of the prevention trials carried out so far have been able to 
demonstrate any effects on dementia incidence.  Given the difficulties of carrying out prevention 
trials with dementia incidence as a primary endpoint, including the length of follow-up required, 
this will be difficult to achieve.  In order for the field of AD prevention trials to advance, one 
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suggestion is to identify the cognitive tests or domains that are most associated with dementia 
onset, and to use them (or a composite score based on several tests that are the most predictive 
of AD) in initial trials.  Based on data from the GuidAge trial, tests of episodic and semantic 
memory may be particularly useful as sensitive endpoints for future trials, while global and 
functional measures, such as the MMSE and IADL, may also be of use.   
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3.4 CHAPTER CONCLUSION 
This chapter examined the suitability of alternative endpoints for AD prevention and treatment 
trials.  Firstly, the CDR-SB was evaluated in order to assess its suitability as a single primary 
endpoint for AD trials, instead of the usual co-primary endpoint approach.  The results 
suggested that it may be a suitable candidate for a sole primary endpoint since it measures both 
cognition and function simultaneously, and shows good internal responsiveness.  Change over 
time was similar in both very mild and mild-moderate stages of AD, and there were few floor or 
ceiling effects over two years, suggesting that the CDR-SB could be a suitable endpoint at 
different stages of the disease.  It will be useful to assess the CDR-SB in subjects with even earlier 
symptoms of the disease, such as those with amnestic MCI (or prodromal AD).  Data from the 
GuidAge study can be used to study the utility of the CDR-SB as an endpoint for prevention trials, 
although the initial analyses suggested that change during the first year of follow-up on the CDR-
SB was not predictive of future dementia.  It might be particularly interesting to examine the 
CDR-SB in subjects from the GuidAge trial who had a CDR global rating of 0.5 at baseline (but 
who were free of dementia).     
The development of new clinical endpoints for AD trials is complicated since they must be 
compared with other clinical measures which themselves are not necessarily perfect measures 
of disease status or progression.  Indeed, it is particularly difficult to determine what constitutes 
a “clinically relevant” change on continuously rated scales.  The CDR-SB is not as sensitive to 
minor cognitive changes as neuropsychological cognitive tests which provide objective 
measures of cognitive performance, but a 1 point change on the CDR-SB is probably more 
clinically meaningful.  Furthermore, performance-based cognitive tests can be prone to learning 
effects, and can be affected by stress induced by the testing situation.  The CDR-SB avoids such 
problems by taking a more global approach based on participant- and informant-interviews.   
The second part of this chapter examined the rate of cognitive decline as an alternative endpoint 
for prevention trials.  Whilst these analyses remain very preliminary and will require 
confirmation, they suggest that it may remain difficult to detect treatment effects even in trials 
using cognitive decline as the primary endpoint instead of dementia incidence, since the overall 
rate of decline in prevention trials may remain very low, even though subjects who go on to be 
diagnosed with dementia do undergo decline prior to diagnosis.  An alternative way of analysing 
cognitive decline might be to study the proportion of patients dropping below a certain 
threshold on cognitive measures.  Tests of episodic or semantic memory might be particularly 
useful markers of early changes, while global or functional measures might reflect more 
imminent dementia onset.  However, the clinical relevance of changes on such measures needs 
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to be better determined.  Furthermore, cognitive decline cannot be considered as a surrogate 
endpoint for dementia incidence at the current time since we cannot be sure that an 
intervention able to slow cognitive decline would delay dementia onset.  Given the difficulties 
currently encountered in prevention trials, the development of biomarkers to be used either for 
selecting the study population, or as surrogate endpoints is an important goal.    
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4. OVERALL DISCUSSION AND CONCLUSIONS  
Disease modifying trials for AD patients 
Initial successes in the development of symptomatic treatments for AD have not been mirrored 
in the development of disease-modifying treatments: all of the phase III trials testing potentially 
disease-modifying drugs in patients with AD have so far failed.  It may be that the drugs 
developed thus far have not been targeting the right disease processes 29 or are simply 
ineffective, but clinical trials for AD could also benefit from a methodological re-think.  So far, the 
design of disease-modifying trials has been largely based on that of trials for symptomatic drugs, 
especially in terms of the target population and endpoints.  One major difference however has 
been the duration of trials, which are now generally 18 months (Table 2, page 30) compared to 6 
months in typical trials for symptomatic drugs (Table 1, page 27).  This longer duration 
increases the risk of missing data, which can decrease statistical power and introduce bias into 
results.  The identification of baseline factors that are predictive of dropout can help to identify 
those patients most at risk of discontinuing the study, and means that strategies aiming to 
prevent dropout can be tailored to these individuals.  We found that the loss of patient 
autonomy, non-use of anti-Alzheimer treatments and use of 1 to 3 other treatments, as well as a 
high level of caregiver burden and having a caregiver other than the patient’s spouse or child, 
were predictive of dropout during 2 years of follow-up in longitudinal cohort study of AD 
patients.  Patients with these characteristics are also likely to be at higher risk of dropping out of 
clinical trials, and so study teams should make particular efforts to maintain contact with these 
subjects.  Further work is required to determine the most effective strategies for participant 
retention in AD trials, including considering how to decrease the burden of study evaluations.   
Better training of study evaluators regarding the completion of study evaluation instruments 
would also help to reduce missing data in AD trials.  A certain amount of missing data is, 
however, almost inevitable in AD trials, and so the management of missing data during statistical 
analysis is an important consideration.  We showed that simple analyses, such as complete case 
or LOCF are clearly unsuitable for AD trials.  Further examination of the management of missing 
data in AD trials is required, in particular with consideration of how best to handle missing data 
due to death and missing data that are MNAR.  
Another difficulty in 18-month trials is the considerable variability in disease progression 
amongst patients.  This is particularly evident on the ADAS-Cog, the most commonly used 
primary endpoint in AD trials, which can limit statistical power to detect treatment effects 257.  
Instruments with less variability would therefore be helpful in order to be able to detect the 
modest efficacy that is expected of disease-modifying treatments.  Furthermore, a single primary 
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endpoint able to capture treatment effects on both cognition and function simultaneously would 
decrease trial sample sizes compared to the currently used co-primary endpoint approach.  Also, 
the instruments used in these relative long-term trials must be able to detect disease 
progression at different stages of the disease.  The use of instruments that are suitable for 
evaluating patients throughout the duration of long-term trials would also help to limit the 
amount of missing data.  The CDR-SB showed similar decline over 2 years in both very mild and 
mild-moderate AD subjects, and showed much less variability than the ADAS-Cog, leading to 
smaller projected sample sizes.  Furthermore, the CDR-SB measures both cognition and function 
simultaneously.  It could therefore be suitable as a sole primary outcome measure for AD trials, 
as an alternative to the usual co-primary approach, even in subjects with very mild AD.  It will be 
interesting to evaluate the CDR-SB further using data collected in clinical trial settings, including 
prevention trials and those for individuals with MCI or prodromal AD.       
Prevention trials 
Prevention trials for AD are also a relatively new field, and the ideal methodology of such trials is 
not yet known.  Most interventions tested so far in AD prevention trials have been based on 
epidemiological evidence from observational studies, but so far results from randomised trials 
have been disappointing.  Numerous potential methodological explanations for the 
discrepancies in results between observational and interventional studies were identified, 
including differences in the study population, design of interventions, window of exposure, 
duration of follow-up and outcome measures, as well as insufficient statistical power in some 
randomised trials.  Prevention trials are complicated to carry out in practice.  Firstly, the 
intervention tested must be safe since it will be given to large numbers of healthy subjects, only 
a small proportion of whom will actually go on to develop the disease.  Secondly, trial duration 
must be relatively long in order for participants to be sufficiently exposed to the intervention 
under study, and in order to accumulate a sufficient number of cases of AD.  AD incidence is the 
gold-standard endpoint for prevention trials, but incidence remains low in prevention trial 
populations, perhaps due to selection bias since participants in such trials are not a 
representative sample of the general population.  Also, the use of this endpoint is complicated by 
the fact that it is difficult to determine the precise moment of dementia onset in subjects who are 
being followed-up on a regular basis, and due to the subjective nature of dementia diagnosis, all 
cases must be validated by an external committee.  Therefore, many trials have instead 
measured the effects of an intervention on the rate of cognitive decline instead of dementia 
incidence (Table 3).  This is a more objective endpoint since it can be measured using a 
standardised battery of neuropsychological tests, and also more sensitive cognitive changes can 
be detected.  Also, statistical power should be increased in a repeated measures analysis 
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compared to a time to event analysis.  However, our preliminary analyses of a temporary dataset 
from a prevention trial suggested that, as in some other prevention trials 81,  the majority of 
prevention trial participants may undergo little decline and so it may still be complicated to 
detect intervention effects using this endpoint.  Furthermore, while cognitive decline is clearly 
predictive of future dementia, we still do not know what magnitude of effect is required on 
cognitive decline in order to significantly delay AD onset or whether or not cognitive measures 
can capture all potential intervention effects on the dementia syndrome.  The clinical relevance 
of statistically significant intervention effects on the rate of cognitive decline also need to be 
better assessed.  Further analyses of data from prevention trials such as GuidAge which measure 
both dementia incidence and cognitive decline are therefore required.   
Future perspectives for AD trials 
In addition to the methodological points highlighted in this work, future AD trials should be 
greatly helped by the development and validation of biomarkers.  The ultimate goal perhaps, 
especially for prevention trials, is a biomarker that can be used as a surrogate endpoint.  
Biomarker surrogate endpoints might enable interventions aiming to prevent AD to be tested at 
a much earlier stage, since we would not have to wait for the onset of clinical symptoms which 
are thought to occur long after the initial biological changes associated with AD.  However, as 
shown with the work on cognitive decline, the validation of surrogate endpoints is a complicated 
process, and therefore we are not yet close to having a validated biomarker surrogate endpoint 
for either dementia prevention or treatment trials 254.  Therefore, in the short-term, the most 
likely use of biomarkers in AD trials will be to define the target population.  Patients diagnosed 
with AD may have a variety of neuropathologies 258 and so biomarkers could help to select a 
more homogenous population which could decrease the variability in drug effects and in disease 
progression 29, 257.  They could also be used in order to select a particular patient population in 
whom a given drug is expected to have the greatest effect 259.  In prevention trials too, 
biomarkers could play an important role in the selection of the target population.  In this way, it 
would be possible to select those individuals who already show pathological signs of AD in the 
absence of clinical symptoms.  The failure of many MCI trials has been blamed on the fact that 
many of the participants did not have AD 260, and in prevention trials involving asymptomatic 
individuals, this problem is emphasised since an even smaller proportion of the participants will 
go on to develop AD.  However, in practice it may be complicated to select target populations for 
prevention trials on the basis of biomarker evaluations due to cost, acceptability and ethical 
considerations.  The most advanced candidate biomarkers for selecting target populations at the 
current time are based on costly imaging techniques or CSF measurements obtained through 
lumbar puncture, an invasive procedure which healthy participants may not accept to undergo 
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during screening for a prevention trial.  Therefore, the development of more easily obtainable 
biomarkers, such as blood-based or even ocular biomarkers 261, would be of great use for 
prevention trials.  It must be remembered that for any trials using biomarkers to select the 
target population, potential drug approval would be limited to the same criteria used to define 
participants 257.  However, it may be that the greatest chance of success in the development of 
disease-modifying drugs for AD will come about once we can conduct trials that incorporate 
validated biomarker as well as clinical assessments.   
 Conclusion 
In conclusion, the methodology of AD trials is still developing.  Due to the failures of recent trials, 
the field is trying to move towards a situation in which there will be less heterogeneous study 
populations, and where potentially disease-modifying treatments can be tested in the very 
earliest stages of AD, perhaps even before the onset of clinically detectable symptoms.  Advances 
in biomarker and imaging technology in particular should help to reach these goals, but the 
methodological issues highlighted in this work will continue to remain relevant.  Investigators 
must endeavour to develop and employ relevant, reliable and multidimensional measures for 
clinical endpoints which will most likely be used alongside biomarker endpoints in trials in the 
near future.  Endpoints must be relevant to the stage of disease under study and must remain so 
right through to the end of long-term trials.  The CDR-SB appears to be a suitable candidate 
primary endpoint, at least for trials conducted in individuals with Alzheimer’s dementia.  
Adequate training, monitoring and quality control procedures are required to guarantee more 
accurate data and reduce variability in outcome measures, as well as limiting the amount of 
missing data.  The frequency, duration and complexity of study evaluations need to be assessed 
in order to avoid stress to patients and caregivers and to limit withdrawals.  Limiting missing 
data in this way, as well as closely following-up participants who are most at risk of dropping 
out (those with lower functional or cognitive status at baseline, those not using ChEIs, those 
looked after by someone other than their spouse or child, those with caregivers reporting high 
levels of subjective burden), will help to improve the internal and external validity of AD trials, 
and the use of appropriate methods for managing missing data, such as multiple imputation or 
maximum likelihood analyses, will help to limit bias.     
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INTRODUCTION
Dementing disorders are major causes of disability,
institutionalization, and death in the elderly [1–3] and
are a growing public health problem. High incidence
and prevalence make dementia one of the most com-
mon diseases of the elderly. There are varying preva-
lence estimates, but it is thought that at least 26 mil-
lion people in the world are currently living with this
condition [4,5], and that the number of affected peo-
ple could quadruple by 2050, due to a huge unprece-
dented increase in life expectancy in most developed
countries and in a fast growing number of developing
countries [4,6]. By this time, it is estimated that as
many as 1 in 85 persons worldwide will be living with
Alzheimer’s disease (AD), one of the most common
forms of dementia [4].
Economically, dementia has a huge impact on af-
fected individuals and their caregivers, as well as on
society [7–12].
Just as cardiovascular diseases have been targeted
for prevention efforts over the last two decades, the fast
growing burden of dementia must now be targeted ur-
gently. In the absence of a curative treatment, interven-
tions able to delay dementia onset and/or progression,
even on a relatively small scale, could have large public
health effects [13]. For example, in AD, even a rela-
tively small 1-year delay in disease onset would result
in nearly 12million fewer casesworldwide by 2050 [4].
Delaying the onset of clinically detectable dementia to
a later age may bring about a competitive risk of mor-
tality from other morbidities. Thus preventionmay not
affect overall life expectancy but this delay of onset of
clinical symptoms should bring about increased quality
of life for affected individuals, and should reduce costs
through reducing the burden of AD.
The most important risk factors identified so far for
dementia, including age, the apolipoprotein E (APOE)
ε4 genotype, and a family history of dementia [14–16],
are non-modifiable. However, potentially modifiable
factors, including cardiovascular factors [17–20] and
lifestyle factors, such as diet, physical exercise, cog-
nitive stimulation, marital status and social contacts
have also been linked with dementia or cognitive de-
cline [21–23]. Additionally, some potential preventive
treatments have been suggested, some of which have
been investigated,mostly inAD, includinghormone re-
placement therapy (HRT) in women, antioxidants and
anti-inflammatory agents [24–26]. Prevention studies
with these compoundshave repeatedly failed to demon-
strate clinical benefits. While this could be due to
a real lack of effect of the compound tested, several
methodological problems could explain these failures,
including multiple effects of the drugs tested, insuffi-
cient sample sizes [27], a lack of validated cognitive
outcomes [28], exposure to the intervention over too
short a period [29], and non-adherence to recommenda-
tions [30]. The demonstration of the possible preven-
tive efficacy of such treatments is an important goal for
primary prevention. Large-scale intervention trials for
dementia prevention are therefore required. However,
such trials raise specific methodological questions be-
cause they are relatively new in the field of neurodegen-
erative diseases and involve large numbers of subjects
and a long follow up period. In this paper, we examine
issues relating to the target population, study endpoints,
and methods of data analysis in primary prevention tri-
als. We present a review of the literature addressing
primary prevention trials, and a summary of the points
raised during discussions of this review by experts in
the field of dementia prevention trials.
METHODS
A MEDLINE search was conducted in March 2007
using the Medical Subject Heading (MeSH) terms and
subheadings “Cognition disorders/prevention and con-
trol”, “Dementia/prevention and control” and “Alzhei-
mer disease/prevention and control” combined with
“randomized controlled trials (RCTs)”. No date or lan-
guage limitations were used. This search retrieved 97
publications. Further non-MeSH searches were car-
ried out using combinations of the terms “cognition”,
“cognitive”, “dementia”, “Alzheimer disease”, “pre-
vention” and “(randomized controlled) trials”. The ab-
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stracts of retrieved citations were examined, and arti-
cles pertaining to RCTs examining the effect of an in-
tervention on the primary prevention of neurodegener-
ative dementia or cognitive decline were retained. The
references of relevant articles, including review arti-
cles, were examined in order to identify additional stud-
ies. The web-based clinical trials databases clinical-
trials.gov and controlledtrials.com were also searched
using the terms “dementia” and “prevention” to iden-
tify additional trials of interest. These searches were
updated in March 2008.
Trials involving subjects with a diagnosis of demen-
tia were excluded, as were secondary prevention tri-
als which selected subjects with some specific form of
cognitive impairment, such as mild cognitive impair-
ment (MCI) or “cognitive impairment-no dementia”
(CIND) [31,32].
The results of the literature review and the method-
ological issues raised were discussed during two meet-
ings involving experts identified as specialists in the
field ofADprevention trials. The first of thesemeetings
took place in Europe (Lisbon, Portugal) as an ancil-
lary to a European AD Consortium (EADC) meeting,
and the second, involving North American experts in
AD prevention trials, took place in Albuquerque, New
Mexico.
RESULTS
The literature search allowed the identification of six
studies specifically addressing the primary prevention
of dementia [33–40], three of which are ongoing [33–
35] (Table 1, part i). The following treatments were
assessed in these trials: antioxidants, HRT and anti-
inflammatory drugs. In addition, 16 studies specifi-
cally addressing the primary prevention of cognitive
decline were identified [29,41–57] (Table 1, part ii),
as were 13 [58–73] which studied primary prevention
of dementia or cognitive decline as a secondary study
objective (Table 1, part iii), and four other RCTs [74–
78] in which cognitive function was assessed at one
time point only (Table 1, part iv). These last two types
of studies make use of existing study populations and
infrastructure, therefore reducing the cost of studying
dementia prevention, but they are not specifically de-
signed for this purpose, so the study duration, inclusion
criteria and assessments may not be ideal.
Target populations and methods of recruitment
Dementia primary prevention studies
All six of the large scale primary prevention trials
for dementia involved subjects aged 60 years or above
(Table 1, part i). Three trials (GEM, PREADVISE,
and WHIMS) selected their study populations solely
on the basis of age, which is an important risk factor
for dementia, although only one study (GEM) had a
minimum age of 75 years. The three remaining stud-
ies included subjects thought to be at greater risk of
developing dementia due to subjective memory com-
plaints expressed to a general practitioner (GuidAge) or
a family history of memory problems or AD (ADAPT,
PREPARE). Some studies (GEM, GuidAge, ADAPT)
specifically stated that a study partner or collateral in-
formant had to be available to carry out proxy evalua-
tions of participants.
Subjects meeting pre-specified criteria for demen-
tia or cognitive impairment were excluded during en-
rolment in the GuidAge, GEM, WHIMS and ADAPT
studies. The WHIMS studies excluded participants
with a Modified Mini Mental State Examination
(3MS) [79] score of 72 or less (76 or less for participants
having completed at least 9 years of education) [37].
The 3MSwas also administered at the screening visit in
GEM, alongwith the proxy-completedDementiaQues-
tionnaire (DQ) [34,80]. Participants with a passing
score in all or all but one cognitive domain (“normal’
and “mild cognitive impairment”) in these assessments
were eligible for entry into the study. Like GEM, the
GuidAge study allowed participation of subjects with
mild cognitive impairment [33]. The two remaining
studies (PREADVISE and PREPARE) also stated that
patients should be free of dementia or significant neu-
rological impairment, but the judgment criteria used
were not specified [35,40].
The size of the study populations ranged from 500 to
10,800, and participants were recruited using a variety
of strategies. The GuidAge study recruited participants
via general practioners (GPs) [33]. TheGEM,PREAD-
VISE and WHIMS studies were all ancillary studies,
and therefore recruited at least some of their partici-
pants from the established populations of their parent
studies [35,37,81]. Participants were recruited from
the general population only in the ADAPT study [36].
Cognitive decline studies
Many of the cognitive decline studies also used age
as a major inclusion criterion (Table 1, part ii). In
12 studies [29,41,43–47,49–54,56], participants had to
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be aged at least 60 years, including one study which
only involved very elderly subjects aged 85 years or
more [56]. On the contrary, one study [42] included
subjects as young as 20 years. Other inclusion criteria
depended on the type of intervention being tested. For
example, three studies examined the effect ofHRT [47–
49] or phytoestrogens [57] on cognitive decline, and
so only included older women in the study popula-
tion. Additionally, two studies using nutritional in-
terventions had nutrition-related inclusion criteria [29,
45].
Eight studies [29,46–48,50,52–54,56] excluded pa-
tients on the basis of Mini-Mental State Examination
(MMSE) [82] scores, with the lowest permitted scores
ranging from 19 to 24. Four other studies [45,49,51,
57] also had some form of cognitive exclusion crite-
ria. Furthermore, the ACTIVE study [52,53] excluded
patients having already experienced substantial func-
tional decline, as this was a primary outcome in this
trial.
The cognitive decline studies mostly involved
healthy subjects, so standard recruitment techniques
(e.g., media campaigns, mass mailings) targeted at el-
derly people were generally used [29,41,45,47–51,56,
57]. One study recruited participants from electoral
rolls [42], and one [46] recruited participants via med-
ical professionals. The size of the study populations
was very variable, and only three studies enrolledmore
than 300 participants.
Studies assessing prevention of dementia or cognitive
decline as a secondary study objective
The prevention of dementia or cognitive decline has
also been studied as a secondary objective in interven-
tion studies initially focused on other medical condi-
tions which generally affect older people, such as car-
diovascular disease (Table 1, part iii). The size of the
study populations ranged from 460 to 14240, with the
majority of studies involving between 2000 and 6100
participants. 10 studies [58,59,63–69,71–73] stated a
minimum age for participants, ranging between 40 and
70 years. The MORE study [60,61] involved post-
menopausal women, with a mean age of approximately
66 years at inclusion. The HYVET-COG study [69]
included only very elderly subjects (80 years or more).
The SCOPE study [65] excluded participants with an
MMSE scores < 24, while the Syst-Eur study [64] ex-
cluded patients who had anMMSE score< 24 at inclu-
sion andwho could be diagnosedwith dementia accord-
ing to DSM-III-R criteria [83]. The VISP study [70] al-
so stated that patients with severe cognitive impairment
were excluded.
Other inclusion and exclusion criteria related to the
primary objectives of these studies, for example, sub-
jects with a history of hypertension, or diabetes, or
those with a particular nutritional status.
Other studies
The remaining studies [74–78] were also primarily
focused on conditions other than dementia, but again
mostly involved subjects in older age groups, such as
post-menopausalwomen, subjects with age-related eye
disease, or those at substantial risk of coronary heart
disease (Table 1, part iv). Participants with dementia
were excluded from theHeart Protection Study [76,77].
Outcomes
Dementia primary prevention studies
The six large scale dementia primary prevention tri-
als all measured dementia or AD incidence as a pri-
mary outcome (Table 2, part i). Secondary outcomes
included MCI incidence (WHIMS [37]), cognitive de-
cline (GuidAge, GEM and ADAPT [33,34,36]) and
functional outcomes (GEM, GuidAge [33,34]). Sever-
al trials (GuidAge, GEM, ADAPT and WHIMS) used
independent committees to confirm all suspected cases
of dementia or AD [33,34,36–39].
Cognitive decline studies
Cognitive decline or changes in cognitive function
at the end of observation was measured as a primary
outcome in 16 intervention studies (Table 2, part ii),
some of which [42,47,51,57] also assessed emotional
or quality of life outcomes, notably depression.
Studies assessing prevention of dementia or cognitive
decline as a secondary study objective
Seven of these studies (MORE, PROGRESS, Syst-
Eur, SCOPE, HYVET-COG, SHEP and WISDOM-
COG) [60,62,64,65,67,69,71,72] examined dementia
incidence as a cognitive outcome (Table 2, part iii). In
addition, the MORE study also examined the assessed
MCI incidence [60]. Suspected diagnoses of dementia
(and cognitive impairment in the MORE study) were
validated by a dementia specialist or an adjudication
committee blinded to patients’ treatment allocation in
most studies. Cognitive function was studied as a cog-
nitive outcome in 13 studies [58–60,62–73].
S. Andrieu et al. / Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia 243
T
ab
le
2
O
u
tc
o
m
es
an
d
as
se
ss
m
en
ts
C
o
g
n
it
iv
e
 a
s
s
e
s
s
m
e
n
ts
: 
d
o
m
a
in
S
tu
d
y
P
ri
m
a
ry
 
o
u
tc
o
m
e
(s
) 
V
a
li
d
a
ti
o
n
 
o
f 
d
e
m
e
n
ti
a
 
d
ia
g
n
o
s
is
 
S
e
c
o
n
d
a
ry
 
o
u
tc
o
m
e
(s
) 
F
u
n
c
ti
o
n
a
l/
 
E
m
o
ti
o
n
a
l 
a
s
s
e
s
s
m
e
n
ts
G
lo
b
a
l 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
E
x
e
c
u
ti
v
e
 
fu
n
c
ti
o
n
M
e
m
o
ry
A
tt
e
n
ti
o
n
S
p
e
e
d
 o
f 
p
ro
c
e
s
s
in
g
O
th
e
r
(i
) 
D
e
m
e
n
ti
a
 p
ri
m
a
ry
 p
re
v
e
n
ti
o
n
 t
ri
a
ls
 
G
u
id
A
g
e
 [
3
3
] 
A
D
 i
n
c
id
e
n
c
e
  
(D
S
M
-I
V
 &
 
N
IN
C
D
S
-
A
D
R
D
A
 
c
ri
te
ri
a
) 
M
e
m
o
ry
 
c
lin
ic
s
; 
v
a
lid
a
te
d
 b
y
 
in
d
e
p
e
n
d
e
n
t 
c
o
m
m
it
te
e
 
T
im
e
 t
o
 
c
o
n
v
e
rs
io
n
 t
o
 
d
e
m
e
n
ti
a
 
(f
ro
m
 n
o
rm
a
l 
to
 M
C
I 
a
n
d
 
fr
o
m
 M
C
I 
to
 
d
e
m
e
n
ti
a
) 
 
C
o
g
n
it
iv
e
 
c
h
a
n
g
e
 
IA
D
L
, 
b
a
la
n
c
e
 
M
M
S
E
; 
C
D
R
V
e
rb
a
l 
fl
u
e
n
c
y
; 
T
M
T
 B
  
G
ro
b
e
r 
&
 
B
u
s
c
h
k
e
 t
e
s
t;
 
V
e
rb
a
l 
fl
u
e
n
c
y
 
(s
e
m
a
n
ti
c
 
m
e
m
o
ry
);
 V
A
S
 
M
e
m
o
ry
 
im
p
a
ir
m
e
n
t 
in
 
e
v
e
ry
d
a
y
 l
if
e
 
T
M
T
 A
  
T
M
T
 A
 
G
E
M
 [
3
4
] 
D
e
m
e
n
ti
a
 
in
c
id
e
n
c
e
  
U
n
iq
u
e
 
c
o
g
n
it
iv
e
 
d
ia
g
n
o
s
ti
c
 
c
e
n
te
r 
 
C
o
g
n
it
iv
e
 a
n
d
 
fu
n
c
ti
o
n
a
l 
d
e
c
lin
e
; 
 
In
c
id
e
n
c
e
 o
f 
v
a
s
c
u
la
r 
e
v
e
n
ts
, 
a
n
d
 
m
o
rt
a
lit
y
. 
A
D
L
, 
IA
D
L
, 
C
E
S
D
 
3
M
S
; 
A
D
A
S
-
C
o
g
; 
In
fo
rm
a
n
t 
q
u
e
s
ti
o
n
n
a
ir
e
 
fo
r 
c
o
g
n
it
iv
e
 
d
e
c
lin
e
 
T
M
T
- 
B
; 
R
a
v
s
 
C
o
lo
u
re
d
 
P
ro
g
re
s
s
iv
e
 
M
a
tr
ic
e
s
§
; 
S
tr
o
o
p
 C
o
lo
r/
 
W
o
rd
 t
e
s
t;
 W
o
rd
 
G
e
n
e
ra
ti
o
n
; 
B
lo
c
k
 D
e
s
ig
n
 
C
V
L
T
; 
 
D
e
la
y
e
d
 R
e
c
a
ll 
R
e
y
-O
s
te
rr
ie
th
 
M
o
d
if
ie
d
 F
ig
u
re
 
(W
A
IS
-R
);
 D
ig
it
 
S
p
a
n
 
B
a
c
k
w
a
rd
s
 &
 
F
o
rw
a
rd
s
 
T
M
T
 A
; 
D
ig
it
 
S
p
a
n
 
F
o
rw
a
rd
s
; 
S
tr
o
o
p
 
C
o
lo
r/
W
o
rd
 
te
s
t 
T
M
T
 A
 
N
a
ti
o
n
a
l 
A
d
u
lt
 
R
e
a
d
in
g
 T
e
s
t§
 
(i
n
te
lli
g
e
n
c
e
);
 
B
lo
c
k
 D
e
s
ig
n
 
(p
ra
x
is
);
 B
o
s
to
n
 
N
a
m
in
g
 T
e
s
t 
(l
a
n
g
u
a
g
e
) 
 
P
R
E
A
D
V
IS
E
 
[3
5
] 
A
D
 i
n
c
id
e
n
c
e
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
A
D
A
P
T
 [
3
6
] 
D
e
m
e
n
ti
a
 
in
c
id
e
n
c
e
 
(D
S
M
-I
V
 &
 
N
IN
C
D
S
-
A
D
R
D
A
 
c
ri
te
ri
a
) 
C
lin
ic
a
l 
te
a
m
; 
re
v
ie
w
e
d
 b
y
 
a
 n
o
n
-
in
d
e
p
e
n
d
e
n
t 
C
o
m
m
it
te
e
  
C
o
g
n
it
iv
e
 
d
e
c
lin
e
 
G
D
S
 
3
M
S
; 
M
M
S
E
*
G
e
n
e
ra
ti
v
e
 
v
e
rb
a
l 
fl
u
e
n
c
y
; 
T
M
T
* 
R
iv
e
rm
e
a
d
 
B
e
h
a
v
io
u
ra
l 
M
e
m
o
ry
 T
e
s
t;
 
B
ri
e
f 
V
is
u
o
s
p
a
ti
a
l 
M
e
m
o
ry
 T
e
s
t-
R
e
v
is
e
d
; 
S
e
lf
 
R
a
ti
n
g
 o
f 
M
e
m
o
ry
 
F
u
n
c
ti
o
n
s
; 
H
V
L
T
-R
; 
G
e
n
e
ra
ti
v
e
 
v
e
rb
a
l 
fl
u
e
n
c
y
; 
W
o
rd
 L
is
t 
M
e
m
o
ry
*;
 
L
o
g
ic
a
l 
M
e
m
o
ry
*;
 
B
e
n
to
n
 V
is
u
a
l 
R
e
te
n
ti
o
n
 t
e
s
t*
; 
C
o
n
tr
o
lle
d
 O
ra
l 
W
o
rd
 
A
s
s
o
c
ia
ti
o
n
 
T
M
T
* 
T
M
T
* 
S
h
o
rt
 B
o
s
to
n
 
N
a
m
in
g
 T
e
s
t*
 
(l
a
n
g
u
a
g
e
);
 
C
o
n
s
tr
u
c
ti
o
n
a
l 
P
ra
x
is
* 
(p
ra
x
is
) 
244 S. Andrieu et al. / Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia
T
ab
le
2
,
co
n
ti
n
u
ed
C
o
g
n
it
iv
e
 a
s
s
e
s
s
m
e
n
ts
: 
d
o
m
a
in
S
tu
d
y
P
ri
m
a
ry
 
o
u
tc
o
m
e
(s
) 
V
a
li
d
a
ti
o
n
 
o
f 
d
e
m
e
n
ti
a
 
d
ia
g
n
o
s
is
 
S
e
c
o
n
d
a
ry
 
o
u
tc
o
m
e
(s
) 
F
u
n
c
ti
o
n
a
l/
 
E
m
o
ti
o
n
a
l 
a
s
s
e
s
s
m
e
n
ts
G
lo
b
a
l 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
E
x
e
c
u
ti
v
e
 
fu
n
c
ti
o
n
M
e
m
o
ry
A
tt
e
n
ti
o
n
S
p
e
e
d
 o
f 
p
ro
c
e
s
s
in
g
O
th
e
r
T
e
s
t*
 
W
H
IM
S
 [
3
7
] 
 
D
e
m
e
n
ti
a
 
in
c
id
e
n
c
e
, 
A
D
 
(D
S
M
-I
V
 
c
ri
te
ri
a
) 
P
h
y
s
ic
ia
n
s
; 
v
a
lid
a
te
d
 b
y
 
in
d
e
p
e
n
d
e
n
t 
a
d
ju
d
ic
a
to
rs
M
C
I 
in
c
id
e
n
c
e
 
G
D
S
 
3
M
S
; 
A
C
B
C
 
T
M
T
 B
 
C
E
R
A
D
 
n
e
u
ro
lo
g
ic
a
l 
b
a
tt
e
ry
: 
w
o
rd
 
lis
t 
m
e
m
o
ry
, 
w
o
rd
-l
is
t 
re
c
a
ll,
 
w
o
rd
-l
is
t 
re
c
o
g
n
it
io
n
; 
R
e
c
o
g
n
it
io
n
 
ta
s
k
s
 
T
M
T
 A
 
T
M
T
 A
 
C
E
R
A
D
 
n
e
u
ro
lo
g
ic
a
l 
b
a
tt
e
ry
: 
c
o
n
s
tr
u
c
ti
o
n
a
l 
p
ra
x
is
 t
e
s
ts
 
(p
ra
x
is
);
 B
o
s
to
n
 
N
a
m
in
g
 T
e
s
t 
(l
a
n
g
u
a
g
e
) 
P
R
E
P
A
R
E
 
[4
0
] 
D
e
m
e
n
ti
a
 
in
c
id
e
n
c
e
  
- 
- 
- 
- 
- 
- 
- 
- 
- 
(i
i)
 
C
o
g
n
it
iv
e
 d
e
c
li
n
e
 s
tu
d
ie
s
 
E
u
s
s
e
n
 e
t 
a
l.
 
2
0
0
6
 [
2
9
] 
C
h
a
n
g
e
 i
n
 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
 
G
D
S
 
M
M
S
E
 
M
o
to
r 
p
la
n
n
in
g
 3
 
(c
o
m
p
u
te
ri
z
e
d
);
 
R
a
v
e
n
; 
S
tr
o
o
p
 
T
e
s
t;
 S
im
ila
ri
ti
e
s
 
(W
A
IS
);
 w
o
rd
 
fl
u
e
n
c
y
, 
le
tt
e
r 
&
 
a
n
im
a
ls
; 
F
ig
u
re
 
o
f 
R
e
y
, 
c
o
p
y
  
F
ig
u
re
 o
f 
R
e
y
, 
im
m
e
d
ia
te
 
re
c
a
ll;
 D
ig
it
 
s
p
a
n
, 
fo
rw
a
rd
 &
 
b
a
c
k
w
a
rd
; 
F
ig
u
re
 o
f 
R
e
y
, 
d
e
la
y
e
d
 r
e
c
a
ll;
 
1
5
 w
o
rd
 
le
a
rn
in
g
, 
d
e
la
y
e
d
 r
e
c
a
ll;
 
1
5
 w
o
rd
 
le
a
rn
in
g
, 
re
c
o
g
n
it
io
n
 
D
ig
it
 s
p
a
n
-
fo
rw
a
rd
 
F
in
g
e
r 
ta
p
p
in
g
 
c
o
m
p
u
te
ri
s
e
d
; 
m
o
to
r 
p
la
n
n
in
g
 
2
 -
c
o
m
p
u
te
ri
z
e
d
 
F
ig
u
re
 o
f 
R
e
y
, 
c
o
p
y
 (
p
ra
x
is
) 
W
o
lt
e
rs
 e
t 
a
l.
 
2
0
0
5
 [
4
1
] 
C
o
g
n
it
iv
e
 
p
e
rf
o
rm
a
n
c
e
 
 
 
 
 
 
P
a
tt
e
rn
 
re
c
o
g
n
it
io
n
 t
e
s
t 
fr
o
m
 B
A
T
 
W
A
IS
-I
II
 
S
y
m
b
o
l 
s
e
a
rc
h
 
te
s
t 
K
A
I 
(i
n
te
lli
g
e
n
c
e
) 
B
ry
a
n
 e
t 
a
l.
 
2
0
0
2
 [
4
2
] 
 
C
o
g
n
it
iv
e
 
p
e
rf
o
rm
a
n
c
e
 
C
h
a
n
g
e
 i
n
 
m
o
o
d
 
C
E
S
D
, 
P
O
M
S
V
e
rb
a
l 
fl
u
e
n
c
y
; 
T
M
T
;
S
tr
o
o
p
 
T
e
s
t;
 S
e
lf
-
O
rd
e
re
d
 P
o
in
ti
n
g
 
T
e
s
t;
 E
x
c
lu
d
e
d
 
L
e
tt
e
r 
F
lu
e
n
c
y
; 
W
A
I-
II
I 
L
e
tt
e
r-
N
u
m
b
e
r 
S
e
q
u
e
n
c
in
g
; 
W
A
I-
II
I 
D
ig
it
 
S
y
m
b
o
l 
C
o
d
in
g
 
V
e
rb
a
l 
fl
u
e
n
c
y
; 
W
A
I-
II
I 
D
ig
it
 
S
p
a
n
-
B
a
c
k
w
a
rd
s
; 
A
c
ti
v
it
y
 R
e
c
a
ll;
 
R
A
V
L
T
; 
W
A
I-
II
I 
V
o
c
a
b
u
la
ry
 
W
A
I-
II
I 
L
e
tt
e
r-
N
u
m
b
e
r 
S
e
q
u
e
n
c
in
g
; 
W
A
I-
II
I 
D
ig
it
 
S
y
m
b
o
l 
C
o
d
in
g
; 
W
IA
S
-
II
I 
S
y
m
b
o
l 
s
e
a
rc
h
 t
e
s
t;
 
B
o
x
e
s
 T
e
s
t 
S
p
o
t 
th
e
 W
o
rd
 
(v
e
rb
a
l 
a
b
ili
ty
);
 
U
s
e
s
 f
o
r 
C
o
m
m
o
n
 
O
b
je
c
ts
 
(p
ra
x
is
);
 W
A
I-
II
I 
V
o
c
a
b
u
la
ry
 
(l
a
n
g
u
a
g
e
) 
 
W
H
S
 
 
c
o
g
n
it
iv
e
 
C
o
g
n
it
iv
e
 
p
e
rf
o
rm
a
n
c
e
 
C
h
a
n
g
e
 i
n
 
g
e
n
e
ra
l 
T
IC
S
 
C
a
te
g
o
ry
 f
lu
e
n
c
y
E
a
s
t 
B
o
s
to
n
 
M
e
m
o
ry
 T
e
s
t 
 
S. Andrieu et al. / Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia 245
T
ab
le
2
,
co
n
ti
n
u
ed
C
o
g
n
it
iv
e
 a
s
s
e
s
s
m
e
n
ts
: 
d
o
m
a
in
S
tu
d
y
P
ri
m
a
ry
 
o
u
tc
o
m
e
(s
) 
V
a
li
d
a
ti
o
n
 
o
f 
d
e
m
e
n
ti
a
 
d
ia
g
n
o
s
is
 
S
e
c
o
n
d
a
ry
 
o
u
tc
o
m
e
(s
) 
F
u
n
c
ti
o
n
a
l/
 
E
m
o
ti
o
n
a
l 
a
s
s
e
s
s
m
e
n
ts
G
lo
b
a
l 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
E
x
e
c
u
ti
v
e
 
fu
n
c
ti
o
n
M
e
m
o
ry
A
tt
e
n
ti
o
n
S
p
e
e
d
 o
f 
p
ro
c
e
s
s
in
g
O
th
e
r
s
u
b
s
tu
d
y
 [
4
3
, 
4
4
] 
 ,
n
oiti
n
g
o
c
 
v
e
rb
a
l 
m
e
m
o
ry
 a
n
d
 
c
a
te
g
o
ry
 
fl
u
e
n
c
y
 o
v
e
r 
ti
m
e
 
im
m
e
d
ia
te
 &
 
d
e
la
y
e
d
 r
e
c
a
ll;
 
T
IC
S
 1
0
-w
o
rd
 
lis
t 
M
c
M
a
h
o
n
 e
t 
a
l.
 2
0
0
6
 [
4
5
] 
C
o
g
n
it
iv
e
 
p
e
rf
o
rm
a
n
c
e
 
 
 
 
M
M
S
E
 
R
a
v
e
n
s
 
P
ro
g
re
s
s
iv
e
 
M
a
tr
ic
e
s
; 
C
a
te
g
o
ry
 W
o
rd
 
T
e
s
t;
 M
a
a
s
tr
ic
h
t 
a
g
in
g
 s
tu
d
y
: 
le
tt
e
r 
d
ig
it
 
s
u
b
s
ti
tu
ti
o
n
 t
e
s
t 
R
A
V
L
T
; 
W
e
c
h
s
le
r 
M
e
m
o
ry
 S
c
a
le
s
 
 p
a
ra
g
ra
p
h
-
re
c
a
ll 
te
s
ts
; 
C
o
n
tr
o
lle
d
 O
ra
l 
W
o
rd
 
A
s
s
o
c
ia
ti
o
n
 
T
e
s
t 
o
f 
th
e
 
M
u
lt
ili
n
g
u
a
l 
A
lp
h
a
-s
ia
 
E
x
a
m
in
a
ti
o
n
; 
 
R
e
it
a
n
 T
M
T
; 
M
a
a
s
tr
ic
h
t 
a
g
in
g
 s
tu
d
y
: 
le
tt
e
r 
d
ig
it
 
s
u
b
s
ti
tu
ti
o
n
 
te
s
t 
O
P
A
L
 [
4
6
] 
C
o
g
n
it
iv
e
 
p
e
rf
o
rm
a
n
c
e
 
 
 
 
 
V
e
rb
a
l 
fl
u
e
n
c
y
; 
 
V
e
rb
a
l 
fl
u
e
n
c
y
; 
D
ig
it
 s
p
a
n
 
fo
rw
a
rd
s
 &
 
b
a
c
k
w
a
rd
s
 
(W
A
IS
);
 C
V
L
T
; 
W
e
c
h
s
le
r 
M
e
m
o
ry
 S
c
a
le
 
 i
m
m
e
d
ia
te
 
a
n
d
 d
e
la
y
e
d
 
re
c
a
ll 
o
f 
a
 s
h
o
rt
 
s
to
ry
; 
T
e
s
ts
 o
f 
p
ro
s
p
e
c
ti
v
e
 
m
e
m
o
ry
; 
S
p
a
ti
a
l 
M
e
m
o
ry
 
D
ig
it
 s
p
a
n
 
fo
rw
a
rd
s
 
(W
A
IS
);
 
T
im
e
d
 l
e
tt
e
r 
s
e
a
rc
h
/ 
c
a
n
c
e
lla
ti
o
n
 
ta
s
k
 
T
im
e
d
 l
e
tt
e
r 
s
e
a
rc
h
/ 
c
a
n
c
e
lla
ti
o
n
 
ta
s
k
; 
246 S. Andrieu et al. / Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia
T
ab
le
2
,
co
n
ti
n
u
ed
C
o
g
n
it
iv
e
 a
s
s
e
s
s
m
e
n
ts
: 
d
o
m
a
in
S
tu
d
y
P
ri
m
a
ry
 
o
u
tc
o
m
e
(s
) 
V
a
li
d
a
ti
o
n
 
o
f 
d
e
m
e
n
ti
a
 
d
ia
g
n
o
s
is
 
S
e
c
o
n
d
a
ry
 
o
u
tc
o
m
e
(s
) 
F
u
n
c
ti
o
n
a
l/
 
E
m
o
ti
o
n
a
l 
a
s
s
e
s
s
m
e
n
ts
G
lo
b
a
l 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
E
x
e
c
u
ti
v
e
 
fu
n
c
ti
o
n
M
e
m
o
ry
A
tt
e
n
ti
o
n
S
p
e
e
d
 o
f 
p
ro
c
e
s
s
in
g
O
th
e
r
A
lm
e
id
a
 e
t 
a
l.
 2
0
0
6
 [
4
7
] 
C
h
a
n
g
e
s
 i
n
 
c
o
g
n
it
io
n
, 
d
e
p
re
s
s
io
n
 
a
n
d
 Q
O
L
 
 
 
 
C
A
M
C
O
G
 
V
e
rb
a
l 
fl
u
e
n
c
y
; 
B
D
 
V
e
rb
a
l 
fl
u
e
n
c
y
; 
T
e
s
t 
fa
c
e
s
; 
C
V
L
T
-I
I;
  
B
D
 (
p
ra
x
is
) 
P
o
lo
-K
a
n
to
la
 
e
t 
a
l.
 1
9
9
8
 
[4
8
] 
C
o
g
n
it
iv
e
 
p
e
rf
o
rm
a
n
c
e
 
 
 
 
 
D
ig
it
 s
y
m
b
o
l;
 
S
tr
o
o
p
 
C
o
lo
r/
w
o
rd
 t
e
s
t 
(c
o
g
n
is
p
e
e
d
 
v
e
rs
io
n
) 
D
ig
it
 s
p
a
n
-
fo
rw
a
rd
; 
B
e
n
to
n
 
v
is
u
a
l 
re
te
n
ti
o
n
 
te
s
t 
(f
o
rm
 C
);
 
s
u
b
tr
a
c
ti
o
n
 t
e
s
t;
 
s
ta
te
m
e
n
t 
v
e
ri
fi
c
a
ti
o
n
 t
e
s
t
P
a
c
e
d
 
a
u
d
it
o
ry
 s
e
ri
a
l 
a
d
d
it
io
n
 t
e
s
t;
 
D
ig
it
 s
p
a
n
-
fo
rw
a
rd
; 
s
u
b
tr
a
c
ti
o
n
 
te
s
t;
 
s
ta
te
m
e
n
t 
v
e
ri
fi
c
a
ti
o
n
 
te
s
; 
v
ig
ila
n
c
e
 
te
s
t;
 S
tr
o
o
p
 
C
o
lo
r/
w
o
rd
 
te
s
t 
(c
o
g
n
is
p
e
e
d
 
v
e
rs
io
n
) 
D
ig
it
 s
y
m
b
o
l;
 
1
0
-c
h
o
ic
e
 
re
a
c
ti
o
n
 t
im
e
 
te
s
t 
S
u
b
tr
a
c
ti
o
n
 t
e
s
t 
(c
o
n
c
e
n
tr
a
ti
o
n
) 
B
in
d
e
r 
e
t 
a
l.
 
2
0
0
1
 [
4
9
] 
C
o
g
n
it
iv
e
 
p
e
rf
o
rm
a
n
c
e
 
G
D
S
 
T
M
T
 B
; 
V
e
rb
a
l 
fl
u
e
n
c
y
; 
W
o
rd
 
fl
u
e
n
c
y
 
V
e
rb
a
l 
fl
u
e
n
c
y
; 
W
e
c
h
s
le
r 
A
s
s
o
c
ia
te
 
L
e
a
rn
in
g
 a
n
d
 
2
0
 m
in
 d
e
la
y
e
d
 
re
c
a
ll;
 W
o
rd
 
fl
u
e
n
c
y
 
T
M
T
 A
; 
C
a
n
c
e
lla
ti
o
n
 
R
a
n
d
o
m
 
L
e
tt
e
r 
a
n
d
 
R
a
n
d
o
m
 
F
ig
u
re
 T
e
s
ts
 
T
M
T
 A
; 
C
a
n
c
e
lla
ti
o
n
 
R
a
n
d
o
m
 L
e
tt
e
r 
a
n
d
 R
a
n
d
o
m
 
F
ig
u
re
 T
e
s
ts
 
M
a
h
n
c
k
e
 e
t 
a
l.
 2
0
0
6
 [
5
0
] 
C
h
a
n
g
e
s
 i
n
 
n
e
u
ro
-
p
s
y
c
h
o
lo
g
ic
a
l 
fu
n
c
ti
o
n
 
 
 
 
R
B
A
N
S
 
 
 
 
 
 
O
k
e
n
 e
t 
a
l.
 
2
0
0
6
 [
5
1
] 
C
h
a
n
g
e
 i
n
 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
 
P
O
M
S
 
S
tr
o
o
p
 
C
o
lo
r/
W
o
rd
 T
e
s
t;
 
W
A
IS
 I
II
 L
e
tt
e
r-
N
u
m
b
e
r 
S
e
q
u
e
n
c
in
g
; 
T
e
s
t 
re
la
te
d
 t
o
 
th
e
 W
is
c
o
n
s
in
 
C
a
rd
-S
o
rt
in
g
 
T
e
s
t 
1
0
-w
o
rd
 l
is
t 
le
a
rn
in
g
 t
a
s
k
; 
 
S
tr
o
o
p
 
C
o
lo
r/
W
o
rd
 
T
e
s
t 
 
W
A
IS
 I
II
 
L
e
tt
e
r-
N
u
m
b
e
r 
S
e
q
u
e
n
c
in
g
 
E
E
C
 m
e
a
s
u
re
 
o
f 
a
le
rt
n
e
s
s
 
A
C
T
IV
E
 [
5
2
, 
5
3
] 
C
o
g
n
it
iv
e
 a
n
d
 
fu
n
c
ti
o
n
a
l 
p
e
rf
o
rm
a
n
c
e
 
IA
D
L
, 
A
D
L
 
E
v
e
ry
d
a
y
 
P
ro
b
le
m
s
 T
e
s
t;
 
C
o
m
p
le
x
 
R
e
a
c
ti
o
n
 T
im
e
 
R
A
V
L
T
; 
R
iv
e
rm
e
a
d
 
B
e
h
a
v
io
u
ra
l 
P
a
ra
g
ra
p
h
 
C
o
m
p
le
x
 
R
e
a
c
ti
o
n
 
T
im
e
 t
a
s
k
 
C
o
m
p
le
x
 
R
e
a
c
ti
o
n
 T
im
e
 
ta
s
k
; 
F
ie
ld
 o
f 
v
ie
w
 s
u
b
s
c
a
le
s
E
v
e
ry
d
a
y
 
P
ro
b
le
m
s
 T
e
s
t 
(j
u
d
g
e
m
e
n
t)
; 
L
e
tt
e
r 
s
e
ts
, 
S. Andrieu et al. / Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia 247
T
ab
le
2
,
co
n
ti
n
u
ed
C
o
g
n
it
iv
e
 a
s
s
e
s
s
m
e
n
ts
: 
d
o
m
a
in
S
tu
d
y
P
ri
m
a
ry
 
o
u
tc
o
m
e
(s
) 
V
a
li
d
a
ti
o
n
 
o
f 
d
e
m
e
n
ti
a
 
d
ia
g
n
o
s
is
 
S
e
c
o
n
d
a
ry
 
o
u
tc
o
m
e
(s
) 
F
u
n
c
ti
o
n
a
l/
 
E
m
o
ti
o
n
a
l 
a
s
s
e
s
s
m
e
n
ts
G
lo
b
a
l 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
E
x
e
c
u
ti
v
e
 
fu
n
c
ti
o
n
M
e
m
o
ry
A
tt
e
n
ti
o
n
S
p
e
e
d
 o
f 
p
ro
c
e
s
s
in
g
O
th
e
r
ta
s
k
 
R
e
c
a
ll 
T
e
s
t;
 
H
V
L
T
 
le
tt
e
r 
s
e
ri
e
s
 &
 
w
o
rd
 s
e
ri
e
s
 
(r
e
a
s
o
n
in
g
 
a
b
ili
ty
) 
S
to
tt
 e
t 
a
l.
 
2
0
0
5
 [
5
4
] 
C
h
a
n
g
e
 i
n
 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
 
IA
D
L
 
T
IC
S
m
 
L
e
tt
e
r 
D
ig
it
 
C
o
d
in
g
 T
e
s
t 
L
e
tt
e
r 
D
ig
it
 
C
o
d
in
g
 T
e
s
t 
L
e
w
e
ri
n
 e
t 
a
l.
 
2
0
0
5
 [
5
5
] 
C
o
g
n
it
iv
e
 
p
e
rf
o
rm
a
n
c
e
 
P
L
M
 
b
lo
c
k
 d
e
s
ig
n
; 
d
ig
it
 s
y
m
b
o
l 
D
ig
it
 s
p
a
n
 
fo
rw
a
rd
/ 
b
a
c
k
w
a
rd
; 
V
is
u
a
l 
re
p
ro
d
u
c
ti
o
n
; 
T
h
u
rs
to
n
e
s
 
P
ic
tu
re
 M
e
m
o
ry
 
T
e
s
t 
D
ig
it
 s
p
a
n
 
fo
rw
a
rd
 
Id
e
n
ti
c
a
l 
fo
rm
s
; 
d
ig
it
 s
y
m
b
o
l 
b
lo
c
k
 d
e
s
ig
n
 
(p
ra
x
is
);
 
s
y
n
o
n
y
m
s
 
(v
e
rb
a
l 
a
b
ili
ty
);
 
F
ig
u
re
 
c
la
s
s
if
ic
a
ti
o
n
 
(i
n
d
u
c
ti
v
e
 
re
a
s
o
n
in
g
) 
D
o
d
g
e
 e
t 
a
l.
 
2
0
0
8
 [
5
6
] 
M
ild
 c
o
g
n
it
iv
e
 
d
e
c
lin
e
 (
C
D
R
 
0
 t
o
 0
.5
);
 
D
e
c
lin
e
 i
n
 
m
e
m
o
ry
 
fu
n
c
ti
o
n
 o
v
e
r 
ti
m
e
 
M
M
S
E
 
 
C
E
R
A
D
 1
0
-
w
o
rd
 l
is
t,
 
d
e
la
y
e
d
 r
e
c
a
ll 
 
 
 
H
o
 e
t 
a
l.
 
2
0
0
7
 [
5
7
] 
C
o
g
n
it
iv
e
 
c
h
a
n
g
e
 
S
F
-3
6
 
M
M
S
E
 
T
M
T
; 
v
e
rb
a
l 
fl
u
e
n
c
y
 
H
o
n
g
 K
o
n
g
 L
is
t 
L
e
a
rn
in
g
 T
e
s
t;
 
R
e
y
-O
s
te
rr
ie
th
 
C
o
m
p
le
x
 F
ig
u
re
 
T
e
s
t;
 W
M
S
-R
 
D
ig
it
 s
p
a
n
 
(W
A
IS
-R
 &
 
W
M
S
);
 d
ig
it
 
v
ig
ila
n
c
e
 
F
in
g
e
r 
ta
p
p
in
g
 
te
s
t 
B
o
s
to
n
 N
a
m
in
g
 
T
e
s
t 
(l
a
n
g
u
a
g
e
);
 R
e
y
 
O
s
te
rr
ie
th
 c
o
p
y
 
tr
ia
l 
o
f 
th
e
 
v
is
u
a
l 
re
p
ro
d
u
c
ti
o
n
 
s
u
b
s
e
t 
o
f 
th
e
 
W
M
S
-R
 
(i
ii
) 
S
tu
d
ie
s
 o
f 
d
e
m
e
n
ti
a
 p
re
v
e
n
ti
o
n
 o
r 
c
o
g
n
it
iv
e
 d
e
c
li
n
e
 a
s
 a
 s
e
c
o
n
d
a
ry
 o
u
tc
o
m
e
 
F
A
C
IT
 [
5
8
] 
C
h
a
n
g
e
 i
n
 
c
o
g
n
it
iv
e
 
p
e
rf
o
rm
a
n
c
e
 
 
 
 
M
M
S
E
* 
V
e
rb
a
l 
fl
u
e
n
c
y
; 
S
tr
o
o
p
 C
o
lo
r/
 
W
o
rd
 T
e
s
t;
 
M
a
a
s
tr
ic
h
t 
a
g
in
g
 
s
tu
d
y
: 
C
o
n
c
e
p
t 
s
h
if
ti
n
g
 t
e
s
t 
V
e
rb
a
l 
fl
u
e
n
c
y
; 
M
a
a
s
tr
ic
h
t 
a
g
in
g
 s
tu
d
y
: 
W
o
rd
 l
e
a
rn
in
g
 
te
s
t 
S
tr
o
o
p
 C
o
lo
r/
 
W
o
rd
 T
e
s
t 
W
E
S
T
 [
5
9
] 
C
o
g
n
it
iv
e
 
d
e
c
lin
e
 
 
S
p
e
c
if
ic
 
d
o
m
a
in
s
 o
f 
c
o
g
n
it
io
n
 
C
E
S
D
 
M
M
S
E
 
W
o
rd
 L
is
t 
G
e
n
e
ra
ti
o
n
; 
D
ig
it
 s
p
a
n
; 
D
e
la
y
e
d
 
N
a
m
in
g
; 
D
is
k
 
s
p
a
ti
a
l 
D
ig
it
 s
p
a
n
; 
 
M
o
d
if
ie
d
 B
o
s
to
n
 
N
a
m
in
g
 T
e
s
t 
(l
a
n
g
u
a
g
e
) 
248 S. Andrieu et al. / Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia
T
ab
le
2
,
co
n
ti
n
u
ed
C
o
g
n
it
iv
e
 a
s
s
e
s
s
m
e
n
ts
: 
d
o
m
a
in
S
tu
d
y
P
ri
m
a
ry
 
o
u
tc
o
m
e
(s
) 
V
a
li
d
a
ti
o
n
 
o
f 
d
e
m
e
n
ti
a
 
d
ia
g
n
o
s
is
 
S
e
c
o
n
d
a
ry
 
o
u
tc
o
m
e
(s
) 
F
u
n
c
ti
o
n
a
l/
 
E
m
o
ti
o
n
a
l 
a
s
s
e
s
s
m
e
n
ts
G
lo
b
a
l 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
E
x
e
c
u
ti
v
e
 
fu
n
c
ti
o
n
M
e
m
o
ry
A
tt
e
n
ti
o
n
S
p
e
e
d
 o
f 
p
ro
c
e
s
s
in
g
O
th
e
r
R
e
c
o
g
n
it
io
n
 
M
O
R
E
 
 
d
e
m
e
n
ti
a
 
a
n
c
ill
a
ry
 
s
tu
d
y
 [
6
0
, 
6
1
] 
A
D
 (
N
IN
C
D
S
-
A
D
R
D
A
 
c
ri
te
ri
a
),
 M
C
I 
a
n
d
 d
e
m
e
n
ti
a
 
in
c
id
e
n
c
e
; 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
 
S
u
s
p
e
c
te
d
 
c
a
s
e
s
 
e
v
a
lu
a
te
d
 b
y
 
e
x
p
e
rt
s
; 
v
a
lid
a
te
d
 b
y
 
a
d
ju
d
ic
a
ti
o
n
 
c
o
m
m
it
te
e
. 
 
R
is
k
 o
f 
v
a
s
c
u
la
r 
d
e
m
e
n
ti
a
 
(S
ta
te
 o
f 
C
a
lif
o
rn
ia
 
A
lz
h
e
im
e
r
s
 
D
is
e
a
s
e
 
D
ia
g
n
o
s
ti
c
 
a
n
d
T
re
a
tm
e
n
t 
C
e
n
te
rs
 
c
ri
te
ri
a
) 
a
n
d
 
c
o
g
n
it
iv
e
 
im
p
a
ir
m
e
n
t 
 
S
B
T
 
T
M
T
 B
 ;
 W
o
rd
 
L
is
t 
F
lu
e
n
c
y
 T
e
s
t
W
o
rd
 L
is
t 
M
e
m
o
ry
 a
n
d
 
R
e
c
a
ll 
T
e
s
ts
; 
W
o
rd
 L
is
t 
F
lu
e
n
c
y
 T
e
s
t 
T
M
T
 A
  
T
M
T
 A
 
P
R
O
G
R
E
S
S
 
[6
2
] 
D
e
m
e
n
ti
a
 
(D
S
M
-I
V
 
c
ri
te
ri
a
) 
a
n
d
 
c
o
g
n
it
iv
e
 
d
e
c
lin
e
 
S
u
s
p
e
c
te
d
 
d
e
m
e
n
ti
a
 
S
u
s
p
e
c
te
d
 
c
a
s
e
s
 
e
v
a
lu
a
te
d
 b
y
 
e
x
p
e
rt
s
 
M
M
S
E
 
 
 
 
 
 
S
y
s
t-
E
u
r 
 
fo
llo
w
-u
p
 
d
e
m
e
n
ti
a
 
p
ro
je
c
t 
[6
3
, 
6
4
] 
D
e
m
e
n
ti
a
 
in
c
id
e
n
c
e
 
(D
S
M
-I
II
 
c
ri
te
ri
a
),
 
c
h
a
n
g
e
 i
n
 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
 
A
ll 
c
a
s
e
s
 o
f 
d
e
m
e
n
ti
a
 
v
a
lid
a
te
d
 b
y
 
a
 c
o
m
m
it
te
e
 
M
M
S
E
 
 
 
 
 
 
S
C
O
P
E
 [
6
5
] 
D
e
m
e
n
ti
a
 
in
c
id
e
n
c
e
 
(m
o
d
if
ie
d
 
IC
D
-1
0
 
c
ri
te
ri
a
),
 
c
o
g
n
it
iv
e
 
d
e
c
lin
e
 
In
d
e
p
e
n
d
e
n
t 
C
o
m
m
it
te
e
  
M
M
S
E
 
 
 
 
 
 
M
R
C
 
tr
e
a
tm
e
n
t 
tr
ia
l 
o
f 
h
y
p
e
rt
e
n
s
io
n
 
in
 o
ld
e
r 
a
d
u
lt
s
 [
6
6
] 
C
o
g
n
it
iv
e
 
p
e
rf
o
rm
a
n
c
e
 
 
P
A
L
T
 
T
M
T
-A
 
T
M
T
-A
 
 
S
H
E
P
 
D
e
m
e
n
ti
a
 
 
A
D
L
, 
C
E
S
D
 
S
h
o
rt
-C
A
R
E
 
 
 
 
S
o
c
ia
l 
N
e
tw
o
rk
 
S. Andrieu et al. / Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia 249
T
ab
le
2
,
co
n
ti
n
u
ed
C
o
g
n
it
iv
e
 a
s
s
e
s
s
m
e
n
ts
: 
d
o
m
a
in
S
tu
d
y
P
ri
m
a
ry
 
o
u
tc
o
m
e
(s
) 
V
a
li
d
a
ti
o
n
 
o
f 
d
e
m
e
n
ti
a
 
d
ia
g
n
o
s
is
 
S
e
c
o
n
d
a
ry
 
o
u
tc
o
m
e
(s
) 
F
u
n
c
ti
o
n
a
l/
 
E
m
o
ti
o
n
a
l 
a
s
s
e
s
s
m
e
n
ts
G
lo
b
a
l 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
E
x
e
c
u
ti
v
e
 
fu
n
c
ti
o
n
M
e
m
o
ry
A
tt
e
n
ti
o
n
S
p
e
e
d
 o
f 
p
ro
c
e
s
s
in
g
O
th
e
r
in
c
id
e
n
c
e
 a
n
d
 
c
o
g
n
it
iv
e
 
d
e
c
lin
e
 
Q
u
e
s
ti
o
n
n
a
ir
e
s
 
(b
e
h
a
v
io
u
ra
l 
e
v
a
lu
a
ti
o
n
) 
M
A
V
IS
 [
6
8
] 
C
h
a
n
g
e
 i
n
 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
 
V
e
rb
a
l 
fl
u
e
n
c
y
 
V
e
rb
a
l 
fl
u
e
n
c
y
; 
D
ig
it
 s
p
a
n
 
fo
rw
a
rd
 
D
ig
it
 s
p
a
n
 
fo
rw
a
rd
 
H
Y
V
E
T
-C
O
G
 
[6
9
] 
 
D
e
m
e
n
ti
a
 
in
c
id
e
n
c
e
 
A
ll 
c
a
s
e
s
 
v
a
lid
a
te
d
 b
y
 
a
 c
o
m
m
it
te
e
C
o
g
n
it
iv
e
 
d
e
c
lin
e
 
M
M
S
E
 
 
 
 
 
 
V
IS
P
 [
7
0
] 
C
o
g
n
it
iv
e
 
d
e
c
lin
e
 
M
M
S
E
 
 
 
 
 
 
W
IS
D
O
M
-
C
O
G
 [
7
1
, 
7
2
] 
D
e
m
e
n
ti
a
 
in
c
id
e
n
c
e
; 
c
o
g
n
it
iv
e
 
d
e
c
lin
e
 
A
D
 i
n
c
id
e
n
c
e
 
 
 
W
e
c
h
s
le
r 
L
o
g
ic
a
l 
M
e
m
o
ry
 
R
e
c
a
ll 
 
 
 
A
C
C
O
R
D
-
M
IN
D
 [
7
3
] 
D
e
c
lin
e
 i
n
 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
 (
d
ig
it
 
s
y
m
b
o
l 
s
u
b
s
ti
tu
ti
o
n
 
te
s
t)
 
C
h
a
n
g
e
 i
n
 
to
ta
l 
b
ra
in
 
v
o
lu
m
e
 (
M
R
I 
s
c
a
n
) 
[i
n
 a
 
s
u
b
s
e
t 
o
f 
s
u
b
je
c
ts
];
 
c
o
g
n
it
iv
e
 
c
h
a
n
g
e
 
(c
o
m
b
in
e
d
 
te
s
t 
s
c
o
re
s
) 
P
a
ti
e
n
t 
H
e
a
lt
h
 
Q
u
e
s
ti
o
n
n
a
ir
e
M
M
S
E
 
S
tr
o
o
p
 t
e
s
t 
R
A
V
L
T
 
(i
m
m
e
d
ia
te
 &
 
d
e
la
y
e
d
 r
e
c
a
ll)
 
E
; 
S
p
a
n
is
h
 
E
n
g
lis
h
 V
e
rb
a
l 
L
e
a
rn
in
g
 t
e
s
t 
(i
m
m
e
d
ia
te
 &
 
d
e
la
y
e
d
 r
e
c
a
ll)
S
 
D
ig
it
 s
y
m
b
o
l 
s
u
b
s
ti
tu
ti
o
n
 
te
s
tE
; 
S
y
m
b
o
l 
d
ig
it
 S
(i
v
) 
O
th
e
r 
s
tu
d
ie
s
 
A
R
E
D
S
 [
7
4
] 
C
o
g
n
it
iv
e
 
p
e
rf
o
rm
a
n
c
e
 
 
C
E
S
D
 
3
M
S
 
A
n
im
a
l 
c
a
te
g
o
ry
; 
L
e
tt
e
r 
F
lu
e
n
c
y
 
D
ig
it
s
 
B
a
c
k
w
a
rd
s
; 
L
o
g
ic
a
l 
M
e
m
o
ry
 
P
a
rt
 I
 &
 I
I 
(W
e
c
h
s
le
r 
M
e
m
o
ry
 S
c
a
le
 
R
e
v
is
e
d
);
 
Im
m
e
d
ia
te
 
R
e
c
a
ll 
&
 W
o
rd
 
L
is
t 
M
e
a
n
 
(B
u
s
c
h
k
e
 
S
e
le
c
ti
v
e
 
R
e
m
in
d
in
g
 
T
e
s
t)
 
 
 
 
H
E
R
S
 
 
C
o
g
n
it
iv
e
 
 
 
A
D
L
, 
G
D
S
 
3
M
S
; 
 
T
M
T
-B
; 
V
e
rb
a
l 
F
lu
e
n
c
y
 
W
o
rd
 L
is
t 
M
e
m
o
ry
 a
n
d
 
 
 
M
o
d
if
ie
d
 B
o
s
to
n
 
N
a
m
in
g
 T
e
s
t 
250 S. Andrieu et al. / Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia
T
ab
le
2
,
co
n
ti
n
u
ed
C
o
g
n
it
iv
e
 a
s
s
e
s
s
m
e
n
ts
: 
d
o
m
a
in
S
tu
d
y
P
ri
m
a
ry
 
o
u
tc
o
m
e
(s
) 
V
a
li
d
a
ti
o
n
 
o
f 
d
e
m
e
n
ti
a
 
d
ia
g
n
o
s
is
 
S
e
c
o
n
d
a
ry
 
o
u
tc
o
m
e
(s
) 
F
u
n
c
ti
o
n
a
l/
 
E
m
o
ti
o
n
a
l 
a
s
s
e
s
s
m
e
n
ts
G
lo
b
a
l 
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
E
x
e
c
u
ti
v
e
 
fu
n
c
ti
o
n
M
e
m
o
ry
A
tt
e
n
ti
o
n
S
p
e
e
d
 o
f 
p
ro
c
e
s
s
in
g
O
th
e
r
c
o
g
n
it
iv
e
 
fu
n
c
ti
o
n
 
s
u
b
s
tu
d
y
 [
7
5
] 
p
e
rf
o
rm
a
n
c
e
  
 )
e
g
a
u
g
n
al(
 
st
s
e
T ll
a
c
e
R
H
e
a
rt
 
P
ro
te
c
ti
o
n
 
S
tu
d
y
 [
7
6
, 
7
7
] 
C
o
g
n
it
iv
e
 
im
p
a
ir
m
e
n
t 
T
IC
S
-m
 
 
 
 
 
 
P
H
S
-I
I 
(b
e
ta
 
c
a
ro
te
n
e
 
a
rm
) 
[7
8
] 
C
o
g
n
it
iv
e
 
p
e
rf
o
rm
a
n
c
e
 
C
o
g
n
it
iv
e
 
d
e
c
lin
e
 
(s
u
b
s
e
t 
o
f 
p
a
rt
ic
ip
a
n
ts
)
T
IC
S
 
V
e
rb
a
l 
fl
u
e
n
c
y
 
(c
a
te
g
o
ry
) 
E
a
s
t 
B
o
s
to
n
 
M
e
m
o
ry
 T
e
s
t 
(i
m
m
e
d
ia
te
 &
 
d
e
la
y
e
d
 r
e
c
a
ll)
; 
1
0
-w
o
rd
 l
is
t 
d
e
la
y
e
d
 r
e
c
a
ll 
 
 
 
S. Andrieu et al. / Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia 251
Other studies
The other studies [74–78] also measured cognitive
function as a secondary study outcome (Table 2, part
iv).
Assessment of outcomes
Dementia primary prevention studies
The Diagnostic and Statistical Manual of Mental
Disorders, 4th Edition (DSM-IV) [84], National Insti-
tute of Neurological and Communicative Diseases and
Stroke/Alzheimer’s Disease and Related Disorders As-
sociation (NINCDS-ADRDA) [85] and National Insti-
tute of Neurological Disorders and Stroke-Association
Internationale pour la Recherche et l’Enseignement
en Neurosciences (NINDS-AIREN) [86] criteria were
used to diagnose dementia in three primary prevention
trials [33,36–39] (the criteria for dementia were not
stated in the remaining studies). In addition, a vari-
ety of cognitive assessments and neuropsychological
test batteries were employed (Table 2, part i). The tri-
als for which this information is available (GuidAge,
GEM, ADAPT, WHIMS) measured global cognitive
function, as well as the specific cognitive domains of
executive function and memory [33,34,36,37]. Some
studies also measured other domains, such as praxis
and language. The most widely used cognitive tests
were the MMSE/3MS [79,82] (which measure global
cognitive function), the Trail Making Tests [87] (ex-
ecutive function, attention, speed of processing), ver-
bal fluency tests [88] (semantic memory and executive
function), and the Boston Naming test [89] (language).
Various aspects of memory were assessed using a num-
ber of different tests. In particular, episodic memory
was assessed using the Grober & Buschke test [90], the
Delayed Recall Rey-Osterrieth Modified Figure [91],
Hopkins Verbal Learning Test-Revised [92], and Word
List Memory and Recall tests from the Consortium to
Establish a Registry for Alzheimer’sDisease (CERAD)
neuropsychological test battery [93]. All four trials
also measured functional and/or emotional outcomes
using assessments such as Activities of Daily Living
(ADL) [94] or Instrumental Activities of Daily Living
(IADL) [95] (functional), and the Geriatric Depression
Scale (GDS) [96] or the Center for Epidemiological
Studies – Depression Scale (CESD) [97] (emotional).
Cognitive decline studies
Eight of the 16 cognitive decline studies used a mea-
sure of global cognitive function, but always in con-
junction with assessments of other specific cognitive
domains, such as executive function, memory or atten-
tion (Table 2, part ii). All but four studies measured
executive function, most often using tests of verbal flu-
ency [88]. The Stroop Color/Word test [98] was used
in four studies [29,42,48,51]. Various aspects of mem-
ory were assessed in 14 studies, particularly semantic
memory using Digit Span of the WAIS [91] and verbal
fluency tests [88]. Episodic memory was assessed us-
ing Figure of Rey – immediate and delayed recall [99];
15-word learning, immediate and delayed recall [100];
recall of symbols from Digit-Symbol-Coding (Wech-
sler Adult Intelligence Scale – III [WAIS-III]) [101];
Activity recall [42]; East BostonMemoryTest – Imme-
diate and Delayed Recall [102]; paragraph recall test
and immediate and delayed recall of a short story from
the Wechsler Memory Scales (WMS) [103]; Wechsler
Associated Learning and 20 minute recall test [104];
Rivermead Behavior paragraph recall test [105]; and
the CERAD 10-word list delayed recall [93]. Sever-
al studies also measured functional or emotional out-
comes, for example using the ADL [94], IADL [95],
GDS [96], CESD [97] or Profile of Mood States Ques-
tionnaire [106]. All assessments of cognitive function
in the WHS cognitive substudy [43,44] were adminis-
tered by telephone.
Studies assessing prevention of dementia or cognitive
decline as a secondary objective
Dementia was assessed using DSM-IV [84], DSM-
III-R [83], NINCDS-ADRDA [85] or International Sta-
tistical Classification of Diseases, 10th Revision (ICD-
10) [107] criteria in six studies as a secondary out-
come [60,62–65,69,71].
Ten studies measured global cognitive function, ei-
ther alone or in addition to other specific cognitive
domains [58–60,62,61–65,67,69,70,73] (Table 2, part
iii). The most widely used global cognitive tests were
the MMSE [82] or 3MS [79]. Five studies [58–60,
68,73] measured executive function, using, for exam-
ple, tests of verbal fluency [88] or the Trail Making
Test (part B) [87], as well as various aspects of mem-
ory, with the Digit Span [91] being used most often.
The Word Learning [108]; Delayed Naming [109] and
Word List Memory and Recall (CERAD) [93] tests
were used to assess episodic memory. These five stud-
ies also measured various other cognitive domains.
Three studies [59,67,73]measured depression using the
CESD [97] or Patient Health Questionnaire [110], and
only one study [67] assessed functional outcomes, us-
ing the ADL [94]. One study [73] is also using MRI
scans to assess imaging outcomes, such as total brain
volume.
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Other studies
The remaining studies [74–78]measured global cog-
nitive function, using either the 3MS or the Telephone
Interview for Cognitive Status [111,112], a telephone
adaptation of the MMSE (Table 2, part iv). The HERS,
AREDS and PHS-II studies [74,75,78] also assessed
executive function and memory.
Observed and expected incidence of dementia and AD
in intervention trials
Dementia primary prevention studies
So far, WHI-PERT and WHI-ERT, the two branch-
es of the Women’s Health Initiative Memory Study
(WHIMS) [37], are the only primary prevention trials to
have published observed dementia incidence rates for
long-term follow-up periods. The participants in these
trials were female and aged between 65 and 79 years.
In WHI-PERT, the overall incidence of dementia at the
end of treatment (mean follow-up4.05years)was 1.3%,
with 1.8% incidence in the treatment group (estrogen+
progestin) and 0.9% in the placebo group, giving rates
of 4.5/1000 person years and 2.2/1000 person years,
respectively [38]. AD was the most common form
of dementia in both groups. The observed increased
risk of dementia in women being treated with estrogen
plus progestin led to the early termination of treatment.
The overall incidence of dementia in WHI-ERT, which
involved treatment with estrogen alone, was found to
be 1.6% at the end of treatment (mean follow-up 5.21
years), with 1.9% (3.7/1000 person years) and 1.3%
(2.5/1000person years) incidence rates in the treatment
and placebo groups, respectively [39]. Both of these
studies also examinedMCI incidence,but no significant
difference was found between treatment and placebo
groups in either study. The rate of MCI per 1000 per-
son years was 6.3 and 5.9 in the treatment and placebo
groups, respectively, in WHI-PERT, and 10.3 and 7.6
in the treatment and placebo groups, respectively, in
WHI-ERT [38,39].
In the ADAPT study, an all-cause dementia rate of
7/1000 person years was observed after a median of
approximately 2 years follow-up in 2125 subjects (me-
dian age 74 years at inclusion) who were allocated to
either placebo or one of two active treatment groups
(naproxen220mg bid or celecoxib 200mg bid), exclud-
ing seven individuals who had dementia at the time of
randomization without being detected by the screening
protocol [36]. There was no difference in dementia
rates between treatment groups.
Expected incidence rates have been published for
three the remaining studies, and were based on exist-
ing epidemiological studies. In PREADVISE, a tri-
al involving men aged 60 years or above, age spe-
cific expected rates ranged from 0.675/1000 person
years for 60–64 year olds to 27.6/1000 person years
for subjects aged 85 years and older [35]. In GEM,
a trial involving participants aged 75 years and above,
the expected annual incidence of dementia was set at
4% by the sponsoring agency (approximately 37/1000
person-years),2 while in GuidAge, whose participants
had subjective memory complaints and were aged 70
years and above at inclusion, the expected incidence
was 2.4% in the first year, with a 10% proportional
increase in subsequent years (approximately 28/1000
person-years1) [33,34]. The expected dementia inci-
dence rates in GEM and GuidAge are considerably
higher than those observed in theWHIMS andADAPT
studies.
Studies assessing prevention of dementia as a
secondary study objective
In the MORE study, involving post-menopausal
women with osteoporosis (mean age 66.4 years at in-
clusion), dementia incidence was found to be 1.0% af-
ter 3 years (n = 52, including 36 cases of AD, 1 case
of vascular dementia and 15 cases of indeterminate or
other dementia) (approximate incidence rate of demen-
tia was 3/1000 person years,3, and that of AD was
2/1000 person years2) [60]. In addition, the incidence
of MCI was found to be 3.4% (approximately, 11/1000
person years2). There was no significant difference be-
tween the placebo group and the low dose (60 mg/day)
raloxifene group in the risk of developing MCI, AD,
dementia from any cause or any cognitive impairment
(dementia and MCI combined), but women in the high
dose group (120 mg/day) had a significantly lower risk
of developing MCI (33% lower).
In the PROGRESS study, which included subjects
with a history of cerebrovascular disease (mean age
64 years), dementia incidence was found to be 6.4%
(16/1000 person years) in the active treatment group
(perindopril 4mg/day and indapamide 2–2.5 mg/day)
and 7.1% (19/1000 person years) in the placebo group,
2Approximate calculation based on the expected incidence given
as a percentage by the study authors, the expected sample size and
expected length of follow-up.
3Approximate calculation based on the observed incidence given
as a percentage, the initial sample size and the mean length of follow-
up.
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a non-significant difference [62]. The overall inci-
dence of dementia in the trial was 6.7% (approximately
17/1000 person years)4 after a mean follow-up of 3.9
years.
In the Syst-Eur trial involving hypertensive subjects
aged on average 66.9 years at inclusion, active treat-
ment (10–40mg/day Nitrendipine which could be later
combined with or replaced by 5–20 mg/day analapril
maleate and/or 12.5–25 mg/day hydrochlorothiazide)
was found to reduce the incidence of dementia by 50%
from 7.7 to 3.8 cases per 1000 patient years (21 vs.
11 patients, p = 0.05) compared to placebo [64]. The
study was extended into an open-label, active treatment
follow-up study in the same population and based on
the original active study medication (Syst-Eur 2), and
incidence rates were found to be 7.4 and 3.3 cases per
1000 patient years in the control and treatment groups,
respectively [63]. The expected incidence rate of de-
mentia for this study was 16 cases/1000 patient-years
in the placebo group.
The observed incidence of dementia in the SCOPE
trial, which involved 70 to 89 year old hypertensive sub-
jects, was 6.8/1000 patient years in the treatment group
and 6.3/1000 patient years in the control group, and no
significant difference was found between groups [65].
Finally, in the HYVET-COG study involving very
elderly hypertensive subjects [69], the expected rate
of dementia incidence is 36/1000 patient-years in the
placebo group, and 24/1000 patient-years in the active
group.
Summary of results from cognitive decline studies
Of the 23 completed studies which examined
changes in cognitive performance as a primary or sec-
ondary outcome, the majority [29,41,43–45,47–49,51,
54–57,60,61,65–68,70] found no difference between
active treatment and placebo groups, although in a sub-
group analysis of compliant subjects only, Dodge et al.
found that healthy, cognitively intact elderly subjects
(> 85 years) receiving 240mg ginkgo biloba extract
had a lower risk of cognitive decline compared to those
receiving placebo [56]. Five studies [42,50,53,58,59]
obtained more promising results. In the FACIT study
of folic acid supplementation in older adults (aged 50-
70 years, mean age 60 years) with raised plasma homo-
cysteine, the 3-year changes in memory, information
4Approximate calculation based on the observed incidence given
as a percentage, the initial sample size and the mean length of follow-
up.
processing speed and sensorimotor speed were signifi-
cantly better in the folic acid group (800 µg/day) than
in the placebo group [58]. Folic acid did not affect the
domains of complex speed or word fluency, nor did it
affect performance on the MMSE [82].
In the ACTIVE study, 2832 participants with a mean
age of 73.6 years were randomly assigned to receive 10
sessions of memory, reasoning or speed of processing
training, or to a control group [53]. Five years after
the start of the intervention, the reasoning group (but
not the other two groups) reported significantly less
difficulty in the instrumental activities of daily living
(IADL) [95] than the control group (effect size, 0.29;
99% CI, 0.03–0.55). Each intervention maintained ef-
fects on its specific targeted cognitive ability over the
5 year period (memory: effect size 0.23, 99% CI 0.11–
0.35; reasoning: effect size 0.26, 99% CI 0.17–0.35;
speed of processing: effect size 0.76, 99% CI 0.62–
0.90). Booster training in a random sample of partic-
ipants in each training group produced additional im-
provement in reasoning and speed of processing per-
formance.
Mahncke et al. [50] reported that following an 8–
10 week experimental computerized cognitive training
intervention, significant improvement was observed in
directly trained measures of speed of processing (p <
0.001) and forward word recognition span (p = 0.022)
in subjects aged 60 years or more after a 3-month no-
contact follow-up period. Furthermore, participants
in the experimental training group showed significant
improvement on a measure of global auditory memory
(p = 0.019; effect size 0.25), while no change was
detected in the active and no-contact control groups.
The WEST trial involved 664 post-menopausal
women (mean age 70 years)with a recent stroke or tran-
sient ischemic attack, and anMMSE score ranging from
11–30 (median score 28) at inclusion [59]. Among the
participants withdrawn alive without stroke, estrogen
therapy (1mg Estradiol 17 β/day) did not have a signif-
icant effect on cognitive measures after an average of
3 years. However, in women with normal MMSE (28–
30; n = 268) at entry, estrogen therapy was associated
with less cognitive decline (relative risk, 0.46, 95% CI,
0.24–0.87).
Bryan et al. [42] reported that short-term supplemen-
tation (1month ofFolate (750µg),vitaminB12 (15µg),
or vitamin B6 (75 mg)) had a significant positive effect
on some measures of memory performance (immedi-
ate recall and delayed recognition of words) and one
measure of executive function in females in three age
groups (20–30 yrs; 45–55 yrs; 65–92 years), but did
not affect other measures of cognitive performance or
mood.
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Scheduled follow-up period and frequency of study
visits
Dementia primary prevention studies
The scheduled length of follow-up ranged from 3 to
8.5 years (Table 3, part i). The GEM study planned
to increase its follow-up period from 5 to 9 years due
to initial low observed dementia incidence rates. In
the ADAPT study, it was also planned to extend the
follow-up period (originally set at 5 years) before the
early termination of this study [113]. PREPARE [40]
had the shortest scheduled follow-up, but this studywas
also terminated prematurely due to safety concerns.
Participants are now being followed observationally
until the planned study end.
Cognitive assessments were generally carried out
at annual visits (GuidAge, ADAPT and WHIMS), al-
though the GEM study also performed some cogni-
tive and functional assessments every 6 months, with
a more exhaustive assessment once a year [33,34,36–
39]. Additional contacts were made with participants,
either by telephone or in person, every 3 months in
the GuidAge, GEM and ADAPT studies. The frequen-
cy of study contacts therefore varied between 1 and 4
contacts per year. In the WHIMS studies, participants
underwent annual cognitive assessments, but may have
been required to attend other visits for the main WHI
study.
Cognitive decline studies
Studies of cognitive decline are generally shorter
than primary dementia prevention trials (Table 3, part
ii), with the majority having a follow-up period of 1
year or less. Five studies however [43–46,52,56] had
scheduled follow-up periods ranging between 2 and
5 years. Due to their relatively short duration, three
studies [41,42,55] only assessed participants at baseline
and the study end, with no intermediate contact. Of
the other shorter studies, cognitive function was also
assessed at baseline and study end in 5 trials [29,47,50,
51,57], but contact wasmadewith participants between
these assessments in order to take blood samples, assess
adverse events, check that participants were carrying
out the intervention correctly or to assess general health
changes. Cognitive assessments were carried out more
frequently in the remaining short studies [48,49,54].
In the studies of longer duration, cognitive assess-
ments were performed at the start and end of the trial
only in 2 studies [43,44,46], but both of these studies
maintained regular contact with participants, for exam-
ple through appointments with study nurses, or checks
on compliance. Cognitive assessment was carried out
annually in the three remaining studies [45,52,56],with
some type of additional intermediate contact.
Studies assessing prevention of dementia or cognitive
decline as a secondary study objective
Nearly all of the studies examining dementia or cog-
nitive decline as a secondary outcome had a follow
up period of at least 3 years (Table 3, part iii). The
two remaining studies (MAVIS&VISP) had follow-up
periods of 1 and 2 years, respectively [68,70].
The majority of the studies performed cognitive
assessments roughly annually [59,60,62,64,66,68], or
even more frequently [65,67,70]. In the VISP study,
cognitive function was assessed at baseline, 6 months,
and 12 months, with the 6 month assessment being
conducted by telephone [70]. The FACIT trial [58]
measured cognitive function at the study start and end
only, but maintained regular contact with participants
throughout the study.
Other studies
The remaining studies onlymeasured cognitive func-
tion at one time point, and therefore could not study
cognitive decline over time (Table 3, part iv), although
the PHS-II did assess cognitive change in a small subset
of participants who had cognitive functionmeasured at
two time points [78].
Attrition and management of missing data
Dementia primary prevention studies
Expected dropout rates ranged from 0.5%/year in
PREADVISE (minimum age 60 years) to 5%/year in
ADAPT (minimum age 70 years) and GuidAge (mini-
mum age 70 years), and a combined dropout/mortality
rate of 6%/year is expected in GEM (minimum age 75
years) (Table 3, part i).
Observed rates of attrition are available for four stud-
ies. In the WHI-PERT and WHI-ERT studies (min-
imum age 65 years), 2.2% and 7.1% of participants,
respectively, had dropped out of the study (including
deaths) at the end of treatment, after a mean follow-up
of 4.05 years in WHI-PERT and 5.21 years in WHI-
ERT [38,39]. Initial observed dropout rates are avail-
able for two studies: in GuidAge, a dropout rate of
15.8% was observed after approximately 2 years of
follow-up, which is slightly higher than the expected
rate of 5%/year [33], and in ADAPT, 11% had dropped
out after a mean follow-up of 21 months, which is sim-
ilar to the expected rate of 5%/year [36].
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Three trials (GEM,ADAPT,WHIMS) state that anal-
ysis has been or will be carried out using the intention
to treat (ITT) principle [34,36–39]. However, none of
these trials discuss the specific management of missing
data.
Cognitive decline studies
All except one of the cognitive decline studies have
been completed. The OPAL study (involving subjects
aged 70–79 years) is ongoingwith an expected dropout
rate of 20% [46]. In the studies with less than 1 year of
follow-up, observed rates of dropout at the end of the
trial ranged from 8.7% to 25.2% (Table 3, part ii). The
highest attrition rate in these studies was observed in a
6-month trial of HRT [47] in women aged 73.8 years
on average at inclusion. The lowest attrition rate was
observed in a 6-month trial of multivitamin capsules
(see Table 1 for details) in healthywomenwith amedian
age of 63 years at inclusion [41]. The minimum age of
participants in these two studies was 70 and 60 years,
respectively.
In a study of homocysteine lowering in subjects with
a mean age of 73 years at inclusion [45], a dropout
rate of 8.33% was observed after 2 years, which was
slightly lower than expected. An attrition rate of 33%
was observed after five years follow-up in the ACTIVE
study of cognitive training interventions, which was
very similar to the predicted rate of 35% for this time
point [52,53]. The mean age of subjects in this study
varied from 73.4 to 74.1 depending on the treatment
group. In theWHS study of vitamin E in womenwith a
mean age of 66 years at inclusion, the observed dropout
rate was 4% at 4 years, and 20% at 6 years.
Four of the cognitive studies [46,47,52,57] carried
out ITTdata analyses,with one study [47] also perform-
ing a per protocol (PP) analysis. Missing values were
replaced by the “last observation carried forward” in
the study byAlmeida et al. [47]. Eight of the remaining
studies [29,41,45,48–51,55] used only PP analyses.
DISCUSSION
The aim of this work was to review the methodol-
ogy of primary prevention trials for neurodegenerative
dementia, especially AD. Only six true large scale pri-
mary prevention trials were identified which assessed
the effects of an intervention on AD or dementia inci-
dence as a primary outcome. We therefore expanded
our inclusion criteria to also include trials that assessed
dementia or AD incidence as a secondary outcome, or
those which assessed cognitive decline as a primary or
secondary outcome. Smaller studies of the impact of an
intervention on late life cognition could be considered
as proof of concept studies for larger trials focusing on
either cognitive decline or dementia.
We did not use a formal definition of primary preven-
tion as some trials allowed some participants with MCI
or with memory complaints. However, we did exclude
trials involving only subjects with a specific form of
cognitive impairment (i.e., dementia, MCI, CIND).
Outcomes and assessments
Dementia incidence may seem an obvious outcome
for primary prevention trials, as it is the most clinically
relevant criteria, but it is likely to remain low in healthy
elderly populations [35], leading to large study sizes
and long follow-upperiods. Furthermore, dementia is a
heterogeneous condition, and so an intervention which
has an effect on overall dementia incidence may not
affect the incidence of specific subtypes of dementia,
such as AD. Intervention studies using dementia inci-
dence as a primary outcome remain rare, and three of
the six such trials identified in this review were termi-
nated prematurely due to safety concerns regarding the
treatment being tested.
Cognitive decline can be measured more gradual-
ly than conversion to dementia and so may be a suit-
able additional or substitute outcome for dementia in-
cidence. Although it has not been conclusively proven
that cognitive decline is a valid surrogate marker of de-
mentia [114,115], some studies have indicated that peo-
ple with cognitive impairment are at increased risk of a
subsequent dementia diagnosis [116–118]. Future pri-
mary prevention trials may be able to validate cognitive
decline as a surrogate marker of dementia by assessing
both dementia incidence and cognitive decline. How-
ever, statistically significant cognitive decline mea-
sured by a sensitive cognitive test may not necessarily
be clinically meaningful, so it will be important to con-
sider cognitive decline as an outcome in conjunction
with other clinically pertinent outcomes [119], such as
functional or emotional (depression/anxiety) changes.
In the early stages of cognitive dysfunction, it may
be particularly important to assess limitations in more
complex ADL [120,121] rather than basic ADL which
are often used as outcomes in trials involving patients
already diagnosed with dementia, but which may re-
main relatively unchanged in pre-dementia patients.
Validated instruments and measures must be used to
assesswhichever outcomes are chosen,and theymay be
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completed by a variety of individuals (trial participants
themselves, a proxy, study staff, independent clinical
specialists). Initial assessments may be carried out for
example by postal or telephone questionnaires, espe-
cially as part of a screening process. Study partners or
collateral informants, such as a spouse or other family
member may also be asked to assess the study partici-
pant. Informantswhomaintain regular contact with the
individual being assessed, especially those living with
the individual, are able to accurately assess cognitive
performance, even before a stage of clinically recogniz-
able impairment is reached [122–124]. In addition, fu-
ture cognitive decline can more accurately be predicted
based on informant rather than patient reports of mem-
ory or cognitive complaints [125,126]. More thorough
assessments may be carried out during face-to-face ap-
pointments in study centers, or by independent special-
ists as the diagnosis of dementia must ultimately be
made by a clinician based on a face-to-face interview
with the subject and information from a relative, and
should be based on standard international criteria, for
example those of the DSM-IV [84], ICD-10 [107] or
NINCDS-ADRDA [85]. The confirmation of suspect-
ed dementia diagnoses by an independent committee
or specialist will ensure the homogeneity of diagnoses
throughout the study, which may be conducted in mul-
tiple centers, and will help to detect false positive diag-
noses. However, it will not detect false negative cases.
Screening cut-off criteria must be sensitive enough in
order that all cases of dementia are detected.
Instruments measuring cognitive function must be
sensitive enough to detect very early signs of dementia
or small changes in cognitive function. Global cog-
nitive measures, such as the MMSE, may not be able
to detect small domain-specific cognitive changes. For
example, the FACIT trial would not have detected any
cognitive differences between groups if only theMMSE
alone had been used, but the use of sensitive domain
specific tests in addition to global cognitive measures
allowed the detection of relevant changes in memory
and information processing speed [58]. The MMSE is
a widely used instrument, and while it may be useful
in defining the target population, or as part of a demen-
tia screening evaluation, it is not a suitable marker of
cognitive decline for primary prevention trials.
There was much variation in the choice of cognitive
tests used in the different trials, making comparison of
results across different studies difficult. Furthermore,
some tests were not adequate for detecting cognitive
change in personswith nomajor impairment. It may be
useful to develop standard tests or test batteries in order
to improve the comparability of results, and to ensure
that suitable outcome measures are used in prevention
trials. Several standard assessment batteries have been
developed for use in clinical drug trials involving AD
patients, the first of which was the Alzheimer’s Dis-
ease Assessment Scale – Cognitive Subscale (ADAS-
Cog) [127]. This scale is now considered as the “gold
standard” cognitive outcome measure in RCTs for AD
patients. Another neuropsychological battery was in-
cluded in the Uniform Data Set (USD) which was im-
plemented in all National Institute on Aging (NIA) AD
centers in the US in 2005 to improve the homogeneity
and comparability of data used to characterize individ-
uals with mild AD or MCI in different centers [128].
More recently, amore sensitive neuropsychological test
battery (NTB)was developed for a specific clinical trial
in very earlyAD [129], and has since been incorporated
into other clinical trials for AD [130]. However, these
batteries may not include ideal measures for primary
prevention trials. It is important therefore to develop
a consensus on the most relevant cognitive tests to be
used for primary prevention trials, and to ensure that
they have undergone suitable psychometric validation.
The cross-cultural applicability and validity of cog-
nitive assessments is important, as primary prevention
studies may be carried out in more than one country
and in more than one language, as seen, for example, in
the ACCORD-MIND study [73]. Assessment of cog-
nitive functioning must be culturally and linguistically
appropriate in order to ensure the reliability of research
results in ethnically diverse populations. Furthermore,
it is important that test results be compared to indi-
vidual population normative data, rather than global
norms [131].
It is also important to consider the acceptability of
cognitive testing to participants, especially due to in-
strument length and test procedures. So far, tele-
phone cognitive assessments have not been widely em-
ployed: the Telephone Interview for Cognitive Status
(TICS) [132] was used for screening in GEM, and dur-
ing follow-up in some studies of cognitive decline on-
ly. Telephone, mail and web-based assessments may
be helpful in future primary prevention trials in order
to reduce participant and investigator burden, as well
as minimizing study costs. However, older age groups
may not have a personal computer or be at ease with us-
ing the internet, so it may not yet be feasible to use web-
based assessments with elderly subjects. The ongoing
“Alzheimer’s Disease Cooperative Study – Prevention
Instrument” project is evaluating instruments intended
primarily for “home-based” assessments in a number of
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domains in primary prevention trials [133]. In the study
by Dodge et al. [56] involving elderly persons aged 85
years or older, initial screening assessments were car-
ried out by telephone, followed by further screening as-
sessments in the subjects’ home carried out by trained
staff.
Target population and dementia incidence rates
Primary prevention trials may target asymptomatic
unselected elderly individuals in the general popula-
tion, or target groups thought to be at particular risk of
developing dementia or cognitive decline, such as very
elderly subjects or subjects with a first degree fami-
ly history of dementia [134]. Most of the identified
studies used age as one of their main inclusion criteria,
with 26 studies stating a minimum age of 60 years or
more. Age is a major risk factor for dementia, and so
is an important consideration for the target population.
Trials involving asymptomatic individuals with no par-
ticular risk factors other than age may have low rates
of dementia incidence or cognitive decline if the mini-
mum age of participants is only 60-65 years [135,137],
and so may require relatively long follow-up periods.
It may therefore seem logical to target older persons,
but if subjects are very old, there is a greater risk of
co-morbidities and competing risks of death, both of
which may bring about a high rate of attrition from the
trial.
There may be potential differences between those
who volunteer to participate and those who do not [81].
Actual or perceived cognitive impairment may play
a role in patient participation, with people with low-
er cognitive performance being less likely to partici-
pate [138]. Those volunteering to participate may be
more educated and more concerned about health than
those who do not take part, which may in itself cause
them to be at reduced risk of dementia or cognitive
decline [113], thus bringing about a potential impor-
tant selection bias. This so-called “healthy volunteer
effect” can lead to lower than expected dementia inci-
dence rates.
The use of target populations with known dementia
risk factors should lead to a higher incidence of demen-
tia or a quicker rate of cognitive decline during the trial,
and thus the efficacy of potential new preventive treat-
ments could be demonstrated in smaller samples over
shorter follow-up periods. However, results for these
selected populations will not necessarily be applicable
to the general elderly population [113,139]. It remains
to be seen in practice whether or not such studies do
actually observe increased rates of dementia incidence
or cognitive decline. While all prevalent dementia cas-
es must be excluded at baseline, some studies allow the
participation of patients with some isolated mild form
of cognitive decline. If these subjects were excluded,
the observed dementia rates may be significantly lower
than expected. These subjects may be those with the
greatest need for an effective preventive treatment, thus
they should not be excluded from prevention trials.
Future primary prevention trials may consider using
target populations with cardiovascular risk factors, as
such patients may also be at increased risk for demen-
tia [17,19,20]. Such patients have so far only been
targeted in studies examining dementia prevention as a
secondary objective. The APOE ε4 genotype has also
been suggested as a significant risk factor for the de-
velopment of AD [14], and so it is important to con-
sider this genotype when analyzing results of preven-
tion interventions. However, the selection of subjects
according to genetic status raises ethical issues [140].
Other potential risk factors for dementia or AD in-
clude diabetes [141–144] and neuroimaging [145,146]
or biomarker [147–149] abnormalities, all of which
could be included in the definition of target populations
for future primary prevention trials.
Depending on the mechanism of action of the inter-
vention, target populations may also be enriched with
subjects in whom the intervention may have the great-
est effect. For example, as seen in the FACIT trial,
subjects with raised homocysteine levels may be an
appropriate target for certain nutritional interventions.
Alternatively, stratified analyses may be used to deter-
mine if the intervention has a greater effect in certain
sub-groups of the study populations, for example in
the oldest age group, in groups with altered biomarker
profiles, or according to compliance to the intervention
under study.
The cost of recruiting large numbers of non-
demented older adults for primary prevention trialsmay
be very high, partly due to low response rates [81]
which may be brought about by a perceived lack of
benefit of the intervention [150,151]. The definition of
the target population may help to define the most ap-
propriate recruitment strategies, which can include re-
cruitment via medical professionals or the use of media
campaigns or public registers. Additionally, patients
may be recruited from previously defined cohorts that
have been used primarily to study other conditions or
treatments, forming ancillary studies. Specific inclu-
sion and exclusion criteria can be used to identify a
sub-group of participants from the original trial who
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are suitable for dementia prevention studies. Ancillary
studies may decrease the cost of primary prevention
trials as they make use of existing study cohorts and
infrastructure.
Lifestyle factors, such as diet and exercise, may
be involved in several chronic diseases, including car-
diovascular disease [152] or cancer [153], as well as
neurodegenerative disease [23]. A given intervention
might therefore have beneficial effects onmore thanone
condition, and future studies could be specifically de-
signed to assess at least two or three primary outcomes
relating to different chronic conditions. The study pop-
ulation formulti-condition trials might be based on risk
factors that are common to all of the conditions under
study. For example, the highest dementia incidence
rates observed so far in primary prevention trials were
found in trials involving subjects with a history of cere-
brovascular disease, or with hypertension [62,64,65].
Follow-up period
The scheduled follow-up period of primary preven-
tion trials depends in part on the chosen study popu-
lation, and on the main study outcomes, as well as on
the type and predicted efficacy of the study interven-
tion. The frequency of study visits may be determined
by the length of the trial as it may be too expensive
to carry out regular assessments over a long period of
follow-up, but if visits are too far apart, (i) participants
may lose interest in the study and drop out, and (ii) de-
termination of the time of conversion to the end-point
may be obscured. On the other hand, if study visits
are too frequent, they may become too burdensome for
participants, which could also be a cause of attrition.
Telephone contacts may help to retain subjects’ atten-
tion in the study, while keeping the burden of study
visits to a minimum.
Dropouts/attrition and management of missing data
Attrition (including losses to follow-up,dropouts and
mortality) is a major source of potential bias in clini-
cal trials, especially in those involving elderly partici-
pants [154]. An examination of the characteristics of
dropouts may help to determine whether a process of
differential dropout has occurred, and to explore po-
tential effects of attrition bias on results. In contrast to
the results of the Syst-Eur study of anti-hypertensive
treatment [64], the similar SHEP study involving hy-
pertensive subjects aged 60 years and above found no
effect of active treatment on the incidence of cogni-
tive decline or dementia [67]. The SHEP investiga-
tors therefore examined the possibility that their results
may have been biased by differential dropouts [155]. A
dropout rate of 18.04%was observed in this study after
4 years of follow-up, and those who dropped out were
more likely to be in the placebo group than the active
treatment group. In sensitivity analyses in which 20, 25
or 30% of dropouts were considered to have an abnor-
mal cognitive score, the active treatment significantly
decreased the risk of an abnormal cognitive score, at
least in years 1–3 of follow-up, indicating that the orig-
inal results may have been biased by a differential loss
of data.
Attrition may be influenced by both trial constraints
(such as treatment modalities (e.g., injections) and side
effects, length of total follow-up, frequency and type
of contacts with study investigators, etc.) and par-
ticipant characteristics (age, presence of concomitant
medical conditions, level of autonomy). This may lead
to inter-related and conflicting issues during study de-
sign [156]. For example, the study length may large-
ly be determined by the expected dementia incidence
rate in the chosen study population. This rate may be
higher in older subjects (i.e., >75 years), but this age
group is likely to be at increased risk for attrition due to
various factors, including high morbidity and mortality
levels, and decreased autonomy compared to younger
subjects [157]. Such patients may also discontinue par-
ticipation if they move into a nursing home or other as-
sisted care facilities, especially as dementing disorders
are associated with a loss of autonomy. Some of these
problems may be overcome by enrolling younger par-
ticipants, but this is likely to decrease the incidence of
dementia, and so may lead to longer follow-up periods,
which may cause more patients to drop out. Withdraw-
al or refusal may occur for several reasons, including
adverse effects of the drug, a lack of perceived benefit
leading to non compliance, time consuming treatment
protocols, and subjects not feeling “involved” in the
study.
Much of the attrition observed in primary prevention
trials may conceivably be due to a lack of efficacy and
the burden of study visits for both the participant and
the study partner [158]. Future trials may need to con-
sider the possibility of carrying out home visits in order
to reduce this burden. The determination of the reasons
for drop out will help to direct other strategies for min-
imizing attrition. It should be remembered that attri-
tion may depend on factors relating to the informant or
other family members, in addition to the subjects them-
selves. Furthermore, it might be useful to compare the
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characteristics of patients who drop out with those who
remain in the trial. Such information could help to im-
prove the design of future trials as attrition prevention
strategies could be specifically targeted at participants
at greater risk of dropping out. It may also be useful to
verify whether home-based assessments (by telephone,
mail, or web or during home visits) actually decrease
attrition rates. Whatever the actions taken, some level
of attrition is inevitable. Retrieved dropout visits can
be used in order to obtain outcome information for sub-
jects who have discontinued participation in the trial
and may help to minimize attrition bias.
Observed rates of attrition varied across the different
prevention studies. Low rates were observed in certain
studies, for exampleWHI-PERT [38], and FACIT [58].
Interestingly, the FACIT study used a wide variety of
strategies (e.g., coupons, parties, newsletters, Christ-
mas cards, days out, etc.) in order to retain subjects’
interest in the trial [58], but it should be noted that
participants in the FACIT study were younger (50–70
years) than those in other studies with higher attrition
rates. The dropout rate observed in the WHI-ERT tri-
al [39] was higher than that observed in its sister study
WHI-PERT, perhaps partly due to participant safety
fears after the WHI-PERT arm was suspended. Higher
attrition rates were observed in some of the cognitive
decline studies, for example 23% after 6 months in the
study by Eussen et al. [29], and 25.2% after 5 months
in the study by Almeida et al. [47]. Eussen et al. noted
that much of the attrition in their study was due to ill-
ness, which is perhaps unsurprising as the mean age of
the participants was 82 years.
The method of data analysis and the management of
missing data are important considerations for primary
prevention trials, and should be mentioned explicitly
in reports and publications. Traditionally, ITT analysis
has been considered the “gold standard” for random-
ized controlled trials. Due to the nature of primary
prevention trials, notably the age of participants and
the duration of follow-up, it is particularly important
that attrition is taken into account during data analy-
sis. Methods of adjustment currently used in longitudi-
nal population epidemiology studies, includingmodels
which take into account age at entry, censorship and
truncation,may help to copewith these problems [159].
CONCLUSION
This review underlines some important methodolog-
ical issues in preventive trials for neurodegenerativede-
mentia. The trials completed so far have not shown a
major effect on either dementia incidence or cognitive
decline, although some did show some encouraging re-
sults. This lack of effect may have been due to the in-
efficacy of the interventions tested, but methodological
factors probably also played a part.
The prevention strategies tested so far in RCTs may
have been implemented too late in life [160], thus miss-
ing the critical period of exposure. Various studies have
shown that the risk factors for this disease may have an
effect from the moment that the subject is exposed dur-
ing their lifetime, often long before the AD diagnosis.
The “midlife” period, around the ages of 40–50 years,
would seem to be particularly important for certain fac-
tors [161]. Some risk factors may have an effect even
during the very early stages of life, and can accumu-
late throughout the lifespan [162] and may have a dif-
ferent effect according to the period of exposure (e.g.,
hypertension, cholesterol) [163,164]. For risk factors
that play a role early on in the life course, public health
interventions at the population level, rather than RCTs,
may be the best means of prevention.
Potentially interlinked protective factors have rarely
been studied at the same time, although an intervention
which combined different preventive approaches (nu-
trition and physical exercise) has been found to be effec-
tive in an older population in a different context [165].
Modifiable lifestyle factors may play an important role
in the prevention of neurodegenerative dementia. In
the past, the WHO has promoted actions for healthy
aging directed towards physical activity, nutrition and
social integration [166]. Some public health initiatives
promoting physical exercise and a healthy diet have
shown positive results and proved that it is possible to
change lifestyle habits, even in elderly persons [165].
These strategies were not targeted towards a specific
aging related disease such as AD, but increasing evi-
dencewill emphasize the need for future trials based on
multiple interventions for prevention in the field of AD.
Dementia prevention trials have so far mainly target-
ed pharmacological intervention strategies, and it will
be important in future trials to also evaluate lifestyle
interventions.
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The prevention of neurodegenerative dementias, such as Alzheimer disease, is a growing public health
concern, because of a lack of effective curative treatment options and a rising global prevalence. Various potential
risk or preventive factors have been suggested by epidemiologic research, including modifiable lifestyle factors,
such as social contacts, leisure activities, physical exercise, and diet, as well as some preventive pharmacologic
strategies, such as hormone replacement therapy, nonsteroidal antiinflammatory drugs, and Ginkgo biloba. Some
factors have been targeted by interventions tested in randomized controlled trials, but many of the results are in
conflict with observational evidence. The aim of this paper is to review the epidemiologic data linking potential
protective factors to dementia or cognitive decline and to discuss the methodological limitations that could explain
conflicting results. A thorough review of the literature suggests that, even if there are consistent findings from large
observational studies regarding preventive or risk factors for dementia, few randomized controlled trials have
been designed specifically to prove the protective effects of interventions based on such factors on dementia
incidence. Because of the multifactorial origin of dementia, it appears that multidomain interventions could be
a suitable candidate for preventive interventions, but designing such trials remains very challenging for
researchers.
Alzheimer disease; bias (epidemiology); cognition disorders; dementia; epidemiologic research design; primary
prevention; randomized controlled trials as topic; risk factors
Abbreviations: APOE, apolipoprotein E; NSAID, nonsteroidal antiinflammatory drug; WHIMS, Women’s Health Initiative Memory
Study; WHISCA, Women’s Health Initiative Study of Cognitive Aging; WHS, Women’s Health Study.
INTRODUCTION
Neurodegenerative dementias, such as Alzheimer dis-
ease, are a growing public health concern. The global prev-
alence of dementia was estimated at 24.3 million in 2001 (1)
and that of Alzheimer disease was estimated at 26.55 mil-
lion in 2006 (2). Over the next 40 years, the prevalence is
expected to quadruple, with a particularly dramatic increase
in the number of cases in developing regions (1, 2). There
are currently no effective treatment options for this condi-
tion, making its prevention a priority. Prevention is feasible
due to the long asymptomatic latent period of this disease.
Even an intervention that delayed disease onset by just a few
years could dramatically reduce the burden of this disease
on society and public health-care systems (3).
To this end, there has been a recent focus on the identi-
fication of potential preventive factors for dementia, and
epidemiologic research has suggested various candidates,
including modifiable lifestyle factors, such as social
contacts, leisure activities, physical exercise, and diet, as
well as some pharmacologic strategies, such as hormone
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replacement therapy, nonsteroidal antiinflammatory drugs
(NSAIDs), and Ginkgo biloba. In addition, the treatment
of vascular risk factors could be important. Some of these
factors have been targeted by interventions tested in ran-
domized controlled trials, but many of the results obtained
are in conflict with those obtained in observational studies.
The most well-known example of this is the Women’s
Health InitiativeMemory Study (WHIMS) (4, 5), which sug-
gested that hormone replacement therapy may increase the
risk of dementia, contrary to results of observational studies.
The aim of this article is twofold: to explore possible
methodological explanations for the divergent results in de-
mentia observational and interventional prevention studies
and to consider future research perspectives. Results from
recent meta-analyses, reviews, longitudinal studies, and ran-
domized controlled trials assessing the prevention of both
dementia/Alzheimer disease and cognitive decline will be
included.
SEARCH STRATEGY
Recent studies (published in the last 15 years) were iden-
tified by using the search strategy outlined in table 1.
SUMMARY OF FINDINGS FROM PROSPECTIVE
LONGITUDINAL STUDIES AND RANDOMIZED
CONTROLLED TRIALS
The associations among lifestyle, pharmacologic, and
vascular risk or protective factors identified in longitudinal
and experimental studies are described below and summa-
rized in table 2.
Nutrition
Meta-analyses or reviews. Two reviews (6, 7) studied
nutritional factors and dementia or cognitive decline. The
first in 2004 (7) noted that, while there was some evidence to
suggest that antioxidants, homocysteine-related vitamins,
and fatty acids are related to Alzheimer disease, it was not
possible at that time to generate specific dietary recommen-
dations for Alzheimer disease prevention because of a lack
of large observational studies or randomized controlled tri-
als. The second in 2007 (6) concluded that, despite some
conflicting evidence, folate and vitamin B12 seem to have
a protective role on cognitive decline and dementia and that
a balanced combination of several antioxidants may be re-
quired for prevention of cognitive decline or dementia.
Two Cochrane reviews (8, 9) found no evidence for a ben-
eficial effect on cognition of folic acid with or without vi-
tamin B12, in healthy or cognitively impaired older people,
or of vitamin B6 supplementation in older people with or
without vitamin B6 deficiency.
Finally, a meta-analysis of randomized controlled trials
for cognitive and noncognitive disorders underlined that
supplements containing high doses of beta-carotene, vita-
min A, and vitamin E could increase the risk of all-cause
mortality (10).
Prospective longitudinal studies. Homocysteine. Six
studies, conducted mainly in elderly populations aged 65
or more years, found increased homocysteine levels to be
associated with an increased risk of dementia/Alzheimer
disease (11–13) or cognitive decline (14–16), one of which
found this association to be modified by vitamin B12 (11).
However, four studies found no association between homo-
cysteine and dementia (17) or cognitive decline (18–21).
TABLE 1. Search strategy
Study design
Included
study designs*
Exclusion criteria
Databases
searched
Search terms Other sources
Longitudinal
studies
Prospective
longitudinal
studies
Medline ‘‘Dementia’’ (MeSHy) OR
‘‘Alzheimer disease’’
(MeSH) OR ‘‘cognition
disorders’’ (MeSH) AND
‘‘prevention’’ OR ‘‘risk’’z
Reference lists
of review articles;
authors’ own files
and experience
Prospective
nested
case-control
studies
Experimental
studies
Randomized
controlled
trials
Open-label, nonrandomized,
or single-blind studies;
sample size, <50; duration,
<3 months; use of
self-reported or magnetic
resonance imaging
surrogate outcomes; trials
with no baseline cognitive
assessment
Medline Medlinez: ‘‘cognition
disorders/prevention’’ and
‘‘control’’ (MeSH) OR
‘‘dementia/prevention’’ and
‘‘control’’ (MeSH) OR
‘‘Alzheimer disease/prevention’’
and ‘‘control’’ (MeSH) OR
‘‘cognition’’ OR ‘‘cognitive’’ OR
‘‘dementia’’ OR ‘‘Alzheimer(’s)
disease’’ AND ‘‘prevention’’
AND ‘‘randomized controlled
trials’’
Reference lists of
review articles;
authors’ own files
and experience
Clinicaltrials.gov Clinicaltrials.gov: ‘‘dementia’’
OR ‘‘Alzheimer’’ OR
‘‘cognition’’ AND ‘‘prevention’’
* Reviews and meta-analyses were also identified during both searches.
yMeSH, Medical Subject Headings.
z These common search terms were combined with specific terms for each of the risk factors assessed.
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Vitamins B6 and B12 and folate. Eight studies have found
increased intake or serum concentrations of vitamin B6 (16,
22), vitamin B12 (16, 21, 23, 24), or folate (12, 16, 22–26) in
mid- or late life to have a beneficial effect on dementia/
Alzheimer disease incidence or cognitive decline. Nine
studies found no relation between vitamin B6 (26, 27), vi-
tamin B12 (12, 19, 20, 22, 26–29), or folate (19–21, 27, 29)
and dementia/Alzheimer disease or cognitive decline, and
one (24) found that increased dietary folate intake was as-
sociated with increased cognitive decline.
Antioxidants. Fourteen studies, focusing mostly on popula-
tions aged 65 or more years, have suggested that vitamin E
(30–33), vitamin C (30, 33), combined vitamins E and C
(33–37), flavonoids (30, 38, 39), beta-carotene (30, 33, 40),
or overall antioxidant intake (41), as well as serum selenium
concentrations (42, 43), may be associated with reduced de-
mentia/Alzheimer disease incidence or reduced cognitive de-
cline. Five studies found no association between vitamin E
(37, 44, 45), vitamin C (22, 37, 44–46), flavonoids (44), or
beta-carotene (22, 31, 44–46) and dementia/Alzheimer disease
or cognitive decline. Results are sometimes conflicting be-
tween dietary intakes and supplements and may be dependent
on the status of the e4 type of apolipoprotein E (APOE) (31).
Fat intake. Moderate intake of polyunsaturated fatty acids
was related to a lower risk of dementia in one study (47),
and another (48) found high polyunsaturated fatty acid in-
take to be associated with better cognitive performance.
Two studies found borderline significant relations between
high polyunsaturated fatty acid intake and Alzheimer dis-
ease (49) or mild cognitive impairment (50). Higher intakes
of monounsaturated fatty acids were associated with better
cognitive performance in one study (48) and marginally
associated with a decreased Alzheimer disease risk in an-
other (49). One study found no association between a low
intake of monounsaturated fatty acid or n-3 or n-6 polyun-
saturated fatty acid and dementia (51). High plasma phos-
phatidylcholine docosahexaenoic acid was also associated
with a lower risk of all-cause dementia, but not Alzheimer
disease, in one study (52) and less cognitive decline in two
other studies (53, 54).
Dietary patterns. One study suggested that a diverse diet
may reduce the risk of dementia (55), and a second found
a decreased risk of Alzheimer disease in subjects following
a Mediterranean-style diet (56). Increased fish consumption
was associated with a decreased risk of dementia in four
studies (55, 57–59), but in one (57) this relation became
borderline significant when education was controlled for.
Two further studies found higher fish consumption to be
related to lower cognitive decline (60, 61).
Experimental studies (table 3). Homocysteine-lowering
vitamins. Seven randomized controlled trials have tested
the effects of homocysteine-lowering vitamins (vitamin
B6, vitamin B12, and/or folic acid) on cognitive performance
or cognitive decline (62–68). Five (64–68) found no differ-
ence between placebo and active treatment groups, and one
(62) found significant effects of 1-month vitamin B12, vita-
min B6, and folate supplementation on some measures of
memory performance but not on other cognitive measures.
The Folic Acid and Carotid Intima-media Thickness
(FACIT) Study (63) found 3-year folic acid supplementation
to beneficially affect global cognitive function and the specific
cognitive domains of memory and information processing.
Antioxidants. The Women’s Health Study (WHS) (69)
found no benefits of vitamin E on cognition after 9.6 years
of supplementation.
Multivitamins. Two randomized controlled trials (70, 71)
found no effect of multivitamin supplementation (including
antioxidants and homocysteine-lowering vitamins) on cog-
nitive performance, although one (70) found some benefits
in one cognitive domain for the eldest participants and those
at increased risk of micronutrient deficiency.
Limitations. In the domain of nutrition, various doses of
vitamins were used in randomized controlled trials. For ex-
ample, folate supplements ranged from 200 lg (70) to 2,500
lg (67) per day. The lowest dose used was lower than the US
Recommended Daily Allowance (RDA) (400 lg/day). In
the Folic Acid and Carotid Intima-media Thickness Study
(63), which found folate supplementation to have beneficial
effects on cognitive decline, 800 lg were given daily to
elderly individuals with raised homocysteine concentra-
tions. Two trials (66, 67) used higher doses of folate but
detected no cognitive benefits. A longitudinal study (26)
found those in the highest quintile of folate intake
(487.9 lg) to have a lower risk of developing Alzheimer
disease than those in the lowest quintile (292.9 lg), but it is
unlikely that those in the highest quintile had intakes as high
as those used in some randomized controlled trials. The form
of vitamins may also be important. Vitamin E exists in several
different forms, more than one of which may be required for
a protective effect on cognition (32). In the WHS, a supple-
ment containing only the alpha-tocopherol form was used,
and no effect was observed on cognition (69).
The duration of follow-up in the longitudinal studies was
generally 3 or more years, but only two randomized con-
trolled trials (63, 69) were of similar length. The duration of
both supplementation and follow-up may affect the ob-
served effects on cognition in randomized controlled trials,
but the WHS did not observe any cognitive benefits after
more than 9 years of vitamin E supplementation.
In nutritional interventions, particular attention could be
paid to the sensitivity of subjects to the intervention. A trial
of vitamin supplementation may be more beneficial in those
with poor nutritional status than in those who already have
sufficient intakes. One (63) of four trials (63, 64, 66, 68)
targeting persons with a particular nutritional deficiency was
able to demonstrate an effect on cognitive function. Partic-
ipants in dementia prevention randomized controlled trials
may be in good health or may already be receiving nutri-
tional fortification through public health measures, and they
may not be those at most risk of cognitive impairment (72).
Nutrient intakes were found to be related to dementia
incidence in some longitudinal studies, but none of the ran-
domized controlled trials used dementia incidence as an
outcome.
In addition, interactions between different micro- and
macronutrients should be considered, especially in terms
of food groups or dietary patterns (55, 56).
The analysis of the associations between consumption of
nutrients and cognition is complex, and it is unlikely that
one nutrient alone will play a major role. From a public
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TABLE 2. Summary of associations between risk/preventive factors and dementia or cognitive outcomes in longitudinal and
experimental studies
Factor and association
Study design and outcome
Longitudinal studies Experimental studies
Dementia/
Alzheimer
disease
Cognitive
impairment
or decline
Dementia/
Alzheimer
disease
Cognitive
impairment
or decline
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
Nutrition
High homocysteine concentration
Increased risk 2 11, 13 1 15
Increased risk in subgroup analysis 1 12 1 14
Increased risk for certain outcomes only 1 16
No association 1 17 4 18–21
Decreased risk
Decreased risk in subgroup analysis
Decreased risk for certain outcomes only
Other
Total no. of studies 4 7
High intake or serum concentration of
homocysteine-lowering vitamins
Increased risk 1 24
Increased risk in subgroup analysis
Increased risk for certain outcomes only
No association
B6 1 27 4 19–21, 29 2 64, 66
B9 1 27 3 19, 20, 29 2 65, 67
B12 4 12, 22, 27, 28
Decreased risk
B9 2 22, 26 2 62, 63
Decreased risk in subgroup analysis
B12 1 24
Decreased risk for certain outcomes
only (vitamins B6, B9, B12)
1 16
Other
Low levels of vitamin B9 associated
with an increased risk
1 12 1 25
Low levels of vitamins B9 and B12
associated with an increased risk
1 23
High concentration of
holotranscobalamin (marker
of reduced vitamin B12)
associated with more rapid
cognitive decline)
1 21
Total no. of studies 9 8
High intake or serum concentration of
antioxidants
Increased risk
Increased risk in subgroup analysis
Increased risk for certain outcomes only
No association 4 22, 31, 37, 38 1 46 1 69
Decreased risk 4 30, 32, 37, 38 6 31, 32, 34,
35, 39, 41
Table continues
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TABLE 2. Continued
Factor and association
Study design and outcome
Longitudinal studies Experimental studies
Dementia/
Alzheimer
disease
Cognitive
impairment
or decline
Dementia/
Alzheimer
disease
Cognitive
impairment
or decline
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
Decreased risk in subgroup analysis
Vitamin E 1 31
Vitamins E and C 1 36
High beta-carotene 1 40
Decreased risk for certain outcomes only
Other
Lower intakes of vitamin C and
vitamin E associated with
acceleration of cognitive decline
1 33
Decline in selenium associated
with cognitive decline
2 42, 43
Total no. of studies 10 11 1
High intake of fatty acids
Increased risk 2 30, 59 1 58
Increased risk in subgroup analysis
Increased risk for certain outcomes only
No association 1 58
Decreased risk 2 49, 52 3 48, 50, 61
Decreased risk in subgroup analysis 1 47
Decreased risk for certain outcomes only 2 53, 54
Other
Total no. of studies 5 7
Social engagement and cognitive, physical, and leisure activities
High level of social engagement in late life
Increased risk
Increased risk in subgroup analysis
Increased risk for certain outcomes only
No association 3 92–94
Decreased risk 7 76–82 6 83–86, 88, 89
Decreased risk in subgroup analysis
Decreased risk for certain outcomes only 1 87
Decreased risk for certain types of
exposure only
2 90, 91
Other
Total no. of studies 7 12
Cognitive activities or training in late life
Increased risk
Increased risk in subgroup analysis
Increased risk for certain outcomes only
No association
Decreased risk 7 76–78, 95–98 6 92, 93,
97–100
2 131, 132
Decreased risk for certain types of
exposure and certain outcomes only
1 133
Table continues
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TABLE 2. Continued
Factor and association
Study design and outcome
Longitudinal studies Experimental studies
Dementia/
Alzheimer
disease
Cognitive
impairment
or decline
Dementia/
Alzheimer
disease
Cognitive
impairment
or decline
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
Decreased risk for certain outcomes only 1 87
Other
Total no. of studies 7 7 3
Physical activities or exercise in late life
Increased risk
Increased risk in subgroup analysis
Increased risk for certain outcomes only
No association 6 78, 96, 97,
116, 117, 122
4 92, 118–120
Decreased risk 5 76, 77, 101,
102, 104
9 87, 104,
108–111,
113–115
Decreased risk in subgroup analysis 4 95, 103,
105, 121
1 112
Decreased risk for certain outcomes only 1 107
Other (details) 1 106
Total no. of studies 16 15
High no. of leisure activities in late life
Increased risk
Increased risk in subgroup analysis
Increased risk for certain outcomes only
No association
Decreased risk 1 77 4 94, 111, 123, 124
Other
Total no. of studies 1 4
Hormone replacement therapy
Use of unspecified hormone replacement
therapy or estrogen with or
without progestin in
postmenopausal women
Increased risk
Increased risk in subgroup analysis
Increased risk for certain outcomes only
No association 4 157–160
Decreased risk 1 154 1 155
Decreased risk in subgroup analysis
Decreased risk for some outcomes only 1 156 1 4
Other
Total no. of studies 1 6 1
Use of estrogen in postmenopausal women
Increased risk 1 4
Increased risk in subgroup analysis
Increased risk for certain outcomes only
No association 3 161, 163, 167
13* 162, 164, 166
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TABLE 2. Continued
Factor and association
Study design and outcome
Longitudinal studies Experimental studies
Dementia/
Alzheimer
disease
Cognitive
impairment
or decline
Dementia/
Alzheimer
disease
Cognitive
impairment
or decline
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
Decreased risk 3 146–148 1 150
Decreased risk in subgroup analysis 1 151
Decreased risk for some outcomes only 2 149, 152
Other (trends for increased risk in
long-term users for certain
outcomes only)
1 153
Total no. of studies 3 5 1 6
Use of estrogen and progestin in
postmenopausal women
Increased risk 1 150 1 4
Increased risk in subgroup analysis
Increased risk for certain outcomes only 1 153
Inconsistent results (detrimental effect
for certain cognitive domains,
beneficial effects on others)
1 165
No association
Decreased risk
Decreased risk in subgroup analysis
Decreased risk for some outcomes only 1 152
Other
Total no. of studies 3 1 1
Nonsteroidal antiinflammatory drugs
Use of all types of NSAIDsy or unspecified
NSAIDs
Increased risk
Increased risk in subgroup analysis
Increased risk for certain outcomes only
No association 1 181
Decreased risk
Decreased risk in subgroup analysis 1 189
Decreased risk for some outcomes only
Other (decreased risk but did not
remain in sensitivity analysis)
1 104
Total no. of studies 2 1
Use of aspirin
Increased risk
Increased risk in subgroup analysis 1 188
Increased risk for certain outcomes only
No association 3 179, 182, 187 2 184, 185 1 191
Decreased risk 1 178
Decreased risk in subgroup analysis
Decreased risk for some outcomes only 1 180
Decreased risk in sensitivity analysis 1 186
Other
Total no. of studies 6 3 1
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TABLE 2. Continued
Factor and association
Study design and outcome
Longitudinal studies Experimental studies
Dementia/
Alzheimer
disease
Cognitive
impairment
or decline
Dementia/
Alzheimer
disease
Cognitive
impairment
or decline
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
Use of nonaspirin NSAIDs
Increased risk
Increased risk in subgroup analysis
Increased risk for certain outcomes only
Increased risk in sensitivity analysis 1 190
No association 2 182, 188 3 180, 183, 184
Decreased risk 3 178, 186, 187
Decreased risk in subgroup analysis 1 179
Decreased risk for some outcomes only
Other
Total no. of studies 6 3
Ginkgo biloba
Ginkgo biloba supplementation
Increased risk
Increased risk in subgroup analysis
Increased risk for certain outcomes only
No association 1 199 2 201, 202
Decreased risk
Decreased risk in subgroup analysis
Decreased risk for some outcomes only 1 200
Other
Total no. of studies 1 3
Blood pressure
High blood pressure in midlife
Increased risk 4 236–239 1 240
Increased risk in subgroup analysis
Increased risk for certain outcomes only 1 122 2 242, 244
Increased risk for certain exposures only 3 241, 243, 245
No association 1 246
Decreased risk
Decreased risk in subgroup analysis
Decreased risk for certain outcomes only
Other
Total no. of studies 5 7
High blood pressure in late life
Increased risk 1 211 4 82, 213, 216, 219
Increased risk in subgroup analysis 1 209 2 214, 218
Increased risk for certain outcomes only 3 107, 210, 212
Increased risk for certain exposure
measures (i.e., SBPy or DBPy)
only
3 215, 217, 220
No association 5 104, 230–233 2 234, 235
Decreased risk 2 221, 223 1 224
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TABLE 2. Continued
Factor and association
Study design and outcome
Longitudinal studies Experimental studies
Dementia/
Alzheimer
disease
Cognitive
impairment
or decline
Dementia/
Alzheimer
disease
Cognitive
impairment
or decline
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
Decreased risk in subgroup analysis 1 222
Other
U-shaped relation between late-life
blood pressure and dementia/
cognitive decline
1 228 3 225–227
High SBP and low DBP associated
with an increased risk
1 229
Low DBP associated with an
increased risk
Total no. of studies 15 15
Use of antihypertensive medication
Increased risk
Increased risk in subgroup analysis
Increased risk for certain outcomes only
No association 3 104, 221, 250 1 253 3 253–255
Decreased risk 3 228, 247, 248 2 251, 252
Decreased risk in subgroup analysis
Decreased risk for certain outcomes only 1 249
Other
Total no. of studies 7 3 3
Diabetes
Diabetes in midlife
Increased risk 2 122, 285
Increased risk in subgroup analysis
Increased risk for certain outcomes only
No association 1 277
Decreased risk
Decreased risk in subgroup analysis
Decreased risk for certain outcomes only
Other
Total no. of studies 3
Diabetes in late life
Increased risk 6 231, 263, 280,
281, 283, 284
4 267, 269,
271, 273
Increased risk in subgroup analysis 2 276, 279
Increased risk for certain outcomes only 10 215, 242,
263–266, 268,
270, 274, 275
No association 6 107, 267, 270,
282, 286, 287
2 218, 272
Decreased risk
Decreased risk in subgroup analysis
Decreased risk for certain outcomes only
Other
Total no. of studies 14 16
Treatment of diabetes
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health perspective, it is important to assess in more depth the
associations among groups of nutrients or particular dietary
habits that may have an impact on cognition.
Social contacts, leisure activities, and physical
exercise
Meta-analyses or reviews. Three reviews have assessed
the effects of social and mental lifestyle factors and/or phys-
ical exercise on dementia and cognitive decline (73–75).
The first (73) concluded that an active and socially inte-
grated lifestyle in the elderly might protect against demen-
tia, although it was suggested that the effects of social,
mental, and physical lifestyle components may act through
common pathways. The other two reviews (74, 75) noted
some benefits of physical activity on cognition in the el-
derly, mainly based on longitudinal studies, but found little
evidence to suggest a link with dementia/Alzheimer disease,
because of a lack of randomized controlled trials in this area.
Prospective longitudinal studies. Social contacts and so-
cial engagement. Fourteen studies have found an inverse
relation between the level of late-life social contacts or
engagement and the risk of dementia/Alzheimer disease
(76–82) or cognitive decline (83–89). Midlife social en-
gagement was assessed by one of these studies (82) but
was not found to be related to dementia risk.
Two studies (90, 91) found only certain measures of so-
cial engagement to be associated with better cognitive func-
tion, and four studies found no association between
participation in social activities (92, 93) or social network
or support measures (91, 94) and cognition.
Cognitive activities in late life. Twelve studies have dem-
onstrated a relation between increased participation in cog-
nitive activities in late life and a decreased risk of dementia
(76–78, 95), Alzheimer disease (95–98), vascular dementia
(95), or cognitive decline or impairment (87, 92, 93, 97, 99,
100). No studies were identified that failed to find an asso-
ciation between cognitive activities and outcomes, although
the positive effects in one of the above-mentioned studies
(87) were seen only in some specific cognitive domains.
Physical exercise. An increased frequency or intensity of
physical exercise or activities in late life was associated with
a decreased risk of dementia/Alzheimer disease (76, 77, 95,
101–107) or cognitive decline/impairment in 19 studies (87,
104, 108–115). However, nine studies found no association
with dementia/Alzheimer disease (78, 96, 97, 116, 117) or
cognitive decline/impairment (92, 118–120). Two studies ex-
amined the effects of midlife physical exercise on the risk of
dementia in late life and found conflicting results (121, 122).
Leisure activity. Five studies found that high levels of
leisure activities decreased the risk of dementia (77) or cog-
nitive function (94, 111, 123) or decline (124), and one
study (117) found the individual activities of traveling,
odd jobs, knitting, and gardening to be associated with a re-
duced risk of dementia. Contrastingly, two studies (99, 125)
did not find any of the individual everyday activities as-
sessed (including social, experimental, and developmental
activities) to be associated with cognition, although overall
domain scores remained associated with the development of
cognitive impairment in one study (99). Other studies (77,
93–95) have also assessed the effects of individual activities,
in addition to activity domains, but there are no consistent
results. Furthermore, two studies noted that the beneficial
effects of cognitive, social, and physical activities on de-
mentia (76) or cognitive decline (87) were greatest when
older persons had high levels of participation in activities
TABLE 2. Continued
Factor and association
Study design and outcome
Longitudinal studies Experimental studies
Dementia/
Alzheimer
disease
Cognitive
impairment
or decline
Dementia/
Alzheimer
disease
Cognitive
impairment
or decline
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
No. of
studies
Reference
no(s).
Increased risk 2 282, 283
Increased risk in subgroup analysis 1 264
Increased risk for certain outcomes only
No association
Decreased risk
Decreased risk in subgroup analysis
Decreased risk for certain outcomes only
Other (increased for regimen or insulin
treatment, similar risk for oral
hypoglycemic drugs) 1 269
Total no. of studies 2 2
* Estrogen with or without progestin according to hysterectomy status.
y NSAID, nonsteroidal antiinflammatory drug; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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in two or more domains. Again, some results were confined
to only some of the cognitive domains tested (87, 123).
Experimental studies (table 4). Cognitive training. There
has been much research into the effects of cognitive training
on cognition but often with major methodological limita-
tions, such as a lack of randomization or blinding (126,
127), small sample sizes (128), or short follow-up (129,
130).
Three recent methodologically sound randomized con-
trolled trials (131–133) have considered the effects of cog-
nitive training on cognitive function in the elderly; two were
relatively small scale with short follow-up periods (131,
133). In the Advanced Cognitive Training for Independent
and Vital Elderly (ACTIVE) Study (132), 2,832 participants
received a 6-week intervention (focused on memory, reason-
ing, and speed of processing) and were followed up for 5
years. All trials found cognitive training to have some ben-
eficial effects on cognition, especially in the cognitive do-
mains directly related to the intervention, and these effects
were found to last up to 5 years in this study, which also
found some effects on everyday functioning (132).
Physical exercise. Few trials have assessed the efficacy of
standardized physical exercise on cognitive outcomes (134).
Oken et al. (135) assessed the effects of a 6-month yoga in-
tervention on cognition and quality of life in healthy seniors.
Despite improving physical and quality-of-life measures, this
intervention did not affect cognitive outcomes. Kramer et al.
(136) compared two exercise interventions (aerobic vs. anaer-
obic) in the elderly and found after 6 months a substantial
improvement in a specific domain (executive control tasks) in
participants in the aerobic group, although other cognitive
domains remained equivalent between groups.
Limitations. Exposure definition and measurement vary
greatly among studies (73): Some used quantitative meas-
ures of numbers of social contacts or activities (77, 94, 111,
117), while others attempted to gauge their frequency or
intensity (78, 95, 97) or satisfaction with social interactions
(80). Several studies simultaneously assessed the effects of
different types of leisure activities on dementia or cognitive
decline, often grouping them into categories of ‘‘social,’’
‘‘physical,’’ or ‘‘intellectual’’ activities (77, 78, 87, 92, 93,
95, 99). However, some activities may be associated with all
three domains (e.g., traveling, going to the theater/concerts,
engaging in family/charity work), making it difficult to dis-
tinguish the effects of each domain. One study (76) rated the
mental, social, and physical components of each activity and
then compiled domain scores, meaning that one activity
could contribute to more than one domain. These research-
ers found that all three component scores were related to
dementia risk and that the most beneficial effect was present
for subjects with high scores in several components. Thus, it
is hard to distinguish the effects of different exposures.
Consequently, it may be hard to develop interventions con-
cerning leisure activities on the basis of the longitudinal
evidence gained so far. No randomized controlled trials have
tested the effects of social engagement interventions on
cognition and, although there have been various studies of
cognitive training interventions, many were not methodo-
logically sound randomized controlled trials. The random-
ized controlled trials described above all found some
positive effects on cognition, but it is not clear if the im-
provements are beneficial in real-life situations, or if they
affect dementia incidence.
For physical exercise, it is important to distinguish be-
tween aerobic and anaerobic exercise. The trial by Kramer
et al. (136) found aerobic, but not anaerobic, exercise to
improve executive function. Consistently, the yoga interven-
tion, considered as anaerobic exercise, had no effect on
cognition (135). In both studies, the duration of intervention
and follow-up may have been too short to demonstrate any
effect. Participants in the yoga study were healthy seniors,
but exercise may be more beneficial in less healthy subjects.
The participants in both trials were highly motivated to
volunteer for an exercise intervention and probably differed
from those who did not take part.
The frequency of exercise interventions may be impor-
tant. The yoga intervention was carried out only once
a week, but it may have had greater effects on cognitive
function if it was carried out more often (135). It is not clear
which specific aspects of cognitive function may be most
affected by physical activity (137).
The window of exposure is important, even if the two
longitudinal studies that assessed the effect of physical ex-
ercise in midlife report contradictory results (121, 122). The
methodology was relatively similar, but the opposing results
could be explained by differential adjustment for potential
confounders or by the type of activity concerned. In one
study (121), only leisure activities were assessed, while in
the other, work-related physical activity was also considered
(122). The ‘‘well-being’’ effect provided by leisure activi-
ties, suggested by certain authors as a mechanism explain-
ing the beneficial effect of physical exercise on cognition,
could explain the different results.
There remain several uncertainties in the domain of phys-
ical exercise, including how long exercise effects last after
cessation of training or how much exercise is needed to
reinstate previously observed benefits (137).
In conclusion, the results of longitudinal studies, many of
which came from well-established, population-based cohort
studies focused on aging, are largely concordant and suggest
an inverse relation between the level of social contacts or
engagement or of social, cognitive, or physical activities and
the risk of dementia or cognitive decline. Although there is
limited evidence from experimental studies, a mentally,
physically, and socially active lifestyle is to be recommen-
ded in late life, because even if the cognitive benefits have
not yet been entirely elucidated, at the very least, this life-
style should bring about improved quality of life and overall
health.
Hormone replacement therapy
Meta-analyses or reviews. Various reviews and meta-
analyses have assessed the effects of hormone replacement
therapy on dementia and cognition (138–145), although
most were conducted before the latest published random-
ized controlled trials. Meta-analyses differ in the type and
characteristics of included studies. Two meta-analyses
found inconsistent results (139, 141) while others reported
decreased risks, but most showed statistical heterogeneity
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(138, 141, 144) and were based on studies of poor quality
(138, 139, 141, 144). It was noted that results of longitudinal
studies often suggested a protective effect of hormone re-
placement therapy (138, 144), while earlier randomized
controlled trials were inconclusive. The most recent meta-
analysis (140), conducted according to Cochrane guidelines,
analyzed 16 randomized controlled trials including the re-
cent WHIMS trial. It showed ‘‘with good evidence’’ no
improvement in cognition and a potential deleterious effect
of some hormone replacement therapy regimens.
Prospective longitudinal studies. Seven studies have sug-
gested that current or previous estrogen use alone may be
associated with a decreased risk of dementia (146–148) or
cognitive decline (149, 150), although in some cases effects
were limited to only some specific cognitive domains or to
subjects with the APOE*E4 genotype (149, 151, 152). In
two of them, an increased duration of estrogen was associ-
ated with decreased risk of dementia (147, 148). One study
(153) found a trend for cognitive decline in long-term users
of estrogen alone.
Past or present use of estrogen plus progestin or unspec-
ified ‘‘hormone replacement therapy’’ was associated with
a decreased risk of dementia (154) or cognitive decline
(155) in four studies, although the relation was sometimes
confined to certain cognitive domains (152, 156). Four stud-
ies found no clear relation between hormone replacement
therapy and cognitive decline (157–160), while two (150,
153) found an increased risk of cognitive decline in long-
term users.
Experimental studies (table 5). Eight randomized con-
trolled trials (4, 5, 144, 161–166) studied the effects of
hormone replacement therapy on dementia or cognitive de-
cline in postmenopausal women. Participants were aged 65
or more years in all except two studies (163, 164). WHIMS
(4, 5) was by far the largest study with 6,500 women treated
with estrogen alone (WHI-ERT), estrogen plus progestin
(WHI-PERT), or placebo for more than 5 years. The Wom-
en’s Health Initiative Study of Cognitive Aging (WHISCA)
(165), an ancillary study of WHIMS, assessed cognitive
decline in the WHI-PERTarm. The other trials involved less
than 500 subjects, with shorter follow-up (from 3 months to
3 years). The type of menopause (natural or surgical) was
usually not stated. This can affect the type of hormone re-
placement therapy and the characteristics of the women,
who may differ in terms of age, and therefore prognosis
for cognitive decline. The type of hormone replacement
therapy (estrogen alone (4, 161, 163, 167), estrogen with
or without progestin according to hysterectomy (162, 164,
166), or estrogen plus progestin (5, 165)), route of admin-
istration (mainly oral), and dose used (e.g., between 0.01
and 2 mg of estrogen daily) were variable.
Six randomized controlled trials found no association be-
tween cognition and estrogen replacement therapy with or
without progestin according to hysterectomy status (161–
164, 166, 167).
The three studies based on the same trial found no pro-
tective effect of hormone replacement therapy: Estrogen
plus progestin was associated with an increased risk of prob-
able dementia (5) and decline in some cognitive functions
(165), and estrogen alone (4) was associated with an in-
creased risk of the combined mild cognitive impairment-
dementia endpoint.
Limitations. There has been much discussion of the con-
flicting results of longitudinal and experimental evidence
(138, 139, 168–171). Exposure definition and measurement
varied greatly between longitudinal studies with lack of pre-
cision (ever/never use or past/current/never use) and assess-
ment at one or two time points only.
Longitudinal studies cannot control for the type and dose
of hormone replacement therapy, so regimen variations could
explain the discrepancies observed. For example, the type of
estrogen (conjugated equine estrogen) used in WHIMS may
have more deleterious cognitive effects than estradiol, which
is usually assessed in longitudinal studies (168).
In summary, estrogen alone or hormone replacement
therapy cannot be recommended for cognitive improve-
ment in older postmenopausal women without cognitive
impairment, because the risks (notably cardiovascular dis-
ease and stroke) outweigh the potential cognitive benefits
(172).
Aspirin and other NSAIDs
Meta-analyses or reviews. Three meta-analyses of ob-
servational studies (cohort and nonprospective) were iden-
tified (173–175). Two assessed NSAIDs and aspirin (173,
174), and one assessed nonaspirin NSAIDs (175). The
outcomes were Alzheimer disease alone (175), dementia/
Alzheimer disease (174), and Alzheimer disease and any
cognitive impairment (173). Some had more stringent in-
clusion criteria (175) than others (174). Only one (175)
assessed the quality of the studies included, and two showed
statistical heterogeneity (173, 174).
Etminan et al. (174) concluded that only nonaspirin
NSAIDs, especially with long-term use, could decrease the
risk of Alzheimer disease. These results should be taken with
caution because of potential confounding (176) and hetero-
geneity. de Craen et al. (173) assessed 25 studies (21 of which
studied Alzheimer disease, 10 prospectively) and reported
conflicting results according to study design. Beneficial ef-
fects were attributed to bias. Szekely et al. (175) assessed 11
studies (including four prospective studies) and concluded
that nonaspirin NSAIDs may prevent or delay the onset of
Alzheimer disease, especially with long-term use.
A review of observational studies (177) concluded that
long-term use of NSAIDs could significantly reduce the risk
of dementia.
Prospective longitudinal studies. The use of NSAIDs
(104, 178, 179) or aspirin (178, 180) was associated with
a decreased risk of dementia or cognitive decline in four
studies, although associations were restricted to some do-
mains and age groups (180) or those with an APOE*E4
allele (179) and, in one case, the relation did not persist after
sensitivity analyses (104).
However, six studies found no clear association between
NSAIDs (181–184) or aspirin (182, 184–187) and dementia
or cognitive decline, and one (188) found the use of aspirin
to increase the risk of dementia in APOE*E4-negative in-
dividuals. Four studies found increased duration of NSAID
use (178, 186, 187, 189) to be associated with a lower risk of
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dementia or cognitive decline, although in one, the associ-
ation was restricted to APOE*E4-positive individuals (189).
Contrastingly, one study (179) found no relation with dura-
tion of use.
Certain studies using the ‘‘lag time’’ method (i.e., ex-
cluded exposure data from 1–2 years before diagnosis)
found a beneficial effect in people exposed before this
2-year period (178, 186, 187), but others did not (179).
Experimental studies (table 6). Two randomized con-
trolled trials tested the effects of NSAIDs (190) or aspirin
(191) on dementia or cognitive decline. In the Alzheimer
Disease Antiinflammatory Prevention Trial (ADAPT) Study
(190), specifically designed as a dementia primary preven-
tion trial but prematurely terminated because of safety con-
cerns, celecoxib and naproxen showed trends for increased
risks of Alzheimer disease compared with placebo. The
WHS cognitive cohort (191) involved 6,377 women aged
over 65 years who were treated with low-dose aspirin or
placebo for 9.6 years on average. Active treatment had no
effect on cognitive performance or decline at either cogni-
tive assessment.
Limitations. The findings of positive observational stud-
ies could result from bias (e.g., recall, prescription (192), or
publication (173) bias). However, some longitudinal studies
still found a protective effect after making particular at-
tempts to reduce bias (e.g., exposure determined from ex-
tensive national pharmacy databases (187)).
Only two randomized controlled trials have assessed the
effects of NSAIDs on cognition. The Alzheimer Disease
Antiinflammatory Prevention Trial Study (190) found an
increased risk of dementia among subjects receiving
NSAIDs, but few dementia events were observed in the
shortened follow-up period, making it difficult to draw con-
clusions. Participants may not have benefited from NSAID
treatment because of their relatively high age (70 years).
The WHS found no effect of aspirin on cognitive decline,
despite a relatively long follow-up period. It assessed cog-
nitive decline rather than Alzheimer disease incidence, but
most longitudinal studies on aspirin found little evidence for
a beneficial effect on cognitive decline (180, 184, 185, 189).
Although it was not specifically designed to assess cognitive
outcomes, this trial had sufficient power to detect a signifi-
cant effect on cognitive decline.
The aspirin dose used in the WHS may not have been
strong enough to provide an antiinflammatory effect on cog-
nition, although one longitudinal study (180) found low-
dose aspirin to protect against memory decline.
The type of NSAID is important. Although it is difficult to
determine which specific NSAIDs are associated with the
cognitive benefits seen in some longitudinal studies, they are
probably not those used in the randomized controlled trials.
Furthermore, the randomized controlled trial treatments are
not those thought to have the greatest effects on the
42-amino-acid form of amyloid beta protein (193–195).
Longitudinal evidence has suggested that longer-term use
of NSAIDs, beginning in midlife, may be more beneficial
(187). This could explain the absence of protective effects in
the randomized controlled trials. Furthermore, two studies
(175, 189) suggest that NSAID use in the 2 years preceding
dementia onset offers no protection. T
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In conclusion, the risk-benefit ratio of NSAIDs is not
clear, and safety concerns have been raised with some treat-
ments. Further clinical trials are needed to establish the
cognitive effects, but the treatment used must be safe.
Ginkgo biloba supplementation
Meta-analyses or reviews. Two reviews have assessed
Ginkgo biloba for secondary prevention (196, 197) and
noted that, although some trials found protective effects,
overall results were inconsistent.
Prospective longitudinal studies. Although other types of
epidemiologic studies have provided evidence for a protec-
tive effect of Ginkgo biloba on cognition (198), one pro-
spective longitudinal study reported no association between
ginkgo use and dementia risk (199).
Experimental studies (table 7). One short-term random-
ized controlled trial (200) involving middle-aged subjects
found a Ginkgo biloba-Panax ginseng combination to have
positive effects on some measures of cognition, but another
(201) found no effect of Ginkgo biloba with other supple-
ments on cognition. A 3.5-year trial of Ginkgo biloba in 118
elderly persons aged 85 or more years found no significant
effect on cognitive decline overall but did find a protective
effect in compliant patients (202).
Limitations. Only one longitudinal study and three ran-
domized controlled trials were identified. Evidence con-
cerning the effects of Ginkgo biloba on the prevention of
dementia or cognitive decline is therefore limited. In light of
the apparent safety of this intervention, further research is
merited. The results of two large ongoing prevention trials
(203, 204) will provide important data.
Hypertension
Meta-analyses or reviews. A comprehensive review
(205) concluded that available longitudinal evidence sug-
gests that high blood pressure in midlife is a risk factor
for cognitive impairment and dementia/Alzheimer disease
in late life, but that results are inconsistent for the effects of
late-life blood pressure.
A Cochrane meta-analysis (206) assessed the effects of
three blood pressure-lowering interventions of at least 6
months’ duration on cognition in individuals without prior
cerebrovascular disease. No significant effect on cognitive
function or the incidence of dementia was detected, but
there was heterogeneity between trials. Two other meta-
analyses (207, 208) with much less stringent inclusion/ex-
clusion criteria noted modest or borderline protective effects
of antihypertensive treatment on dementia or certain cogni-
tive domains.
Prospective longitudinal studies. Late-life blood pres-
sure. Fourteen studies found increased late-life blood pres-
sure to be associated with increased dementia (107, 209–
212), mild cognitive impairment (213), or cognitive impair-
ment/decline (83, 214–220), although in some cases the
association was restricted to a certain age group (209), either
systolic (209, 215, 220) or diastolic (217) blood pressure
only, medicated hypertension (218), or vascular dementia
but not Alzheimer disease (107, 210, 212).
Four studies, however, suggested that higher late-life
blood pressure is associated with a decreased risk of demen-
tia (221–223) or impaired cognitive function (224), and
other studies have found U-shaped (225–227) or other
(228, 229) relations.
Seven studies found no association between late-life
blood pressure and dementia (104, 230–233) or cognition
(234, 235).
Midlife blood pressure. Eleven studies found midlife
hypertension to be associated with an increased risk of
dementia (122, 236–239) or cognitive decline (240–245)
during late life, although the relation was sometimes re-
stricted to a certain type of dementia (vascular dementia not
Alzheimer disease) (122), either systolic or diastolic blood
pressure (241, 243–245), untreated hypertension (237),
or older participants (242). One study (246) found no as-
sociation between midlife blood pressure and late-life
cognition.
Antihypertensive treatment. Three studies found use or
increased duration of use of antihypertensive treatment to
be associated with a decreased dementia/Alzheimer disease
risk (228, 247, 248). One study found that antihypertensive
treatment was associated with a decreased risk of vascular
dementia but not Alzheimer disease (249), while three
found no association with dementia (104, 221, 250).
Experimental studies (table 8). Five large-scale (2,500
subjects) randomized controlled trials (251–255) examined
the effects of antihypertensive treatment on dementia or
cognitive decline in elderly subjects for at least 3 years,
although not as a primary outcome. Two studies (251,
252) found that treatment reduced the risk of dementia al-
though, in one case (251), it was associated with only re-
duced risks of recurrent stroke-associated dementia and
cognitive decline. The other three studies found no effect
on dementia or cognition.
Limitations. Consistent longitudinal evidence points to
raised midlife blood pressure as a risk factor for dementia/
Alzheimer disease or cognitive decline, but experimental
studies of antihypertensive treatment were carried out in late
life, perhaps missing the ideal window of exposure. Longi-
tudinal studies present an unclear picture of the effects of
late-life blood pressure. Furthermore, follow-up in the ran-
domized controlled trials may have been too short to dem-
onstrate an effect.
Of five randomized controlled trials, two (251, 252) were
positive, but in the Perindopril Protection against Recurrent
Stroke Study (PROGRESS), treatment was linked to a lower
risk of only recurrent stroke-related dementia, and in the
Systolic Hypertension in Europe (Syst-Eur) trial, the rela-
tion was borderline significant (256). Other randomized
controlled trials failed to demonstrate any protective effects.
In the Study on Cognition and Prognosis in the Elderly
(SCOPE) trial, because of ethical reasons, experimental
treatment was compared with usual treatment rather than
placebo as originally planned, which probably reduced the
detectable between-group effects.
Different types of antihypertensive treatments may have
different effects on dementia or cognition. Specifically, cal-
cium channel blockers and angiotensin-converting enzyme
inhibitors may have the greatest effects, which may be
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brought about through mechanisms other than blood pres-
sure lowering (257, 258).
There is relatively strong evidence that hypertension in
midlife is a risk factor for dementia or cognitive decline, but
associations with late-life blood pressure remain unclear.
There is little evidence to suggest that antihypertensive
treatment in late life reduces risks of dementia or cognitive
decline. Initiation of antihypertensive treatment in midlife
needs to be assessed in future randomized controlled trials.
Diabetes
Meta-analyses or reviews. Two reviews (259, 260) stud-
ied the relation between diabetes and cognitive decline and
concluded that, compared with people without diabetes,
people with diabetes have a 1.5-fold greater risk of cognitive
decline.
A review of 14 longitudinal based studies (261) compared
the incident risk of dementia (Alzheimer disease, vascular
dementia, and mixed dementia) in diabetic and nondiabetic
subjects. They concluded that there is convincing evidence
that shows an increased risk of dementia in people with
diabetes, but there are few details on the modulating and
mediating effects of glycemic control, other vascular risk
factors, and microvascular complications.
In addition, a Cochrane review (262) of the effect of type
2 diabetes treatment on cognitive decline was unable to
carry out a meta-analysis of randomized controlled trials
because of a lack of studies of suitable quality.
Prospective longitudinal studies. Sixteen studies (215,
218, 242, 263–275) have explored the link between diabetes
and cognitive decline. All but two (218, 272) found that
diabetic adults have more cognitive decline compared with
nondiabetic adults; psychomotor efficiency, executive func-
tion, and learning and memory skills are often the most
affected domains.
Seventeen studies (107, 122, 231, 263, 270, 276–286)
have examined the association between diabetes and
Alzheimer disease incidence. The risk of Alzheimer disease
tended to be largest in the three (122, 277, 285) studies that
measured the risk factor in midlife and had a long follow-up
period. However, one study (277) found no association be-
tween diabetes in midlife and risk of Alzheimer disease, and
six studies (107, 270, 278, 282, 286, 287) found no associ-
ation between diabetes in late life and risk of Alzheimer
disease. Diabetes treatment might also be a relevant factor.
Two studies indicate that the risk of dementia is higher in
diabetic subjects treated with insulin (282, 283).
Experimental studies. Five randomized controlled trials
(288–292) evaluating the effect of diabetes treatment on
cognitive function over short durations (<1 year) or with
questionable methodology (lack of double blinding) have
reported contradictory results.
There are currently no intervention trials of high method-
ological quality assessing cognitive decline. The Action to
Control Cardiovascular Risk in Diabetes Memory in Diabetes
(ACCORD-MIND) Study (293) was testing the effects of
long-term glycemic control on cognitive decline and struc-
tural brain changes in patients with type 2 diabetes, but treat-
ment has been stopped because of safety concerns (294).
Limitations. There is consistent longitudinal evidence to
suggest that diabetes is associated with dementia and cog-
nitive decline, although nine studies were negative. In one of
these studies, subjects were 85 or more years (272). There
may be a ‘‘survivor effect,’’ where individuals who reach old
age, despite having multiple vascular risk factors, are survi-
vors and might be less susceptible to the adverse effects of
these risk factors.
Of the six studies finding no effect of diabetes on
Alzheimer disease, five distinguished between vascular
dementia and Alzheimer disease. The boundary between
vascular dementia and Alzheimer disease remains contro-
versial, so the possibility of misdiagnosis must be consid-
ered and might explain some of the negative results.
An increased risk of Alzheimer disease was seen in di-
abetic subjects treated by insulin (282, 283); whether these
results show the severity of diabetes or an effect of insulin
treatment itself is unknown.
In conclusion, diabetes is a risk factor for cognitive de-
cline and dementia, but at this time, there are no high quality
intervention studies examining the effect of metabolic con-
trol on cognition.
COMMON METHODOLOGICAL ISSUES
Some common methodological limits could apply to var-
ious domains. The measurement of some exposures can
suffer from a lack of precision: Self- or proxy-report rather
than objective measures can lead to misclassification. In two
studies (218, 277), diabetes was assessed only through de-
clarative data, which may have led to an underestimation of
the effect.
In longitudinal studies, exposure is often measured at one
time point, and exposure variations over time are not con-
sidered. For example, few studies assessed changes in social
interactions or activity participation over time, which may
be especially important around the time of retirement.
The window of exposure might also be important, as
some interventions may have differential effects according
to the time of exposure. It has been suggested that hormone
replacement therapy needs to be started around the imme-
diate postmenopausal period for a beneficial effect (143,
168, 170, 295–297) but that randomized controlled trial
participants were perhaps too old. Subjects included in nu-
tritional randomized controlled trials were generally aged
over 60 years, but nutrients may affect the neurodegenera-
tive process at an early stage (7). One successful nutritional
trial (63) was conducted in a slightly younger population,
aged 50–70 years.
Observational studies often fail to take into account all
potential confounding factors, such as depression or baseline
cognitive performance. From this review, we can see the
importance of adjusting for the presence of APOE*E4, but
many studies did not consider this factor. We suggest that
a minimum set of confounders including age, education,
and baseline cognitive performance should be considered,
but some studies did not adjust for all of the these factors
simultaneously. Furthermore, recorded exposure variables
could be a marker of unrecorded characteristics. For example,
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a healthy diet or use of vitamin supplements could reflect
overall healthier behavior, leading to ‘‘healthy user’’ bias
(298). In addition, postmenopausal treated women may have
fewer hormone replacement therapy contraindications (hy-
pertension, diabetes, history of stroke). Controlling for such
confounders diminished the effect of hormone replacement
therapy on cognition (138, 153, 159). Social engagement or
activity participation could also be an indicator of previous
life experiences (299), such as education or socioeconomic
status, but generally only education was controlled for (73).
Protopathic bias is important. A low level of exposure
(e.g., social engagement or activity participation) may be
indicative of a neurodegenerative process that is not yet
clinically apparent. However, in several domains, all ob-
served associations remained after controlling for baseline
cognitive function or after sensitivity analysis, excluding
persons who developed dementia or cognitive decline soon
after exposure measurement.
Outcome definition is variable. Some studies evaluated
dementia incidence (assessed using standard international
criteria with or without independent validation committees).
Other studies considered different aspects of cognition by
using a variety of cognitive tests and definitions of impair-
ment or decline. Thus, the comparison of studies is difficult,
and some authors questionably assume that cognitive de-
cline is a validated surrogate marker of dementia. Further-
more, the clinical relevance of cognitive decline is rarely
mentioned (300). Furthermore, some hypertension studies
assessed all-cause dementia, including vascular forms, and
therefore were more likely to be related to hypertension or
an antihypertensive drug, while others specifically assessed
Alzheimer disease.
Insufficient statistical power is a frequent limitation. For
example, of the 10 nutritional randomized controlled trials,
only two were large scale (68, 69). Given that interventions
may have relatively modest effects, randomized controlled
trials need sufficient power to detect small changes on cog-
nitive outcome measures. Ancillary studies initially de-
signed for noncognitive outcomes could be underpowered
for cognitive outcome, since dementia/Alzheimer disease
incidence remains relatively low.
Attrition rates are rarely considered. In nutritional inter-
vention, the trial with the lowest attrition rate was the only
trial able to demonstrate significant benefits of supplemen-
tation (63). In the Systolic Hypertension in the Elderly
Program (SHEP) Study, which found no effect of antihyper-
tensive treatment on cognitive decline or dementia, sensi-
tivity analyses suggested that differential dropout may have
obscured potential treatment effects (301). Some other trials
of antihypertensives reported high rates of dropout (255) or
discontinuation of study medication (251), which could
have affected results.
Concerning statistical analysis, few studies used methods
that took into account variation of covariates with time,
which is important with many years of follow-up. Further-
more, it is difficult to compare longitudinal studies analyz-
ing only subjects followed for the entire study period (e.g.,
excluding deaths and dropouts) and studies considering un-
equal durations of follow-up (i.e., survival analysis) or miss-
ing value(s) (i.e., mixed models).
MULTIPLE EXPOSURE AND MULTIDOMAIN
INTERVENTIONS
Because of the multifactorial nature of Alzheimer dis-
ease, it would seem logical to initiate multidomain interven-
tions designed to examine not only the individual effects of
each intervention but also any potential synergistic effects.
Several intervention trials of this nature are currently un-
derway (302, 303).
Some specific challenges need to be underlined in design-
ing trials involving multidomain interventions. First, sur-
rounding the specific selection of subjects, we can
imagine that subjects who agree to modify multiple lifestyle
domains are likely to have a higher level of education and
better overall health, meaning that it may be difficult to
demonstrate an effect of the intervention. Observance in
multidomain trials is difficult to assess if the intervention
combines different lifestyle factors. If the intervention is
based on lifestyle recommendations, it will be difficult to
evaluate actual behavioral modifications precisely. In these
interventions, it is impossible to maintain double-blind con-
ditions and difficult to define an adequate control group,
especially for physical exercise interventions. It is also dif-
ficult to identify the independent effects of each factor, be-
cause they may act through common mechanisms (e.g., via
cardiovascular mechanisms), and there may be between-
group contamination.
CONCLUSION
In this review, many methodological explanations for di-
vergent observational and experimental results for dementia
prevention were identified.
The evidence for preventive strategies for neurodegener-
ative dementia remains inconsistent, especially because of
the lack of randomized controlled trials assessing dementia
incidence as a primary outcome. At present, it is not possi-
ble to determine any specific recommendations for pharma-
cologic strategies or lifestyle changes. Future epidemiologic
studies must attempt as much as possible to minimize bias
and confounding, in order to generate reliable hypotheses on
which to base randomized controlled trials.
If it existed, a preventive strategy based on the use of
a pharmacologic treatment would seem to be a relatively
simple method of preventing dementia/Alzheimer disease.
A good risk-benefit ratio would be imperative because of the
number of subjects who will be exposed to the intervention
without ever developing the disease. In the absence of such
a treatment, even if it is difficult to change lifestyle habits,
lifestyle factors (diet, social engagement, cognitive stimula-
tion, physical exercise) seem the most reasonable candidates
for prevention trials at the current time, in particular because
of their safety. As a result of the difficulties in conducting
a multidomain intervention, randomized controlled trials
may not represent the ‘‘gold standard’’ in this field, and
large public health interventions at the population level
could be required. However, such interventions would have
to be feasible, cost effective, and easily transferable in order
to have a real public health impact.
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Introduction
Elderly populations have traditionally been excluded from
medical trials. However, large scale prevention trials are now
being developed in geriatric research to improve understanding
of specific drug efficacy in the elderly or in age-related disease,
such as Alzheimer disease. These trials require long term
follow up in order to collect data about exposures and health
outcomes. High attrition rates may be expected in these long
term follow up studies involving elderly participants due to
high levels of morbidity and mortality in this population.
Furthermore, such participants may have lower autonomy than
younger subjects, and their participation in research studies
may be reliant on the availability of family members or
caregivers. Elderly subjects may also discontinue their
participation in a study if they move into nursing homes or
other assisted care facilities.    
Attrition, understood as a total loss to follow-up (LTFU) of
individuals from a trial once the respondent has actually
initiated participation, is a long-recognized problem (1, 2). It
may be brought about by several situations: (1) death (2) frailty,
illness, or worsened health, which may be related to disease
progression and depend on the subjects health status at
inclusion, (“healthy survivor effect”) (3) refusal (4) withdrawal
or discontinued participation and (5) “real” losses to follow up
(the subject cannot be traced by the investigator despite
attempts to make contact).  Withdrawal from a study may occur
for several multidimensional reasons, including unpleasant
adverse effects of the drug, unperceived benefit of the
intervention or real lack of efficacy, non compliance, time
consuming treatment protocols, and subjects not feeling
“involved” in the study. 
This paper aims to quantify attrition rates observed in
randomised trials involving healthy or chronically ill elderly
populations, to discuss the consequences of attrition on research
findings, and to provide solutions to manage and limit this
phenomenon. Here we use the terms attritors, dropouts, and
losses to follow-up interchangeably.  
How important is the attrition rate in studies/randomised
trials involving elderly subjects?  
Attrition rates may vary across different studies involving
elderly populations according to trial (type of treatment and its
effects, length of follow-up period, frequency and type of
contacts with study coordinators, specific attrition prevention
strategies) or participant (age, presence of medical conditions,
autonomy) characteristics. Tables 1 and 2 present the attrition
rates observed in some recent examples published in major
journals of randomised trials involving either healthy elderly
populations or elderly populations with chronic disease. It is
difficult to compare attrition rates across different studies for
various reasons. Firstly, there is no standard definition of
attrition, so each study may use different criteria to determine
the attrition rate at a given time, or give no definition of
attrition at all. For example, patients who discontinue treatment
before the end of a study may be classed as losses to follow-up
in some studies (and therefore included in the attrition rate),
while other studies may continue to measure outcomes in these
patients until the study end and not include them in the attrition
rate. Varying lengths of follow-up period or time of
measurement of the attrition rate also hinder the comparison of
attrition rates from different studies.  
In recent studies involving healthy elderly participants,
attrition rates varying from approximately 1% to 10% have
been observed after one year of follow-up (3-7). Specific
attrition prevention strategies, such as pre-study compliance
testing or active follow-up of subjects who do not attend study
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visits may help to minimise attrition in such populations.
Attrition rates are generally higher in studies of elderly subjects
with chronic illnesses. After one year’s follow-up, attrition
rates ranging from approximately 2% to 30% have been
observed in studies of elderly patients with various pathologies
(8-18). Particularly high attrition rates (approximately 10% to
56% at one year) have been observed in studies involving
elderly subjects with cognitive impairment, with a trend for
increasing attrition rates with increasing severity of cognitive
impairment (19-22).  Cognitively impaired subjects could be
considered particularly at risk for attrition, because in addition
to the usual factors associated with attrition, caregiver
characteristics, such as anxiety or depression related to the
burden of caring for the patient, may also affect trial
participation (23, 24).  
Effect of attrition on results 
Attrition is a major source of potential bias in clinical trials
(25), and may threaten internal and external validity. Little and
Rubin (26) suggested that attrition can arise via the following
mechanisms :
- Missing Completely at Random (MCAR): missingness is
independent of both observed and unobserved data, and dropout
and the outcome of interest are independent. For example, in a
trial where the outcome variable is body mass index (BMI), this
type of attrition could arise from a missed study visit because of
weather conditions or a transport strike. In this case, lost
subjects are not systematically different from the remaining
patients, and analyses conducted on non missing data do not
affect the validity of the study (27). However, this type of
attrition is uncommon.
- Missing at Random (MAR): missingness only depends on
the observed data before drop out, but not the missing
(unobserved) data. Using the example mentioned above,
subjects who had a high BMI during previous visits may avoid
the next visit, regardless of any weight loss or gain, because of
embarrassment. Lost subjects are different from the remaining
patients. 
- Missing not at Random (MNAR): missingness is
informative, depends on unobserved data and cannot be
deduced. In the same example, subjects having gained weight
in the days preceding a study visit may avoid the visit, even if
their weight was stable on previous appointments. 
Potential causes of attrition have been briefly discussed in
the previous sections. In reality, attrition rarely occurs at
random, and participants who drop out of trials tend to differ
systematically from those who stay in. Attrition may be related
to specific characteristics leading to a selective patient dropout,
and the remaining patients may be a biased sample (i.e. more
homogenous and unrepresentative) of the original population
from which they were taken. Thus, external validity may be
affected, and it may not be possible to generalise findings due
to a low accuracy in the process studied (28). Moreover,
attrition may also be associated with the dependent variable
itself, resulting in a differential attrition between groups (2)
which is not controlled by randomization and may jeopardized
internal validity (29). In a trial comparing a new treatment
versus placebo, treatment effectiveness may be overestimated if
subjects for whom the treatment is not beneficial are more
likely to drop out. The strength and the direction of the bias
produced depend on the underlying sense and the mechanism of
dropouts. 
Furthermore, attrition, whether it occurs completely at
random or not, provides a constant loss of statistical power, and
if the number of participants remaining in the end of a trial
decreases below the estimated sample size, the trial will be
unable to detect the effectiveness of the treatment. 
How can attrition be minimised?
Only a few studies have examined the factors associated
with attrition, using various methodologies in different
populations. Chatfield and al (30) have recently carried out a
review of attrition in the elderly. In general, factors associated
with attrition differ according to the study population, the
definition of attrition, and the moment chosen for comparison,
but two major factors are often identified: age and cognitive
impairment (30). Some attrition-related factors depend on the
participant, while others may depend on the study design: a
population based on unstable criteria (e.g. place of residence
rather than medical criteria), no attempt to re-contact
participants after dropout by study staff,  as well as factors
relating to the topic of the study, the time required for
participation, and attention given to the participant (31).
Knowledge of subject characteristics associated with certain
types of attrition, such as withdrawal or loss to follow-up,
allows specific strategies to be developed and targeted towards
subjects at higher risk of attrition from enrolment to the study
end. For example, characteristics associated with refusal are of
particular interest because it is likely to change. Such strategies
allow contact to be maintained with subjects at risk of attrition
in order to enhance participation until the last endpoint.
Different strategies have been suggested to minimise attrition,
depending on the population studied and the resources
available. Some examples include tracking, bonding, and
incentives. Whichever method is used, it must be planned
during the study design phase and comply with the ethical and
financial constraints of the study (32). Below, we present
various strategies for minimising attrition. Such strategies have
often been initially developed for use in longitudinal cohort
studies, but many are also applicable to long-term randomised
preventive intervention studies in geriatric research. Further
detail regarding these strategies can be found in reviews by
Hunt and Ribisl (33, 34).  
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During enrolment, it is important to create a project identity.
In order to maximise investment by participants, it is important
to provide complete and appropriate information about the
research, its principles, objectives and study schedule,
including the required number and duration of visits, and the
right to refuse participation in individual parts of the study (35).
An explanation of the reasons why a maintained participation
of all subjects is important is also crucial. Tracking rules, their
justification and the methods employed must be explained, to
avoid surprise or concern (36). Tracking is one of the methods
proposed to reduce attrition, and its use is essential. Various
tracking techniques can be performed, which may be more or
less complex, time consuming, or expensive. Such techniques
must be planned during study preparation, and should be
appropriate to the study’s length, resources, sample size and
socio-cultural context. A tracking protocol should be
established and should include rules and tracking limits. The
most widely-used tracking strategy is the collection of
extensive personal information at baseline in order to be able to
track hard-to-find participants, or determine their vital status. It
is useful to collect demographic information of participants
(name, date and place of birth, address, phone number, social
security number, driver’s license number), as well as those of
relatives, a secondary contact, and even health care providers
(34, 37).   
Once the participant is enrolled, frequent personal contact
has to be maintained. The frequency of follow up visits may
vary between 6 and 24 months but it is recommended to keep
the time between visits to a minimum (36). To reduce attrition,
appointment cards and reminder phone calls can be used to
remind participants of follow-up appointments. If a visit is
missed, additional mailings and telephone calls must be
systematically initiated. If full participation is not possible, a
short questionnaire or proxy interviews can be used to collect
information on primary outcomes and vital status. If subjects
are unable to attend study visits, telephone contact should be
maintained, and home visits should be made if possible, with
flexibility remaining the goal. At each study visit, participants
should be encouraged to make an appointment for their next
visit, and after each appointment, a thank you postcard could be
sent.
If a participant does not attend study visits, formal
registration and government records can be useful to help to
locate the participants (e.g. US postal Service, telephone
directories, medical records, national death index, death
certificates, obituaries, health registers, municipal records,
census lists, voter lists, driving licence records, social security
administration, or church records).
To avoid attrition, particular attention should be paid during
initial contacts with participants; personalised contact is
important, and stressful examinations should be minimised
(35). Reassurance is also recommended during certain
assessments, such as cognitive tests (23). Where possible,
contact should be continued with the same interviewer (36).
Staff members should ideally have personal skills that enhance
participation and compliance of participants, for example
commitment to the project, enthusiasm, competence, training,
confidentiality, tact, discretion, as well as being non judgmental
and open. Careful supervision of study staff by senior
investigators is also important.
During follow up, bonding is important to maintain
participant commitment and to help subjects feel actively
involved in the study. Personalisation of correspondence is
recommended, for example with a study logo. This enhances
the credibility of the study, facilitates the recognition of
correspondence and allows the participants to identify with the
study. Participants’ interest can be maintained through the
sending of newsletters or study updates (38) providing
feedback on the study, as well as birthday cards and change of
address cards. 
Some studies have found that financial incentives, small
mementos with study logo (pill organisers, magnets, clocks,
coffee mugs etc.), have contributed to increased retention rates
as they remind subjects of their participation throughout the
year. However, such actions could be considered unethical.  
How to manage with attrition?  
In the case of attrition, several methods adjust for non-
response, and complex models for missing data estimates are
available (26). The choice of method used to take missing
values into account depends on the observed attrition rate, the
pattern of missing data, the missingness mechanism (MAR,
MCAR, MNAR), and the methods used to analyse repeated
data (39). We focus here on the main statistical methods used to
manage with attrition, but the methods listed are not exhaustive. 
Initially, the main method available to analyse continuous
longitudinal data was MANOVA for repeated measurements. If
one measurement was missing for a subject, all other data from
that subject were excluded from the analysis. Consequently,
imputation methods for missing data have been developed to
overcome this problem (26). In the 1980s, new methods
appeared, such as Generalised Estimating Equations (GEE)
(40). In GEE, if a subject has at least one data item missing, the
remaining available data can be used in analyses, and so
estimation of the missing data is less crucial than in MANOVA
for repeated measurements.  
As the main risk of attrition is bias, its impact on findings
(effect and direction) must be properly estimated. The pattern,
degree and causes of attrition must be described. At the very
least, a careful reporting of various characteristics of attritors is
essential, and if possible, by cause of drop out (34). This
description must be as broad as possible, containing usual
demographic characteristics, but also social factors, the disease
studied, outcome and confounding factors (30). These
characteristics can be used to compare LTFU with patients who
stay in the study to identify non at random missingness.  
If dropouts are rare and data is MCAR, subjects with
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missing values are assumed to constitute a random subsample
of the baseline sample, and so they can be ignored and deleted
from the analysis sample. Complete case analysis or observed
case analysis, which include only subjects who complete the
study, are only valid for data MCAR. This analysis is simple,
but involves a loss of information and a loss of power. The
precision of estimations depends on the attrition rate. In the
case of data MCAR, other methods are also valid, including
regressions using means of available cases, non parametric tests
and GEE. However, MCAR is rare.
Intention to treat analysis (ITT) is the goal in randomised
controlled trials and should be favoured in order to obtain
convincing results. ITT analysis takes into account all patients
according to their initial treatment group, as designated by the
randomization procedure, whether or not they finish the trial.
The most extreme method of analysis in this case is worst case
analysis: in the case of informative missing data, if the variable
of interest is dichotomous (success or failure), the worst score
is assigned to any missing value in the tested group and the best
score is assigned in the control group. 
Incomplete data can be replaced by single or multiple
imputations. Various imputation methods are available,
depending on the type variable, with more possibilities for
quantitative than for qualitative data. The data used may be
taken from data collected at a previous time point from the
attritor or from data collected at the correct time point from
other subjects. 
Several cross sectional imputations exist: (i) means of series
imputation methods and all variants: the average value of the
available data for the considered variable is calculated for all
subjects and replaces the missing value. This method is simple,
and useful when attrition rate is low and variables are
quantitative; (ii) the hot deck imputation method: the missing
value is imputed with an observed value of another respondent,
such as the average value of a subset of comparable
characteristics (subjects with same age, same gender…) or the
observed value of the “closest” subject. 
Various longitudinal imputations exist; the most widely used
is last observation carried forward (LOCF). This method
replaces quantitative missing values with the last observed
value for the subject. This method involves the strong and often
unrealistic assumption of a constant profile after the last
observed value.   
Both cross sectional and longitudinal imputations are quite
simple and commonly carried out. Their major drawback is that
the variance of the parameter is underestimated because the
uncertainty of the missing data is not taken into account. To
reduce this decreased variability, some authors suggest
imputation of a value randomly chosen from a range of values,
for instance, covering the 95% CI around the mean or predicted
value (41). The second problem caused by single imputation is
the risk that the underlying assumptions are not valid. 
Multiple imputation (MI) was developed, mainly by Rubin
(42, 43), to resolve the reduction of variance observed with
single imputation. Many MI procedures are valid for data
MAR. Numerous (“n”) consecutive imputations are carried out
for each item of missing data.  These “n” imputations lead to
“n” datasets. The more “n” is high, the more accurate the
estimates are. Contrary to single imputation, estimated standard
errors are higher than those obtained with a complete dataset,
reflecting uncertainty in the estimation caused by missing
values (26). One of the advantages of MI is that it can be
adapted to adjust to suspected nonignorability (39). MI is in
theory the most robust solution, and is preferred by the
scientific community. This solution is complex and strongly
depends on the model chosen for the missing data. Its use has
increased with software availability and powerful computers.
Finally, for data MNAR, a more complicated modelling of
the dropout process is required (44, 45). The dependence of the
missingness probablility on the missing value must be
estimated, but these estimates can be unreliable and are difficult
to compute (39).
In conclusion, there is no consensus as to the best statistical
methods for correcting attrition, as no method can completely
eliminate bias and perfectly deal with missing data. In addition,
the underlying assumptions of each method must be verified. If
these assumptions hold, single imputation is reliable in the case
of low rates of missing value. Whichever strategy is chosen, it
is highly recommended to perform sensitivity analyses, and to
employ at least two different methods producing bias in
opposite direction (46). The more robust methods should be
used where possible. The complications associated with each
method available for dealing with attrition highlight the need
for substantial efforts to prevent and minimize attrition in the
first place.
Conclusion
Attrition can introduce bias, but its impact is not easy to
predict. Before planning studies, consideration should be given
to preventing loss to follow up. This may often be expensive
and time consuming, but is the most desirable approach and the
only way to assure that selection bias will not occur.
Nevertheless, all studies should investigate the extent to which
attrition has occurred and if it is likely to bias results, and to
take it into account in the best possible way. Exploration of
response profiles of dropouts by reasons is necessary. However,
the best method to ensure that attrition does not bias study
results is to minimise or avoid it.
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of both patient and caregiver factors predictive of attrition 
is of particular interest for the development and targeting of 
attrition prevention strategies. In patients with chronic dis-
eases, particular attention should be paid to caregiver well-
being to limit attrition. 
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 Introduction 
 Prognosis studies provide useful insights into the nat-
ural history of a disorder, as well as examining associa-
tions between risk factors and health outcomes in patient 
populations. However, the quality of the results of such 
studies may be jeopardized by various types of bias, in-
cluding attrition  [1] . Attrition, defined as premature 
study dropout during follow-up, is a frequently observed 
phenomenon which can threaten the validity of results in 
longitudinal studies, regardless of the study population 
involved. Attrition systematically reduces statistical pow-
er by reducing the size of the study population, and it can 
introduce bias if dropouts differ from subjects remaining 
in the study  [2] . It is important to identify factors associ-
ated with attrition so that subjects at high risk of attrition 
can be identified and targeted in order to limit the impact 
of this phenomenon. The analysis of factors associated 
 Key Words 
 Attrition  ? Bias  ? Dropouts  ? Alzheimer’s disease  ? 
Longitudinal study  ? Cohort study  ? Caregiver 
 Abstract 
 Background: Attrition, i.e. patient dropout, can threaten the 
validity of results in longitudinal studies. The aim of this 
study was to identify patient and caregiver factors predictive 
of attrition in a cohort of Alzheimer disease (AD) patients. 
 Methods: 686 patients with mild to moderate AD were in-
cluded in the multicenter prospective REAL.FR study. Stan-
dardized gerontological evaluations were carried out twice 
yearly. Factors associated with attrition were assessed by 
survival analysis using a Cox proportional hazard model.  Re-
sults: After 2 years, 278 (40.5%) patients had dropped out. 
Causes of attrition included refusal (20.9%), death (20.1%), 
institutionalization (19.8%), and loss to follow-up (19.8%). At-
trition rates between each 6-month wave were constant at 
12%. After adjustment, several independent factors re-
mained associated with attrition: patients cared for by an un-
related caregiver [HR 1.7; 95% CI (1.08–2.59)], loss of autono-
my [HR = 1.37; (1.03–1.82)], increasing caregiver burden 
[HR = 1.014; (1.005–1.022)], use of cholinesterase inhibitors 
[HR = 0.40; (0.27–0.59)], use of 1 to 3 other types of medica-
tion [HR = 0.57; (0.36–0.89)].  Conclusions: The identification 
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with attrition can also help to determine whether the at-
trition is selective, and whether it affects the generaliz-
ability of findings  [3] . 
 There are several types of attrition, including death, 
refusal, contact failure and inability to respond. In elder-
ly populations, death may be an important source of at-
trition  [3, 4] . Attrition rates may vary across different 
studies involving elderly participants according to the 
chosen definition of attrition, as well as design (observa-
tional or interventional study, length of follow-up, fre-
quency and type of study contacts, use of attrition 
 prevention strategies such as tracking or bonding) or par-
ticipant (age, comorbidities, frailty, autonomy) charac-
teristics  [5, 6] .
 There may be a particularly high risk of attrition in 
cohorts of elderly subjects with cognitive impairment, 
such as mild cognitive impairment or Alzheimer disease 
(AD), as has been observed in randomized controlled tri-
als: for example, 20–30% after 6 months to 1 year of fol-
low-up  [6] . There is less data available regarding attrition 
in long-term longitudinal studies of AD patients  [7–9] . 
 Attrition in research involving cognitively impaired 
elderly patients may be particularly affected by death, re-
fusals to participate (by the patient and/or his or her fam-
ily) and loss of autonomy. Furthermore, the follow-up of 
elderly subjects with AD may also require the active par-
ticipation of a caregiver, for example to accompany the 
participant to study visits, or to carry out assessments of 
the participant. 
 Very few studies have specifically examined factors as-
sociated with attrition in elderly cognitively impaired 
subjects  [10, 11] , and caregiver-related factors have never 
been assessed.
 The main objective of this study was to identify and 
describe both patient- and caregiver-related factors asso-
ciated with attrition in a cohort of elderly patients with 
AD after 2 years of follow-up. Our hypothesis was that 
caregivers may be an independent source of attrition.
 Population and Methods 
 The REAL.FR study is a multicenter prospective study of AD 
patients which began in 2000, with the objectives of studying the 
natural history of AD and its management. A detailed protocol of 
the study has been published elsewhere  [12] . This study was ap-
proved by the Institutional Review Boards of each participating 
university. 
 Briefly, REAL.FR was carried out in 16 university hospitals in 
France. The study population consisted of ambulatory commu-
nity dwelling AD patients enrolled during a hospital consultation. 
At the time of enrolment, subjects met DSM-IV and NINCDS-
ADRDA (National Institute of Neurological and Communicative 
Diseases and Stroke/Alzheimer Disease and Related Association) 
criteria for AD  [13, 14] , and presented a Mini Mental State Ex-
amination (MMSE)  [15] score between 10 and 26. All patients 
were required to be looked after by an informal caregiver. 
 At inclusion and twice yearly, patients underwent a standard-
ized gerontological evaluation (MMSE  [15] , Alzheimer’s Disease 
Assessment Scale-cognitive subscale  [16] , Clinical Dementia Rat-
ing  [17] , Activities of Daily Living (ADL)  [18] , Instrumental Ac-
tivities of Daily Living  [19] , Neuropsychiatric Inventory (NPI) 
 [20] , and Mini Nutritional Assessment (MNA)  [21] ). Socioeco-
nomic data were also collected. Furthermore, the caregiver-pa-
tient relationship and the level of caregiver burden, assessed using 
the Zarit Burden Interview  [22] , were recorded. This scale uses 22 
items evaluated on a 5-point Likert scale. Scores range from 0 to 
88, with a score greater than 20 representing some level of burden. 
Events such as hospitalization, institutionalization, and treat-
ment changes were noted. Date of death or admission to a nursing 
home was obtained from the caregiver, a family member or some 
other qualified informant. 
 Subjects who missed follow-up visits were contacted by tele-
phone, and mail if necessary, in order to determine the reason for 
nonattendance ( fig. 1 ). In the case of refusal, a second visit was 
offered to the caregiver, with or without the patient, and if this 
was not possible or was refused, a short questionnaire was admin-
istered by telephone or at the patient’s/caregiver’s home to assess 
the patient’s status [mobility, autonomy, cognitive functions, oc-
currence of medical event(s), change in the patient’s entourage 
and cholinesterase inhibitor (ChEI) use]. For real losses to follow-
up, the general practitioner and the second caregiver were tele-
phoned in order to obtain data regarding the patient.
 Causes of attrition were classified as follows: patient or family/
caregiver refusal, death, institutionalization if it prevented the pa-
tient from attending study visits, difficult to locate (i.e. lost to fol-
low-up), other (relocation, patient medical problems, worsened 
health preventing continued participation, caregiver problems, 
transfer to another study center, others).
 Attrition was considered as a binary dependent variable. The 
outcome ‘length of follow-up/time to dropout’ was documented 
for each subject, and defined as the difference between the date of 
inclusion and the censored date (attrition whatever its cause or 
final 2-year endpoint).
 In the statistical analysis of the study population at inclusion, 
mean values  8 standard deviation (SD) and proportions were 
used to describe quantitative and qualitative variables, respec-
tively. A survival analysis was performed to identify baseline fac-
tors associated with the time of dropout, using relative hazard 
ratios and 95% confidence intervals (CI). The time variable was 
the duration of follow-up, with attrition considered as failure. 
Each variable was tested using log-rank tests. A multivariate anal-
ysis was then performed using a statistical significance level  ! 0.25 
in the bivariate survival analysis. A Cox proportional hazard 
model was also used, with adjustment for the center (nonpropor-
tionality stratification  [23] ), and backward stepwise regression. 
Tests based on interaction with time were used to assert the pro-
portional hazards assumption. Statistical interactions were veri-
fied. p values were based on two-sided tests and considered sta-
tistically significant if p  ! 0.05.
 All analyses were performed using SAS software (version 9.1, 
SAS institute Inc., Cary, N.C., USA). 
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 Results 
 A total of 686 patients were included in the REAL.FR 
study between 2000 and 2002, and followed for an aver-
age of 2 years (954.34 person-years, median duration of 
follow-up 651 days). The demographic and biological 
characteristics of the patients at baseline are summarized 
in  table 1 . At inclusion, the patients, who were mostly re-
cruited from geriatric departments (83.4%), were aged 
77.9  8 7 years. Although they had been diagnosed with 
AD for a mean of 13.2  8 13.4 months (mean age at diag-
nosis 76.8  8 7 years), many patients were still at a stage 
of moderate cognitive impairment, with 54% completely 
independent for basic activities of daily living (ADL 
score). 87.6% had at least one behavioral disturbance ac-
cording to the NPI.
 The proportion of patients with 2 or more comorbidi-
ties was 40.7%. The mean MNA score was 24  8 3, and 
one third of the patients were at risk of malnutrition 
(MNA  ^  23.5). Following the baseline visit, 89% (n = 611) 
of patients in the cohort were treated with a ChEI (87.6% 
were treated before this visit, and 76 patients were pre-
scribed a ChEI for the first time during this visit). Al-
though all patients were required to have an informal (i.e. 
nonprofessional) caregiver, more than a quarter lived 
alone, regardless of dementia severity. 60% of patients 
had a female caregiver, most often the wife or daughter. 
At inclusion, the mean caregiver score on the Zarit scale 
was 22.6  8 16, and 50% of caregivers reported some de-
gree of burden (Zarit  1 20). At this early stage of the dis-
ease, the level of health care support remained low: 20% 
of patients had nursing help, either at home or in a private 
practice, 44% had a home-help, and only 2% used day 
care facilities. 
 Of the 686 patients, 278 had dropped out by 2 years of 
follow-up, representing 40.5% of the initial cohort ( fig. 2 ) 
and an incidence rate of 29.13/100 person years (95% CI: 
25.70–32.56).
Attempt to contact patient/ 
caregiver to determine reason for 
missed visit
No contact madeContact made
Discontinuation of study (dropout )
Reason = death Reason = medical 
problem
Reason = 
institutionalization
Reason = 
refusal/‘other’
Attempt to contact GP or 2nd
designated caregiver
Obtain date, 
place & cause 
of death
Determine nature 
of problem from 
GP or caregiver
Attempt to 
continue follow-up 
as planned
Attempt to 
rearrange missed 
visit (caregiver +/–
patient)
Attempt to administer mini patient evaluation
refused
Impossible/ 
refused
Missed follow-up visit
Study visit missed but 
continuation of follow-up
 Fig. 1. Contact procedures after missed follow-up visits for the 686 patients enrolled in the REAL.FR study. 
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Table 1. Baseline demographic and clinical characteristics of the REAL.FR cohort
All patients 
(n = 686)
Patients remai-
ning in the study 
(n = 408)
Dropouts
(n = 278)
pa
Mean age 8 SD, years 77.986.8 77.186.7 79.086.8 <0.001
Sex, %
Male 
Female
28.9
71.1
27.0
73.0
31.6
68.4
0.183
Number of comorbidities, %
0
1
≥2
24.2
35.1
40.7
29.2
36.7
34.1
17.0
32.8
50.2
<0.001
ChEI useb, % 89.1 93.1 83.1 <0.001
MMSE 20.084.2 20.5084.0 19.384.4 <0.001
ADAS-cog 17.988.2 16.787.3 19.589.1 <0.001c
Total ADL (out of 6) 5.480.9 5.680.7 5.281.1 <0.001d
IADL, %
≤2
>2
49.2
50.8
57.4
42.6
37.3
62.7
<0.001
CDR, %
0.5
1
2 or 3
34.2
42.1
23.7
40.3
41.6
18.1 
25.2
42.8
32.0 
<0.001 
NPI frequency ! severity 15.3815.3 14.4814.1 16.7816.9 0.126e
MNA ≤23.5, % 33.2 29.2 39.1 0.008
Medical assistancef, % 68.2 67.0 70.0 0.415
Non-medical assistanceg, % 50.5 47.9 54.2 0.105
Level of education, %
Technical/high school certificate or higher
Early secondary education
Primary school certificate
Elementary or illiterate
20.1
22.3
36.3
21.3
20.5
23.2
33.3
23.0
19.6
21.0
40.6
18.8
0.250
Caregiver status and patient living 
arrangements, %
Spouse
Child, noncohabitingh
Child, cohabiting 
Other
53.4
21.6
16.0
9.0
57.1
23.0
12.5
7.4
47.9
19.4
21.2
11.5
0.002
Caregiver sex, %
Female 59.3 56.0 64.1 0.034
Caregiver age, years 64.7813.2 65.2813.3 63.9813.0 0.214
Zarit 22.6815.9 21.4814.8 24.4817.2 0.117e
ADAS-cog = Alzheimer Disease Assessment Scale-cognitive subscale; CDR = Clinical Dementia Rating; 
IADL = Instrumental Activities of Daily Living. 
a Between patients remaining in the study and dropouts. Unless stated otherwise, p values are Student’s t test 
for continuous variables, and x2 tests for categorical variables.
b Including patients who were prescribed a ChEI during the baseline visit.
c Test carried out after log transformation of variable.
d Kruskal-Wallis test.
e Test carried out after square root transformation of variable.
f Outpatient clinics, nurse home visits, speech therapist, physiotherapist, doctor.
g Home help, day center, nighttime assistance, daytime assistance, meals on wheels, personal alarm.
h ‘Cohabiting’ implies that the patient was not living alone, but it does not necessarily mean that the patient 
was living with the caregiver. 
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 The frequency of dropouts between each wave (per-
centage of the remaining patients at the beginning of each 
wave) was constant at around 12%, giving a cumulative 
rate of attrition of 12.4, 23, 32.2 and 40.5% at 6, 12, 18, and 
24 months, respectively. 
 The reasons for dropout were refusal (n = 58; 20.86%), 
death (n = 56; 20.14%), nursing home placement (n = 55; 
19.78%), lost to follow-up (n = 55; 19.78%), moved house 
(n = 15; 5.4%), medical problem (n = 14; 5%), caregiver 
problem (n = 7; 2.5%), follow-up in another center (n = 6; 
2.16%), and other causes (n = 12; 4.3%). Due to the small 
sample size, the last five causes were merged together in 
‘other causes’ (n = 54; 19.42%).
 Over the course of the study, the proportion of drop-
outs due to death and institutionalization tended to in-
crease, the proportions of dropouts due to refusals and 
losses to follow-up appeared to be greatest in the first 
waves, and the proportion of patients dropping out due 
to other reasons remained relatively stable ( fig. 3 ).
 In the bivariate survival analysis, patient age was the 
only sociodemographic factor associated with an in-
creased risk of attrition ( table 2 ). In addition, patients 
with a history of cardiac problems, poorer nutritional sta-
tus, and increasing cognitive or functional decline were 
at greater risk of dropping out of the study ( table 3 ). Of 
the behavioral disturbances evaluated by the NPI, only 
hallucinations were found to be significantly associated 
with attrition.
 Conversely, patients who were diagnosed with AD be-
tween 6 and 24 months ago were less likely to drop out 
than those diagnosed less than 3 months ago, as were 
those using a ChEI treatment or those using one to three 
other types of medication (as compared to no other types 
of medication). 
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 Fig. 2. Total attrition between each 6-
month visit in the REAL.FR study, defined 
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the number of patients remaining at the 
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 Fig. 3. Percentage of each specific cause of 
attrition in the REAL.FR study during 
each 6-month period of follow-up. The 
number of dropouts for each cause during 
waves 1, 2, 3, and 4 was, respectively: death 
13, 15, 14, 14 (total n = 56); institutionaliza-
tion 9, 15, 20, 11 (total n = 55); lost to fol-
low-up 21, 13, 11, 10 (total n = 55); refusal 
27, 16, 8, 7 (total n = 58); others 15, 14, 10, 
15 (total n = 54). 
 Coley et al. Neuroepidemiology 2008;31:69–7974
Table 2. Patient sociodemographic factors predictive of attrition in the bivariate survival analysis: relative haz-
ard for time to dropout
Inclusion parameters HR 95% CI p (x2)
Sex (n = 686)
Female 
Male
1
1.17
–
0.91–1.50
–
0.229
Age, years (n = 686) 1.03 1.02–1.05 <0.001
Level of education (n = 681)
Technical school, high school certificate or higher
Early secondary education
Primary school certificate
Elementary or illiterate
1
1.003
1.25
0.94
–
0.69–1.45
0.91–1.73
0.64–1.38
0.250
–
0.986
0.172
0.763
Monthly household income, EUR (n = 680)
>2,287 EUR
1,500–2,287 EUR
<1,500 EUR 
1
1.30
1.30
–
0.93–1.82
0.97–1.74
0.174
–
0.129
0.077
HR = Hazard ratio.
Inclusion parameters HR 95% CI p (x2)
Length of time since diagnosis (n = 686)
<3 months
3–6 months
6–12 months
12–24 months
≥24 months
Not available
1
0.80
0.46
0.65
0.79
0.74
–
0.52–1.21
0.30–0.68
0.45–0.94
0.55–1.14
0.49–1.12
0.006
–
0.290
0.0001
0.021
0.205
0.156
History of cardiac problems (atrial fibrillation/arrhythmia, 
angina, MI, arteritis, congestive heart failure; n = 686)
No
Yes
Not available
1
1.53
0.79
–
1.18–1.98
0.47–1.32
0.002
–
0.001
0.366
MNA (n = 671)
>23.5
≤23.5
1
1.40
–
1.10–1.78
–
0.006
Medical assistance1 (n = 667)
No
Yes
1
1.13
–
0.87–1.47
–
0.343
Non-medical assistance2 (n = 670)
No
Yes
1
1.21
–
0.95–1.54
–
0.117
ChEI (at end of first visit; n = 686)
Not treated
Treated
1
0.46
–
0.34–0.63
–
<0.001
Number of other treatments (n = 684)
0
1–3
≥4
1
0.67
0.89
–
0.45–1.01
0.60–1.33
0.040
–
0.059
0.586
Total MMSE score (n = 684) 0.95 0.93–0.98 <0.001
Total ADAS-cog score (n = 673) 1.03 1.01–1.04 <0.001
Table 3. Patient medical factors predictive of attrition in the bivariate survival analysis: relative hazard for time 
to dropout
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 Caregiver status combined with living arrangements, 
and level of caregiver burden were also associated with 
higher attrition rates, while patients with a male care-
giver were less likely to drop out of the study ( table 4 ).
 597 patients were included in the multivariate analy-
sis, including 249 dropouts and the 348 remaining pa-
tients ( table 5 ). 
 After adjustment for all variables found to be signifi-
cant in the bivariate analysis, several independent factors 
remained associated with attrition: (i) AD patients cared 
for by an unrelated caregiver, i.e. not a spouse or child 
[HR 1.7 (1.08–2.59); p = 0.021], (ii) a loss of autonomy ( 6 1 
limitation) on the ADL scale [HR = 1.37 (1.03–1.82); p = 
0.03], (iii) increasing caregiver Zarit burden score [HR = 
1.014 (1.005–1.022); p = 0.001], (iv) the use of a ChEI 
[HR = 0.40 (0.27–0.59); p  ! 0.0001], and (v) the use of one 
to three other types of medication compared to the use of 
no other types of medication [HR = 0.57 (0.36–0.89); p = 
0.01].
Inclusion parameters HR 95% CI p (x2)
CDR score (n = 682)
0.5
1
2 or 3
1
1.50
2.13
–
1.11–2.01
1.56–2.91
<0.001
–
0.007
<0.001
Number of ADL limitations (n = 686)
0
≥1
1
1.75
–
1.38–2.22
–
<0.001
Number of IADL (activities of daily living/5; n = 665)
≤2
>2
1
1.84
–
1.44–2.36
–
<0.001
NPI delusions (n = 686)
Yes 1.19 0.88–1.62 0.256
NPI hallucinations (n = 686)
Yes 1.87 1.26–2.77 0.001
NPI agitation/aggression (n = 686)
Yes 1.02 0.80–1.30 0.870
NPI depression/dysphoria (n = 686)
Yes 1.05 0.82–1.33 0.704
NPI anxiety (n = 686)
Yes 1.23 0.97–1.56 0.083
NPI euphoria (n = 686)
Yes 0.92 0.57–1.46 0.711
NPI apathy/indifference (n = 686)
Yes 1.02 0.81–1.30 0.843
NPI disinhibition (n = 686)
Yes 1.36 0.97–1.92 0.076
NPI irritability/lability (n = 686)
Yes 0.95 0.75–1.22 0.709
NPI aberrant motor activity (n = 686)
Yes 0.92 0.69–1.22 0.552
NPI sleep disturbances (n = 686)
Yes 1.24 0.91–1.70 0.168
NPI appetite abnormalities (n = 685)
Yes 1.12 0.85–1.47 0.437
ADAS-cog = Alzheimer Disease Assessment Scale-cognitive subscale; CDR = Clinical Dementia Rating; 
IADL = Instrumental Activities of Daily Living; MI = myocardial infarction. 
1 Outpatient clinics, nurse home visits, speech therapist, physiotherapist, doctor. 
2 Home help, day center, nighttime assistance, daytime assistance, meals on wheels, personal alarm.
Table 3 (continued)
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 Discussion 
 The aim of this study was to describe the level and 
causes of attrition after 2 years of follow-up in an AD lon-
gitudinal study. The attrition rate at 2 years was 41%. 
Each cause of attrition (death, refusal, institutionaliza-
tion, loss to follow-up, others) accounted for around 20%, 
although the percentage of attrition attributable to each 
cause varied over time. The perceived burden of study 
visits may have discouraged certain patients from taking 
part, but those that were enrolled may have been more 
compliant, because this study was carried out in expert 
centers belonging to the national network of AD centers. 
In addition, the tracking methods used ( fig. 1 ) may have 
limited the level of attrition.
 The frequency of attrition in this study remained stable 
over time, at approximately 12% per 6-month wave. This 
corresponds with the findings in some longitudinal stud-
ies of the elderly  [24, 25] , but is lower than others  [26] .
 In the literature, there are relatively few longitudinal 
cohorts made up entirely of patients with AD or other 
forms of dementia. It is difficult to compare the rate of 
attrition in REAL.FR with all other AD longitudinal 
studies due to methodological differences, for example 
the definition of attrition and the study population, and 
the length of follow-up.
 Of the three studies – LASER-AD  [9] , PREDICTORS 
study  [7], Starkstein et al.  [11] – that included death as a 
cause of attrition, the attrition rate appears to be lower 
than that observed in our study. In the Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD) 
cohort, an attrition rate, excluding deaths, of 10.5% was 
observed amongst 978 AD patients and 466 controls (of-
ten a spouse of the AD patient) in the first year of follow-
up  [10] . This rate is lower than the 19% observed after 1 
year excluding death in REAL.FR, but the CERAD rate 
also includes control subjects. 
 The attrition rate in REAL.FR appears to be relatively 
high as compared to these other AD cohorts. This could 
be explained by methodological differences, for example, 
inclusion criteria concerning the severity of the disease 
 [6] . In REAL.FR, death accounted for a smaller propor-
tion of attrition than in other studies, indicating that oth-
er causes, such as loss of contact, institutionalization and 
medical problems were more prominent. 
 There are no guidelines regarding an acceptable level 
of attrition for longitudinal studies. Some authors have 
Table 5. Adjusted HR for characteristics associated with dropout 
in the Cox multivariate model stratified by center (n = 597)
HR 95% CI p (x2)
Caregiver status and living 
arrangements 
(ref.: spouse) 
Child, noncohabiting  
Child, cohabiting  
Other 
1
0.78
1.04
1.67
–
0.54–1.12
0.72–1.50
1.08–2.59
0.023
0.183
0.840
0.021
Number of ADL limitations: 
≥1 vs. 0 1.37 1.03–1.82 0.030
Total Zarit score 1.014 1.005–1.022 0.001
Use of ChEI1 (yes vs. no) 0.40 0.27–0.59 <0.001
Number of other treatments
(ref.: 0)
1–3 
≥4
1
0.57
0.68
–
0.36–0.89
0.43–1.06
0.046
0.014
0.087
The following variables were also introduced into initial mod-
els, but did not remain in the final model: MMSE, time elapsed 
since diagnosis, history of cardiac problems, CDR score, patient 
age, MNA, number of IADL limitations and hallucinations on 
NPI scale. 
1 At end of baseline visit.
Inclusion parameters HR 95% CI p (x2)
Caregiver sex (n = 678)
Female
Male
1
0.78
–
0.61–0.99
–
0.045
Caregiver age, years (n = 668) 0.995 0.987–1.004 0.313
Caregiver status and living arrangements (n = 686)
Spouse
Child, noncohabiting 
Child, cohabiting
Other
1
0.98
1.75
1.67
–
0.71–1.34
1.29–2.38
1.13–2.46
<0.001
–
0.882
<0.001
0.009
Caregiver burden (Zarit score) (n = 638) 1.009 1.002–1.017 0.015
Table 4. Caregiver factors predictive of 
attrition in the bivariate survival analysis: 
relative hazard for time to dropout
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suggested that in randomized controlled trials, a loss to 
follow-up of 5% or less may be of little concern, but that 
losses of 20% or more may introduce considerable bias 
 [27] . However, it may be unwise to set an explicit value to 
assess the risk for bias because the type of missing data 
must also be taken into account  [28] . In practice, the oc-
currence of missing data is generally not random. Instead 
it is important to consider overlapping methodological 
issues and the direction of the potential bias on a case-by-
case basis, and to determine whether or not dropout is 
associated with outcome (i.e. whether or not it is random) 
 [29] .
 Studies of factors associated with attrition in AD co-
horts have mainly been based on unadjusted analyses. 
Certain factors have been suggested, such as age, race, 
MMSE score, apathy, level of education, and type of de-
mentia diagnosis  [10, 11, 30] , but results are inconsistent 
across studies The findings of our study are in accor-
dance with those reported in unadjusted analyses in the 
literature regarding population-based studies of elderly 
people for the role of age, and level of cognitive impair-
ment  [4] .
 In our multivariate analysis, patients with at least one 
limitation on the ADL scale had a risk of attrition that 
was 1.37 times higher than that of subjects with no limi-
tations. Functional impairment may be a more important 
indicator of attrition than cognitive impairment. It may 
be more difficult for a caregiver to ensure attendance at 
study visits if the patient has functional impairment com-
pared to cognitive impairment, as functional impairment 
may bring about more practical problems that the care-
giver may have difficulties in overcoming.
 Patients not using a ChEI were 2.5 times more likely 
to drop out than treated patients. The REAL.FR cohort 
was established in 2000, meaning that a high proportion 
of subjects (89% including those who were prescribed a 
ChEI during the baseline visit) were treated with ChEIs. 
The efficacy of ChEIs has been demonstrated for mild to 
moderate AD patients  [31] , so it is probable that treated 
patients are more likely to attend consultations in order 
to receive their medication, demonstrating a ‘protective’ 
effect of ChEI use on attrition.
 An explanation for the non-use of ChEIs, apart from 
contraindications, could be that certain patients or their 
caregivers may refuse this type of treatment, perhaps be-
cause they have difficulties in accepting the pathology 
and in receiving medical care or advice. Such patients 
may therefore be less likely to remain in the study. Pa-
tients who were non-users of ChEIs at baseline may have 
previously been prescribed this medication and discon-
tinued use because adverse drug reaction, which may af-
fect the patients’ or caregiver’s confidence in the medical 
care being received, thus making them more likely to 
drop out of the study.
 Patients using one to three types of medication other 
than ChEIs were found to be 1.75 times less likely to drop 
out of the study than those taking no other types of med-
ication. The use of several types of medication may indi-
cate that such patients are likely to receive increased med-
ical care and attention, and we hypothesize they may 
present an increased compliance in medication use as 
well as in the study.
 The remaining factors concern caregiver characteris-
tics. Firstly, patients looked after by an unrelated care-
giver (i.e. not a spouse or son/daughter) were found to be 
1.7 times more likely to drop out of the study than those 
cared for by their spouse. This finding is in accordance 
with the results reported by Koss et al.  [10] , who noted 
that patients whose spouse was also included in the study 
(in their case as a control) were less likely to drop out than 
patients who did not have a spouse taking part.
 We found that an increase of 1 point on the Zarit bur-
den scale was associated with a 1.4% increase in the risk 
of attrition. To our knowledge, caregiver burden has nev-
er been examined as a determinant of attrition in studies 
of AD patients, although it has been found to be associ-
ated with institutionalization  [32] .
 It is therefore important to be able to recognize and 
support exhausted caregivers in order to limit attrition in 
studies involving AD patients. For example, home assis-
tance could be offered in order to reduce the caregiver 
burden. It has been suggested that caregivers play an im-
portant role in decision making regarding patient care, 
for example regarding medication use  [33, 34] , yet attri-
tion prevention strategies have generally not been target-
ed towards caregivers  [35] . It is important to convince the 
caregiver of the importance of regular medical care and 
attention for the patient. Even if the objective of natural 
history studies of AD is not to bring about a direct thera-
peutic benefit, regular medical assessment is likely to im-
prove the overall management of the disease, thus pro-
viding potential benefits for both the patient and the 
caregiver. Attention should be paid to ensure that care-
givers understand the benefits of taking part in such 
studies for both themselves and the AD patient.
 In a recent systematic review of attrition in large pop-
ulation-based studies (i.e. not specifically focused on AD) 
Chatfield et al.  [4] noted that in multivariate analyses, 
increasing age and poor cognitive performance were the 
only factors consistently associated with preventable at-
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trition (i.e. all types of attrition excluding death), but nei-
ther of these factors remained significant in our multi-
variate model. Our results may indicate that above a cer-
tain level of cognitive impairment, differences in the 
cognitive performance between patients may not affect 
attrition.
 We have only identified one other study which has 
specifically analyzed factors associated with attrition in 
a cohort of AD patients in multivariate analyses. In this 
study, Koss et al.  [10] reported three factors associated 
with attrition: non-white status, patients’ spouse not en-
rolled in the study as a control, and inadequate involve-
ment by the study site, but we did not assess these factors 
in our study as they were either not relevant or not avail-
able (due to national ethical guidelines). However, as in 
our study, patient age, level of education, and cognitive 
status were not associated with attrition.
 We included death in our definition of attrition be-
cause our first objective was to identify subjects with 
missing data, whatever the cause. However, some authors 
exclude death as a cause of attrition. It is important to es-
tablish the factors associated with preventable attrition 
(i.e. all causes of attrition excluding death), and so we per-
formed a sensitivity analysis using a multivariate model 
to establish predictive factors of preventable attrition in 
our study. The results were stable compared to the multi-
variate model presented above, except that caregiver sta-
tus and living arrangements were no longer predictive of 
attrition (data not shown).
 This study was an exploratory investigation into the 
causes of attrition and may have some limitations. Our 
population is probably unrepresentative of the entire AD 
population, because the patients included in our study 
had a diagnosis of probable AD, and had been referred to 
an AD expert center. 
 Our results are largely dependent upon the definition 
of attrition used. Moreover, we only considered baseline 
factors as possible determinants of attrition and did not 
take into account the fact that some of these factors (e.g. 
caregiver burden, cognitive status) may have changed 
during the follow-up period.
 Other studies have considered determinants of refus-
al, both before and during studies, rather than determi-
nants of total attrition  [36, 37] . We could have examined 
subgroups of attrition, such as refusal, but our investiga-
tion was limited by the number of participants in our 
study.
 Despite these limitations, this study of attrition is use-
ful because the REAL.FR study involves one of the largest 
cohorts of AD patients so far studied, in which determi-
nants of attrition have seldom been studied. Further-
more, this study is the first to examine caregiver charac-
teristics as factors associated with attrition. 
 Conclusion 
 Long-term prognostic studies are necessary in order 
to improve our understanding of chronic diseases such as 
AD. Attrition may threaten the validity and generaliz-
ability of such studies, meaning that it is important to 
minimize dropouts. The identification of subjects who 
are at greater risk of dropping out is essential so that they 
can be specifically targeted by attrition prevention strate-
gies, and closely monitored throughout the study. Care-
giver factors, as well as those related to patients and study 
design may all influence attrition. Thus, particular atten-
tion should be paid to caregiver well-being to improve 
attrition.
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TITRE : Aspects méthodologiques spécifiques aux essais de prévention et de traitement de la maladie 
d’Alzheimer  
 
RESUME : La prévention et le traitement de la maladie d’Alzheimer (MA), maladie neurodégénérative chronique 
liée à l'âge, devient un enjeu majeur de santé publique étant donné le poids de la maladie et le vieillissement de la 
population. Aujourd’hui, seuls des traitements symptomatiques existent; le développement de nouveaux 
traitements capables de ralentir l'évolution de la maladie est donc une priorité. L'efficacité des nouveaux 
traitements doit être démontrée dans des essais randomisés, mais ces essais incluant des personnes âgées atteintes 
ou à risque d'une MA soulèvent de nombreux problèmes méthodologiques, par exemple le choix de la population 
cible, la durée de suivi et du critère de jugement principal et un taux de données manquantes élevé.   
 
Les données manquantes étant une source potentiellement majeure de biais dans les essais cliniques sur la MA, 
nous avons analysé les déterminants de l’attrition (sorties d’étude), une source majeure de données manquantes, 
dan une étude longitudinale de la MA. Nous avons également montré l’importance du choix de la méthode 
statistique de gestion des données manquantes lors de l’analyse d’un essai longitudinal. 
 
La définition du critère de jugement principal est aussi un choix important.  Les essais pour les patients présentant 
des symptômes cliniques de la MA doivent être positifs sur deux types de critères (cognition, fonction). Une 
analyse a donc été réalisée pour étudier la possibilité d'utiliser un seul critère global, la CDR-SB. Aussi, dans les 
essais de prévention, étant donné la difficulté d'utiliser la conversion au stade de démence comme critère de 
jugement principal, l'alternative d'utiliser le déclin cognitif a été étudiée. 
 
MOTS CLES : maladie d’Alzheimer ; déclin cognitif ; méthodologie des essais cliniques ; prévention ; données 
manquantes ; attrition ; critères de jugement ; validation psychométrique 
 
 
 
 
TITLE: Methodological aspects of clinical trials for the prevention and treatment of Alzheimer’s disease 
 
ABSTRACT: The prevention and treatment of Alzheimer’s disease (AD), a chronic progressive 
neurodegenerative disorder primarily affecting older people, is a growing public health concern given the burden 
of the disease, and the aging of the global population. Currently only symptomatic treatments are available, so the 
development of new treatments able to slow or stop the disease process is a research priority. Randomised trials 
are therefore required to demonstrate the efficacy (or lack thereof) of new treatments, but trials involving older 
people diagnosed with or at risk for AD raise numerous methodological challenges, including the definition of the 
target population, primary endpoint, and duration of follow-up, as well as the problems of a high level of dropouts, 
the burden of cognitive evaluations, and the increasing dependency of the trial participants. 
 
As missing data are a major potential source of bias in AD trials, the determinants of attrition, a major cause of 
missing data, were analysed in a longitudinal AD study.  The impact of using different methods for handling 
missing data in statistical analyses of AD trials was also investigated.  
 
The choice of the primary endpoint is another important choice during the design of AD trials. Trials for 
symptomatic patients must demonstrate positive effects on two types of criteria (cognition and function).  The 
suitability of using a single global primary endpoint, the CDR-SB, for such trials was therefore evaluated. Also, 
for prevention trials, given the difficulties of measuring conversion to dementia as the primary endpoint, the 
alternative of using cognitive decline as a surrogate endpoint was assessed. 
 
KEYWORDS: Alzheimer’s disease; cognitive decline; clinical trial methodology; prevention; missing data; 
attrition; endpoints; psychometric validation;  
 
 
 
 
 
 
 
 
 
